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Fracture non-unions and bone defects represent a recalcitrant problem in the field of 
orthopaedic surgery.  Although the current gold-standard treatment, autologous bone 
grafting, has a relatively high success rate, the technique is not without serious 
problems.  The emerging field of regenerative medicine may have the potential to 
provide an alternative treatment.  One promising strategy involves the delivery of 
both cells and multiple growth factors with different release profiles. 
 
A range of scaffolds was developed from Poly(ε-caprolactone) (PCL), Poly(lactide-
co-glycolide) (PLGA), and two blends of PCL (Mn 42,500) and PLGA.  The 
scaffolds were manufactured utilising a novel modified fused deposition modelling 
system, using polymer/dichloromethane solutions.  The scaffolds were found to have 
pore sizes suitable for bone regenerative medical applications (373±9.5 µm in the Y-
direction and 460±13 µm in the X-direction).  However, the scaffolds were found to 
be only 52±3 µm in height.  This means that the two-layer scaffolds were relatively 
flat.  This was undesirable, as direct control of the complete 3D geometry was the 
favoured strategy, though it may not be a necessary requirement. 
 
Five scaffold coatings were also developed from alginate, chitosan (crosslinked using 
sodium hydroxide or tripolyphosphate), Type-I collagen and Type-A gelatin.  The 
scaffold coatings were screened in vitro for their cell-compatibility with human 
marrow stromal cells (hMSCs), human osteoblasts and MG63 cells.  This was 
assessed using an assay for cell death, and assessing total cell counts.  From these 
studies, Type-I collagen was found to be the optimum coating.  For hMSCs, their 
death rates were found to be 19.1±6.3% for alginate, 5.3±3.6% and 2.9±1.4% for 
chitosan crosslinked with tripolyphosphate and sodium hydroxide respectively, 
compared to 0.11±0.07% for Type-I collagen, and 0.15±0.13% and 0.16±0.12% for 
0.1% and 0.2% gelatin respectively.  Type-I collagen was found to be the most cell-




Similarly, PCL scaffolds vacuum dried for 1 hr were found to be cell-compatible.  
No detectable clinically significant difference was found in either total cell counts, or 
the proportion of cell death in; hMSCs exposed to PCL scaffolds processed with 
dichloromethane, hMSCs either exposed to scaffolds known to be biocompatible, or 
hMSCs cultured in the absence of scaffolds.  When cell morphology was compared, 
scaffolds vacuum dried for 1 hr or more were found to have a similar morphology to 
the cells cultured in the absence of scaffolds.  It was therefore concluded that a 
vacuum drying time of 1 hr was sufficient for cell-compatibility. 
 
The scaffold materials were screened both for their encapsulation efficiencies and 
release characteristics using the model drug, methylene blue.  The encapsulation 
efficiency was found to be both relatively high and consistent for both Mn 42,500 and 
80,000 PCL as well as PCL:PLGA 66:33, at 71±6%, 71±5%, and 78±10% 
respectively, relative to the low efficiencies recorded for both PCL:PLGA 66:33 and 
PLGA: 57±5% and 38±10% respectively. 
 
The release rate of methylene blue from PCL (Mn 42,500), was found to be relatively 
slow, controlled, and consistent between batches (between 21±2% and 20±3% 
released in the first 24 hr).  Despite the release rate being consistent for PCL (Mn 
80,000), the release rate was thought to be too high, since between 29±3% and 
39±5% of the test compound was released in the first 24 hr period.  The release rate 
of methylene blue from the PCL/PLGA blends (between 17±2% – 30±7% and 
18±4% – 31±6% in the first 24 hr) and PLGA (between 7.1±3.4% – 9.3±2.9% in the 
first 24 hr) were found to be inconsistent, and low in the case of PLGA, even taking 
the different loading efficiencies into account.  Therefore, PCL (Mn 42,500) was 
selected as the favoured candidate scaffold material. 
 
The loading content and release profiles from methylene blue loaded collagen 
scaffold coatings were also evaluated.  The drug loading capacity was found to be 
suitable for use as a drug delivery system (65±5 µg/g of methylene blue per unit 
scaffold mass).  The release of methylene blue was observed to be rapid (between 
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54±10% – 70±17% in the first 24 hr), which was thought to be desirable for the 
coating delivery system. 
 
Recombinant human bone morphogenetic protein-7 (rhBMP-7) was used as a 
representative growth factor of interest for bone regenerative medical applications.  It 
was loaded in collagen scaffold coatings (CoatBMP 1.25) and encapsulated within PCL 
(Mn 42,500) scaffolds (ScaffBMP 1.25).  Control coatings and scaffolds were designated 
CoatPBS and ScaffPBS respectively.  Both delivery systems were found to release 
detectable quantities of rhBMP-7 (releasing 2.8±0.2 µg/g and 87±7 ng/g respectively 
in the first 24 hr), even after 14 days.  The release rate of the growth factor from the 
scaffold coating was higher than that from the encapsulating scaffolds.  However, the 
cumulative release profiles were found to deviate from the desired ideal release 
profiles, and burst release was observed from both delivery systems.  Although 
differences were observed for the two delivery systems, this difference may not be of 
clinical significance.   
 
Nevertheless, scaffolds with less than ideal delivery properties may still be of 
potential clinical use.  The bioactivity of the rhBMP-7 released from the test 
scaffolds was therefore assessed by quantifying the area of normalised ALP staining 
of hMSCs.  The release of rhBMP-7 from the collagen coating of the PCL (Mn 
42,500) scaffolds (CoatBMP 1.25ScaffPBS) was capable of statistically significantly 
increasing hMSC normalised ALP expression, although the actual differences were 
often relatively small.  Therefore, at least a proportion of the growth factor released 
is likely to have been bioactive.  The release from scaffolds encapsulating rhBMP-7 
(CoatPBSScaffBMP 1.25) did not have this effect on the hMSCs, indicating that either the 
concentration released was too low, or the growth factor released was no longer 
bioactive. 
 
However, when the cells were seeded directly onto the scaffolds, the activity of ALP, 
normalised by a DNA assay, was statistically significantly increased for the 
CoatPBSScaffBMP 1.25 scaffolds, in hMSCs from all three test patient donors (by 
35±10% on the control).  ALP activity was also significantly increased in hMSCs 
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from two of the three patients seeded onto CoatBMP 1.25ScaffBMP 1.25  scaffolds (by 
39±10% on the control).  ALP activity was only statistically significantly increased 
for one of the hMSC patients when seeded onto CoatBMP 1.25ScaffPBS scaffolds (by 
35±14% on the control). 
 
The functional osteoinductive capacity of Type-I collagen coated PCL (Mn 42,500) 
scaffolds loaded with rhBMP-7 was assessed using C2C12 cells seeded onto the 
scaffolds, and quantified using qRT-PCR.  The genes of interest were; Type-I 
collagen (Col1), osteopontin (OP), ALP, osteocalcin (OC) and runt related 
transcription factor 2 (Runx2).  The CoatBMP 1.25ScaffPBS scaffolds had an early 
osteoinductive effect on the C2C12 cells, as ALP, OC and Runx2 were elevated 
during the first 2 days only, compared to the control (e.g. by 44±12%, 128±42%, 
60±25% and 46±25% respectively at the 24 hr mark). 
 
The CoatPBSScaffBMP 1.25 scaffolds also had an osteoinductive effect on the cells, 
which was more sustained than that observed for the CoatBMP 1.25ScaffPBS group.  
While OP, ALP and Runx2 were up-regulated in the first 24 hr compared to the 
control (by 38±10%, 208±82% and 72±31% respectively), statistically significant 
up-regulation of the late marker OC was delayed until the 48 hr mark (by 73±49%).  
The effect was found to be sustained until day 7, when OC and Runx2 were both 
statistically significantly up-regulated compared to the control (by 151±91% and 
93±27% respectively). 
 
The CoatBMP 1.25ScaffBMP 1.25 scaffolds were found to combine the early effect of the 
CoatBMP 1.25ScaffPBS scaffolds, with the more sustained effect of the CoatPBSScaffBMP 
1.25 scaffolds.  ALP, OC and Runx2 were all up-regulated at the 24 hr mark (by 
312±56%, 329±39% and 96±25% respectively).  This osteoinductive effect was 
sustained until day 7 when Col1, ALP and Runx2 were still up-regulated compared 
to the control (by 174±78%, 72±24% and 178±78% respectively).   
 
These data suggest that the scaffolds containing rhBMP-7 have a weak 
osteoinductive effect on the cells seeded onto them.  The different delivery systems 
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were found to affect the cells differently.  The clinical significance of this was not 
assessed in these studies. 
 
1,25-dihydroxyvitamin D3 (1,25(OH)2D3) was used as a model drug to assess the 
feasibility of releasing lipid-soluble active factors from the scaffolds.  This was 
assessed by quantifying the area of normalised ALP staining of hMSCs.  The release 
of 1,25(OH)2D3 from the loaded collagen scaffold coatings and the encapsulating 
scaffolds significantly increased ALP expression compared to the control scaffold 
groups (by 115±28% and 69±25% respectively).  Furthermore, ALP expression was 
significantly increased when the two delivery systems were used together, when 
compared to either delivery system on its own. 
 
These data suggest that the delivery of lipid-soluble active factors is feasible from 
collagen coated PCL scaffolds, and that the coating and encapsulating delivery 
systems are mutually compatible. 
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Abbreviations 
1,25(OH)2D3    1,25-dihydroxyvitamin D3  
3D     Three dimensional 
+ve     Positive 
–ve     Negative 
αj,x     Area of ALP staining per cell in well j in  
     group x 
aFGF      Acidic FGF 
Ai     Area of ALP staining in field i  
ALK     Activin receptor-like kinase 
ALP      Alkaline phosphatase 
ANOVA    One-way analysis of variance 
APC      Adenomatosis polyposis coli 
bFGF      Basic FGF 
BMPs     Bone morphogenetic proteins 
BRUs      Bone remodelling units 
BSA     Bovine serum albumin 
CoatPBS    Coating with PBS 
CoatBMP 0.63    Coating with low rhBMP-7 dose 
CoatBMP 1.25    Coating with high rhBMP-7 dose 
Coatethanol    Coating with ethanol 
Coat1,25(OH)2D3    Coating with 1,25(OH)2D3 
Ca2+     Calcium ions 
CaCl2     Calcium chloride 
CAD     Computer aided design 
CaHPO4    Dibasic calcium phosphate 
Calcein-AM    Calcein-acetoxymethyl 
CAM     Computer aided manufacture 
Cbfa1     Core binding factor alpha1 
CBP/p300    CREB-binding protein 
cDNA     Complementary deoxyribonucleic acid 
CFU-F     Fibroblastic colony-forming cells 
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CK1α     Casein kinase-1α 
CMB     Concentration of Methylene Blue (µg/ml) 
CMB,A     Apparent concentration of Methylene Blue 
(µg/ml) 
CO2     Carbon dioxide 
Col1     Type 1 Collagen 
CrhBMP-7    Concentration of rhBMP-7 (pg/ml) 
DAB     Diffusivity of A in B (m
2/s) 
DAPI     4’,6-diamino-2-phenylindole 
DBM     Demineralised bone matrix 
DCM     Dichloromethane 
dH2O     Distilled water 
Dlx5     Distal-less homeobox-5 
Dkk     Dickkopf 
DMEM    Dulbecco’s Modified Eagle’s Medium 
DNA     Deoxyribonucleic acid 
Dvl     Dishevelled 
ECM     Extracellular matrix 
ELISA     Enzyme-linked immunosorbent assay 
ERK      Extracellular-signal-regulated kinase 
FAK     Focal adhesion kinase 
FCS     Foetal calf serum 
FDM     Fused deposition modelling 
FGF     Fibroblast growth factor 
FZD     Frizzled 
GAPDH    Glyceraldehyde 3-phosphate dehydrogenase 
GSK-3β     Glycogen synthase kinase-3β 
HA     Hydroxyapatite 
HCl     Hydrochloric acid 
hESCs     Human embryonic stem cells 
Hh     Hedgehog 
HLA     Human leukocyte antigen 
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hOB     Human osteoblast 
hPL     Human platelet lysine 
HBSS     Hanks’ balanced salt solution 
IGF     Insulin-like Growth Factor 
Ihh     Indian hedgehog 
IL-1     Interleukin-1  
IL-6     Interleukin-1 
IMS     Industrial methylated spirit 
iPSCs     Induced pluripotent stem cells 
VJA     Molar flux of A with respect to mean volume  
     velocity (mol/[m2s]) 
JNK      c-Jun N-terminal kinase 
LRP     Low-density lipoprotein receptor-related  
     Protein 
MAP      Mitogen-activated protein 
Msx2     Msh homeobox 2 
Mt/M∞     Fraction of drug released 
Na+     Sodium ions 
NaCl     Sodium chloride 
NaOH     Sodium hydroxide 
NC     Numerical control 
NC,i     Number of calcein positive cells in field i 
Ni     Number of cells in field i  
NP,i     Number of PI positive cells in field i 
MCSF     Macrophage Colony Stimulating Factor 1 
MgCl2     Magnesium Chloride 
MSCs     Marrow stromal cells 
OC     Osteocalcin 
OD     Optical density (-) 
ON     Osteonectin 
OP     Osteopontin 
OPG     Osteoprotegerin 
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Osx     Osterix 
PBS     Phosphate buffered saline 
PBT      Poly(butylene terephthalate) 
PCL     Poly(ε-caprolactone) 
PDGF     Platelet derived growth factor 
PEGT     Poly(ethylene glycol)-terephthalate 
PGA     Poly(glycolic acid) 
PI     Propidium iodide 
PLA     Poly(lactic acid) 
PLGA     Poly(lactide-co-glycolide) 
pNP     Para-nitrophenol 
pNPP     Para-nitrophenylphosphate 
PTH     Parathyroid hormone 
PDGF     Platelet derived growth factor 
qRT-PCR    Quantitative reverse transcription polymerase 
chain reaction 
Ptch1     Patched1 
RGD     Arginine glycine aspartic acid 
RNA     Ribonucleic acid 
Runx2     Runt related transcription factor 2 
ScaffPBS    Scaffold encapsulating PBS 
ScaffBMP 0.63    Scaffold encapsulating low rhBMP-7 dose 
ScaffBMP 1.25    Scaffold encapsulating high rhBMP-7 dose 
Scaffethanol    Scaffolds encapsulating ethanol 
Scaff1,25(OH)2D3    Scaffolds encapsulating 1,25(OH)2D3 
SEM     Standard error of the mean 
Smad     Mothers against decapentaplegic homolog 
Smo     Smoothened 
SOST     Sclerostin 
Sox9     SRY (sex determining region Y)-box 9 
t     Time (hr) 
T0     Time zero 
22 
TC     Treated tissue culture 
TCP     Tricalcium phosphate 
TGF-β     Transforming growth factor-β 
TNF-α     Tumour necrosis factor-α 
TPP     Tripolyphosphate 
USFDA    United States Food and Drug Administration 
VEGF     Vascular endothelial growth factor 
 
Prefixes 
µ     Micro (×10-6) 
G     Giga (×109) 
k     Kilo (×103) 
M     Mega (×106) 
m     Milli (×10-3) 
p     Pico (×10-12) 




bar     Pressure in bar 
°C     Temperature in degrees Celsius 
K     Temperature in degrees Kelvin 
M     Concentration in moles per litre 
m     Length in metres 
mol     Quantity in moles 
Pa     Pressure in Pascals 
% (v/v)    Percent, volume by volume 
















Chapter 1 : General Introduction 
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1.1. Problems in Orthopaedics 
1.1.1. Bone Biology 
1.1.1.1. Introduction 
The skeletal system, which consists of bone and cartilage tissue, is a complex organ 
which fulfils a variety of different functions (Karsenty, 2003).  The primary 
functions of bone are: to support locomotion by providing sites for muscle 
attachment; to protect the vital organs of the body such as the brain, spinal cord, 
heart, lungs, and bone marrow; and to produce cells of the haematopoietic lineage 
(Baron, 1996; Harada and Rodan, 2003).  As a secondary function, bone acts as a 
store for calcium and phosphate ions that participate in serum homeostasis 
(Felsenfeld and Rodriguez, 1999). 
 
Despite its static appearance, bone is a dynamic tissue.  Throughout life, it is 
continually remodelled, both to adapt to mechanical stimuli, and to remove damaged 
areas of matrix resulting from everyday use (Wolff, 1892; Turner, 1992).  The local 
balance between osteoclastic bone resorption, and osteoblastic bone formation is 
subject to a number of controls aimed at maintaining homeostasis (Figure 1.1). 
 
1.1.1.2. Bone Structure 
Calcified bone contains about 25% organic matrix, including cells (2 – 5%), 5% 
water, and 70% hydroxyapatite crystals (Philipson, 1965; Sommerfeldt and Rubin, 
2001).  The organic component of bone is made up of approximately 85 – 90% 
Type-I collagen (Carter et al., 1991; Baron, 1996).  The remainder may be involved 











Figure 1.1: Determinants of skeletal homeostasis and bone mass. 
A schematic representation of the factors affecting bone homeostasis.  Stimulators 
are represented by arrows, whereas inhibitors are shown by blunt arrows.  The 
thickness of the arrow is approximately proportional to the impact of the factor. 
(Adapted from Harada and Rodan, 2003). 
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Anatomically there are two main types of bones: flat bones, such as the skull, 
mandible, and scapula, and long bones such as the femur, tibia, and radius (Dempster 
et al., 2006).  The long bones consist of a shaft (the diaphysis), which gradually 
increases in diameter at either end to form the metaphyses, culminating in the 
epiphyses (Figure 1.2).  At the joints, these are capped with articular cartilage.  
Except for the joints, bones are covered by a membrane: the periosteum.  This 
fibrous tissue contains adult mesenchymal progenitor cells, osteoblasts, fibroblasts, 
blood vessels and sympathetic nerves (Shapiro et al., 1977; Allen et al., 2004). 
 
The long bones are composed of cortical and trabecular (or cancellous) bone (Figure 
1.2).  Cortical bone has a dense structure of irregular branching channels known as 
osteons, which are orientated in the direction of maximal stress (Einhorn, 1996; 
Miller et al., 2002).  Each osteon contains a blood vessel enclosed in a Harversian 
canal, surrounded by concentric lamellae and interstitial bone. 
 
On a macroscopic level, cancellous bone is a honeycomb-like network of 
interconnected trabecular plates and bars, surrounded by bone marrow (Dempster et 
al., 2006).  The trabeculae themselves are also made from osteons, and are arranged 
to resist mechanical loading (Weiner et al., 1999; Sikavitsas et al., 2001).  Due to its 
porous structure, cancellous bone is able to deform and thereby distribute mechanical 













Figure 1.2: Schematic of bone anatomy. 
A schematic diagram of bone anatomy.  The macroscopic anatomy of a human femur 
is shown, along with the microstructure of both cortical and cancellous bone 
(Adapted from: Liebschner and Wettergreen, 2003) 
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1.1.1.3. Bone Modelling 
Modelling is the process by which bones are either shaped or re-shaped.  It occurs 
when bone formation by osteoblasts is out of balance with bone resorption by 
osteoclasts.  Although the majority of modelling occurs during growth, it can also 
occur in normal adult bone, primarily as a result of mechanical loading (Pead et al., 
1988; Burr et al., 1989; Dempster et al., 2006). 
 
There are two forms of bone formation, the first being intramembranous ossification 
(Ogden et al., 1975).  This happens when marrow stromal cells (MSCs) differentiate 
into osteoblasts (Brighton and Hunt, 1991).  These osteoblasts deposit collagen fibres 
in a disorganised fashion.  The matrix quickly mineralises to form woven bone, 
which is eventually remodelled into mature lamellar bone (Hawke and Jahn, 1975; 
Bernard, 1969; Baron, 1996; Sikavitsas et al., 2001).  Growth of the flat bones, and 
increases in girth of the long bones occurs by intramembranous ossification. 
 
The second type of modelling is endochondral ossification (Ogden et al., 1975).  In 
this case, MSCs differentiate into chondroblasts, which secrete cartilaginous matrix 
(Brighton and Hunt, 1986b).  In the growth plate, the chondroblasts become encased 
in their own matrix, becoming chondrocytes.  As the proliferation zone progresses 
on, the chondrocytes become larger and the matrix calcifies.  After chondrocyte 
apoptosis, this matrix is first remodelled into woven bone, before being further 
remodelled to lamellar bone (Brighton et al., 1973; Baron, 1996; Weiner and 
Wagner, 1998; Carter et al., 1996).  Endochondral ossification is responsible for the 
longitudinal growth of the long bones. 
1.1.1.4. Bone Remodelling 
“The stability and immutability of dry bones and their persistence for centuries, and 
even millions of years after the soft tissues have turned to dust, give us a false 
impression of bone during life.  Its fixity after death is in sharp contrast to its 
ceaseless activity during life.” (Cooke, 1955). 
 
The ceaseless activity referred to by Cooke (1955), is bone remodelling (Dempster et 
al., 2006).  In healthy bone, this process involves the two major cell lineages in bone, 
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osteoclasts and osteoblasts, working in balance in groups of cells termed bone 
remodelling units (BRUs) (Frost, 1969).  The function of the BRUs is to replace old 
or damaged bone with new bone.   
 
Exactly what initiates the remodelling cycle is unclear, though it is possible that 
signalling caused by osteocyte apoptosis, in response to microcrack formation, may 
fulfil this role (Noble et al., 2003; Verborgt et al., 2000).  Mononucleated osteoclast 
precursors then bind to the bone surface, and fuse to form multinucleated osteoclasts 
(Baron et al., 1986; Kurihara et al., 1990).  The osteoclasts then digest both the 
mineral and organic bone matrix before undergoing apoptosis (Hughes et al., 1995; 
Hill, 1998). 
 
Afterwards, osteoblast precursors populate the cavities formed by the osteoclasts.  
This process is tightly coupled to bone resorption, though the exact stimulus is 
currently unknown (Andersen et al., 2008).  The osteoblasts then secrete collagenous 
matrix, which they then mineralise, in part, by releasing matrix vesicles (Bianco et 
al., 1993, Zaidi, 2007).  After matrix formation, the majority of osteoblasts die by 
apoptosis.  The remainder either become embedded in their own matrix, becoming 
osteocytes, or stay on the surface, becoming bone-lining cells (Hill, 1998). 
1.1.1.5. Bone cells 
Osteoclasts form from haematopoietic precursors from either the bone marrow or 
peripheral blood (Husheem et al., 2005; Vaananen and Laitala-Leinonen, 2008).  
Their function has previously been discussed in §1.1.1.4.  Osteoclast formation, 
activation and activity are governed by local factors such as RANKL/osteoprotegerin 
(OPG), interleukins -1 and -6 (IL-1 and IL-6), and Macrophage Colony Stimulating 
Factor 1 (MCSF), as well as the systemic hormones such as 1,25-dihydroxyvitamin 
D3 (1,25(OH)2D3) (Udagawa et al., 1990; Yasuda et al., 1998; Lacey et al., 1998; 
Boyle et al., 2003). 
 
Osteoblasts are of mesenchymal origin (see Figure 1.3), and were thought to derive 
exclusively from MSCs (Castro-Malaspina et al., 1980; Friedenstein et al., 1987; 
Aubin et al., 1995; Ducy et al., 2000).  However, in recent years, this has been 
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complicated by the discovery of marked phenotypic plasticity in the stromal system 
(Bianco and Robey, 2000).  In vitro, adipocytes or chondrocytes may regress, 
enabling them to differentiate towards osteoblasts (Song and Tuan, 2004).  MSCs 
play a prominent role in bone modelling, remodelling and fracture healing, as 
discussed in §1.1.1.3, §1.1.1.4, and §1.1.2 respectively. 
 
Osteoblast formation and function are influenced by systemic hormones, such as 
parathyroid hormone (PTH), oestrogens, glucocorticoids, and 1,25(OH)2D3 
(Krishnan et al., 2003; McCarthy et al., 2003; Zhou et al., 2006; Smith and Frenkel, 
2005; Bouillon et al., 2008; Marie, 2008), as well as local signals, including; bone 
morphogenetic proteins (BMPs), transforming growth factor-β (TGF-β), and platelet 
derived growth factor (PDGF) (Chen et al., 1991; Ryoo et al., 2006; Cheng et al., 
2003a; Kells et al., 1995; Chandrasekhar and Harvey, 1996; Fiedler et al., 2002) (see 
Figure 1.3).  The primary function of osteoblasts is to secrete new bone matrix.  In 
so doing, they express such genes as; Type-I collagen, alkaline phosphatase (ALP), 
osteopontin, and osteocalcin (Liu et al., 1994).  Collagen expression is an early event 
in osteoblastic differentiation, occurring after proliferation of pre-osteoblasts.  This is 
followed by ALP expression, which reaches its maximum before mineralisation 
(Yoon et al., 1987; Zaidi, 2007) (see Figure 1.3). 
 
After forming new bone matrix, some osteoblasts remain behind on the bone surface, 
becoming bone-lining cells.  Under conditions of increased mechanical stimulation, 
there is some evidence that they can revert back to osteoblasts (Chow et al., 1998).  
They may create specialised compartments on cancellous bone in which remodelling 
can be initiated (Hauge et al., 2001). 
 
Osteocytes, by far the most numerous cell Type-In bone, are the non-proliferative, 
terminally differentiated endpoint of the osteoblast lineage (Noble, 2008).  During 
modelling or remodelling, between 10 – 20% of osteoblasts become entombed in 
their own matrix to become osteocytes (Aubin and Turksen, 1996).  Their exact 
function has not been well defined, but it is possible that these cells play a role in the 
sensing of microcracks, and the initiation of remodelling (see §1.1.1.4). 
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Figure 1.3: The Osteoblast Lineage. 
Cartoon of growth and differentiation of osteoblast lineage cells.  A) Various marker 
genes are up-regulated (shown in green) by runt related transcription factor 2 
(Runx2).  B) Progression through the osteoblast lineage from multipotent MSCs to 
mature osteocytes is regulated by physiological signals.  (Adapted from Stein et al., 
2004). 
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1.1.2. Fracture Healing 
Unlike many other tissues in the adult body that heal with the formation of poorly 
organised scar tissue, bone fracture healing can largely restore the properties of the 
original bone (Einhorn, 1998).  Although the macroscopic processes of fracture 
healing are well understood, particularly in the murine model, less is known about 
the regulation of these events (Reed et al., 2002). 
 
Histologically, fracture healing is divided into primary (or direct) healing and 
secondary (or indirect) healing.  Primary healing occurs when BRUs remodel bone 
across the fracture site, thus re-establishing cortical continuity.  This form of healing 
is comparatively rare, as it requires rigid internal fixation (Phillips, 2005).  
Secondary healing is much more common, and is a coordinated response of the bone 
marrow, the cortex, the periosteum, and the adjacent soft tissue.  In contrast to 
primary healing, it is stimulated by micromotion of the fracture (McKibbin, 1978). 
1.1.2.1. Secondary Healing 
The first stage in secondary healing is the formation of a haematoma, caused by the 
bleeding from the medullary cavity and periosteum, as well as from tearing of the 
adjacent soft tissue (Wraighte and Scammell, 2006).  The haematoma itself releases 
signalling molecules which may initiate cellular cascades crucial to fracture healing.  
These include IL-1, IL-6, TGF-β, and PDGF (Bolander, 1992; Einhorn et al., 1995).  
A fibrin mesh forms within the haematoma, as the latter is replaced by granulation 
tissue. 
 
In secondary healing, new bone forms by both endochondral and intramembranous 
ossification.  MSCs from the marrow, trapped in the haematoma, and from the 
periosteum adjacent to the fracture site, differentiate to chondrocytes and form 
cartilage (Bielby et al., 2007).  This is termed the soft or cartilaginous callus.  The 
soft callus stabilises the fracture fragments, and provides early bridging across the 
fracture.  In a similar process to that which occurs in growth plates, chondrocytes 
stop proliferating and become hypertrophic.  They also participate in calcifying their 
matrix (Brighton and Hunt, 1986a).  Once the cartilage is calcified, the chondrocytes 
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undergo apoptosis, and the soft callus becomes a target for the ingrowth of blood 
vessels (Carano and Filvaroff, 2003). 
 
MSCs, chiefly from the periosteum a few millimetres from the fracture site, also 
differentiate to osteoblasts and form woven bone directly by intramembranous 
ossification (Nikolaou and Tsiridis, 2007).  This is termed the hard callus. 
 
Bony union is restored across the fracture as the soft callus is remodelled to woven 
bone.  It undergoes further remodelling to form mechanically competent lamellar 
bone, largely restoring the properties of the original tissue (Einhorn, 1998). 
 
Locally acting signalling molecules as well as systemic agents are thought to play a 
major role in the coordination of the fracture healing process (Nikolaou and Tsiridis, 
2007).  These can be further classified into; pro-inflammatory cytokines, growth 
factors, and hormones. 
1.1.2.2. Pro-Inflammatory Cytokines 
Pro-inflammatory cytokines IL-1, IL-6, and tumour necrosis factor-α (TNF-α) are 
signals thought to be secreted by macrophages and other inflammatory cells (Kon et 
al., 2001).  In murine models, they are known to be up-regulated during the first 
three days of fracture healing, and during the bone remodelling phase (Prisell et al., 
1993).  In the early stages of fracture healing, they are thought to be chemotactic for 
inflammatory cells, to encourage extracellular matrix production, and to stimulate 
angiogenesis (Nikolaou and Tsiridis, 2007). 
1.1.2.3. Bone Morphogenetic Proteins 
The existence of BMPs was first hypothesised in 1965 by Urist (1965).  Since then, 
at least 14 isoforms have been identified.  Of these, BMP-2, -4, -6, and -7 are thought 
to be the most important in bone (Westerhuis et al., 2005).  They are pleiotropic 
morphogens, and are members of the TGF-β superfamily.  They are produced by 
MSCs, osteoblasts and chondrocytes, and play a crucial role in the regulation of 
growth, differentiation and apoptosis for various cell types, including MSCs, 
osteoblasts and chondroblasts (Sakou, 1998; Kloen et al., 2003). 
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BMPs have a variety of functions.  In animal knockout models, BMP-2 deficient 
mice were found to be non-viable due to developmental cardiac defects (Zhang and 
Bradley, 1996).  BMP-7 knockout mice died shortly after birth because of kidney 
abnormalities.  Development of the eyes was also affected, as well as skeletal 
patterning (Luo et al., 1995).  However, in the adult body, the primary function of 
BMPs appears to be in bone and cartilage formation (Kang et al., 2004; Bessa et al., 
2008).  Indeed, in vitro they are known to stimulate both osteogenic and 
chondrogenic differentiation of MSCs (Knippenberg et al., 2006; Edgar et al., 2007) 
 
The BMPs do, however, have different roles and different temporal expression 
patterns during fracture healing.  For example, in murine models BMP-2 is expressed 
throughout the first 21 days of fracture healing, while BMP-7 is up-regulated from 
days 14 – 21 (Cho et al., 2002).  They may also act at different points as MSCs 
differentiate to osteoprogenitors, osteoblasts, and finally osteocytes (Cheng et al., 
2003a). 
 
Both BMP-2 and BMP-7 are members of the TGF-β superfamily and have signalling 
pathways according to the general TGF-β signalling pathway for MSCs (see Figure 
1.4).  Once the BMPs bind to BMP receptors types I (BMPR-IA and BMPR-IB) and 
II (BMPR-II), BMP-7 is thought to phosphorylate the receptor-regulated mothers 
against decapentaplegic homologs (Smads)-1 and -5, whereas BMP-2 also 
phosphorylates Smad-8 (Aoki et al., 2001).  This process is thought to be inhibited 
by Smad-6 and Smad-7 (Itoh et al., 2001a).  The activated Smads then bind to Smad-
4 (Shen et al., 2002).  The resulting complex translocates to the nucleus, where it 
influences the expression of target genes including Dlx5, which in turn induces the 
expression of runt related transcription factor 2 (Runx2) (Miyama et al., 1999; Lee et 







Figure 1.4: TGF-β Superfamily Signalling Pathway. 
Ligand binding-induced heteromerisation of Type-II and Type-I receptors leads to 
Type-I receptor phosphorylation by the Type-II receptor followed by R-Smad 
phosphorylation by Type-I receptors. A complex is formed of phosphorylated R-
Smad with the Co-Smad, and this complex translocates to the nucleus where it 
regulates transcription. The components of extracellular binding proteins, Type-I 
receptors, Type-II receptors, and Smad proteins are indicated.  (From Roelen and 
Dijke (2003)). 
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Recombinant human BMPs (rhBMPs) are now used clinically for fracture healing.  
This is discussed in §1.1.6.6. 
1.1.2.4. Transforming Growth Factor-β 
The five TGF-β isoforms form a subset of the larger TGF-β superfamily.  They are 
thought to be released by platelets after the clot forms at the time of fracture (Robey 
et al., 1987).  Although the TGF-βs are known to inhibit the activity of the 
osteogenic transcription factor Runx2 in vitro (Kang et al., 2005), they are also 
known to stimulate formation of new bone in vivo (Sumner et al., 1995; Baylink et 
al., 1993).   
 
This apparent paradox may be explained as the TGF-βs are thought to have a potent 
chemotactic effect on MSCs, and to stimulate MSC, chondrocyte and osteoblast 
proliferation (Lieberman et al., 2002).  Hence the pool of cells available for 
endochondral and intramembranous ossification is increased.  TGF-βs may also 
enhance bone formation in indirect ways, such as stimulating the synthesis of BMPs 
(Bostrom, 1998) and inhibiting RANKL production by osteoblasts and thereby 
decreasing bone removal (Fox and Lovibond, 2005). 
 
In terms of differentiation, it is thought that TGF-β1 may be involved in 
chondrogenesis and early osteogenesis (Lieberman et al., 2002).  TGF-β3 has been 
found to stimulate chondrogenesis (Jin et al., 2006; Miyanishi et al., 2006; Tang et 
al., 2009) in mesenchymal cells.  TGF-β2 and TGF-β3 may be primarily involved in 
chondrogenesis, though they may also play a role in endochondral ossification 
(Thorp et al., 1992). 
 
In endothelial cells, both TGF-β1 and -β3 bind to activin receptor-like kinase (ALK) 
-1 and ALK5 (which act as Type-I receptors) and TβR–II to activate Smad-1 and -5 
for ALK1, and Smad-2 and -3 for ALK5 (Goumans et al., 2002; Pen et al., 2008).  
These form a complex with Smad-4, which translocates to the nucleus and affects the 
expression of target genes.  It is thought that the Smad-1/5 pathway (which is only 
activated by TGF-βs in endothelial cells) stimulates endothelial cell migration and 
proliferation, whereas the Smad-2/3 pathway induces angiogenesis.  Particularly with 
37 
TGF-β1, this is thought to occur in a dose-dependant manner, with low doses 
activating the Smad-1/5 pathway whereas higher doses stimulate the Smad-2/3 
pathway (Goumans et al., 2002). 
 
For MSCs the TGF-βs follow the general TGF-β Superfamily signalling pathway 
(see Figure 1.4).  TGF-βs 1, 2 and 3 bind to the receptors TβR-I and TβR -II, which 
leads to the activation of Smad-2 and -3.  Again, these form a complex with Smad-4, 
which translocates to the nucleus and affects the expression of target genes.  In cells 
of the osteoblast lineage, Smad-3 appears to inhibit osteogenic differentiation by 
physically interacting with Runx2, and inhibiting its function (Alliston et al., 2001).  
Additionally, Smad-3 forms a complex with SRY (sex determining region Y)-box 9 
(Sox9) and CREB-binding protein (CBP/p300) to activate genes for chondrogenesis 
(Furumatsu et al., 2005; Furumatsu et al., 2009).  Smad -3 is also thought to be 
important for the maintenance of articular cartilage by preventing chondrocytes from 
undergoing terminal hypertrophic differentiation (Yang et al., 2001).  Hence TGF-βs 
are thought to be important in early chondrogenic differentiation (Song et al., 2009). 
1.1.2.5. Other Growth Factors in Fracture Healing 
PDGF is thought to be released by degranulating platelets, macrophages, and 
monocytes during the early stages of the fracture healing process (Andrew et al., 
1995).  In vitro studies have indicated that it is mitogenic for osteoblasts, however its 
role in fracture healing has yet to be clearly defined (Canalis et al., 1989; Lieberman 
et al., 2002).  Recent studies have found that PDGF-AA can be release by hMSCs 
(Salazar et al., 2009), potentially this may have an effect on their ability to stimulate 
bone formation in vivo. 
 
Fibroblast growth factor (FGF) is also involved in fracture healing.  In the FGF 
family, there are at least nine structurally related proteins, the most abundant in 
normal adult tissue being FGF-1 and -2 (Lieberman et al., 2002).  These are also 
called acidic FGF (aFGF) and basic FGF (bFGF), respectively.  Both proteins are 
released early in fracture healing, and are associated with angiogenesis as well as 
chondrocyte and osteoblast activation (Radomsky et al., 1998).  FGF signalling is 
discussed in §1.1.3.5. 
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The insulin-like growth factor (IGF) family has two members, namely IGF-I and -II.  
In vitro, IGF-I is known to stimulate osteoblast activity and chemotaxis (Panagakos, 
1993).  IGF-I has also been found to induce proliferation and chondrogenic 
differentiation in MSCs (Longobardi et al., 2006).  During fracture healing, IGF-II is 
known to play a role in endochondral ossification by stimulating Type-I collagen 
production, cartilage matrix synthesis, and chondrocyte proliferation (Prisell et al., 
1993; Nikolaou and Tsiridis, 2007). 
 
IGF-I in particular has been examined as a potential therapeutic agent for fracture 
healing.  However, studies using animal fracture models have yielded inconsistent 
results, and more work needs to be done to reveal its true therapeutic potential 
(Carpenter et al., 1992; Aspenberg et al., 1989; Bak et al., 1990; Thaller et al., 
1993). 
 
Vascular endothelial growth factor (VEGF) was first discovered on 1989, and since 
then has been described as playing a cornerstone role in the angiogenesis component 
of fracture healing (Keramaris et al., 2008).  Indeed the potent angiogenic activity of 
human fracture haematoma is thought to be predominantly due to VEGF (Street et 
al., 2000), and it may be involved in the tight coupling of angiogenesis and 
osteogenesis during bone repair (Peng et al., 2002).  VEGF production is known to 
be stimulated by other growth factors, such as FGF-2 and BMP-2, and may mediate 
their angiogenic action (Claffey et al., 2001; Deckers et al., 2002).  Interestingly, 
recent studies have found that hMSCs have the ability to secrete VEGF.  This may 
enhance their ability to repair tissue in vivo (Zisa et al., 2009), although the precise 
mechanism for this is currently unknown (Wang et al., 2009c). 
1.1.3. Signal Cascades 
Sections §1.1.3.1 – §1.1.3.5 below, outline simplified summaries of the current 
knowledge of some of the signal cascades thought to be important in bone biology.  
However, it should be noted that, although the protein interactions are becoming 
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clearer, in this emerging field, it is possible that some of the conclusions in the 
literature may have been premature. 
1.1.3.1. Smad-Dependent Pathways 
As discussed in §1.1.2.3 BMPs -2 and -7 are thought to stimulate the expression of 
distal-less homeobox-5 (Dlx5) (Lee et al., 2003b; Holleville et al., 2007).  This 
transcription factor has been found to increase osteocalcin expression and 
mineralisation (Miyama et al., 1999; Tadic et al., 2002).  Dlx5 is thought to stimulate 
Runx2 and Osterix (Lee et al., 2003b; Lee et al., 2003c). 
 
The transcription factor Runx2 is thought to act as a “master switch” during the 
commitment of mesenchymal stem cells to the osteoblastic lineage (Ducy et al., 
1997).  As discussed below in §7.3, Runx2 binding sites have been found in the 
promoter region of many genes associated with osteogenesis, including osteocalcin 
(Ducy and Karsenty, 1995; Ducy et al., 1997), Type-I collagen (Kern et al., 2001) 
and osteopontin (Ducy et al., 1997). 
 
More recently, the transcription factor Osterix (Osx) has been identified as being 
necessary for bone formation, and is thought to act down-stream of Runx2 
(Nakashima et al., 2002), however Osx expression may not be entirely dependant on 
Runx2 (Matsubara et al., 2008) (see Figure 1.5).  Osx has been found to have an 
inhibitory effect on the Wnt signalling pathway, thereby inhibiting osteoblast 
proliferation and stimulating differentiation (Zhang et al., 2008).  Although it should 
be noted that Wnt signalling may have a positive role in the commitment of 
osteochondroprogenitors to the osteoblastic lineage (Day et al., 2005; Hill et al., 
2005) (see §1.1.3.3).  It is possible that Osx interacts with Runx2 to activate 
osteoblastic markers, as Osx-null mouse embryos, which express near wild-type 
levels of Runx2, have been found to lack expression of Type 1 collagen and 
osteocalcin (Nakashima et al., 2002).  It has also been hypothesised that Osx mainly 




In addition to the Smad pathways leading to chondrogenesis for TGF-βs described in 
§1.1.2.4, Msh homeobox 2 (Msx2) is thought to be a target for TGF-β signalling 
(Hosokawa et al., 2007) (see Figure 1.5).  Some studies have also found that BMP-2 
treatment also results in elevated levels of Msx2 in human osteoprogenitors (Osyczka 
et al., 2004).  While Msx2 is known to be important in osteogenesis and skeletal 
development (Satokata et al., 2000; Wilkie et al., 2000), the method of action is 
currently unclear.  Some studies have suggested Msx2 has a pro-proliferative effect 
on osteoprogenitors and suppresses their differentiation (Dodig et al., 1999; Kim et 
al., 2004).  It has been hypothesised that this effect could be due to antagonism of 
Dlx5 (Ryoo et al., 2006).  However, other studies have suggested Msx2 has a 
positive effect on osteoprogenitor differentiation, independent of Runx2, potentially 
acting through Osx (Cheng et al., 2003b; Ichida et al., 2004; Matsubara et al., 2008) 
(see Figure 1.5). 
 
As yet, the Smad-dependant pathways are not fully understood.  Although the protein 
interactions are becoming clearer, further work may be needed to elucidate these 









Figure 1.5: Smad Pathways. 
A cartoon showing a working model of the molecular switches involved in Smad-
dependent BMP-induced osteoblastic differentiation.  The dashed lines indicate 
possible effects that are yet to be fully substantiated (adapted from Ryoo et al. 
(2006)). 
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1.1.3.2. MAP Kinase Pathway 
Although the Smad-dependent signalling pathways are thought to be the major 
signalling pathways involved in BMP-induced osteogenesis, Smad- independent 
pathways are also thought to be important.  During osteoblastic differentiation, BMP-
2 has been found to activate the mitogen-activated protein (MAP) kinases; 
extracellular-signal-regulated kinase (ERK), c-Jun N-terminal kinase (JNK), and P38 
(Guicheux et al., 2003;  Lai and Cheng, 2002; Ulsamer et al., 2008) (see Figure 1.6).  
In the case of P38 and JNK, this may be through PKD (see Figure 1.6).  In turn, 
Dlx5 is activated via these MAP kinases, leading to osteoblastic differentiation 
through Runx2 and Osx as described in §1.1.3.1.  However, it should be noted ERK 
has also been found to mediate FGF-2 and TGF-β stimulated proliferation in human 
osteoblastic cells (Lai et al., 2001). 
 
Interestingly, the MAP Kinase pathway may be one of the most important pathways 
involved in mechanosensing by osteoblasts (Kapur et al., 2003).  Bone is known to 
respond to increased mechanical loading by increasing bone formation, and 
suppressing resorption (Hillam and Skerry, 1995).  The converse is also thought to be 
true (Bikle and Halloran, 1999). 
 
Integrins have been suggested as candidates for mediating mechanical strain and 
ERK activation (Schmidt et al., 1998; Zhang et al., 2003a).  One potential model of 
the mechanism of osteoblast mechanosensing involves the activation of focal 
adhesion kinase (FAK) by the stimulation of integrins (Hanks et al., 1992), although 
this activation may not act directly (Gao et al., 1997).  The activation of FAK is 
thought to lead to the binding of Src family kinases (Calalb et al., 1995).  Together 
with Grd2, FAK-Src is thought to lead to the activation of ERK2 (Schlaepfer et al., 
1994; Boutahar et al., 2004), which in turn, may enhance osteoblast proliferation and 
differentiation (Lai et al., 2001).  It should be noted however, that even if correct, 
this is unlikely to be the only pathway connected to mechanosensing in osteoblasts 
 
43 
As yet, the MAP Kinase pathway is not fully understood.  Although the protein 
interactions are becoming clearer, further work may need to be undertaken before 










Figure 1.6: MAP Kinase Pathway. 
A cartoon showing a working model of the molecular switches involved in MAP 
Kinase BMP-induced osteoblastic differentiation. 
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1.1.3.3. Canonical Wnt Signalling 
Wnts are a family of secreted glycoproteins.  Although Wnt signalling is involved in 
many different aspects of cell biology, canonical Wnt signalling is thought to be 
particularly important in bone (Day et al., 2005; ). 
 
Canonical Wnt signalling begins with the binding of Wnt to cell surface receptor 
complexes consisting of frizzled (FZD) and low-density lipoprotein receptor-related 
protein (LRP)5 or LRP6 (Bhanot et al., 1996; Yang-Snyder et al., 1996; Wehrli et 
al., 2000) (see Figure 1.7).  A signal is then thought to be generated through 
dishevelled (Dvl) (Hay et al., 2005), which is thought to disrupt a protein complex 
which may contain, amongst others, glycogen synthase kinase-3β (GSK-3β), casein 
kinase-1α (CK1α), adenomatosis polyposis coli (APC) and Axin (Behrens et al., 
1998; Itoh et al., 1998; Hamada et al., 1999).  There is also evidence that Axin can 
bind to LRP5/6 in a Wnt dependant manner, facilitating the disruption of the 
complex (Mao et al., 2001; Tolwinski et al., 2003; Tamai et al., 2004). 
 
Consequently, GSK-3β no longer phosphorylates β-catenin.  This is thought to 
stabilise it, leading to its accumulation (Salic et al., 2000) (see Figure 1.7).  β-
catenin translocates to the nucleus, where it is thought to interact with, amongst 
others, TCF (Tolwinski and Wieschaus, 2004).  β-catenin is thought to displace 
Groucho, which may convert TCF into a transcription factor (Daniels and Weis, 
2005), which then activates or represses a considerable number of target genes, a list 
of which may be found at (http://www.stanford.edu/~rnusse/pathways/targets.html). 
 
Members of sclerostin (SOST) and Dickkopf (Dkk) are thought to inhibit the 
canonical Wnt signalling pathway by binding LRP5/6 (Semenov et al., 2005; Mao et 
al., 2002).  Mutations to the Dkk1 gene have been found to increase the proliferation 
of osteoblastic cells in mice (Morvan et al., 2006).  Furthermore, overexpression of 
Dkk1 appears to decrease the number of osteoblasts (Li et al., 2006b).  Studies such 
as these have led to the hypothesis that Wnt signalling has a positive effect on the 
proliferation of osteoblast progenitors (Zhang, 2010).  Wnt signalling may also 
facilitate bone formation by playing a role in the commitment of 
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osteochondroprogenitors to the osteoblastic lineage (Day et al., 2005; Hill et al., 
2005), and by inhibiting osteoclast formation (Glass et al., 2005).   
 
It should be noted that the full complexity of canonical Wnt signalling is not fully 
understood.  It is therefore, likely that Wnt has further effects in bone outwith those 









Figure 1.7: Canonical Wnt Signalling Pathway. 
A cartoon showing a simplified model of the canonical Wnt signalling pathway, 
showing two states: in the absence and presence of Wnt (from Eisenmann (2005)). 
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1.1.3.4. Hedgehog Signalling 
Two multipass transmembrane proteins, Smoothened (Smo) and Patched1 (Ptch1) 
are thought to be involved in hedgehog (Hh) signalling (Marigo et al., 1996; Stone et 
al., 1996; Taipale et al., 2002).  Ptch1 is thought to act as an inhibitor of Smo, 
however Hh is able to bind to Ptch which remove the inhibition of Smo (Taipale et 
al., 2002) (see Figure 1.8).  Once activated, Smo is thought to increase the 
transcription of Ptch1 (Goodrich et al., 1996), Gli1 (Bai et al., 2002) and Hip1 
(Chuang and McMahon, 1999). 
 
There is evidence that the Hh signalling pathway is important in bone.  For example, 
mice lacking Indian hedgehog (Ihh), show an absence of expression of the 
transcription factor Runx2 (Razzaque et al., 2005).  Other studies have indicated that 
Hh signalling plays a role in osteogenic differentiation, particularly in the early 
stages, potentially through, and upstream, of Wnt signalling (Hu et al., 2005).  Ihh 
signalling may also be necessary for endochondral bone formation (St-Jacques et al., 
1999). 
 










Figure 1.8: Hedgehog Signalling Pathway. 
A cartoon showing a simplified model of the hedgehog signalling pathway (from 
Day and Yang (2008)). 
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1.1.3.5. FGF Signalling 
FGFs are thought to influence intramembranous ossification, by acting through their 
receptors (Fgfr1 – Fgfr4) to activate ERK and p38 in osteoblasts (Hurley et al., 1996; 
Chaudhary and Avioli, 1997; Kozawa et al., 1999; Tokuda et al., 2000; Xiao et al., 
2002) and this in turn influences osteogenesis through the MAP kinase pathway (see 
§1.1.3.2) (see Figure 1.9).  There is also some evidence that FGF signalling 
stimulates expression of Runx2 through PKC (Kim et al., 2003b) (see Figure 1.9).  
However, this effect on cells of the osteoblastic lineage, appears to act in the early 
stages of differentiation, as FGF signalling may inhibit the transition from immature 
to mature osteoblasts (Jacob et al., 2006). 
 
Furthermore, deletion of FGF-2 has also been found to lead to a loss of trabecular 
bone volume in mice (Montero et al., 2000), while studies investigating mice lacking 
FGF-9 and -18, found delayed ossification during mid-gestation skeletogenesis 
(Colvin et al., 1999; Liu et al., 2002; Ohbayashi et al., 2002). 
 
FGF signalling may also play a role in endochondral ossification.  The receptor Fgfr3 
is expressed in proliferating chondrocytes and Fgfr1 is expressed in prehypertrophic 
and hypertrophic chondrocytes (Peters et al., 1992; Peters et al., 1993; Deng et al., 
1996).  In addition, mice lacking FGF-18 showed decreased endochondral and 
intramembranous ossification (Liu et al., 2002). 
 
As with the other pathways discussed in this section, FGF signalling is not currently 








Figure 1.9: FGF Signalling Pathway. 
A cartoon showing a simplified model of the FGF signalling pathway in cells of the 
osteoblastic lineage (adapted from Huang et al. (2007)). 
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1.1.4. Fracture Non-Union 
The treatment of fracture non-union is a serious challenge in orthopaedic surgery.  
Sufferers often endure multiple operations, prolonged hospitalisation, and years of 
disability and pain, before either union is achieved or the limb is amputated (Phieffer 
and Goulet, 2006).  Although definitions of this condition vary, the United States 
Food and Drug Administration (USFDA) defines it as: a fracture with a minimum 
age of nine months, that has not shown radiographic signs of progression towards 
healing for three consecutive months (USFDA, 1988). 
 
While there are many different classification systems (Weber and Cech, 1976; 
McKee, 2000; Paley et al., 1989), fracture non-unions are traditionally classified as 
being hypertrophic, oligotrophic or atrophic (LaVelle, 1998) (see Figure 1.10).  
They may be further categorised as; stiff or mobile, septic or aseptic, and open or 
closed (Panagiotis, 2005). 
 
Hypertrophic non-unions have a large callus and an adequate blood supply.  
Similarly, oligotrophic and stiff atrophic non-unions have a sufficient blood supply 
although their fracture callus is considerably smaller (Reed et al., 2002; Reed et al., 
2003).  For these types of fracture, the primary cause of non-union is thought to be 
inadequate fixation.  Once properly immobilised, they are thought not to require 
additional biological solutions to achieve union (Phieffer and Goulet, 2006; Olson 
and Hahn, 2006).  
 
In contrast, mobile atrophic non-unions lack a fracture callus, and bone resorption is 
present at the fracture site (Figure 1.10).  In this case, both mechanical and 
biological solutions must be employed to achieve union.  This is because such 
fractures have a deficient biologic healing process (Phieffer and Goulet, 2006).  This 
is usually thought to be caused by deficient blood supply, due to their avascular 
appearance in bone scintigrams (Frölke and Patka, 2007). 
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While much is understood about the process of normal fracture healing, 
comparatively little is known about how these mechanisms are regulated, and still 
less about what causes them to fail (Reed et al., 2002).  There are multiple causes of 
non-union, and a number of risk factors are known to be important (Gaston and 
Simpson, 2007).  Some of the more important risk factors are summarised in Table 
1.1. 
 
The prevalence of fracture non-union of the long bones was estimated by Phieffer 
and Goulet (2006) to be 2.5%.  This result was derived from 22 studies, with a total 
of 5517 fractures which were predominantly closed, low energy fractures of the tibia.  
This figure rises to 13-16% for open fractures (Clancey and Hansen, 1978; Velazco 
et al., 1983).  Dickson et al. (1994) even found that the incidence of non-union was 
as high as 35%, when there was a vascular injury associated with the fracture. 
 
Donaldson et al. (2008) estimated there are approximately 1.0 long bone fractures 
per year per 100 people in England.  Assuming this is true for Scotland, Northern 
Ireland and Wales, this would mean that there are approximately 15,000 long bone 
fracture non-unions in the UK every year.  Furthermore, there are some 150,000 
wrist, vertebral, and hip fractures due to osteoporosis, annually costing the National 
Health Service £17 billion (Dawson and Oreffo, 2008; Jordan and Cooper, 2002). 
 
There is a range of treatment options available to orthopaedic surgeons.  These are 











Figure 1.10: The Weber and Cech classification of fracture non-unions. 
Both biologically active and inactive non-union classifications are illustrated.  (From 
Olson and Hahn, 2006) 
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Table 1.1: Risk factors for fracture non-unions. 
 
Risk Factor References 
Patient Effects  
Malnutrition Phieffer and Goulet, 2006 
Smoking Phieffer and Goulet, 2006 
Old Age Panagiotis, 2005 
Cachexia Panagiotis, 2005 
Medication (anti-inflamatories, 
anticoagulants, and steroids) 
Panagiotis, 2005 
Diabetes Perumal and Roberts, 2007 
Local Effects  
High Energy Fracture Phieffer and Goulet, 2006 
Open Fracture Panagiotis, 2005 
Infection Olson and Hahn, 2006 
Limitation of Blood Supply Phieffer and Goulet, 2006 
Periosteal Stripping Phieffer and Goulet, 2006 
Burns Panagiotis, 2005 
Radiation Panagiotis, 2005 
Insufficient Mechanical Stability Frölke and Patka, 2007 
Poor Bone Contact Perumal and Roberts, 2007 
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1.1.5. Bone Defects 
Bone defects are often classified as a subset of biologically inactive fracture non-
unions (Weber and Cech, 1976) (see Figure 1.10).  However, some authors regard 
them as a separate classification in their own right (Phieffer and Goulet, 2006). 
 
True fracture non-unions result when the normal mechanisms of repair are either 
compromised or absent.  Bone defects commonly occur when large sections of bone 
are removed during tumour excision, or during the surgical debridement after a high 
energy fracture (Paley and Maar, 2000). 
1.1.6. Current Treatments 
1.1.6.1. Stabilisation 
All fracture non-unions require adequate fixation, in terms both of alignment and 
mechanical stability, in order to achieve union.  Indeed, as previously stated, this 
may be the only treatment required in the case of hypertrophic, oligotrophic and stiff 
atrophic non-unions. 
 
Reamed intramedullary nailing is the most common form of fixation for non-unions 
with no history of infection.  The autologous graft created by the reamer appears to 
stimulate bone repair (Phieffer and Goulet, 2006).  It is also more mechanically 
stable then intramedullary nailing without reaming.  Reamed nailing can yield high 
success rates.  For example Claucey et al. (1982) found that out of 48 patients, 46 
achieved union without any further treatment. 
 
External fixation is often used where there is a history of infection, or in the case of 
serious grade-II and -III open fractures.  The Ilizarov technique (a type of external 
fixation) may also be successful in treating non-unions, particularly when other 
methods of stabilisation have failed, or when correct alignment of the fracture is 
difficult to achieve (Phieffer and Goulet, 2006).  This technique is thought to be 
particularly useful in the treatment of bone defects (Paley and Maar, 2000). 
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Although effective stabilisation of the fracture site is a prerequisite for the healing of 
non-unions, additional biological treatments are often necessary.  This is especially 
true for mobile atrophic non-unions and bone defects.  The remainder of this section 
will focus on the most commonly used biological treatments. 
1.1.6.2. Bone Autografts 
Autologous bone grafting remains the ‘Gold Standard’ treatment for the biological 
problems associated with both fracture non-unions and bone defects (Phieffer and 
Goulet, 2006; De Long et al., 2007; Sen and Miclau, 2007).  Of these techniques, 
cancellous bone grafting from the iliac crest into the defect site is the most common.  
Indeed it is the standard to which all biological solutions are usually compared (Sen 
and Miclau, 2007). 
 
Autografting has been found to have a high success rate.  For stabilised atrophic, 
aseptic non-unions of the long bones, clinical studies report the success rate as being 
87 – 100% (Babhulkar et al., 2005; Finkemeier and Chapman, 2002; Goulet et al., 
1997).  For non-unions with a history of infection, the success rate has been reported 
as being 53 – 72% after the first operation, and 95 – 100% after further surgical 
intervention (Cove et al., 1997; Ueng et al., 1999). 
 
Cancellous autografts are thought to be so successful because they are osteogenic, 
osteoinductive and osteoconductive.  Even though the majority of the transplanted 
cells die shortly after implantation by necrosis due to ischemia or apoptosis, many 
survive.  Among the cells most resistant to ischemia are primitive mesenchymal cells 
and the progenitors of endothelial cells.  The ability of these cells to form new 
vascularised bone makes autografts osteogenic (Bauer and Muschler, 2000).  
Autografts also have the ability to attract host MSCs to the defect site and cause them 
to differentiate into osteoblasts.  This is achieved by proteins, such as the BMPs, and 
other chemotaxic factors which are released from the matrix of the graft (Phieffer 
and Goulet, 2006).  This makes them osteoinductive.  Finally, the large surface area 
of cancellous bone grafts provides an ideal structure on which new bone can form.  
Hence, they are also osteoconductive (Goldberg and Stevenson, 1987). 
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Despite the high success rate of the technique, it is not without problems.  The supply 
and quality of donor bone is often limited (Arrington et al., 1996; Hall et al., 1991).  
There is often substantial bone morbidity at the donor site (Ahlmann et al., 2002; 
Younger and Chapman, 1989) sometimes leading to pelvic instability or fracture.  
However, the most common complaint associated with the donor site is pain.  Goulet 
et al. (1997) found that 37.9% of patients reported pain six months postoperatively.  
This dropped to 18.7% two years after surgery.  Rarer, but nonetheless serious, 
complications include; nerve damage (Guha and Poole, 1983), vascular injury 
including pseudoaneurysm of the pelvic vasculature (Goulet et al., 1997), and small 
bowel herniation through the donor defect (Arrington et al., 1996). 
1.1.6.3. Bone Allografts 
Currently the dominant alternative to autografting is the use of allogeneic bone.  This 
is where a patient receives bone tissue from a donor.  It can be used either in large 
structural sections (often called massive bone allografts), or in small cancellous or 
cortico-cancellous chips (Marsh, 2006). 
 
Massive bone allografts are often used to treat bone defects caused by tumour 
excision, where there is insufficient material available for bone autografting.  They 
also have an advantage over autografts, as there is no need to harvest bone from the 
patient.  Hence there is no donor site to suffer from morbidity. 
 
The allogeneic bone is usually lyophilised or deep frozen before implantation 
(Finkemeier, 2002).  Allografts can provide mechanical support, and are 
osteoconductive.  They are, however, only weakly osteoinductive.  They also lack 
the cells of autologous grafts, hence they are not osteogenic.  This is thought to be 
the reason why allograft incorporation is slower than of autografts (Bauer and 
Muschler, 2000). 
 
Allografts of this type, typically have a success rate of approximately 57% after one 
operation, and 72% after two or more (Donati et al., 2005).  Despite this success, 
they are never fully remodelled by the host.  Even five years after surgery, the graft 
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remains distinguishable from the host bone by the grain of the osteons, and the centre 
of the graft remains necrotic and acellular (Enneking and Mindell, 1991). 
 
As stated above, allogeneic bone may be prepared as bone chips.  After 
lyophilisation, they too are osteoconductive and provide some mechanical support in 
compression.  They may be used to pack bone defects or to supplement autografts 
when the supply of autologous bone is limited (Finkemeier, 2002). 
 
As with all transplanted tissue, there is a small risk of disease transmission.  This risk 
is minimised as much as possible by the bone banks that collect the tissue.  Members 
of high risk groups are excluded from becoming donors, as are those who are found 
to have occult disease during autopsy.  The grafts are also screened for HIV, 
bacterial contamination, syphilis, and hepatitis B and C (Buck and Malinin, 1994). 
 
Allografts inevitably provoke an immune response from the host.  Indeed many 
studies in animals have found that optimum graft incorporation is achieved when 
histocompatibility differences are minimised or when the grafts are treated to reduce 
their immunogenicity (Bauer and Muschler, 2000).  For example, the 
immunogenicity of allografts may be reduced by deep-freezing or lyophilisation (Yu 
et al., 2007).  A strong host immune response may lead to the failure of the graft. 
 
Apart from the local effects, sensitisation to an expanded pool of human leukocyte 
antigen (HLA) may result.  Although the production of broadly reactive HLA 
antibodies may not have a significant effect on the graft itself (Ward et al., 2008), 
this may make further transplantation of other tissue more difficult (Lee et al., 
1997a). 
1.1.6.4. Demineralised Bone Matrix 
Demineralised bone matrix (DBM) is now widely commercially available in the form 
of powders, pastes or putties.  It is prepared from allogeneic bone which is first 
crushed or pulverised, before being demineralised in hydrochloric acid, and finally 
washed in sterile water, ethanol and ethyl ester (Finkemeier, 2002).  
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Although it offers no mechanical support, DBM is osteoconductive and 
osteoinductive.  This biological activity has been attributed to growth factors and 
various other proteins which are made available by the demineralisation process 
(Wildemann et al., 2007; Bae et al., 2006).  
 
DBM, especially when used in conjunction with bone marrow aspirate, can be 
successful in the treatment of fracture non-union and bone defects (Tiedeman et al., 
1995; Lindsey et al., 2006).  Although promising, there has been a lack of large scale 
randomised controlled studies examining the treatment’s effectiveness (Finkemeier, 
2002).  DBM also suffers from all the disadvantages of potential disease transmission 
and immunogenicity as bone allografts (see §1.1.6.3). 
1.1.6.5. Ceramics 
Almost all calcium phosphate biomaterials can be classified as polycrystalline 
ceramics.  They are constructs of individual crystals of highly oxidised substances 
that have been fused together at the grain boundaries by a high temperature process 
know as sintering (Jarcho, 1981).  Both hydroxyapatite (HA) [Ca10(PO4)6(OH)2], and 
tricalcium phosphate (TCP) [Ca3(PO4)2] are widely commercially available to 
orthopaedic surgeons as blocks, powders or cements. 
 
In general, they are osteoconductive, and do not appear to produce an immune 
response when implanted (Schildhauer et al., 2000).  While calcium phosphate 
ceramics compare favourably to cortical bone in terms of compressive strength, they 
have poor tensile strength and are very brittle (Jarcho, 1981; Kim et al., 2008).  
Indeed, when implanted, they need to be protected from shear stresses by fixation 
(Bucholz et al., 1987).   
 
Although TCP has been used clinically, there are concerns about its unpredictable 
biodegradation profile.  Moreover, TCP biodegradation within bone defects was 





HA blocks have been successfully used to treat tibial plateau fractures (Bucholz et 
al., 1989), yielding similar functional outcomes to the autograft control group.  
However, its brittleness and slow in vivo resorption rate have caused concern among 
clinicians (De Long et al., 2007).  Consequently, HA is seldom used alone. 
 
More recently, a composite material of HA, TCP and Type-I and III collagen, has 
been developed (Collagraft®, Zimmer), which can be combined with autologous 
bone marrow aspirate.  In a prospective, randomized comparison with autologous 
bone grafting, Chapman et al. (1997) reported that it can be effective in the treatment 
of traumatic bone defects in long bones.  After 24 months, union was achieved in 130 
of 132 patients for the collagen-ceramic grafts, compared to 122 of 126 for the 
autograft treatment group.  No statistically significant difference between the 
treatment groups was found.  Although initially promising, more data need to be 
gathered to assess the true efficacy of this bone graft substitute. 
1.1.6.6. Recombinant Human Bone Morphogenetic Proteins 
As discussed in §1.1.2.3, BMPs are thought to play a crucial part in natural fracture 
healing.  Clinical trials by Govender et al. (2002) and Friedlaender et al. (2001) were 
instrumental in the granting of USFDA approval for the application of rhBMP-2 and 
-7 respectively, for the treatment of delayed and non-union fractures (USFDA, 2004; 
USFDA, 2001).  Both use collagen sponges as delivery systems, and both are now 
used clinically under the names INFUSE® Bone Graft and OP-1™ Implant. 
 
Nevertheless, some aspects of these trials have been questioned (Sen and Miclau, 
2007).  The study by Friedlaender et al. (2001), compared the rhBMP-7 implant 
against bone autografting in the treatment of tibial fracture non-unions.  The authors 
found no difference between the groups, and concluded that the rhBMP-7 implant 
was an effective alternative to autografting.  However, reamed intramedullary nailing 
was used to stabilise all the fractures.  As discussed in §1.1.6.1, this technique 
introduces autologous bone, and possibly BMPs, to the defect site.  It is therefore 
unclear whether it was the surgical procedures or the administered rhBMP-7 that 
contributed most to healing (Sen and Miclau, 2007).  Similar criticisms have been 
made of other clinical trials using rhBMP-7 such as those of Dimitriou et al. (2005). 
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Govender et al. (2002) used both reamed and unreamed nailing in their study.  
Despite admitting that reaming could make a positive difference to the healing of 
delayed union fractures, they still used a significantly higher proportion of reamed 
nailing in the rhBMP-2 groups than the control group. 
 
However, the delivery of rhBMPs and other growth factors may prove to be a 
powerful strategy for augmenting fracture healing (Simpson et al., 2006).  This 
strategy is currently limited by the lack of a satisfactory delivery system (Dawson 
and Oreffo, 2008).  Hence the development of growth factor delivery systems is an 
important area of orthopaedic research. 
1.2. Regenerative Medicine 
1.2.1. Introduction 
The need for alternatives for organ transplantation extends beyond the field of 
orthopaedics.  In the UK, as well as many developed countries, the waiting list for 
kidney, pancreas, heart, lung and liver transplants continues to increase, while the 
number of donor organs available remains relatively static (NHS, 2008) (see Figure 
1.11).   
 
The increasing shortfall between the number of patients requiring transplant, and the 
number of operations performed, has motivated the development of the relatively 
new field: regenerative medicine.  Regenerative medicine has been described as: 
“–an umbrella term given to varied strategies of repairing or replacing damaged or 














Figure 1.11: UK Transplant and waiting list statistics 
The number of deceased donors and transplants in the UK (1st April 1998 – 31st 





Potential regenerative medical solutions have been investigated for most major 
organs in the body, including; small intestine (Gupta et al., 2006), trachea 
(Kobayashi et al., 2006), smooth muscle (Rodriguez et al., 2006), liver and kidney 
(Leclerc et al., 2006), heart valves (Mendelson and Schoen, 2006), and bone (Fisher 
and Reddi, 2003).  Indeed, since bone has the highest potential for regeneration of 
any tissue, bone regenerative medicine is expected to form the vanguard of advances 
in the field (Fisher and Reddi, 2003). 
1.2.2. Strategy and Scaffold Design Criteria 
It has been stated that successful regenerative medical constructs must comprise 
three elements: cells, growth factors, and a scaffold (Lavik and Langer, 2004; Fisher 
and Reddi, 2003; Barron and Pandit, 2003).  This strategy has been termed the 
combined approach (see Figure 1.12). 
 
Although in-growth of host cells into a scaffold following implantation is possible 
(Ellis and Yannas, 1996), in most cases a host or donor derived cell source is 
necessary (Lavik and Langer, 2004).  Several groups have stated that it is critical to 
create the correct chemical environment for the cells, including growth factors 
(Babensee et al., 2000; Elisseeff et al., 2001, Kaigler et al., 2003), particularly in the 
hostile environment of defect sites, where the cells may be further from blood vessels 
than the oxygen diffusion limit of 100 – 200 µm (Carmeliet and Jain, 2000). 
 
Scaffolds are necessary to act as a delivery system for both the cells and growth 
factors.  They are also essential for providing a tailored environment for the cells 
(Langer and Vacanti, 1993; Lavik and Langer, 2004).  Since the scaffolds are 
required to act in a multifunctional capacity, their engineering design criteria are very 
demanding (Lavik and Langer, 2004; Barron and Pandit, 2003; Stock and Vacanti, 
2001), namely:  
 
1) Scaffolds must be biocompatible, including being non-toxic, with non-toxic 
breakdown products. 
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2) Scaffolds must not produce an adverse effect, such as an immune response, or 
induce neoplasia. 
3) Scaffolds should provide the correct three-dimensional (3D) geometry. 
4) Scaffolds should be sufficiently porous such that nutrients can diffuse to the 
cells, and cell waste products can be removed. 
5) Scaffolds should have appropriate surface chemistry to allow cell attachment, 
proliferation and differentiation. 
6) Scaffolds should degrade at a rate comparable to extracellular matrix 
production. 
7) Scaffolds should have the ability to release bioactive growth factors. 
8) Scaffolds should have similar mechanical properties to the surrounding tissue 
to avoid damage to either. 
9) Scaffolds should be manufactured in a simple and cost-effective manner. 
 
During the relatively short life of the field of regenerative medicine, a variety of both 
materials and fabrication methods have been employed to meet as many of the above 
design criteria as possible.  How these materials and methods relate to bone 
regenerative medicine is discussed in §1.2.5 and §1.2.6. 
 
In the combined approach, the choices of the cell source and of the bioactive 
compounds released from the scaffolds, are also very important.  The options 








Figure 1.12: The Combined Approach 
The combined approach in regenerative medicine utilises cells, active factors, and 
scaffolds to form regenerative medicine constructs.  The active factor represented 
here is BMP-7 (BMP-7 voxel rendered image from Griffith et al. (1996)). 
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1.2.3. Cell Sources 
1.2.3.1. Embryonic Stem Cells 
Embryonic stem cells from mice were first isolated in 1981 independently by Martin 
(1981) and Evans and Kaufman (1981).  The dual capacities of mouse embryonic 
stem cells for unlimited in vitro expansion and multilineage differentiation provoked 
interest in establishing similar cell lines of human origin (Smith, 2001).  Human 
embryonic stem cells (hESCs) were first identified in 1998 (Shamblott et al., 1998; 
Thomson et al., 1998). 
 
hESCs could have great potential for bone regenerative medical applications.  They 
have already been shown to be capable of forming neo-tissues, including blood 
vessels which can integrate with the blood vessels of the host (Levenberg et al., 
2002).  Theoretically they could provide an almost unlimited source of cells, in 
marked contrast to either autologous adult stem cells or differentiated cells 
(Levenberg et al., 2003).  hESCs can also undergo osteogenic differentiation in a 
similar way to MSCs (Tremoleda et al., 2008). 
 
However, there are problems in using hESCs clinically.  Apart from ethical 
considerations, it is necessary to ensure that the cells are successfully differentiated 
before implantation.  Failure to do this could result in teratoma formation (Smith, 
2001).  For a therapy based on hESCs to be approved by the USFDA, it would need 
to be demonstrated that the number of partially differentiated or undifferentiated cells 
is below an as yet undefined threshold (Baker, 2008).  However, the USFDA has 
recently approved the use of hESCs in a Geron funded clinical trial to investigate 
their potential in the treatment of spinal cord injury (Pollack, 2009).  Nevertheless 
there are numerous technical challenges to be overcome in the development of this 
technology. 
1.2.3.2. Induced Pluripotent Stem Cells 
Induced pluripotent stem cells (iPSCs) may provide an alternative cell source for 
regenerative medicine in the future.  These cells can be created by retrovirus-
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mediated induction of four transcription factors (Oct3/4, Sox2, c-Myc, and Klf4) of 
adult fibroblasts (Takahashi and Yamanaka, 2006).  These cells have many of the 
properties of embryonic stem cell including proliferative capacity, teratoma 
formation, and the ability to form adult chimaeras (Okita et al., 2007). 
 
Ultimately, iPSCs may prove to be a superior alternative to hESCs.  Since they could 
be formed from patients’ own somatic cells, the ethical problems with hESCs, as 
well as the possibility of immune rejection, could be overcome (Okita et al., 2007).  
However, human iPSCs have only recently been produced (Park et al., 2008), and 
further work needs to be undertaken before this cell source can be used clinically. 
1.2.3.3. Marrow Stromal Cells 
1.2.3.3.1. General Properties 
Cell sources for regenerative medical applications must strike a balance between 
ethical issues, safety and efficacy (Langer and Vacanti, 1993).  For orthopaedic 
regenerative medicine, the cells must have high osteogenic potential, and should be 
easily expanded and maintained in vitro for long periods of time, in order to produce 
a therapeutically relevant number of cells.  Taking these requirements into account, 
hMSCs are thought to be a promising potential solution (Salgado et al., 2006; Ringe 
et al., 2002; Jorgensen et al., 2004a), particularly as they are involved in the process 
of normal fracture healing, as discussed in §1.1.2.1. 
 
Marrow stromal cells have alternatively been termed mesenchymal stem cells and 
mesenchymal stromal cells, all with the acronym MSC.  They are capable of 
differentiating along the mesenchymal (adipocytic, osteoblastic and chondrocytic) 
lineages (Pittenger et al., 1999, Keating, 2006).  To varying degrees, they are also 
capable of neuronal (Sanchez-Ramos et al., 2000), hepatic (Weng et al., 2003), and 
myocytic (Toma et al., 2002) differentiation.   
 
These multipotent cells are commonly isolated from bone marrow (Beresford et al., 
1994), but similar cells can also be isolated from adipose tissue (Zuk et al., 2002), 
and umbilical cord (Sarugaser et al., 2005).  In particular, the osteogenic potential of 
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bone marrow derived hMSCs has been well characterised (Liao et al., 2008).  There 
are, however, a number of concerns regarding their use in clinical therapies. 
1.2.3.3.2. Characterisation 
Research into hMSCs biology has been impaired by the lack of a universally 
acknowledged characterisation protocol.  In part this is due to the lack of a specific 
surface marker (Horwitz et al., 2005).  hMSC characterisation is further complicated 
by the heterogeneous nature of hMSC cultures (Sengers et al., 2010). 
 
Since hMSCs are relatively rare cells in bone marrow, they would need to undergo 
considerable in vitro amplification in order to achieve sufficient numbers.  Some 
studies have demonstrated that a subset of fibroblast colony-forming cells (CFU-F) 
isolated from bone marrow, are capable of generating bone from a single cell when 
transplanted in vivo (Kuznetsov et al., 1997; Muraglia et al., 2000; Sacchetti et al., 
2007).  However, it is thought that their ability to proliferate and differentiate is 
progressively lost over time in vitro (McCulloch et al., 1991; Banfi et al., 2000; 
Gregory et al., 2005).  This may be due to different sub-populations contributing at 
different degrees to the population-level phenotype emerging over time and passage 
(Sengers et al., 2010). 
 
Therefore, for studies aimed at investigating hMSC biology, characterisation of the 
cells is important.  Apart from plastic adherence and the ability to undergo 
osteogenic, chondrogenic and adipogenic differentiation, expression of surface 
markers is also thought to be important. 
 
The surface marker Stro-1 has been found to be associated with CFU-F in human 
bone marrow (Simmons and Torok-Storb, 1991).  Selecting for Stro-1 positive cells 
in bone marrow aspirates has been found to increase the proportion of CFU-F 
isolated, and the proportion of cells able to undergo osteogenic differentiation 
(Gronthos et al., 1994; Howard et al., 2002).  Stro-1 positive cells from bone marrow 
have also been found to be relatively undifferentiated (Stewart et al., 1999).  Stro-1 
has, therefore, been used to characterise MSCs in a number of studies (Wang et al., 
2003; Tuli et al., 2003; Coipeau et al., 2009; Zhang et al., 2009). 
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Another surface marker of interest in MSC characterisation is CD105.  A common 
source of contamination in MSC cultures are cells of haematopoietic origin.  CD105 
is thought to be expressed by MSCs, but not cells of the haematopoietic lineage 
(Haynesworth et al., 1992b), furthermore CD105 expression is thought to disappear 
upon differentiation (Barry et al., 1999; Goussetis et al., 2005).  CD105, also called 
endoglin, is thought to form part of the TGF-β signalling system (Cheifetz et al., 
1992).  It is, however, not specific to MSCs, as it has also been detected in 
endothelial cells (Gougos and Letarte, 1990).  Nevertheless, in conjunction with 
other markers, CD105 has been widely used in characterisation processes for MSCs 
(Keating, 2006; Meinel et al., 2004; Kotobuki et al., 2005; Harting et al., 2008; Liu 
et al., 2008a). 
 
The surface marker CD73 has also been found on MSCs (Barry et al., 2001).  Early 
studies indicated that antibodies for CD73 (SH-3 and SH-4) were specific for MSCs, 
and did not react with other cells present in the bone marrow, including cells of the 
haematopoietic lineage (Haynesworth et al., 1992a).  However, CD73 is thought to 
be expressed by a number of cell types, including lymphocytes (Yamashita et al., 
1998).  CD73 has also been widely used in characterisation processes for MSCs 
(Dominici et al., 2006; Liu et al., 2008a; Harting et al., 2008; Coipeau et al., 2009). 
 
CD90, alternatively called Thy-1, is another surface marker thought to be expressed 
by MSCs, indeed it is one of the surface markers specified by the International 
Society for Cellular Therapy in their definition of MSCs (Dominici et al., 2006).  
CD90 expression has also been found to correlate with the proliferative potential of 
MSCs (Campioni et al., 2008).  The expression of this surface marker is, however, 
not restricted to MSCs, as it is also expressed by hepatic progenitor cells (Masson et 
al., 2006), and neurons in humans (Kemshead et al., 1982).  CD90 has also been 
widely used in characterisation processes for MSCs (Dominici et al., 2006; Harting 
et al., 2008; Liu et al., 2008a; Campioni et al., 2009). 
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The surface marker CD34, also called MY10, is thought to be expressed by 
haematopoietic progenitor cells (Civin et al., 1984; Katz et al., 1985).  HLA-DR is 
also expressed by haematopoietic progenitor cells (Civin et al., 1987), as well as the 
more mature myeloid and erythroid progenitors (Robinson et al., 1981).  CD45, also 
called leukocyte-common antigen is thought to be expressed by B- and T-
lymphocytes (Kincade, 1987; Hathcock et al., 1992; Lefrancois and Goodman, 1987; 
Spickett et al., 1983), and endothelial cells (Forsyth et al., 1993).  It is, therefore, 
generally recognised that MSCs should lack CD34, CD45 and HLA-DR expression 
(Dominici et al., 2006).  These markers have been used in studies characterising 
MSCs to test for the presence of cells of the haematopoietic lineage (Kotobuki et al., 
2005; Campioni et al., 2006; Liu et al., 2008a). 
 
The surface marker CD14 is thought to be expressed on a number of cell types 
including; macrophages, monocytes, polymorphonuclear neutrophils, chondrocytes, 
dendritic cells and B-lymphocytes (Tobias and Ulevitch, 1993; Verhasselt et al., 
1997; Schumann et al., 1994).  CD11b is thought to be expressed on monocytes, 
granulocytes, macrophages and natural killer cells (Coxon et al., 1996; Ding et al., 
1999; Solovjov et al., 2005).  CD79 is thought to be expressed on B-cells (Mason et 
al., 1992).  CD19, also termed B4 antigen, is also thought to be expressed on B-cells 
and dendritic cells (Nadler et al., 1983; Tedder and Isaacs, 1989).  Hence, MSCs are 
thought to lack any of these markers (Dominici et al., 2006), and have been used to 
test for the presence of cells of the haematopoietic lineage (Liu et al., 2008a; Sudres 
et al., 2006; Mansilla et al., 2006). 
 
Recently, the International Society for Cellular Therapy attempted to ameliorate the 
situation by publishing minimum criteria for defining hMSCs (Dominici et al., 
2006); 
1) Plastic-adherent under standard culture conditions. 
2) Express CD105, CD73, and CD90.  Lack CD45, CD34, CD14 or CD 11b, 
CD79 or CD19, and HLA-DR. 
3) Differentiate into osteoblasts, adipocytes and chondroblasts in vitro. 
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It should be noted, however, that MSC characterisation is an evolving field of 
research, and that other markers such as Stro-1, may be included in future attempts to 
define MSCs, whereas other markers may ultimately prove to be less important. 
1.2.3.3.3. Application in Regenerative Medicine 
Outwith the issues associated with hMSC isolation, there are other potential 
problems connected to hMSC expansion in culture.  Currently, hMSCs are routinely 
cultured in media containing foetal calf serum (FCS).  This carries the risks of prion 
and zoonotic transmission, as well as the possibility of activation of the host immune 
system by the introduction of foreign molecules (Lepperdinger et al., 2008). 
 
Alternatives to FCS are currently being tested, including freshly frozen plasma and 
platelets, and human platelet lysate (hPL).  Recent studies comparing hPL to FCS, 
have found that hPL enhances proliferation without changing morphology, 
immunophenotype or differentiation capacity, and does not induce any obvious 
genetic abnormalities (Doucet et al., 2005; Lange et al., 2007).  
 
It is also feared that hMSCs may undergo spontaneous transformation during the 
expansion process.  This concern is mostly based on the rapid accumulation of 
chromosomal abnormalities in cultures of murine MSCs, resulting in sarcoma 
formation when implanted (Miura et al., 2006).  However, this has not been reported 
to be the case for hMSCs (Bernardo et al., 2007).  Although transformation of 
hMSCs is thought to be an exceptional event, the matter is still debated (Lazennec 
and Jorgensen, 2008). 
 
Of all the cell sources currently being considered for bone regenerative medicine, 
hMSCs are possibly the closest to being used therapeutically.  Bone marrow 
aspirates, containing hMSCs, have been used to treat fracture non-unions by injecting 
them at the defect site (Goel et al., 2005; Hernigou et al., 2005).  Indeed, Hernigou et 
al. (2005) found that the efficacy of the treatment was related to the number of 
progenitor cells injected.  hMSCs have also been successfully used in other branches 
of regenerative medicine, including the repair of a human trachea (Macchiarini et al., 
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2008).  They are, therefore, the current cell of choice for bone regenerative medical 
applications. 
 
Direct injection of hMSCs is, however, not the preferred option in bone regenerative 
medicine.  As discussed previously in §1.2.2, cells are thought to perform best when 
supported on scaffolds (Stock and Vacanti, 2001): providing the cells with the 
correct 3D geometry and retaining the cells at the defect site.  Co-delivery with 
bioactive factors is also thought to be desirable to provide the correct chemical 
environment (Babensee et al., 2000).  The various options available in bone 
regenerative medicine in terms of active factors and scaffolds are discussed in §1.2.4 
and §1.2.5 respectively. 
1.2.4. Bioactive Compounds 
1.2.4.1. Growth factors 
As discussed in §1.1.2, growth factors perform important functions during the 
normal processes of fracture healing.  As a consequence, they are thought to have the 
potential to increase greatly the efficacy of regenerative medical constructs. 
 
Due to their importance in normal fracture healing (§1.1.2.3), and their approval for 
use in a clinical setting (§1.1.6.6), rhBMP-7 and particularly rhBMP-2 have been 
used to augment the osteogenic capacity of a large number of potential regenerative 
medical constructs.  When used in animal bone defect models, rhBMP-2 has been 
found to improve bone mineralisation and repair significantly (Chen et al., 2007; 
Schmoekel et al., 2005; Kamakura et al., 2004).  Similar results have been observed 
for rhBMP-7 (Donati et al., 2008; Springer et al., 2005; Makino et al., 2005).  Both 
these growth factors show great potential in bone regenerative medical applications. 
 
The role of the five TGF-β isoforms in normal fracture healing is briefly reviewed 
above (§1.1.2.4).  Although most often used for cartilage regenerative medical 
applications, rhTGF-β1 has been used in preclinical studies and was found to 
promote scaffold bone in-growth (Vehof et al., 2002; Szivek et al., 2005).  While 
ineffective on its own, rhTGF-β3 was found to enhance ectopic bone formation 
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within a scaffold in a rat model, when combined with rhBMP-2 (Simmons et al., 
2004).  In general, it seems that the TGF-β isoforms have potential for bone 
regenerative medicine, especially in combination with other osteoinductive growth 
factors. 
 
The roles of other growth factors, such as FGF and VEGF, in normal fracture healing 
are outlined in §1.1.2.5.  They have also been the subject of preclinical studies. 
 
Of the FGF family, FGF-2 is thought to be particularly potent.  Studies involving the 
delivery of rhFGF-2 to rabbit, beagle dog and baboon fracture models have shown 
increases in callus volume and mineral content, MSC proliferation, and final 
mechanical bone strength (Kato et al., 1998; Nakamura et al., 1998; Radomsky et al., 
1999). 
 
The therapeutic potential of rhVEGF has been examined in animal fracture models.  
Recently it has been found to increase the number of blood vessels at the fracture site 
(Kleinheinz et al., 2005), and to help unite fracture non-union models (Eckardt et al., 
2005). 
 
There are, therefore, several growth factors which are capable of a number of in vivo 
functions.  rhBMP-2 and -7, however, remain the only growth factors licensed by the 
USFDA for use in cases of open fracture and fracture non-union.  The most 
successful regenerative medical constructs are likely to employ a number of different 
active factors working in synergistic combination (Cartmell, 2008). 
1.2.4.2. Other Active Factors 
Recently, in vitro studies have led to a number of non-protein based active factors 
being considered for possible bone regenerative medical applications. 
 
Bisphosphonates, also called diphosphonates, are known to suppress osteoclast 
mediated bone resorption (van Beek et al., 1999).  Hence, their therapeutic potential 
for the treatment of bone diseases has been examined.  Zoledronate has been used to 
stabilise orthopaedic implants in osteoporotic rats (Peter et al., 2006), and has been 
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found to improve bone ingrowth into scaffolds in a canine fracture model (Tanzer et 
al., 2005). 
 
Cathepsin K is the most abundant cysteine protease expressed by osteoblasts, and is 
thought to be necessary for osteoclast bone resorption.  Cathepsin inhibitors are, 
therefore, thought to be promising future drugs for the treatment of a number of bone 
diseases such as osteoporosis (Wang and Bromme, 2005; Stoch and Wagner, 2008).  
The in vivo activity of cathepsin inhibitors released from scaffolds has yet to be 
demonstrated. 
 
1,25-dihydroxyvitamin D3 is known to play a key role in calcium and bone 
homeostasis.  It is also active in muscle tissue, the cardiovascular system, the 
immune system, and may also play a role in cancer suppression (Bouillon et al., 
2008).  In vitro, it is capable of inducing osteoblastic differentiation of hMSCs (Zhou 
et al., 2006).  The osteogenic effects of 1,25(OH)2D3 may be further enhanced by the 
addition of TGF-β (Bosetti et al., 2007; Liu et al., 1999). 
 
Hence, 1,25(OH)2D3 has become a promising active factor for bone regenerative 
medical applications.  Indeed a recent study, used critical-sized intercalated bone 
defects in rabbit femurs, to test scaffolds loaded with 1,25(OH)2D3 (Yoon et al., 
2007).  After 10 weeks, the bony callus had increased more than 80% for the 
1,25(OH)2D3 loaded group, compared to 40% with the scaffold alone. 
 
As discussed above, a number of non-protein based active factors are of interest in 
the field of bone regenerative medicine.  Potentially they could prove to be superior 
to growth factors, both in terms of cost, and their ability to maintain their bioactivity 
in harsher biochemical environments.  They are, however, largely untested in animal 
fracture models. 
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1.2.5. Scaffold Materials 
1.2.5.1. Ceramics 
Ceramics, such as HA and TCP, are a widely used class of biomaterials.  Scaffolds 
made from these materials are commercially available, and are used clinically.  They 
are discussed above in §1.1.6.5. 
 
Hench et al. (1971) were the first to develop another class of ceramics for use in 
orthopaedic surgery, which was found to be capable of bonding to bone in vivo, 
without becoming surrounded with scar tissue.  This was a soda lime phosphosilicate 
glass, termed Bioglass 45S5®, consisting of; 45% silicon dioxide, 24.5% sodium 
oxide, 24.5% calcium oxide and 6% phosphorous dioxide.  It has USFDA approval 
as a middle ear prosthesis, and as an implant for the maintenance of the endosseous 
ridge.  It has also been reported that it is capable of up-regulating genes associated 
with osteogenic differentiation in human osteoblasts (hOBs), including; ALP, Type-I 
collagen, osteopontin, osteocalcin and Runx2 (Jell and Stevens, 2006). 
 
Bioglasses have therefore been suggested potential materials for bone regenerative 
medical applications (Bosetti and Cannas, 2005; Dorea et al., 2005). 
1.2.5.2. Natural Polymers 
A number of natural materials are now available for use in bone regenerative 
medicine.  In general, they have the advantage of being bioactive, biocompatible and 
biodegradable.  There are, however, common disadvantages including the difficulty 
in altering their chemical and mechanical properties, as well as their degradation 
rates (Dawson et al., 2008).  Some of the most commonly used natural polymers in 
bone regenerative medicine are described below. 
1.2.5.3. Alginate 
Alginate is an anionic copolymer of β-D-mannuronic acid and α-L-guluronic acid 
residues, extracted from brown algae (see Figure 1.13a).  Chain length varies 
depending on the species used as the source, for example varying from 80 kDa in 
Azotobacter vinelandii to 290 kDa in Pseudomonas aeruginosa (Martinsen et al., 
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1991).  It can be dissolved in aqueous solutions of sodium chloride.  Monovalent 
cations and magnesium ions do not induce gelation, however divalent cations such as 
strontium, barium and calcium induce gelation of sodium alginate (Clark and Ross-
Murphy, 1987).  This is primarily achieved by the exchange of sodium ions from the 
α-L-guluronic acid residues with the divalent cations, and the formation of “egg-box” 
structures (Rees, 1981).  The alginate chains can then dimerise, causing the 
formation of gel networks (Rees and Welsh, 1977) (see Figure 1.13b).  The 
mechanical properties of the resulting gels vary depending on the proportion and 
relative positions of β-D-mannuronic acid and α-L-guluronic acid residues.  Higher 
proportions of α-L-guluronic acid residues adjacent to each other, producing the 
stiffest gels (Smidsrød, 1973). 
 
Alginate has been used to deliver bioactive growth factors in regenerative medical 
applications (Simmons et al., 2004; Mierisch et al., 2002).  However, since alginate 
can inactivate growth factors such as TGF-β1 through charge interactions, additives 
such as polyacrylic acid may be necessary (Mumper et al., 1994).  Since mammalian 
cells do not have receptors for alginate polymers, cellular interaction and adhesion 
are relatively poor.  To a certain extent, this can be alleviated by the covalent 
attachment of the fibronectin-derived adhesion peptide arginine glycine aspartic acid 
(RGD) (Augst et al., 2006). 
 
When used in in vivo studies, alginate has been found to be biodegradable and to 
elicit little in the way of tissue reaction (Wee and Gombotz, 1998).  Calcium alginate 
gels do not degrade by hydrolysis, but are thought to degrade enzymatically or by the 
action of chelating agents (Perka et al., 2000).  However, like all hydrogels, 






Figure 1.13: Chemical structure of alginate. 
Figure a) shows the chemical structure of alginate polymer chains (adapted from 
Phillips et al. (1990)).  Figure b) shows the chemical interaction between alginate 
polymer chains upon gelling, via the interaction of Ca2+ ions with α-L-guluronic acid 





Chitosan is a cationic aminopolysaccharide, composed of glucosamine and N-acetyl 
glucosamine linked in a β(1-4) manner; the glucosamine/ N-acetyl glucosamine ratio 
being referred to as the degree of deacetylation (Di Martino et al., 2005) (see Figure 
1.14b).  It is manufactured by deacetylating chitin (see Figure 1.14a).  Interestingly, 
cell adhesion has been found to correlate with the degree of deacetylation of the 
chitosan (Mao et al., 2004).  Chitosan is able to be degraded by lysozyme by 
hydrolysis, and the rate of degradation is thought to be affected by the degree of 
deacetylation (Hirano et al., 1989).  It is, therefore, biodegradable (Dhanikula and 
Panchagnula, 2004). 
 
The deacetylation enables chitosan to dissolve in aqueous solutions with a low pH, 
which is facilitated by the protonation of the amino groups (Di Martino et al., 2005).  
Hydrogels of chitosan can be formed in a number of different ways, however the two 
most important methods for regenerative medical applications are formed by pH 
changes or ionic crosslinking (see Figure 1.14c).  If the solution is neutralised, 
chitosan becomes insoluble, causing the tangling of the polymer chains, forming a 
gel (Berger et al., 2004b).  Alternatively, a species of anion may be added, such as 
tripolyphosphate (TPP) forming ionically crosslinked networks (Berger et al., 
2004a).  This induces the chains to bond together by the electrostatic interactions 
between the amino groups and the polyanions (Shu and Zhu, 2002). 
 
Chitosan is particularly useful in cartilage regenerative medicine because of its 
structural similarity to, and interaction with, a variety of glycoaminoglycans.  It is 
also thought to be biocompatible (VandeVord et al., 2002).  When used for bone 
regenerative medical applications, it is frequently used in combination with calcium 
phosphate (Zhang et al., 2003b).  Like alginate, its principal function in regenerative 
medicine is often to deliver bioactive growth factors (Lee et al., 2004b; Mattioli-




Figure 1.14: Chemical structures of chitin and chitosan. 
Figure a) shows the chemical structure of chitin.  Figure b) shows the chemical 
structure of chitosan (adapted from Di Martino et al. (2005)).  Figure c) shows the 
charge interactions involved in chitosan gelation, either by increases in pH, or by the 
addition of an ionic crosslinker (adapted from Berger et al. (2004b)). 
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1.2.5.5. Collagen 
Collagens are abundant in mammalian extracellular matrix (ECM), indeed they 
comprise approximately 25% of the total protein mass in most mammals (Drury and 
Mooney, 2003).  There are at least 19 types of collagen, however Type-I is most 
commonly used in bone regenerative medical applications, as it makes up the 
majority of the organic component of bone (Baron, 1996). 
 
Type-I collagen chains, which are approximately 1000 residues in length, are capable 
of self-assembly to form triple helices (see Figure 1.15a) which in turn aggregate to 
form fibrils which again in turn bond together to form fibres (Piez, 1984; Vitagliano 
et al., 1995; Brodsky and Ramshaw, 1997).  The collagen chains are formed from 
repeating sequences of glycine-X-Y, where X and Y are frequently proline and 
hydroxyproline (Hofmann et al., 1980).  Glycine is thought to repeat, as it is the only 
residue capable of fitting in the interior of the helix (Stryer, 1995).  On the ends of 
the chains, there are 9 – 25 residues, which are thought to play a role in the formation 
of fibrils from triple helices (Helseth and Veis, 1981) (see Figure 1.15b).  Although 
hydrogen bonding is absent from within the chains, in the triple helix, the different 
chains are held together by hydrogen bonds (Stryer, 1995). 
 
Fibrillogenesis occurs both in vivo and in vitro.  The length of the fibrils is 
approximately 67 nm in length, however the diameters have been found to vary 
(Chapman, 1989). 
 
One common approach for using Type-I collagen for regenerative medical 
applications is to prepare it as a gel.  Collagen fibres and fibrils may be decomposed 
using acetic acid, to produce small aggregates of collagen monomers dispersed in the 
acid solution (Rajan et al., 2006; Achilli and Mantovani, 2010).  These aggregates 
are capable of self-assembly at pH 7, forming fibrils (Silver et al., 2003).  There is, 
however, a loss of structural organisation which leads to relatively poor mechanical 
properties, making it unsuitable for regenerative medical applications without 
support (Atala and Lanza, 2002). 
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Type-I collagen has a number of favourable properties.  It is non-antigenic (once 
purified), biodegradable and bioreabsorbable, biocompatible, and is synergistic with 
many bioactive compounds (Itoh et al., 2001b; Lee et al., 2001).  Unlike the majority 
of hydrogels, most cells have receptors for collagen and can easily adhere to it.  
Indeed there is some evidence that Type-I collagen specific binding mediates the 
osteogenic response of hMSCs (Yang et al., 2004; Mizuno et al., 2000).  In contrast, 
many other hydrogels are used as post-operative adhesion barriers (West et al., 
1996). 
 
Collagen may be treated using a variety of methods to make it suitable as part of an 
regenerative medical construct.  These include crosslinking with glutaraldehyde, 
formaldehyde or carbodiimide, or by physical treatments such as UV-radiation, 
drying or heating (Drury and Mooney, 2003).  It is capable of releasing bioactive 
growth factors, and is currently used clinically to deliver rhBMP-2 and -7, as 
discussed in §1.1.6.6. 
 
As a biomaterial, collagen does also have disadvantages.  It is relatively expensive, 
and has relatively poor mechanical properties (Lee and Mooney, 2001).  The use of 
chemical crosslinking agents may also be unsuitable for regenerative medical 
applications, due to their high toxicity.  Any residual crosslinking agent release could 
have detrimental effects on the surrounding tissue (van Luyn et al., 1992).  These 









Figure 1.15: Type-I collagen structure. 
Figure a) shows a space-filling model of the collagen triple helix.  The three strands 
are shown in different colours (from Stryer 1995).  Figure b) shows the hierarchy of 




There are two types of gelatin; both are produced by denaturing collagen.  Type-A 
involves acid treatment of the collagen, followed by thermal denaturation.  Type B is 
denatured using a base (Lee and Mooney, 2001).  In both cases, the triple helix 
ordered structure is broken down into random single strands.  It is also interesting to 
note that the mechanical properties of gelatin have been related to the degree of 
renaturation, i.e. the triple helix content (Bigi et al., 1998). 
 
Aqueous solutions can be formed by heating above 40°C.  Gels can then easily be 
formed by cooling or drying the solution.  On gelling, the gelatin molecules undergo 
a conformational disorder-order transition and partly regenerate the collagen triple-
helix structure (Pezron et al., 1991; Ross-Murphy, 1992).  In this case, 
thermoreversible networks are formed, with the helices being held together by 
hydrogen bonds in the junction zones (Bigi et al., 2004).  Although chemically 
similar, gelatin gels are less stable than collagen gels as not all the strands undergo 
renaturation.  This problem can be alleviated by covalent crosslinking with 
substances such as glutaraldehyde (Bigi et al., 2001), however, as with collagen, 
these substances may be unsuitable for regenerative medical applications due to 
residual toxicity (van Luyn et al., 1992). 
 
Gelatin retains the biocompatibility of the original collagen and is capable of 
releasing bioactive growth factors.  Hence it has been used in a number of potential 
regenerative medical growth factor delivery systems (Liu et al., 2007; Kempen et al., 
2008; Komura et al., 2008). 
 
The major disadvantage of gelatin for bone regenerative medicine is its poor 
mechanical properties (Lee and Mooney, 2001).  Therefore, gelatin is usually used 
alongside other biomaterials. 
1.2.5.7. Synthetic Polymers 
In bone regenerative medicine, the most commonly used synthetic polymers are; 
poly(lactic acid) (PLA), poly(glycolic acid) (PGA), and their co-polymer 
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poly(lactide-co-glycolide) (PLGA) (Sokolsky-Papkov et al., 2007).  Poly(ε-
caprolactone) (PCL) is also thought to be a promising biomaterial (Hutmacher, 
2000).  For their chemical structures, see Figure 1.16. 
 
With synthetic polymers, there is considerable scope for altering their physical 
properties such as; mechanical properties, surface and bulk chemistry, and 
degradation rate (Dawson et al., 2008).  Synthetic polymers experience less batch 
variation than natural polymers, and are often easier to purify and sterilise.  
However, synthetic polymers are often less biocompatible than their natural 












Figure 1.16: The chemical structures of PLA, PGA, PLGA and PCL. 
The structural formulae of PLA, PGA, PLGA and PCL.  Each of the polymers is 
made up of repeating units, indicated by the parenthesise, which occur at frequencies 




PCL is a biocompatible, bioresorbable, semicrystaline, aliphatic polyester 
(Hutmacher et al., 2001).  It is relatively hydrophobic, caused by the long saturated 
carbon chains in the molecules (see Figure 1.16).  When fabricated into regenerative 
medical scaffolds, the compressive modulus and yield strength values have been 
reported as ranging from 52 – 67 MPa and 2.0 – 3.2 MPa respectively, lying within 
the lower range of properties for human trabecular bone (Williams et al., 2005). 
 
PCL degrades by hydrolysis under physiological conditions (Pitt et al., 1981), 
although it can also be degraded enzymatically (Pitt et al., 1984).  In addition, it has 
been found that fragments of PCL can be degraded intra-cellularly by macrophages 
(Woodward et al., 1985).  However, the in vivo degradation time has been found to 
be of the order of two years (Ma et al., 2006), although the addition of other 
polymers with higher degradation rates has been found to shorten the degradation 
time (Middleton and Tipton, 2000). 
 
As PCL has a glass transition temperature of approximately -60°C, and a melting 
point of approximately 60°C, at physiological temperatures it exists in a “rubber-
like” state (Engelberg and Kohn, 1991).  This is thought to increase the permeability 
of PCL, enabling the diffusive release of many therapeutic drugs (Pitt et al., 1987). 
 
Because of the relative ease with which it can be processed into regenerative medical 
scaffolds, it has been used as the base for a number of regenerative medical 
constructs (Rai et al., 2005; Williams et al., 2005; Kim et al., 2006).  A relatively 
small number of studies has shown that PCL is capable of releasing proteins (Cao 
and Shoichet, 1999; Goodwin et al., 1998; Ginty et al., 2008).  It has also been used 
as part of a USFDA approved drug delivery device (Hunter et al., 1998). 
 
The degradation time of PCL is relatively long: of the order of two years (Ma et al., 
2006).  This is possibly longer than is desirable for bone regenerative medicine.  
However, the degradation time could potentially be cut by adding other materials 
with higher degradation rates such as DL-lactide (Middleton and Tipton, 2000). 
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1.2.5.9. PLGA, PLA and PGA 
PLA, PGA and particularly PLGA are the most commonly used synthetic polymers 
in bone regenerative medicine.  Scaffold manufacture from these materials is 
relatively easy, and there is scope for tailoring their degradation rates to suit the 
particular situation.  The degradation rate of PLGA can be altered by altering the 
molecular weight, and the copolymer ratio (Sokolsky-Papkov et al., 2007): the more 
lactide units, the longer the degradation time.  PLA, PGA and PLGA are also less 
hydrophobic than PCL due to the higher concentration of carbon to oxygen double 
bonds in the chemical structure, hence increasing its polarity (see Figure 1.16).  
Indeed adding PLGA to PCL has been found to increase its hydrophilicity (Tang et 
al., 2005). 
 
PGA, which is a linear aliphatic polyester made from glycolic acid monomer units, 
has a semicrystaline structure at room temperature.  However, crystallinity may be 
lost at physiological temperatures, as the glass transition temperature is 
approximately 35°C (Engelberg and Kohn, 1991).  PGA is relatively hydrophilic and 
has a tendency to lose its mechanical strength between 2-4 weeks after implantation 
in vivo.  Hence it has been used in the manufacture of biodegradable surgical sutures 
(Reed and Gilding, 1981). 
 
PLA, another linear aliphatic polyester, made from lactic acid monomer units, is 
thought to be more hydrophobic than PGA because of the additional methyl group 
(see Figure 1.16) (Engelberg and Kohn, 1991).  Additionally, the rate of degradation 
of PLA by hydrolysis is lower than that of PGA (Reed and Gilding, 1981). 
 
Unlike glycolic acid, lactic acid is a chiral molecule.  Hence four different 
morphologically distinct polymers are possible (Engelberg and Kohn, 1991).  D-PLA 
and L-PLA are stereoregular polymers.  DL-PLA is the racemic polymer derived from 
D- and L-lactic acid.  Meso-PLA can be derived from DL-PLA.  D-PLA and L-PLA 
have semicrystaline structures whereas DL-PLA is amorphous.  The glass transition 
temperature of PLA varies from 50 – 60°C.  L-PLA is favoured for use in medical 
devices where mechanical strength is important, due to its crystal structure (Leenslag 
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et al., 1987).  Conversely, DL-PLA is favoured for drug delivery devices as its 
amorphous structure increases the permeability of drugs (Delgado et al., 1996). 
 
Interestingly, copolymers of lactic and glycolic acid do not show a linear relationship 
between the ratio of monomer units and their physico-mechanical properties 
(Engelberg and Kohn, 1991).  Changes in morphology caused by altering the ratio 
have been found to alter the rates of hydration and hydrolysis.  In addition, PLGAs 
tend to degrade more rapidly than pure PLA or PGA (Leenslag et al., 1987; Gilding 
and Reed, 1979). 
 
There are disadvantages to using these materials.  On their degradation by 
hydrolysis, they release acidic breakdown products.  Some authors have found this to 
reduce osteogenesis significantly in the healing bone surrounding the scaffold, during 
polymer erosion (Martin et al., 1996).  The breakdown of scaffolds from these 
materials is potentially self-accelerating, as the localised drop in pH could catalyse 
the hydrolysis of the ester bonds (Sokolsky-Papkov et al., 2007).  These polymers 
are also considerably more expensive than other polyesters such as PCL. 
 
However, PLGA has USFDA approval for use in the fixation of bone fractures 
(USFDA, 2008), and has been used in a large number of studies as either a 
regenerative medical scaffold or a drug delivery device, usually in the form of 
microparticles.  The bioactive factors delivered include; rhTGF-β1 (DeFail et al., 
2006), rhPDGF (Wei et al., 2006), rhVEGF (Patil et al., 2007), rhBMP-7 (Wei et al., 
2007), rhBMP-2 (Woo et al., 2001), and rhFGF-2 (Perets et al., 2003). 
1.2.6. Scaffolds as Delivery Systems 
1.2.6.1. Controlled Delivery 
As discussed in §1.2.4.1, growth factors have the potential to be potent therapeutic 
agents for bone regenerative medicine.  Although growth factors can be delivered 
systemically, this is not the preferred delivery method.  For a therapeutic dose to be 
delivered to the defect site by systemic delivery, it has been suggested that there 
could be side effects in other tissues (Chen and Mooney, 2003).  This is because all 
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growth factors are active in more than one tissue.  For example, BMP-7 is active 
during the development of the kidneys and eyes (Luo et al., 1995).  Hence, delivery 
must be locally applied to the defect site. 
 
How the growth factors are presented, both in terms of the concentration and the 
timing, is thought to be extremely important (Chen and Mooney, 2003).  For 
example, simple infusion of rhVEGF failed to stimulate angiogenesis for the 
treatment of myocardial ischemia (Henry et al., 2003).  Therefore bone regenerative 
medicine has concentrated on the controlled delivery of growth factors to the defect 
site.  The most promising scaffold manufacture and growth factor delivery strategies 
are discussed below in §1.2.6.2, §1.2.6.3 and §1.2.6.3.4. 
1.2.6.2. Structural Delivery Systems and Scaffolds 
1.2.6.2.1. Solvent Casting/Particulate Leaching 
Solvent casting is a widely used technique for scaffold manufacture in bone 
regenerative medicine.  Typically, it involves dissolving synthetic polymers, such as 
PLGA and PCL, in an organic solvent (e.g. chloroform or dichloromethane) 
dispersed with water-soluble particles.  The solution is placed in a mould, where the 
solvent is removed by evaporation.  The scaffold is then washed with an aqueous 
solution to remove the particulates, hence creating porosity. 
 
This technique is usually used to produce purely structural scaffolds (Vaquette et al., 
2008; Shin et al., 2008; Kim et al., 2007a), but they are also capable of delivering 
bioactive factors such as; human growth hormone (Goodwin et al., 1998), 
1,25(OH)2D3 (Yoon et al., 2007) and a combination of ascorbic acid and 
dexamethasone (Kim et al., 2003a). 
 
This manufacturing technique does, however, have limitations.  The distribution of 
the soluble salt, and hence the pores, is heterogeneous.  This is caused by differences 
in the density between the salt particles and the liquid polymer/solvent solution (Liao 
et al., 2002).  Also, since the salt particles are completely surrounded by the polymer 
solution, the salt particles cannot be easily removed by washing (Liao et al., 2002).  
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In addition, dense layers often form on the outer surface of the polymer as the 
solvent is removed.  This increases the difficulty of the salt removal step (Nam and 
Park, 1999).  Due to these factors, scaffolds produced by this technique have usually 
been limited to thicknesses of between 500 – 2000 µm (Liao et al., 2002). 
 
In addition, the organic solvents used in the scaffold fabrication must be carefully 
extracted to meet USFDA standards, as they are toxic (Howard et al., 2008). 
1.2.6.2.2. Supercritical Carbon Dioxide Gas Foaming 
A supercritical fluid is a state of matter existing above both the critical pressure and 
temperature.  While it can expand to fill its container, it has a density similar to a 
liquid.  Carbon dioxide (CO2) has a critical point of 73.8 bar, and 304.1 K, and is 
capable of solubilising synthetic polymers such as PLGA or PLA.  Scaffolds can be 
fabricated by reducing the pressure on the solution.  This results in solidification of 
the polymer.  Pores in the scaffold are formed by the foaming of the gaseous CO2.  
 
Such scaffolds can be manufactured at low temperatures and at mild chemical 
conditions.  Hence they are capable of encapsulating and releasing bioactive growth 
factors such as rhVEGF (Kanczler et al., 2007) and rhBMP-2 (Yang et al., 2004).  
Supercritical CO2 is easier to remove completely than organic solvents, which 
theoretically could make the scaffolds toxic if they were not removed sufficiently. 
 
This technique may have great potential for the future, though it does have some 
problems.  There is no direct control over the scaffold porosity, or indeed pore sizes, 
shapes or orientations, although the pore sizes may be influenced by altering the rate 
of depressurisation.  Slower depressurisation has been found to lead to smaller pores 
(Howdle et al., 2001).  The pores are also often not completely connected to one 
another (Mathieu et al., 2006).  Also, suitable porosity for regenerative medical 
applications has been found to be difficult to achieve in polymers that are not 
amorphous (Mooney et al., 1996). 
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The encapsulation efficiency of this technique may also be relatively low.  Murphy et 
al. (2000) estimated the encapsulation efficiency of rhVEGF in their PLA scaffolds 
to be 44±9%. 
1.2.6.2.3. Electrospinning 
Electrospinning is another commonly used technique to manufacture scaffolds.  This 
involves a needle dispensing a fine fibre of a charged polymer solution.  A high 
voltage is applied to the strand, influencing the direction it falls.  The strands harden 
as the solvent evaporates.  This gradually forms a 3D scaffold (Yoshimoto et al., 
2003). 
 
Electrospinning is usually applied to synthetic polymers such as PCL and PLGA, 
dissolved in an organic solvent such as chloroform.  However, it has also been used 
with fibres of gelatin and silk.  This technique is capable of delivering bioactive 
growth factors such as rhBMP-2 (Li et al., 2006a; Nie et al., 2008).  Although the 
pores of electrospun scaffolds are interconnected, there is no direct control over the 
internal architecture of the scaffolds.  In addition, it is difficult to build up significant 
3D structures using this technique, and the scaffolds are very time-consuming to 
produce (Yan et al., 2009; Teo and Ramakrishna, 2006).  This technique also often 
utilises organic solvents, which are toxic if not extracted carefully (Howard et al., 
2008). 
1.2.6.2.4. Sintering 
Scaffolds manufactured from ceramics such as HA and TCP, are usually fabricated 
by sintering, as discussed in §1.1.6.5.  Scaffolds such as these are currently 
commercially available for the treatment of bone defects. 
 
Ceramic scaffolds are capable of being loaded directly with growth factors, such as 
bovine BMP, rhBMP-2, rhBMP-4, rhFGF-2 and rhVEGF, by adsorption, due to the 
high affinity of ceramics for proteins (Noshi et al., 2000; Ziegler et al., 2002).  There 
is often a burst of release in the first few hours of non-adsorbed protein followed by 
slower release due to desorption.  However, ceramic sintered scaffolds cannot protect 
the adsorbed proteins, which are constantly exposed to the hostile chemical 
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environment on the surface.  Hence protein degradation is almost complete within 
the first three days of release (Ziegler et al., 2002).  Structures with interconnected 
pores are also very difficult to achieve with this technique. 
 
Sintered calcium phosphate scaffolds are biocompatible and osteoinductive 
(Schildhauer et al., 2000) and have favourable mechanical properties for bone 
regenerative medicine in compression.  However, they have poor tensile strength, are 
very brittle, and have a long degradation time in vivo (Jarcho, 1981; Kim et al., 
2008).  Indeed, when implanted, they need to be protected from shear stresses by 
fixation (Bucholz et al., 1987). 
1.2.6.2.5. Rapid Prototyping 
Rapid prototyping, also called free-formed fabrication, describes a range of 
computer-aided techniques of scaffold manufacture.  Unlike the methods described 
above, rapid prototyping techniques provide direct control over scaffold architecture 
and porosity.  Indeed, scaffolds can be custom made to fit the 3D shape of the tissue 
defects (Leong et al., 2003). 
 
To manufacture a scaffold, the desired 3D shape is generated by a computer-aided 
design (CAD) program.  The 3D computer model is then interpreted by a computer-
aided manufacture (CAM) system.  The CAM system then directs the manufacture of 
the scaffold, building up 3D structure one layer at a time.  The main rapid 
prototyping techniques used are described in §1.2.6.2.6, §1.2.6.2.7 and §1.2.6.2.8. 
1.2.6.2.6. Selective Laser Sintering 
Selective laser sintering uses a CO2 laser beam to sinter selectively powders of 
polymers or polymer/ceramic composites together to form layers of solid material 
(Leong et al., 2003).  Therefore 3D geometry can by built up layer by layer from 
powder beds.  In addition, since layers are supported by the powder bed during 
manufacture, there is a great flexibility in the geometric control of the scaffolds. 
 
The high temperatures used during conventional laser sintering preclude the 
incorporation of many bioactive factors.  However a relatively new process, termed 
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surface-selective laser sintering, which involves the melting of the particles at the 
surface only, may have the potential to release bioactive growth factors in the future 
(Antonov et al., 2004). 
 
Scaffolds for bone regenerative medicine are usually primarily composed of calcium 
phosphate, hence scaffolds fabricated using this technique tend to be brittle (Leong et 
al., 2003).  Other limitations include shrinking and warping of the scaffold structure 
during the sintering process, which may reduce control over the final scaffold 
geometry (Lee and Barlow, 1994; Vail et al., 1994). 
1.2.6.2.7. 3D Printing 
3D printing involves ink jet printing technology to dispense solvents or adhesives 
into a powder bed.  Again, 3D geometry can then by built up in layers (Park et al., 
1998).  This is an extremely versatile technique, as it can be applied to a variety of 
materials including synthetic polymers (Park et al., 1998), ceramics (Seitz et al., 
2005) and even metals (Li et al., 2006c).  Like laser sintering, there is great 
flexibility in the scaffold geometries that can be achieved.  Due to the support of the 
powder bed, features like overhanging struts, can easily be achieved. 
 
Recent work has shown that, potentially, growth factors could be selectively attached 
at different concentrations to the surfaces of 3D printed scaffolds.  Miller et al. 
(2006) were able to print rhFGF-2 immobilised on fibrin, in patterns onto a fibrin 
substrate.  Cells, from the human osteoblast-like cell line MG-63, seeded on top, 
showed increased proliferation compared to the non-loaded areas.  Subject to future 
development, this could potentially be a powerful tool for bioactive factor delivery. 
 
Although this technique appears to be very promising for the future, there are some 
limitations.  Currently it is difficult to form scaffolds with complex internal 
geometry, partly because of the particle sizes of the powders, limiting the layer 
thickness to between 80 and 250 µm (Hutmacher et al., 2004).  Additionally, the 
capital cost of 3D printers is currently high, costing as much as $100,000 (Vance, 
2010). 
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1.2.6.2.8. Fused Deposition Modelling 
Fused deposition modelling (FDM) involves the extrusion of a material from a 
nozzle.  Variables such as the nozzle’s 3D position and velocity, as well as the 
dispensing pressure of the gas, used to extrude the material, are controlled by the 
CAM system.  The extruded material may be solidified by chemical crosslinking, 
non-solvent-induced phase separation (which involves the precipitation of a polymer 
by immersion in a non-solvent) or freezing polymer melts (Quaglia, 2008) (see 
Figure 1.17).  Hence a 3D structure can be built up, with fully interconnected pores. 
 
This technique is, however, often difficult to apply in practice.  Many materials are 
unsuitable for this technique because of their physical or chemical properties.  For 
example, the liquids to be extruded must have viscosities within a certain range to 
prevent the strands spreading out (Hutmacher et al., 2004).  The extruded strands 
must also solidify quickly to support the next layer laid down on top of them.  Also, 
not all geometries may be manufactured due to need for the preceding layer to 
support the next layer.  For example, for FDM, overhangs are very difficult to 
achieve, in contrast to both selective laser sintering and 3D printing (Ahn et al., 
2002). 
 
FDM has been applied to create scaffolds out of a number of materials, including; 
alginate (Khalil et al., 2005), chitosan/HA blends (Ang et al., 2002), and PCL 
(Hutmacher et al., 2001; Zein et al., 2002; Rai et al., 2005).  Conventional FDM, 
relying on extrusion of polymer melts, is thought to be incapable of incorporating 
bioactive growth factors directly, due to the necessary high processing temperatures.  
However, Rai et al. (2004; 2005) have successfully released bioactive rhBMP-2 from 
a coating of fibrin on PCL scaffolds.  Hydrogel scaffolds plotted using this technique 
are thought to have the potential to deliver bioactive factors, though they may lack 
sufficient mechanical strength for bone regenerative medicine (Landers et al., 2002).   
 
Of all the rapid prototyping techniques, adaptations of conventional FDM are 
thought to have the greatest scope for creating scaffolds directly encapsulating 








Figure 1.17: Schematic Representation of FDM. 
Schematic representation of traditional FDM based on extrusion of PCL melt (From 
Zein et al., 2002). 
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1.2.6.3. Non-Structural Delivery Systems 
1.2.6.3.1. Sponges 
Absorbable sponges of collagen are currently used clinically for the delivery of 
rhBMP-2 and -7, for the treatment of fracture delayed union and non-union (see 
§1.1.6.6).  They are a useful delivery system for bioactive factors, however because 
of their relatively poor mechanical properties, usually some degree of support is 
needed.  For example, the company Stryker manufactures OP-1™ Putty, which 
consists of bovine Type-I collagen, loaded with rhBMP-7 in a putty of 
carboxymethylcellulose.  This product has received USFDA approval for use in 
spinal fusion operations (USFDA, 2003). 
 
However sponges tend to undergo rapid degradation, and consequently release of 
growth factors from sponges tends to be very rapid.  For example, Ueda et al. (2002) 
found that over 25% of the TGF-β1 loaded in collagen sponges was released in the 
first hour of exposure to the release media.  Ueda et al. (2002) also found that 
approximately 75% of the collagen sponges had degraded 10 days after implantation 
in rabbit calvarial defect models. 
1.2.6.3.2. Hydrogels 
Hydrogels are a class of highly hydrated polymer networks with a water content of ≥ 
30% by mass.  Many hydrogels are hydrophilic, biodegradable, biocompatible and 
have similar structural and mechanical properties to ECM.  For the purposes of 
regenerative medicine, hydrogels may be formed from a variety of material 
including; poly(ethylene oxide), poly(vinyl alcohol), poly(acrylic acid), 
poly(propylene furmarate-co-ethylene glycol), alginate, chitosan, collagen and 
hyaluronic acid (Drury and Mooney, 2003). 
 
In general regenerative medicine, they are often used as space fillers, and cell 
delivery systems.  They are often applied as in situ-forming injectable matrices.  In 
certain situations, this strategy can eliminate the need for scaffold implantation, using 
more invasive surgical techniques (Quaglia, 2008).  Hydrogels are also capable of 
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delivering bioactive growth factors.  For example, chitosan has been used to deliver 
rhFGF-1, -2, rhVEGF, and epidermal growth factor (Ishihara et al., 2003; 
Alemdaroglu et al., 2006), whereas alginate can deliver rhFGF-2, rhVEGF, and 
rhTGF-β1 (Lee et al., 2003a; Mierisch et al., 2002). 
 
However, the mechanical properties of hydrogels are ill suited to bone regenerative 
medical applications (Seal et al., 2001) typically having a tensile strength of between 
300 and 50 kPa (Lee et al., 1997b; Johnson et al., 2004), indeed they are more 
commonly used for cartilage regenerative medicine (Liu et al., 1998; Kim et al., 
2003c).  Hence, for this application of regenerative medicine, they require support 
from a structural scaffold.  In addition, cells do not have receptors to many 
hydrogels, indeed they have been used as post-operative adhesion barriers (West et 
al., 1996). 
1.2.6.3.3. Microparticles 
Microparticles are a commonly used method for the delivery of bioactive growth 
factors.  Generally, they are used in conjunction with a structural scaffold to prevent 
their migration away from the defect site and into surrounding tissues.  The material 
of choice for this technique is often PLGA, which is capable of encapsulating growth 
factors by the double emulsion technique.  A number of examples may be found in 
§1.2.5.9. 
 
They are popular as it is believed that the release properties could be altered to match 
any desired drug release profile, simply by altering the degradation rate of the 
polymer.  This could be achieved without the need to alter the manufacturing 
parameters of the scaffold itself (Quaglia, 2008). 
 
This is based on the assumption that the primary method of release is by degradation 
of the microparticles.  However, unless there is a strong charge interaction, or the 
growth factors are covalently bonded to the polymer, the primary mode of release 
has been reported to be diffusion (Wada et al., 1995).  Hence the scope for releasing 
active factors on longer time scales may be limited, as geometric factors (i.e. the radii 
of the microparticles) may play a key role (see Equation 1.1 and Equation 1.2).  
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Microparticles also commonly release a substantial burst of drug in the first few 




































 (where Mt/M∞ > 0.6) 
The above equations represent the rate of release of encapsulated drugs from 
microparticles (from Wada et al., 1995).  Where Mt/M∞ is the fraction of drug 
released , t is time, and DAB represents the diffusivity of species A in media B. 
 
Microparticles are commonly supported on scaffolds (Liebschner and Wettergreen, 
2003).  This is both to provide the necessary mechanical support, and to localise the 
microparticles to the defect site. 
1.2.6.3.4. Dual Delivery Systems 
As discussed in §1.2.4.1, since different growth factors perform different functions, it 
could be advantageous for bone regenerative medical constructs to release two or 
more.  In addition, since the timing of growth factor delivery is thought to be 
important, it may also be advantageous for the release to be from different delivery 
systems, so that the release kinetics of the two factors can be altered independently of 
each other. 
 
There are surprisingly few examples of scaffolds capable of dual delivery in bone 
regenerative medicine.  However, virtually all dual delivery scaffolds in the literature 
(see Table 1.2) release the growth factors from the same delivery system.  Hence the 
release kinetics cannot be adjusted individually.  
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Scaffold Animal Model Reference 
rhTGF-β1, 
rhBMP-2 
Gelatin hydrogel Rat tibial 
segmental defect 
Srouji et al., 2004 
rhTGF- β3, 
rhBMP-2 
Alginate Ectopic SCID 
mouse 

















Patel et al., 2008 
 
There are at least three examples of scaffolds capable of releasing proteins, utilising 
independent delivery systems.  Ginty et al. (2008) presented a scaffold with the 
potential to do this.  They were able to release the model drugs, RNase and 
horseradish peroxidase, from both a PLA scaffold, fabricated using super critical 
CO2, and from alginate fibres crosslinked with calcium and barium chloride.  The 
choice of barium chloride as a crosslinking agent is also possibly a questionable one, 
as barium chloride is toxic.  Their system utilising PLA scaffolds and PCL 
microparticles may have greater potential for bone regenerative medical applications.  
However, as yet these systems have not demonstrated their biocompatibility or 
ability to release bioactive growth factors. 
 
Sohier et al. (2006) were able to coat a scaffold of poly(ethylene glycol)-
terephthalate (PEGT) and poly(butylene terephthalate) (PBT) with successive 
coatings of the same material.  The coatings of PEGT/PBT were formed by a water-
in-oil emulsion, using chloroform as the solvent.  The release kinetics of the model 
drugs, myoglobin and lysozyme, could be altered by varying the combination of the 
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PEGT/PBT blend.  However, the biocompatibility of the system and the bioactivity 
of released growth factors is yet to be demonstrated. 
 
In an elegantly designed study by Richardson et al. (2001) PLGA scaffolds, 
produced by scCO2 gas foaming, and microparticles delivery systems were 
combined, and used to deliver bioactive VEGF and PDGF.  However, release from 
the microparticle delivery system presented, was either virtually identical to the 
release from the scaffold, or was too slow to be of clinical significance.  In addition, 
such scCO2 gas foaming scaffolds, encapsulating growth factors, have been found to 
have a relatively poor encapsulation efficiency (Murphy et al., 2000). 
 
Therefore, it would seem that there is scope for the development of a scaffold 
capable of releasing bioactive growth factors from two (or more) separate delivery 
systems. 
1.3. Summary and Thesis Hypothesis 
Both fracture non-unions and bone defects pose a recalcitrant problem to orthopaedic 
surgeons.  The current gold standard treatment is autologous bone grafting, despite 
the potential problems of morbidity of the donor site, uncontrolled bone resorption, 
and the limited supply and quality of donor bone.  The emerging field of regenerative 
medicine could provide an alternative treatment. 
 
A scaffold able to deliver both multiple bioactive growth factors, and human marrow 
stromal cells, could be advantageous.  However, a satisfactory scaffold delivery 
system for achieving this has yet to be developed.  This thesis describes the 
development of a scaffold potentially capable of accomplishing this, and meeting the 
demanding design criteria for regenerative medicine constructs.   
 
The following hypothesis was tested:  It is possible to manufacture cell-compatible 
scaffolds, with sufficient porosity for the diffusion of cellular nutrients and waste 
products, incorporating two delivery systems, each capable of releasing a bioactive 
growth factor with clinically significantly different release profiles. 
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1.4. Experimental Procedure and Rationale 
1.4.1. Ideal Scaffold Release 
As discussed in §1.2.6.3.4, the dual delivery of growth factors with different 
temporal release profiles may be advantageous, yet few examples exist.  Ideally one 
or more growth factors should be released relatively quickly to stimulate 
angiogenesis, and host osteoblast progenitor chemotaxis and proliferation (see 
Figure 1.18).  Ideally this should be followed by later, and perhaps more sustained, 
delivery of growth factors to induce osteogenic differentiation of osteoprogenitors 
(see Figure 1.18). 
 
As discussed in §1.1.2.5 and §1.2.4.1, VEGF has shown promise in stimulating 
angiogenesis.  However, direct injection of VEGF has been found to fail to stimulate 
angiogenesis in vivo (Henry et al., 2003).  In contrast, release over the course of 
approximately 14 days from scaffolds, has been found to increase blood vessel 
numbers in vivo (Kanczler et al., 2007).  VEGF may, therefore, be a promising 
candidate for early delivery as shown in Figure 1.18. 
 
Isoforms of TGF-β are thought to have a potent chemotactic effect on MSCs, and to 
stimulate MSC, chondrocyte and osteoblast proliferation (Lieberman et al., 2002).  In 
normal healing, the TGF-β isoforms are released early from the platelets after the 
clot forms at the time of fracture (Robey et al., 1987).  Hence, growth factors such as 









Growth factors such as BMP-2 and -7 are thought to induce the differentiation of 
osteoprogenitors (see §1.1.2.3 and §1.1.6.6).  They are therefore promising 
candidates for more sustained release.  In normal fracture healing in mice, expression 
of both BMP-2 and -7 is sustained for the first 21 days (Cho et al., 2002; Bostrom, 
1998; Nikolaou and Tsiridis, 2007).  Therefore, a more sustained release profile may 
be desirable for these growth factors.  Ideally, however, there should be a delay in 
the initial release of these factors, in order not to interfere with any pro-proliferative 











































Figure 1.18: Ideal Growth Factor Release Profiles from Scaffolds. 
This figure represents the ideal release profiles of growth factors from scaffolds for 
bone regenerative medical applications.  The blue line represents the ideal release of 
growth factors intended to stimulate angiogenesis or MSC chemotaxis and 
proliferation.  The red line represents the ideal release of growth factors intended to 
stimulate osteogenic differentiation of osteoprogenitors. 
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1.4.2. Material Selection 
1.4.2.1. Design Philosophy 
As discussed in §1.4.1, an ideal scaffold should have the potential to release different 
growth factors with different temporal release profiles.  It was thought that this 
would be easiest to achieve with two different delivery systems; the first releasing 
rapidly, and the second releasing over a longer period of time (see Figure 1.18). 
 
It was thought that early release could be best achieved by release from a scaffold 
coating.  Since the thickness of the coating would be thinner than the scaffold strands 
and since the coating is on the outer surface, the diffusive release from the coating is 
likely to be higher (Ritger and Peppas, 1987a; 1987b). 
 
It was also thought that the release from within the scaffold would be relatively slow, 
when compared both to the coating, and to microparticles which are a commonly 
used drug delivery system in regenerative medicine.  This was thought to be the case, 
in part, as the different geometry should slow the diffusive release from the scaffold 
(Ritger and Peppas, 1987a; 1987b; Wada et al., 1995). 
1.4.2.2. Coating Material Selection 
The scaffold coating must meet a number of design criteria, though the coating must 
perform two functions in particular.  First, it acts as the primary cell-scaffold 
interface, and second, it must act as a drug delivery device.  The coating materials 
must, therefore, be biocompatible, biodegradable and be capable of releasing 
bioactive growth factors.  Ideally, the coating materials should also be 
osteoconductive. 
 
As discussed in §1.2.5.3, alginate is thought to be biocompatible (Schuh et al., 1996), 
biodegradable (Blaine, 1947), and capable of releasing bioactive growth factors 
(Mierisch et al., 2002; Simmons et al., 2004).  Although alginate is not 




Chitosan is also thought to be biocompatible (VandeVord et al., 2002), 
biodegradable (Dhanikula and Panchagnula, 2004), and capable of releasing 
bioactive growth factors (Lee et al., 2004b; Mattioli-Belmonte et al., 1999) (see 
§1.2.5.4).  Again, chitosan is not thought to be osteoconductive, however, it was 
considered as a potential scaffold coating material. 
 
Type-I collagen was also considered as a potential coating material.  It is 
biodegradable, bioresorbable, biocompatible, and has been used as part of USFDA 
approved devices capable of delivering bioactive rhBMP-2 and -7 (Lee et al., 2001; 
Itoh et al., 2001b; Govender et al., 2002; Friedlaender et al., 2001) (see §1.2.5.5).  In 
fact there is some evidence that Type-I collagen specific binding mediates the 
osteogenic response of hMSCs (Yang et al., 2004; Mizuno et al., 2000). 
 
Type-A gelatin was the final potential scaffold coating material selected.  Type-A 
gelatin has been found to retain the biocompatibility and biodegradability of the 
collagen from which it is manufactured (Link et al., 2008), and is capable of 
releasing bioactive growth factors (Liu et al., 2007; Kempen et al., 2008; Komura et 
al., 2008) (see §1.2.5.6). 
1.4.2.3. Scaffold Material Selection 
The scaffold materials must meet a number of design criteria (see §1.2.2), though in 
particular, the scaffold materials must be; biocompatible, biodegradable, capable of 
delivering bioactive growth factors, and have suitable mechanical properties. 
 
As discussed in §1.2.5.8, PCL is; biocompatible, bioresorbable, capable of releasing 
bioactive growth factors, and has mechanical properties which lie within the lower 
range of properties for human trabecular bone (Hutmacher et al., 2001; Pitt et al., 
1981; Cao and Shoichet, 1999; Goodwin et al., 1998; Ginty et al., 2008; Williams et 
al., 2005).  PCL scaffolds have also been fabricated into scaffolds by fused 
deposition modelling (Vadillo, 2009).  PCL was therefore thought to be a suitable 
potential scaffold material. 
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PLGA is also biocompatible, biodegradable, and has sufficient mechanical properties 
to be used in bone regenerative medical scaffolds (Kim et al., 2007a; Martin et al., 
1996) (see §1.2.5.9).  PLGA has also been widely used to release a variety of 
bioactive growth factors (DeFail et al., 2006; Wei et al., 2007; Woo et al., 2001).  
Like PCL, PLGA has also previously been used to fabricate fused deposition 
modelling (Vadillo, 2009).  PLGA was therefore investigated as a potential scaffold 
material.  PLGA 50:50 is more commonly used in growth factor releasing 
microspheres (DeFail et al., 2006; Wei et al., 2007), however PLGA 75:25 was used 
in an attempt to slow growth factor release.  Additionally, this is the ratio 
successfully employed by Vadillo (2009) to fabricate scaffolds for bone regenerative 
medical applications. 
 
Blends of the two polymers PLGA and PCL were also used as scaffold materials.  It 
was hypothesised that altering the ratio of the two polymers in the blend would have 
an effect on the drug release rate from the resulting scaffolds. 
 
Dichloromethane (DCM) was selected as the organic solvent.  DCM is capable of 
dissolving both PCL and PLGA.  Many previous studies have shown that bioactive 
factors can be delivered by microparticles of synthetic polymers, processed with 
DCM using the double emulsion technique (Bodde et al., 2008; Kim and Park, 2004; 
Phillips et al., 2006a; Wei et al., 2004; Wei et al., 2007; Yang et al., 2006).  DCM 
has yet to be used in the manufacture of scaffolds fabricated by rapid prototyping 
that have been shown to be capable of bioactive growth factor release.  However, 
DCM was thought to be a suitable solvent for the production of scaffolds capable of 
releasing bioactive growth factors. 
1.4.2.4. Active Factors 
As discussed in §1.1.2 and §1.2.4, a plethora of growth factors are involved in 
normal fracture healing, hence many different options are available for bone 
regenerative medical applications.  rhBMP-7 was chosen both as a representative 
growth factor, and as a compound of interest in its own right.  Like many other 
growth factors of interest in the field of bone regenerative medicine, including FGF-
2, PDGF, and BMP-2, BMP-7 is positively charged at physiological conditions and 
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has a similar molecular weight (Quaglia, 2008) (see Figure 4.1).  Therefore the 
release profile of rhBMP-7 is likely to be similar to other growth factors of interest. 
 
rhBMP-7 was also chosen, being of interest in its own right, as it is one of only two 
growth factors to be given USFDA approval for use in the treatment of fracture non-
unions (see §1.1.6.6). 
 
In addition, 1,25(OH)2D3 was used as a model drug to assess the feasibility of 
releasing hydrophobic lipid-soluble active factors for the scaffolds.  For example, 
many cathepsin K inhibitors are hydrophobic (Wang et al., 2004).  However, as 
discussed in §1.2.4.2, 1,25(OH)2D3 has also been considered as a potential 
compound of interest for bone regenerative medicine, particularly in combination 
with an isoform of TGF-β (Bosetti et al., 2007). 
1.4.3. Outcome Measures/Experimental Procedure 
1.4.3.1. Chapter 2 
A feasibility study was conducted to assess whether scaffolds could be fabricated 
from the materials selected in §1.4.2.3, while encapsulating aqueous solutions.  The 
outcome measures for this study were; the regularity of scaffold geometry, and the 
scaffold porosity (see Figure 1.19).  The latter is thought to be particularly important 
to allow the diffusion of nutrients in, and waste products out, and to allow tissue 
ingrowth (Karageorgiou and Kaplan, 2005). 
 
A second feasibility study was undertaken to assess whether the materials selected in 
§1.4.2.2 were capable of coating the scaffolds.  The outcome measures were; the 
uniformity of coating coverage, and the preservation of the original scaffold porosity 
(see Figure 1.19). 
1.4.3.2. Chapter 3 
As discussed in §1.2.2, one of the most important design criteria for materials used in 
regenerative medicine is biocompatibility.  However, this is very difficult to test 
without using animal models.  Nevertheless, in vitro methods of studying cell-
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compatibility are widely accepted for the purpose of primary screening, before 
preclinical trials are undertaken (Wang et al., 2009a; Carinci et al., 2007; Paul and 
Sharma, 2007).  They also have the advantage of giving good control over the 
variables, and their sensitivity is thought, by some authors, to be at least equal to that 
of in vivo studies (Ho et al., 2008). 
 
In the context of bone regenerative medicine, cell-compatibility is commonly taken 
to mean the lack of cytotoxicity, as well as osteoconductivity.  Many methods exist 
to assess cell-compatibility, including MTT or MTS assays (Sgouras and Duncan, 
1990).  However, imaging of cells stained to reveal whether they are viable or 
necrotic (using calcein-acetoxymethyl and propidium iodide respectively) was 
thought to yield the most information (Lichtenfels et al., 1994; Roden et al., 1999; 
Goodell et al., 1996; McKeague et al., 2003).  First, this assay is capable of detecting 
even very low levels of cell death.  Second, the number of cells can be calculated.  
Third, the morphology of the cells can be examined. 
 
For the selection of the optimum coating material, the coatings were exposed to three 
cell types.  First hMSCs, which, as discussed in §1.2.3.3 are a promising cell type for 
bone regenerative medicine.  Second hOBs, which would also come into contact with 
the scaffold in vivo, either formed from the hMSCs delivered with the scaffold, or by 
host in-growth.  Third MG63 to represent more proliferative cells.  The selection of 
the optimum coating material was done using this assay as the coating was the 
primary cell-scaffold interface (see Figure 1.19). 
 
While cell-compatibility was thought to be less important than that of the coating, it 
was important to confirm that sufficient dichloromethane had been removed to avoid 
the release of the cytotoxic organic solvent from the scaffolds.  The live/dead assay 
was therefore performed on the optimum scaffold (as determined from the release 
studies in Chapter 4, see Figure 1.19) using hMSCs.  In this case, the hMSCs were 
seeded primarily on the tissue culture plastic rather than the scaffold material.  This 
enabled accurate quantification of the numbers of viable and dead cells.  This would 
not have been possible for cells seeded onto the scaffolds directly because of the 
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effect the scaffold 3D structure would have had on the microscope field of focus.  
The optimum scaffolds were compared to scaffolds already known to be 
biocompatible as a positive control for cell-compatibility (Vadillo, 2009). 
1.4.3.3. Chapter 4 
Since both PCL and PLGA were known to be biocompatible materials (see §1.2.5.8 
and §1.2.5.9), selection of the optimum scaffold material was made on the basis of 
release profiles and encapsulation efficiency (see Figure 1.19). 
 
This was achieved using the model drug, methylene blue.  A model drug was used, 
both because of economic considerations, and the ease of quantification.  In addition, 
methylene blue may not undergo significant degradation in the release media, in 
contrast to active factors.  Methylene blue has previously been used as a model drug 
(De and Robinson, 2003; Wu et al., 1996; Tu et al., 2005).  Although the molecular 
weight is relatively low (320 Da), since the mode of release and the charge 
interactions were very similar, scaffolds releasing methylene blue more rapidly 
would similarly release rhBMP-7 more rapidly according to the laws of Fickian 
diffusion (Fick, 1855; Ritger and Peppas, 1987a).  It should be noted that this would 
not be the case if the model drug’s molecular weight was identical to the growth 
factor, but had a different charge.  Methylene blue was, therefore, used to assess the 
scaffold materials based on the release profiles and encapsulation efficiencies. 
 
While the optimum scaffold coating material had previously been selected on the 
basis of cell-compatibility, it was important to assess the coating’s drug loading 
capacity to ensure it was adequate, as well as its release profile to ensure it was 
consistent with the design philosophy of the thesis.  This was achieved using 
methylene blue. 
 
While model drugs may be effective for the purposes of preliminary testing and 
screening, it is thought to be necessary to confirm the actual in vitro release profile 
using growth factors themselves (Wang et al., 2009b).  Such release profiles are 
normally investigated using either radioactively labelled forms of the growth factors 
(Wei et al., 2007; Hosseinkhani et al., 2007; Bodde et al., 2008), or by using an 
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appropriate enzyme-linked immunosorbent assay (ELISA) (Kim and Valentini, 2002; 
Moioli et al., 2006; Jaklenec et al., 2008).  This was achieved using rhBMP-7 as a 
representative growth factor (see §1.4.2.4), detected using an ELISA. 
1.4.3.4. Chapter 5 
The release profiles of rhBMP-7 had previously been assessed using an ELISA (see 
Figure 1.19).  However immuno-reactivity does not necessarily show that active 
factor release remained bioactive.  Since the antibodies used in ELISAs only bind to 
a small region of the complete protein structure, the proteins detected may only have 
been deactivated fragments of the original active factors (Bae et al., 2006). 
 
It was therefore necessary to assess whether the rhBMP-7 released was capable of 
affecting cells.  This is commonly achieved employing cell lines, using changes in 
such properties as cell proliferation or ALP expression as outcome measures 
(Meager, 1991; Garrigue-Antar et al., 1995; Parker et al., 2002).  However, such 
assays, which often employ transformed non-human cells, yield little information on 
how primary human cells would behave or what dose of active factor is most 
appropriate. 
 
It was also thought to be important to use human cells to assess their reaction to a 
range of rhBMP-7 concentrations.  Currently, the majority of in vitro studies have 
been conducted using mouse or rat MSCs, however the response of these cells to 
rhBMP-7 has been found to differ from that of human MSCs (Diefenderfer et al., 
2003).  Therefore, the optimum concentration for human cells cannot be deduced 
from these studies.  Nevertheless, there is broad agreement that MSC expression of 
ALP, an early marker for osteogenic differentiation, is increased in response to 
rhBMP-7 in the range 10 – 100 ng/ml (Knippenberg et al., 2006; Edgar et al., 2007; 
Tsiridis et al., 2007).   
 
Normalised ALP expression in hMSCs was therefore used as the main outcome 
measure for assessing which rhBMP-7 dose was most appropriate, and whether the 




The feasibility of releasing hydrophobic active factors was also assessed using a 
similar assay (see Figure 1.19).  As discussed in §1.4.2.4, 1,25(OH)2D3 was chosen 
as a representative active factor.  The sensitivity of the assay for 1,25(OH)2D3 was 
increased by the addition of TGF-β3 to the cell media, as isoforms of TGF-β were 
known act synergistically with 1,25(OH)2D3  to enhance osteogenic differentiation 
(Bosetti et al., 2007). 
 
For both assays, the cells were seeded on tissue culture plastic rather than the 
scaffolds themselves.  This was to enable the study of the release from the scaffolds 
independently from cell-scaffold interactions.  Hence the potential confounding 
factor of variations in scaffold topography was removed, as surface topography is 
known to influence the behaviour of cells of the osteoblast lineage (Dalby et al., 
2002). 
1.4.3.5. Chapter 6 
The rhBMP-7 loaded scaffolds were then tested for their ability to induce osteogenic 
differentiation in hMSCs in vitro.  As discussed in §1.1.1.5, ALP expression and 
matrix mineralisation are well established indicators of osteogenic differentiation.  
Therefore, quantification of ALP activity and calcium deposition, normalised to the 
quantity of DNA present, were used as the main outcome measures.  Such assays 
have been used previously to assess the osteogenic differentiation of cells on 
scaffolds (Bjerre et al., 2008; Liu et al., 2008b; Moreau and Xu, 2009; Holtorf et al., 
2005; Vadillo, 2009; Dadsetan et al., 2008). 
 
Colourimetric assays for ALP activity and calcium deposition were used, as 
quantitative photographic techniques were unsuitable for use on the scaffolds. 
1.4.3.6. Chapter 7 
The ability of the rhBMP-7 loaded scaffolds to induce osteogenic differentiation was 
further assessed by examining the expression of a number of genes associated with 
osteogenesis.  Gene expression was investigated using quantitative reverse 
transcription polymerase (qRT-PCR). 
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The genes selected were; Runx2, Type 1 collagen (Col1), osteocalcin (OC), 
osteopontin (OP), and ALP.  The transcription factor Runx2 is thought to be essential 
for osteoblastic differentiation (Komori et al., 1997; Otto et al., 1997).  Col1 
expression is an early maker of osteoblastic differentiation and is first expressed by 
osteoprogenitor cells, as is OP (Liu et al., 1994).  ALP mRNA expression is also a 
marker of immature osteoblasts, but is thought to occur later than osteopontin (Liu et 
al., 1994).  It is one of the few genes thought to be specific to osteoblasts and 
odontoblasts (Desbois et al., 1994).  Osteocalcin is thought to play a role in 
mineralisation and calcium homeostasis, as well as being a marker of mature 
osteoblasts (Liu et al., 1994). 
 
The cell type selected for these studies was the murine myoblast cell line C2C12.  
This was because previous studies have shown that the differentiation pathway can 
be shifted from myoblastic to osteoblastic in the presence of either rhBMP-2 (Lee et 
al., 1999; Katagiri et al., 1994; Kim et al., 2009) or rhBMP-7 (Gu et al., 2004b; Yeh 




Figure 1.19: Flow diagram of experimental sequence. 
This figure represents a flow diagram of the sequence of experiments conducted in 
this thesis.  The experiments coloured brown were concerned with the selection of 
the optimum coating material by cell-compatibility, and its testing for its suitability 
as a drug delivery system.  The experiments coloured blue were concerned with the 
selection of the optimum scaffold material by its suitability as a delivery system, and 
subsequent evaluation for cell-compatibility.  The experiments coloured green 
investigated the ability of both delivery systems to deliver active factors and to 
















Chapter 2 : Scaffold Development 
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2.1. Abstract 
In bone regenerative medicine, it may be necessary to deliver different bioactive 
factors with different temporal release profiles.  There is however, a near complete 
absence of such dual delivery systems in the literature.  The purpose of the studies 
described in this chapter, was to find the optimum manufacturing parameters for a 
range of scaffolds and scaffold coatings.  Each scaffold and coating was thought to 
have the potential to act as an independent delivery system for bioactive growth 
factors. 
 
Two-layer scaffolds were manufactured from poly(ε-caprolactone) (PCL) (both Mn 
42,500 and Mn 80,000), poly(lactide-co-glycolide) (PLGA), as well as two blends of 
PCL and PLGA.  It was found that aqueous solutions could be incorporated into the 
scaffolds, making it potentially possible to release bioactive factors from them.  The 
pore size of PCL (Mn 42,500) scaffolds manufactured in house, was found to be 
suitable for bone regenerative medical applications: allowing the diffusion of 
nutrients and waste produces to and from the cells.  The four potential scaffold 
materials were subjected to screening based on their drug delivery properties in 
Chapter 4. 
 
It was found that PCL (Mn 42,500) scaffolds could be coated with alginate, chitosan, 
Type 1 collagen and Type-A gelatin, without compromising the porosity of the 
resulting regenerative medical construct.  The five potential scaffold coating 
materials were subjected to screening based on their cell-compatibility to determine 








The Bioplotter™ is a versatile computer aided design/manufacture rapid prototyping 
system, for the manufacture of regenerative medical scaffolds.  The computer aided 
manufacture system controls the three dimensional (3D) position and velocity of a 
pneumatic syringe.  The dispensing pressure can be set manually, and is maintained 
and controlled by a regulator.  Scaffold material extruded from the needle of the 
syringe may be solidified using a number of techniques, depending on the material 
used. 
 
This system has been used in scaffold manufacture from a number of materials.  Ang 
et al. (2002) produced scaffolds using a solution of chitosan and hydroxyapatite 
(HA), by dispensing into a bath of sodium hydroxide solution, followed by freeze 
drying.   
 
Fedorovich et al. (2008) used the Bioplotter™ to fabricate scaffolds of hydrogels 
containing bone marrow derived goat MSCs.  The hydrogels used were; Matrigel, 
Lutrol, alginate and agarose.  The alginate scaffolds, which were manufactured from 
2% (w/v) sodium alginate extruded in a bath of calcium chloride (CaCl2), showed no 
significant decrease in viability of cells within the scaffold, over a seven day period. 
 
Malda et al. (2005) produced scaffolds from a poly(ethylene glycol)-terephthalate / 
poly(butylene terephthalate) molten blend.  The strands of the scaffold were formed 
as the melt cooled and solidified.  The scaffolds were seeded with bovine 
chondrocytes, and transplanted into subcutaneous pockets in nude mice.  The authors 
found that the mass of glycosaminoglycan, normalised against the mass of 
deoxyribonucleic acid (DNA), was significantly higher than for the similar scaffolds 
manufactured using moulding and particulate leaching. 
 
Extensive studies using the Bioplotter™ have also been conducted in-house.  Vadillo 
(2009) manufactured scaffolds using; alginate, chitosan, gelatin, PLGA and PCL.  It 
was found that the system had a dispensing accuracy of 10 µm.  Alginate scaffolds 
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were fabricated from solutions of 3% (w/v) alginate in 0.9% (w/v) sodium chloride 
(NaCl), plotted in a bath of 0.1 M CaCl2.  Chitosan was used at a concentration of 
3% (w/v) in 2% (v/v) acetic acid.  This solution was plotted in a bath of 1% (w/v) 
sodium hydroxide (NaOH) and ethanol in a ratio of 7:3, followed by treatment with 
2% (w/v) TPP and lyophilisation.  Gelatin constructs were produced from a heated 
20% (w/v) solution, crosslinked with glutaraldehyde or transglutaminase. 
 
The most successful scaffolds fabricated by Vadillo (2009), in terms of the scaffold 
mechanical properties, and the extent of control of 3D geometry, were made from 
PCL and PLGA.  Both were plotted at a concentration of 30% (w/v) in glacial acetic 
acid, where the plotting medium was industrial methylated spirit (IMS).  Good 
control over the scaffold 3D geometry was achieved.  The PCL scaffolds were 
seeded with hMSCs and transplanted into critical-sized defects in the skulls of mice 
(Martin et al., 2008).  The scaffolds aided the healing of the defect, and it was found 
that calcium was deposited directly onto the PCL strands.  This shows the 
biocompatibility and osteoconductivity of the PCL scaffolds.  The direct 
encapsulation of growth factors in scaffolds such as these is thought to be 
inappropriate, since the harsh chemical environment caused by the glacial acetic 
acid, would denature encapsulated proteins. 
 
Biocompatible PCL scaffolds have also been fabricated using a rapid prototyping 
technique very similar to the Bioplotter™, based on polymer melts (Rai et al., 2005, 
Zein et al., 2002).  The relatively high temperatures (120°C) used in processing these 
scaffolds, preclude encapsulating growth factors. 
 
As discussed previously (§1.2.5), scaffolds made from natural polymers tend not to 
possess the mechanical properties necessary for bone regenerative medicine.  
However, synthetic polymer scaffolds such as those described above, have 
traditionally been unsuitable for direct encapsulation, because of the harsh processing 
conditions used to produce 3D structure. 
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In contrast to melting or the use of glacial acetic acid, processing with the organic 
solvent dichloromethane (DCM) is relatively mild.  Many studies have shown that 
bioactive factors can be delivered by microparticles of synthetic polymers, processed 
with DCM using the double emulsion technique (Bodde et al., 2008; Kim and Park, 
2004; Phillips et al., 2006a; Wei et al., 2004; Wei et al., 2007; Yang et al., 2006).  
However DCM has yet to be used in the manufacture of scaffolds fabricated by rapid 
prototyping that have been shown to be capable of bioactive growth factor release. 
 
In this study, a range of scaffolds and scaffold coatings was developed, each with the 
potential to release bioactive growth factors.  Structural scaffolds, processed using 
DCM, were manufactured from the synthetic polymers; PCL (Mn 42,500 and 
80,000), PLGA, and blends of the two.  Coating protocols, based on the natural 
polymers; alginate, chitosan, collagen and gelatin, were developed. 
2.3. Materials and Methods 
2.3.1. General Bioplotting Procedure 
The Bioplotter™ (Envisiontec GmbH, Germany) is controlled by two distinct 
computer software programs, namely; PrimCAM (Primus Data, Switzerland) and 
PrimCNC (Primus Data, Switzerland).  PrimCAM is capable of importing 3D 
computer aided design (CAD) files, and combining this with user inputs such as; 
strand spacing in the X and Y axes, strand offset, patterning and the plotting spacing 
between layers in the Z axis.  From this information, PrimCAM produces a 
numerical control (NC) code programme file.  This can be read by PrimCNC, which 
in turn controls the Bioplotter™.  Alternatively, the user may write the NC code 







After loading the NC code programme, a nitrogen gas cylinder was connected to the 
Bioplotter™ via the pressure regulator (see Figure 2.1).  The Bioplotter™ itself was 
housed in a class-two tissue culture hood, to reduce the possibility of contaminating 
the scaffolds with airborne pathogens during manufacture.  To reach the syringe 
(Engineered Fluid Dispensing™, UK), the nitrogen first had to pass through a sterile 
filter (see Figure 2.1), preventing infectious agents in the nitrogen from 











Figure 2.1: The Bioplotter™. 
An annotated photograph of the Bioplotter™ and CAM system, showing the 

















After a blunt needle was attached, the plotting solution was loaded into the syringe.  
The syringe was then fixed securely into the holder, and was connected to the gas 
supply (see Figure 2.1).  The position of the needle was determined using two light 
gate sensors.  The plotting height was manually set to approximately 0.5 mm above a 
glass slide in the plotting bath, which acted as the plotting surface.  After the plotting 
speed was set using the PrimCNC interface, scaffold plotting could then be initiated. 
2.3.2. Scaffolds of Synthetic Polymers 
2.3.2.1. PCL (Mn 42,500) Scaffold Fabrication 
2.3.2.1.1. Optimisation of Plotting Parameters 
Polycaprolactone (Mn 42,500) (Sigma, UK) was dissolved in DCM (dichloromethane 
for peptide synthesis, ≥ 99.8%) (Fluka, UK) at concentrations of 25 and 30% (w/v) 
(i.e. 1.0 or 1.2 g PCL added to 4 ml of DCM).  The solutions were left to dissolve in 
an orbital incubator (Stuart S150), set to 120 rpm (orbital diameter: 1.5 cm) and 
37°C, for 24 hours.  The 30% (w/v) was incubated under the same conditions for a 
further 48 hours.  An NC code programme was written to produce two-layer 
scaffolds with a strand spacing of 0.80 mm in both the X and Y axes (with the 
dimensions 20 × 20 mm), and a Z spacing of 0.14 mm, see Appendix A.  The 
starting plotting speed was 140 mm/min.  The 25% (w/v) PCL/DCM solution was 
then used to manufacture scaffolds as described in the general protocol in §2.3.1, 
using blunt needles (inner diameter: 0.26 mm), 12.7 mm in length (Engineered Fluid 
Dispensing™, UK).  The plotting surfaces used were glass slides (76 × 26 mm, 
Menzel-Gläser, Germany).  Five minutes after plotting, the scaffolds could easily be 
removed from the glass slides using a scalpel.  The plotting speed and pressure were 
optimised by direct experimentation.  Afterwards, the scaffolds were vacuum dried 
using a freeze dryer (Alpha 1-4, Christ, Germany) set to 75 mbar of absolute pressure 
for 60 min. 
 
The plotting parameters were also optimised for scaffolds manufactured using the 
same manufacturing procedure as above, but with the addition of plotting solutions.  
Two plotting solutions were used, namely; 100% industrial methylated spirit (IMS) 
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 (Fisher), and 70% IMS, 30% distilled water (dH2O).  Approximately 250 ml of 
plotting solution were added to the plotting bath (see Figure 2.1). 
 
Representative scaffolds were then examined using a dissecting microscope (Zeiss, 
Stemi 2000-C).  Images were taken at × 2 magnification using a mounted camera 
(Nikon, DXM1200). 
2.3.2.1.2. Incorporation of Aqueous Solutions 
The purpose of these experiments was to determine whether scaffolds could be 
produced which encapsulated aqueous solutions. 
 
Phosphate buffered saline (PBS) (Oxoid, UK) was added to 25% (w/v) solutions of 
PCL/DCM, prepared as in §2.3.2.1.1, at concentrations of; 5, 2, and 1% (v/v), in a 15 
ml centrifuge tube (Corning, UK).  Methylene blue (Sigma) aqueous solutions (5 
mg/ml) were also added at 1% (v/v) to 25% (w/v) solutions of PCL/DCM.  This 
facilitated the examination of the distribution of the aqueous solution in the 
PCL/DCM solution, and in the resulting scaffolds. 
 
Once added, emulsions were created by vigorous manual mixing using sterile 3 ml 
transfer pipettes (Fisher, UK) for approximately 30 seconds.  The resulting emulsions 
were loaded into the syringe of the Bioplotter™.  Scaffolds were then manufactured, 
with no plotting media, using the optimised plotting parameters determined in 
§2.4.1.1.1, and then vacuum dried at 75 mbar (absolute pressure) for 60 min. 
 
To determine scaffold pore sizes and strand thickness, three scaffolds were randomly 
selected from three different scaffold batches of eight.  The batches were 
manufactured from separate 25% (w/v) PCL/DCM solutions encapsulating 1% (v/v) 
PBS.  The scaffolds were then photographed using an inverted microscope (Axio 
Observer, Carl Zeiss Ltd., Germany) at × 10 magnification.  The pore sizes and 
strand thicknesses in both the X and Y axes were measured for three randomly 
selected fields of view for each scaffold. 
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The thickness of the scaffolds used above was also measured directly.  Three 
measurements of scaffold thickness were made for each of the scaffolds using 
Vernier callipers (Farnell Inone, UK). 
2.3.2.1.3. Plotting More Than Two-Layers 
An NC code programme was written to produce 16 layer scaffolds with a strand 
spacing of 0.80 mm in both the X and Y axes (with the dimensions 20 × 20 mm), and 
a Z spacing of 0.14 mm, see Appendix C.  Solutions of 25% (w/v) PCL/DCM were 
produced as described in §2.3.2.1.1.  Scaffolds were then manufactured with either 
no plotting media or IMS, using the optimised plotting parameters determined in 
§2.4.1.1.1. 
2.3.2.2. PCL (Mn 80,000) Scaffold Fabrication 
Polycaprolactone (Mn 80,000) (Sigma, UK) was dissolved in DCM at concentrations 
of 25% (w/v).  The solutions were left to dissolve in an orbital incubator (Stuart 
S150), set to 120 rpm and 37°C, for 24 hours.  The NC code programme was the 
same as that used in §2.3.2.1.1, using a strand spacing of 0.80 mm in both the X and 
Y axes (with the dimensions 20 × 20 mm), and a Z spacing of 0.14 mm, see 
Appendix A. 
 
The starting plotting speed was 140 mm/min, and blunt needles (inner diameter: 0.26 
mm), 12.7 mm in length were used.  Methylene blue aqueous solutions at a 
concentration of 5 mg/ml were added to the PCL/PLGA solutions at 1% (v/v).  Once 
added, emulsions were created by vigorous manual mixing using sterile 3 ml transfer 
pipettes for approximately 30 seconds.  The resulting emulsions were loaded into the 
syringe of the Bioplotter™. 
 
The PCL/DCM solutions were used to manufacture scaffolds as described in the 
general protocol in §2.3.1.  Glass slides were used as the plotting surfaces.  After 
plotting, the scaffolds were vacuum dried at 75 mbar (absolute pressure), for 60 min.  
The plotting speed and pressure were optimised by direct experimentation. 
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2.3.2.3. PLGA Scaffold Fabrication 
Poly(lactide-co-glycolide) (lactide: glycolide 75:25, Mw 66,000 – 107,000) (Sigma) 
was dissolved in dichloromethane at concentrations of 25%, and 30% (w/v).  The 
solutions were left to dissolve in an orbital incubator (Stuart S150), set to 120 rpm 
and 37°C, for 6 hours.  Two NC code programmes were used to produce two-layer 
scaffolds.  The 30% (w/v) solutions were plotted with a strand spacing of 0.80 mm in 
both the X and Y axes (with the dimensions 20 × 20 mm), and a Z spacing of 0.14 
mm, see Appendix A.  The starting plotting speed was 140 mm/min, and blunt 
needles (inner diameter: 0.26 mm), 12.7 mm in length (Engineered Fluid 
Dispensing™, UK) were used.  The solutions of 25% (w/v) were plotted with an X-
Y strand spacing of 1.00 mm (with the dimensions 20 × 20 mm), and a Z spacing of 
0.14 mm, see Appendix B.  The starting plotting speed was 560 mm/min, and blunt 
needles (inner diameter: 0.21 mm), 12.7 mm in length (Engineered Fluid 
Dispensing™, UK) were used. 
 
The PLGA/DCM solutions were used to manufacture scaffolds as described in the 
general protocol in §2.3.1.  The plotting surfaces used were glass slides (76 × 26 
mm, Menzel-Gläser, Germany).  After plotting, the scaffolds were either left on the 
bench to dry, or vacuum dried at 75 mbar (absolute pressure), for 1, 2, 3 or 24 hr.  
The plotting speed and pressure were optimised by direct experimentation. 
 
Methylene blue aqueous solutions at a concentration of 5 mg/ml were also added at 
1% (v/v) to 25% (w/v) solutions of PLGA/DCM.  Once added, emulsions were 
created by vigorous manual mixing using sterile 3 ml transfer pipettes for 
approximately 30 seconds.  The resulting emulsions were loaded into the syringe of 
the Bioplotter™.  Scaffolds were formed using the optimised plotting parameters as 
determined in §2.4.1.3. 
 
Representative scaffolds were then examined using a dissecting microscope (Zeiss, 
Stemi 2000-C).  Images were taken using a mounted camera (Nikon, DXM1200). 
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2.3.2.4. PCL/PLGA Scaffold Fabrication 
Two different PCL/PLGA blends were made.  The mass ratios of PCL:PLGA were 
66:33 and 33:66.  The plastic blends were dissolved in DCM at 25% (w/v). 
 
For both blends, the NC code programme used was that used in §2.3.2.1.1 to produce 
scaffolds from 25% (w/v) PCL/DCM, see Appendix A.  The starting plotting speed 
was 140 mm/min, and blunt needles (inner diameter: 0.26 mm), 12.7 mm in length 
(Engineered Fluid Dispensing™, UK) were used.  Methylene blue aqueous solutions 
at a concentration of 5 mg/ml were added to the PCL/PLGA/DCM solutions at 1% 
(v/v).  Once added, emulsions were created by vigorous manual mixing using sterile 
3 ml transfer pipettes for approximately 30 seconds.  The resulting emulsions were 
loaded into the syringe of the Bioplotter™. 
 
The PCL/PLGA/DCM solutions were used to manufacture scaffolds as described in 
the general protocol in §2.3.1.  The plotting surfaces used were glass slides.  After 
plotting, the 66:33 blend scaffolds were vacuum dried at 75 mbar (absolute pressure) 
for 60 min, whereas the 33:66 blend scaffolds were left on the bench, at room 
temperature, to dry for 72 hr.  The plotting speed and pressure were optimised by 
direct experimentation. 
2.3.3. Scaffold Coatings 
2.3.3.1. Alginate Coating 
PCL scaffolds were manufactured as described in §2.3.2.1.1, with no plotting media, 
using the optimised plotting parameters determined in §2.4.1.1.1.  A stock solution of 
alginate (Alginic Acid Sodium salt from Brown Algae, Sigma, UK) was dissolved at 
3% (w/v) in an aqueous solution of 0.5 M sodium chloride (Sigma, UK).  The 
alginate stock was incubated at room temperature for three days before being 
autoclaved.  A 1.5% (w/v) alginate solution in 0.5 M NaCl was then made up by 
diluting the stock alginate solution. 
 
PCL scaffolds (20 × 20 mm) were cut into four approximately equal (10 × 10 mm) 
parts.  Three of these scaffolds were wetted by immersing them in IMS for 10 min.  
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They were washed with dH2O, then PBS and then immersed in PBS for 5 min.  After 
they had been quickly blotted with a dry medical wipe (Kimberly Clark, UK), the 
scaffolds were immersed in the 1.5% (w/v) alginate solution for 10 min. 
 
Afterwards, the scaffolds were removed and quickly blotted to remove excess 
alginate, using dried medical wipes (Kimberly Clark, USA).  The scaffolds were then 
placed in 15 ml of dH2O in a 30 ml universal container for 5 min (inverting five 
times) before being immersed in 0.1 M aqueous calcium chloride (Sigma, UK) 
solution for 30 min. 
 
From preliminary experiments, it had previously been determined that 0.5% (w/v) 
safranin-o (Sigma, UK) in a 0.1 M sodium acetate (Sigma, UK) aqueous buffer (pH 
4.6) could vividly stain calcium alginate red.  Therefore the alginate coated scaffolds 
were immersed in safranin-o solution for 30 min.  Afterwards they were washed five 
times with 10 ml of distilled water (dH2O), and incubated overnight in dH2O.  
Subsequently the scaffolds were blotted and photographed using an inverted 
microscope (Nikon Eclipse TS 100) at × 10 magnification using a mounted camera 
(Nikon, DXM1200). 
2.3.3.2. Chitosan Coating 
PCL scaffolds were manufactured as described in §2.3.2.1.1, with no plotting media, 
using the optimised plotting parameters determined in §2.4.1.1.1.  A stock solution of 
chitosan (Chitosan from Crab Shells, minimum 85 % deacetylated, Sigma, UK) was 
dissolved at 3% (w/v) in an aqueous solution of 0.5% (v/v) acetic acid (Fluka, 
Germany).  The chitosan stock was incubated at room temperature for three days 
before being autoclaved.  A 1.5% (w/v) chitosan solution in 0.5% (v/v) acetic acid 
was then made up by diluting the stock chitosan solution. 
 
PCL scaffolds (20 × 20 mm) were cut into four approximately equal (10 × 10 mm) 
parts.  Three of these scaffolds were wetted by immersing them in IMS for 10 min.  
They were washed in dH2O, then PBS and then immersed in PBS for 5 min.  After 
they had been quickly blotted with a dry medical wipe (Kimberly Clark, UK), the 
scaffolds were immersed in the 1.5% (w/v) chitosan solution for 10 min.  
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Afterwards, the scaffolds were removed and quickly blotted to remove excess 
chitosan.  The scaffolds were then placed in 15 ml of dH2O in a 30 ml universal tube 
for 5 min (inverting five times) before being immersed in 2% (w/v) aqueous TPP 
(sodium tripolyphosphate, Sigma, UK) solution for 30 min. 
 
From preliminary experiments, it had previously been determined that 0.15% (w/v) 
light green SF yellowish (Sigma, UK) in 0.2% (v/v) aqueous acetic acid, could 
vividly stain chitosan green.  Therefore the chitosan coated scaffolds were immersed 
in light green SF yellowish solution for 30 min.  Then they were washed five times 
with 10 ml of dH2O, and incubated overnight in dH2O.  Afterwards the scaffolds 
were blotted and photographed using an inverted microscope (Nikon Eclipse TS 100) 
at × 10 magnification using a mounted camera (Nikon, DXM1200). 
2.3.3.3. Collagen Coating 
PCL scaffolds were manufactured as described in §2.3.2.1.1, with no plotting media, 
using the optimised plotting parameters determined in §2.4.1.1.1.  Methylene blue 
aqueous solution (5 mg/ml) was added at 1% (v/v) to 1 mg/ml Type-I collagen (rat 
tail, Sigma, UK) in 0.1 M aqueous acetic acid.  This coloured the solution and 
facilitated the later examination of the distribution of the collagen on the scaffolds, 
even though methylene blue was not a direct stain for collagen. 
 
PCL scaffolds (20 × 20 mm) were cut into four approximately equal (10 × 10 mm) 
parts.  Twelve of these scaffolds were wetted by immersing them in IMS for 10 min.  
They were washed in dH2O, then PBS and then immersed in PBS for 5 min.  They 
were then immersed in the collagen/methylene blue solution for 5 min.  Afterwards, 
the scaffolds were removed, and allowed to air dry for 4 hr at room temperature. 
 
Once dry, the scaffolds were photographed using an inverted microscope at × 10 
magnification using a mounted camera.  They were also photographed using a hand 
held digital camera (M1033 Kodak, USA). 
129 
2.3.3.4. Gelatin Coating 
PCL scaffolds were manufactured as described in §2.3.2.1.1, with no plotting media, 
using the optimised plotting parameters determined in §2.4.1.1.1.  Methylene blue 
aqueous solution (5 mg/ml) was added at 1% (v/v) to 2% (w/v) aqueous gelatin 
(Type-A, Sigma, UK).  This coloured the solution and facilitated the later 
examination of the distribution of the gelatin on the scaffolds, even though 
methylene blue was not a direct stain for gelatin. 
 
PCL scaffolds (20 × 20 mm) were cut into four approximately equal (10 × 10 mm) 
parts.  Twelve of these scaffolds were wetted by immersing them in IMS for 10 min.  
They were washed dH2O, then PBS and then immersed in PBS for 5 min.  The 
scaffolds were then immersed in the gelatin/methylene blue solution for 5 min.  After 
which time, they were removed, and allowed to air dry for 4 hr at room temperature. 
 
Once dry, the scaffolds were photographed using an inverted microscope at × 10 
magnification using a mounted camera.  They were also photographed using a hand 
held digital camera (M1033 Kodak, USA). 
2.3.4. Statistical Treatment of Results 
All results are expressed as the sample means ± standard error of the mean (SEM). 
2.4. Results 
2.4.1. Scaffolds of Synthetic Polymers 
2.4.1.1. PCL Scaffold Fabrication 
2.4.1.1.1. Optimisation of Plotting Parameters 
The 25% (w/v) PCL/DCM mixture dissolved to a homogeneous solution within 24 
hr.  In contrast, the 30% (w/v) PCL/DCM mixture was still heterogeneous even after 
72 hr.  What is more, by the end of this period, evaporation of DCM became 




A plotting pressure of 1.00 bar of gauge pressure was selected, and the optimum 
plotting speed was found by direct experimentation.  The initial plotting speed of 140 
mm/min was found to be too low with the result that scaffold porosity was lost (see 
Figure 2.2a).  When the plotting speed was increased by 40% to 196 mm/min, 
defects in the scaffold formed when the second layer was plotted (see Figure 2.2b).  
However, scaffold porosity was retained, and no defects formed, when the plotting 
speed was set to 168 mm/min, an increase of 20% on the initial plotting speed (see 
Figure 2.2e). 
 
When the plotting pressure was varied, scaffold porosity was partially lost when the 
pressure was increased to 1.20 bar (gauge pressure) (see Figure 2.2c).  Plotting 
defects in the second layer were again observed when the pressure was decreased to 
0.80 bar (gauge pressure). 
 
Therefore, the optimum plotting speed was found to be 168 mm/min when the 
plotting pressure was set to 1.00 bar (gauge pressure).  It was found that scaffolds 
could be manufactured using a plotting media of IMS (see Figure 2.3b).  However, 
using plotting solutions of 70% IMS 30% dH2O, caused the PCL/DCM solution to 
detach from the plotting surface, and coalesce into droplets (see Figure 2.3a). 
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Figure 2.2: Optimisation of PCL plotting parameters 
Scaffold images taken using a dissecting microscope.  The plotting parameters were 
a) speed = 140 mm/min, pressure = 1.00 bar (gauge pressure), b) speed = 196 
mm/min, pressure = 1.00 bar (gauge pressure), c) speed = 168 mm/min, pressure = 
1.20 bar (gauge pressure), d) speed = 168 mm/min, pressure = 0.80 bar (gauge 
pressure), e) speed = 168 mm/min, pressure = 1.00 bar (gauge pressure).  The bar 












Figure 2.3: Addition of plotting media.  
Scaffolds plotted in plotting solutions of a) 70% IMS 30% dH2O, b) 100% IMS.  The 
bar represents 20 mm. 
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2.4.1.1.2. Incorporation of Aqueous Solutions 
As can be seen in Figure 2.4, emulsions of aqueous solutions could be formed by 
manual mixing with transfer pipettes.  The aqueous methylene blue solution was 
found to be distributed throughout the organic phase of PCL/DCM. 
 
Attempts to manufacture scaffolds with a 5% (v/v) aqueous solution were 
unsuccessful, since serious disruption of geometry occurred even in the first layer 
(see Figure 2.5a).  Fabricating scaffolds with 2% (v/v) solutions was similarly 
unsuccessful, although the geometrical disruption was less severe (Figure 2.5b and 
Figure 2.5c). 
 
In contrast, scaffolds could be formed with 1% (v/v) aqueous solutions while 
preserving the structure of the scaffold (see Figure 2.5d and Figure 2.5e).  Using 1% 
(v/v) solutions of methylene blue, it was found that aqueous droplets, of various 
sizes, were distributed throughout the resulting scaffold (see Figure 2.5f).  
 
The mean strand diameters and pore thicknesses were measured by image analysis 
(see Figure 2.6).  The results can be found in Table 2.1. 
 
Table 2.1: Mean PCL scaffold pore and strand thicknesses. 











353±9.7 444±3.5 373±9.5 460±13 
 












Figure 2.4: Distribution of aqueous methylene blue solution in 25% 
(w/v) PCL/DCM solution. 
The distribution of the aqueous phase, as shown by methylene blue a) before mixing, 




Figure 2.5: PCL scaffolds plotted encapsulating aqueous solutions. 
PCL scaffolds manufactured with various different concentrations of aqueous 
solutions; a) 5% (v/v), one layer, b) 2% (v/v), one layer, c) 2% (v/v), two layers, d) 
1% (v/v), one layer, e) 1% (v/v), two layers, f) 1% (v/v), two layers on a light 
background, demonstrating the distribution of methylene blue, indicated by the blue 











Figure 2.6: Measurement of scaffold pore and strand thickness. 
A representative negative image of the PCL scaffolds.  The lengths shown were 
measured using Zeiss image analysis software. 
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2.4.1.1.3. Plotting More Than Two-Layers 
Attempts at fabricating scaffolds, from 25 % (w/v) PCL (Mn 42,500)/DCM, greater 
than two-layers in height were unsuccessful.  As the successive layers were plotted, 
the layers underneath were re-dissolved.  Therefore all the layers fused together, and 
flattened out across the glass slide plotting surface, eliminating all porosity.  This 
effect was, however, less pronounced when IMS was used as plotting medium. 
2.4.1.2. PCL (Mn 80,000) Scaffold Fabrication 
The 25% (w/v) solution dissolved to a homogeneous solution within 24 hr of mixing.  
The resulting solutions, especially when mixed with the aqueous solution, were 
found to be more viscous than solutions of PCL (Mn 42,500).  Hence, for a speed of 
168 mm/min, the optimum plotting pressure was found to be 1.5 bar (gauge 
pressure). 
 
The resulting scaffolds could easily be removed from the plotting surface with a 
scalpel approximately 5 min after manufacture (see Figure 2.7). 
 
 
Figure 2.7: PCL (Mn 80,000) Scaffold. 
PCL (Mn 80,000) scaffold manufactured from 25% (w/v) PCL/DCM, with an XY 




2.4.1.3. PLGA Scaffold Fabrication 
The 30 and 25% (w/v) PLGA/DCM mixtures dissolved to homogeneous solutions 
within 6 hr.  It was observed that the viscosity of the solutions was less than that of 
25% (w/v) PCL/DCM. 
 
For the 30% (w/v) solution, using a plotting pressure of 1.00 bar (gauge pressure) as 
a starting point, the optimum speed of the needle was found to be 210 mm/min.  It 
was found that the struts merged together at the end of each row and column (see 
Figure 2.8a).  Large bubbles also formed during the drying process which further 
compromised scaffold geometry (see Figure 2.8a).  Once plotted, the scaffolds 
required a setting time on the bench of approximately 72 hr.  After which time, the 
scaffolds could be removed, although with difficulty, from the glass slides using a 
scalpel. 
 
The starting pressure for the 25% (w/v) solution was 0.70 bar (gauge pressure).  This 
yielded an optimum speed of 672 mm/min.  For these scaffolds, the merging of the 
struts at the edges was limited to approximately 1 mm (see Figure 2.8b).  Bubbles, 
which were a severe problem for the more viscous 30% (w/v) solution, were not 
evident. 
 
The scaffolds required approximately 72 hr to set before they could be removed from 
the plotting surface.  It was found that vacuum drying for 1, 2, 3 or 24 hr had no 
measureable effect on the ultimate scaffold setting time. 
 
When aqueous solutions of methylene blue were added at a concentration of 1% 
(v/v) to 25% (w/v) PLGA/DCM, evenly dispersed emulsions could be achieved.  
Methylene blue dispersion was also observed in the resulting scaffolds (see Figure 
2.8c).  The optimum plotting parameters were found to be identical to those for the 








Figure 2.8: PLGA Scaffolds. 
PLGA scaffolds manufactured from a) 30% (w/v) PLGA/DCM, with an XY strand 
spacing of 0.8 mm, b) 25% (w/v) PLGA/DCM, with an XY strand spacing of 1.0 
mm, and c)  25% (w/v) PLGA/DCM, encapsulating 1% (v/v) methylene blue 
solution.  The bar represents 20 mm. 
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2.4.1.4. PCL/PLGA Scaffold Fabrication 
Both 66:33 and 33:66, 25% (w/v) PCL:PLGA/DCM solutions dissolved to 
homogeneous solutions within 24 hr. 
 
For the 66:33 (PCL rich) blend, for a plotting pressure of 1.5 bar (gauge pressure), 
the optimum plotting speed was 168 mm/min.  The XY strand spacing used was 0.8 
mm.  The resulting scaffolds could be easily removed from the plotting surface with 
a scalpel approximately 5 min after manufacture (see Figure 2.9a).  The scaffolds 
were also found to encapsulate the methylene blue solution (see Figure 2.9c). 
 
The optimum plotting parameters for the 33:66 (PLGA rich) blend were; 1.4 bar 
(gauge pressure) for the plotting pressure, and 266 mm/min for the plotting speed.  
The XY strand spacing used was 0.8 mm.  In contrast to the PCL rich blend, the 
scaffolds required a setting time of approximately 72 hr, though they were also 
capable of encapsulating the methylene blue solution (see Figure 2.9b). 
 
In both cases, the porosity in the XY plain was preserved.  The geometry of the 








Figure 2.9: Scaffolds of PCL/PLGA Blends. 
Scaffolds manufactured from a) 66:33 PCL/PLGA blend, 25% (w/v) 
PCL/PLGA/DCM, with an XY strand spacing of 0.8 mm, and b) 33:66 PCL/PLGA 
blend 25% (w/v) PCL/PLGA/DCM, with an XY strand spacing of 0.8 mm, 
encapsulating methylene blue.  c) 66:33 PCL/PLGA blend, 25% (w/v) 
PCL/PLGA/DCM, with an XY strand spacing of 0.8 mm, encapsulating methylene 
blue.  The blue colour observed within the scaffolds, indicates the presence of 
methylene blue.  The bar represents 20 mm. 
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2.4.2. Scaffold Coatings 
2.4.2.1. Alginate Coating 
Vivid red staining (by safranin-o) was observed to cover all the scaffolds, indicating 
the presence of alginate, as previously the safranin-o had been shown to stain 
alginate but not PCL.  On examination with the inverted microscope, it was found 
that all the scaffold pores had been blocked (see Figure 2.10a).  However, pores of 




Figure 2.10: PCL Scaffolds Coated with Alginate. 
PCL Scaffolds with an XY strand spacing of 0.8 mm coated with alginate 1.5% (w/v) 
a) crosslinked with CaCl2 and b) washed to remove excess alginate before being 
crosslinked with CaCl2.  The bar represents 0.8 mm. 
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2.4.2.2. Chitosan Coating 
Vivid green staining (by light green SF yellowish solution) was observed to cover all 
the scaffolds, denoting the presence of chitosan as previously the light green SF 
yellowish solution had been shown to stain chitosan but not PCL.  On examination 
with the inverted microscope, it was found that all the scaffold pores had been 
blocked (see Figure 2.11a).  However, pores of the scaffolds which were washed 
before the crosslinking step were unobstructed (see Figure 2.11b). 
 
 
Figure 2.11: PCL Scaffolds Coated with Chitosan. 
PCL Scaffolds with an XY strand spacing of 0.8 mm coated with chitosan 1.5% 
(w/v) a) crosslinked with TPP and b) washed to remove excess chitosan before being 
crosslinked with TPP.  The bar represents 0.8 mm. 
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2.4.2.3. Collagen Coating 
The scaffolds were found to be evenly coated with a blue colour, demonstrating the 
presence of collagen (see Figure 2.12a).  This was because methylene blue was co-
dissolved in the collagen coating solution.  On examination with the inverted 




Figure 2.12: PCL Scaffolds Coated with Collagen. 
PCL Scaffolds with an XY strand spacing of 0.8 mm coated with collagen.  a) 
macroscopic view, the bar represents 10 mm.  b) × 10 magnification, the bar 
represents 0.8 mm.   
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2.4.2.4. Gelatin Coating 
The scaffolds were found to be evenly coated with a blue colour, demonstrating the 
presence of gelatin (see Figure 2.13a).  This was because methylene blue was co-
dissolved in the gelatin coating solution.  On examination with the inverted 




Figure 2.13: PCL Scaffolds Coated with Gelatin. 
PCL Scaffolds with an XY strand spacing of 0.8 mm coated with gelatin.  a) 
macroscopic view, the bar represents 10 mm.  b) × 10 magnification, the bar 
represents 0.8 mm. 
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2.5. Discussion 
As outlined in §1.2.6.3.4, few studies have reported regenerative medical constructs 
capable of releasing growth factors by two independent delivery systems, and even 
these are in their early stages of development (Sohier et al., 2006; Ginty et al., 2008).  
However, the ability to deliver different growth factors with different release profiles 
is thought to be highly desirable. 
 
A promising dual delivery strategy was thought to be: encapsulating growth factors 
both within a scaffold, and in a scaffold coating.  The purpose of the studies 
described in this chapter was to determine the feasibility of manufacture of a range of 
scaffolds and scaffold coatings which have the potential to be used as growth factor 
delivery systems. 
2.5.1. Scaffolds of Synthetic Polymers 
2.5.1.1. PCL Scaffold Fabrication 
PCL was the first potential scaffold material to be investigated.  As discussed in 
§1.2.5.8, PCL is biocompatible and has formed part of a USFDA approved drug 
delivery device (Hutmacher et al., 2001; Hunter et al., 1998).  Therefore PCL 
components of a regenerative medical construct are unlikely to fail design criteria 1 
(non-toxic) and 2 (producing no adverse effects) (see §1.2.2).  These “tight design 
criteria” preclude scaffolds which are not biocompatible or are likely to produce an 
adverse reaction, such as an immune response, or induce neoplasia. 
 
PCL may not completely meet the loose design criterion, number 6 (scaffold 
degradation rate matching the rate of extracellular matrix production) (see §1.2.2).  
The degradation time of approximately two years (Ma et al., 2006) is likely to be 
longer than is desirable.  However many current clinical treatments also do not fully 
meet this standard.  For example, bone allografts are not fully remodelled even five 
years after surgery (Enneking and Mindell, 1991).  Failure to fully meet design 
criterion 6 is unlikely to be a significant disadvantage of the final product. 
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Design criterion 8 (similar scaffold mechanical properties to the surrounding tissue) 
(see §1.2.2) is likely to be satisfied by PCL.  Williams et al. (2005) reported that the 
mechanical properties of their PCL scaffolds were within the lower range for human 
trabecular bone.  Finally, PCL is known to be relatively inexpensive, and scaffolds 
have previously been fabricated from it (Martin et al., 2008; Hutmacher et al., 2001).  
Therefore scaffolds fabricated from this material are likely to satisfy design criterion 
9 (scaffold manufacture should be simple and cost-effective). 
 
Hence, PCL was thought to be a near-ideal potential scaffold material. 
2.5.1.1.1. Optimisation of Plotting Parameters 
Experiments were conducted to determine whether it was possible to manufacture 
PCL scaffolds using DCM.  Previously, PCL scaffolds have been manufactured by 
rapid prototyping techniques either by extruding polymer melts (Hutmacher et al., 
2001, Rai et al., 2005) or by dissolving the polymer in glacial acetic acid (Martin et 
al., 2008).   
 
Although the melting point of PCL is approximately 60°C, the polymer melt must be 
processed at 120°C (Hutmacher et al., 2001).  This effectively precludes the 
incorporation of biologically active factors (Brown et al., 1990).  Similarly, since 
glacial acetic acid is fully miscible with water (O'Neil, 2006), the solvent is free to 
interact and denature any bioactive factors present in the polymer solution.  In 
contrast, DCM is largely immiscible with water, having a solubility of only 13g/l 
(O'Neil, 2006).  Hence there is much less scope for the DCM to interact with growth 
factors dissolved in an aqueous solution.  Indeed, a plethora of growth factor delivery 
systems in regenerative medicine rely on DCM as the solvent for synthetic polymers, 
as is discussed in §1.2.6.3.3 and §2.2.  Since DCM is known be a solvent for PCL 
(Luong-Van et al., 2007), this was thought to be a promising system for scaffold 
manufacture. 
 
It was found that scaffolds could be produced in a practical fashion from solutions of 
25% (w/v) PCL/DCM, using the optimised parameters described in §2.4.1.1.1.  
Scaffold porosity and strand regularity were also found to be maintained whether a 
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plotting solution of 100% IMS was used or not (see Figure 2.2e and Figure 2.3b).  
With the improvements made to both the NC code programme and the plotting 
surface from those used by Vadillo (2009), the optimised plotting procedure had a 
very low failure rate, and required little in the way of user input or skill.  Thus, 
practical two-layer regenerative medical scaffolds were manufactured. 
2.5.1.1.2. Incorporation of Aqueous Solutions 
It was of great importance that the scaffolds could be manufactured containing 
aqueous solutions without disrupting their geometry or porosity.  The presence of 
aqueous solutions within the scaffolds could enable the encapsulation and release of 
water soluble drugs, such as growth factors. 
 
As can be seen in Figure 2.5e and f, aqueous solutions of 1% (v/v) could be 
successfully encapsulated within the scaffolds without any significant disruption to 
the geometry or porosity. 
 
The porosity of regenerative medical scaffolds is known to be vital to allow host cell 
infiltration into the scaffold, as well as allowing nutrients and cell waste products to 
flow in and out respectively.  Studies using computational fluid dynamics have 
indicated that scaffolds with pores of the size range 96 – 350 µm, are capable of 
being pervaded with fluids in bioreactor systems (Jungreuthmayer et al., 2008).  
Robinson et al. (1995) tested PLA scaffolds with pore diameters of 100, 200 and 350 
µm in rabbit calvarial defect models.  They found that the scaffolds with pores of 350 
µm allowed the greatest amount of bone ingrowth.  Indeed, Karageorgiou and 
Kaplan (2005) noted that smaller pores favour endochondral ossification, whereas 
larger pores promote vascularisation, and therefore favour intramembranous 
ossification.  They therefore recommend pore sizes greater than 300 µm in diameter. 
 
It was found in §2.4.1.1.2 that the mean pore diameters in the X and Y-directions 
were 373±9.5 µm and 460±13 µm respectively.  Therefore, the pore sizes were 
thought to be suitable for bone regenerative medical applications. 
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The scaffolds were found to be only 52±3 µm in height, whereas the strand 
thicknesses were found to be 444±3.5 µm and 353±9.7 µm in the X and Y-directions 
respectively.  This means that the two-layer scaffolds were relatively flat.  This is in 
contrast to scaffolds manufactured by Vadillo (2009) and Hutmacher (2001), where 
the strand diameters were approximately the same in the X, Y, and Z directions. 
2.5.1.1.3. Plotting More Than Two-Layers 
It was found that 3D geometry was difficult to fabricate using the process developed 
in §2.4.1.1.1 and §2.4.1.1.2.  This was undesirable, as direct control of the complete 
3D geometry was the favoured strategy (see design criterion 3, §1.2.2) (van 
Griensven et al., 2008; Zhang and Ma, 2004), though it may not be a necessary 
requirement (Karp et al., 2003). 
 
3D geometry, however, could be created from two-layer scaffolds, either by binding 
them together using an adhesive, or by packing them into the defect site.  The latter 
is possibly the preferred option, and has two distinct advantages over custom built 
3D scaffolds.  First, the scaffolds would not need to be individually tailored to the 
defect site.  The scaffolds could, therefore, form part of an “off-the-shelf” product, 
which is likely to be both quicker and cheaper to manufacture.  Second, it is known 
that the even seeding of cells onto 3D regenerative medical scaffolds is extremely 
challenging technically.  Indeed it may require the continuous circulation of media in 
a bioreactor system (Sodian et al., 2002; Carrier et al., 1999).  This problem could be 
largely eliminated by using multiple two-layer scaffolds, each of which could be 
seeded statically under identical conditions. 
 
It was concluded that such two-layer scaffolds could form the basis of an 
regenerative medical construct.  Therefore, these scaffolds were subjected to further 
testing and refinement, as described in chapters 3, 4, 5, and 6 of this thesis. 
2.5.1.2. PCL (Mn 80,000) Scaffold Fabrication 
PCL (Mn 80,000) was investigated as a possible alternative scaffold material to PCL 
(Mn 42,500).  It was thought that the difference in the number average molar mass 
would affect the diffusivity of the scaffold, and influence the release rate of 
150 
encapsulated drugs.  This has been found to be the case for other synthetic polymers 
such as PLGA (Wei et al., 2007).  This was investigated in Chapter 4. 
 
It was found that it was feasible to manufacture scaffolds from PCL (Mn 80,000).  
The scaffolds closely resembled the PCL (Mn 42,500) scaffolds described in 
§2.4.1.1.2, though the same degree of rigour in characterisation was not applied to 
them.  This was because, after testing in Chapter 4, the PCL (Mn 80,000) scaffolds 
were found to be inferior to those manufactured from PCL (Mn 42,500).  They were 
therefore not subjected to further testing. 
2.5.1.3. PLGA Scaffold Fabrication 
As discussed in §1.2.5.9, PLGA is a widely used material in bone regenerative 
medicine.  PLGA is thought to be biocompatible (Shive and Anderson, 1997), and 
has been used extensively in drug delivery devices (Oldham et al., 2000; Ruhe et al., 
2003; Wei et al., 2004).  However, there is some evidence that PLGA is less 
biocompatible than PCL, due to the release of acidic breakdown products (Sung et 
al., 2004; Ignatius and Claes, 1996; Linhart et al., 2001).  Nevertheless, it has gained 
USFDA approval for use in the fixation of bone fractures (USFDA, 2008).  
Therefore, components of PLGA in regenerative medical constructs are unlikely to 
cause the failure of design criteria 1 (non-toxic) and 2 (producing no adverse 
reaction) (§1.2.2). 
 
The degradation rate of PLGA is substantially higher than of PCL.  For example, one 
study found that PLGA microparticles degraded completely by hydrolysis within two 
months in PBS (Zhu et al., 2008).  The rate of degradation may also be altered by 
varying the ratio of lactide to glycolide subunits (Sokolsky-Papkov et al., 2007).  
Hence, PLGA scaffolds are likely to meet design criterion 6 (favourable degradation 
rate) (§1.2.2). 
 
In terms of mechanical properties, PLGA is thought to be sufficient for bone 
regenerative medical applications.  It has been reported that the elastic modulus of 
the bulk is approximately 1.31 GPa, although when manufactured as a scaffold, this 
can fall to 1.6 MPa (Leung et al., 2008).  PLGA is significantly more expensive than 
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PCL (by approximately 76-fold), but not prohibitively so for a medical device 
material. 
 
Therefore, it was concluded that PLGA showed great promise as a potential scaffold 
material.  It was found that scaffolds could be manufactured from PLGA containing 
aqueous solutions, using the optimised parameters in §2.4.1.3, see Figure 2.8b. 
 
Although, qualitatively, the scaffolds were found to resemble the PCL scaffolds 
manufactured closely in §2.4.1.1.2, the same degree of rigour in characterisation was 
not applied to them.  This was because, after testing in Chapter 4, the PLGA 
scaffolds were found to be inferior to those manufactured from PCL (Mn 42,500).  
They were therefore not subjected to further testing. 
2.5.1.4. PCL/PLGA Scaffold Fabrication 
Physical blends of PCL and PLGA have been investigated as scaffold materials in 
the regenerative medicine of nerve, skin, and bone (Panseri et al., 2008; Ng et al., 
2004; Marra et al., 1999).  Since they are physical rather then chemical (co-polymer) 
blends, it is likely that scaffolds of PCL/PLGA blends will not necessarily fail design 
criteria 1, 2, 6, 8 and 9 (non-toxic, producing no adverse reactions, having favourable 
degradation rates and mechanical properties, and being cost-effective and simple to 
manufacture) (§1.2.2). 
 
PCL/PLGA blends have previously been employed as they offer scope for tuning the 
mechanical properties and the degradation rates (Panseri et al., 2008).  Similarly, it 
was thought that there was scope for altering the release profiles of encapsulated 
drugs.  This hypothesis was tested in the studies described in Chapter 4 of this thesis. 
 
It was found that scaffolds could be manufactured using two different polymer 
blends (see Figure 2.9).  Again, although the scaffolds appeared to be similar to the 
PCL scaffolds as manufactured in §2.4.1.1.2, they were not characterised further.  
This was because, after testing in Chapter 4, the PCL/PLGA scaffolds were found to 
be inferior to those manufactured from PCL (Mn 42,500) alone.  They were therefore 
not subjected to further testing. 
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2.5.2. Scaffold Coatings 
The primary purpose of the scaffold coating in the strategy used in the studies 
detailed in this thesis, was to act as a second growth factor delivery system.  Four 
materials, which are known to be capable of growth factor release, were selected.  
Each material was examined to determine whether they could feasibly be employed 
as scaffold coatings without compromising scaffold porosity. 
 
In addition to acting as a drug delivery system, it is also important that the scaffold 
coating should facilitate cell-scaffold interaction.  This aspect of the scaffold 
coatings was examined in the studies reported in Chapter 3.  
2.5.2.1. Alginate Coating 
Alginate is most commonly used in regenerative medical applications as a void filler 
and in cell delivery systems (see §1.2.6.3.2), particularly in cartilage regenerative 
medicine (Yamaoka et al., 2006).  Though it also has USFDA approval for use in 
wound dressing for ulcers and 2nd degree burns (USFDA, 2006).  Additionally, it has 
also been used as a growth factor delivery system (Gu et al., 2004a; Mumper et al., 
1994; Lee et al., 2003a).  CaCl2 was used as the crosslinking solution, as CaCl2 is 
compatible with bioactive growth factor release, and it is non-toxic.  The 
concentration chosen was that used by Mumper (1994). 
 
It was found that alginate was capable of forming a coating on PCL scaffolds.  
However, a wash step was found to be necessary to unblock the scaffold pores (see 
Figure 2.10).  While the alginate coating was found to be feasible, it was thought 
that the wash step could have a detrimental effect on the encapsulation efficiency if 
growth factors were added in the coating.  However, as a feasible coating, alginate 
was subjected to further testing in Chapter 3. 
2.5.2.2. Chitosan Coating 
As with alginate, chitosan has been used in a number of regenerative medical 
applications (Di Martino et al., 2005).  Additionally, chitosan has USFDA approval 
for use in haemostatic dressing for severely bleeding wounds (USFDA, 2009).  It is 
also capable of releasing bioactive growth factors (Lee et al., 2004c; Kim et al., 
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2003c; Mattioli-Belmonte et al., 1999), and was therefore considered to be a suitable 
scaffold coating material.  It was decided to crosslink the chitosan using TPP, as it 
was thought to have less potential to denature the encapsulated growth factors than 
the alternative method of using strong alkaline solutions.  A 2% (w/v) solution of 
TPP was used, as the mechanical properties of chitosan crosslinked with this solution 
were found to be superior to that crosslinked with 1% (w/v), as recommended by Shu 
and Zhu (2002). 
 
Also, like alginate, chitosan coatings were found to be feasible, but to require a wash 
step prior to crosslinking.  Again, this is likely to have a detrimental effect on the 
efficiency of encapsulation of the final product.  Nevertheless chitosan was subjected 
to further testing in Chapter 3. 
2.5.2.3. Collagen Coating 
As discussed in §1.1.6.6, collagen is used in USFDA approved devices for the 
delivery of rhBMP-2, and -7.  Collagen has also been shown to support 
mineralisation more than either PCL or PLGA used alone (Phillips et al., 2006b).  
Indeed there is evidence which suggests that Type-I collagen is more capable of 
retaining the osteogenic differentiation potential of hMSCs compared to tissue 
culture plastic alone (Mauney et al., 2006).  Type-I collagen was therefore thought to 
be a near-ideal choice for a scaffold coating material. 
 
Collagen was found to be capable of coating the PCL scaffolds evenly, without 
leaving the pores blocked (see Figure 2.12).  It was thus considered to be a feasible 
coating material, and was therefore subjected to further testing in chapters 3, 4, 5, 
and 6. 
2.5.2.4. Gelatin Coating 
Gelatin is also known to retain much of the biocompatibility of the original collagen 
from which it was derived, and has been used in a number of growth factor delivery 
systems (see §1.2.5.6).  It is known that many growth factors of interest in bone 
regenerative medicine, including PDGF, VEGF, TGF-β, BMP-2, and -7, have 
isoelectric points greater than 7 (Quaglia, 2008).  Since a fast release profile from the 
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scaffold coating was desired, Type-A gelatin was selected.  Since Type-A gelatin has 
an isoelectric point of between 7 and 9 (Cole, 2000), it was thought that there would 
be little attractive charge interaction with growth factors, which might slow the 
release. 
 
Gelatin was found to be a feasible coating material, as it was also found to coat the 
PCL scaffolds evenly without blocking the pores (see Figure 2.13).  Therefore, 
Type-A gelatin was subjected to further testing in Chapter 3. 
2.6. Conclusion 
A range of scaffolds and scaffold coatings was developed from different materials.  
Scaffolds were manufactured from PCL (both Mn 42,500 and Mn 80,000), PLGA, as 
well as two blends of PCL and PLGA.  The pore size of PCL (Mn 42,500) scaffolds, 
was found to be suitable for bone regenerative medical applications.  Each of the 
scaffolds was thought to have the potential to release bioactive growth factors.  The 
five potential scaffold materials were subjected to screening based on their drug 
delivery properties in Chapter 4. 
 
Coatings protocols using alginate, chitosan, Type 1 collagen and Type-A gelatin, 
were developed.  All the coatings were thought to have the potential to release 
bioactive growth factors, and were found not to compromise PCL (Mn 42,500) 
scaffold porosity.  The four potential scaffold coating materials were subjected to 

















Chapter 3 : Primary Screening 
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3.1. Abstract 
Biocompatibility is an essential property which all bone regenerative medical 
constructs must possess.  The purpose of the studies described in this chapter, was to 
quantitatively and qualitatively assess the toxicity and cell-compatibility of the 
scaffolds and scaffold coatings.  This was achieved using live/dead assays, based on 
the staining of test cells with calcein-acetoxymethyl, a marker of cell viability, and 
propidium iodide, used to determine cell death. 
 
The biocompatibility of the potential scaffold coatings noted in Chapter 2 was 
assessed using cell cultures of human marrow stromal cells (hMSCs), human 
osteoblasts (hOBs), and MG63 cells.  The cells were grown to 80% confluency and 
subsequently challenged with well coatings of alginate, chitosan, gelatin and Type-I 
collagen.  At the end of the 72 hr test period, cell viability and death was assessed.  It 
was found that the hydrogels alginate and chitosan (crosslinked with 
tripolyphosphate and sodium hydroxide) were associated with reduced total cell 
numbers (5.0±1.1%, 39±13% and 39±11% relative to the hMSC TC plastic control 
respectively), and increased cell death (absolute values: 19.1±6.3%, 5.3±3.6%, and 
2.9±1.4% respectively), compared to the TC plastic control (0.048±0.011%).  In 
contrast, gelatin (0.1% and 0.2%) and collagen coatings led to similar or increased 
cell numbers (101±8%, 104±14%, and 115±13% for hMSCs relative to the control 
respectively), and comparable cell death (absolute values: 0.11±0.07%, 0.15±0.13%, 
and 0.16±0.12% for hMSCs), compared to the TC plastic control.  Since the Type-I 
collagen groups achieved consistently high cell numbers, and low percentages of cell 
death, this material was selected as the most cell-compatible potential scaffold 
coating.  PCL scaffolds coated with collagen were therefore subjected to testing in 
chapters 4, 5, 6 and 7 of this thesis. 
 
From the studies described in Chapter 4, scaffolds of poly(ε-caprolactone) (PCL) (Mn 
42,500) manufactured with dichloromethane (DCM) were found to be the optimum 
scaffold design from the perspective of controlled drug release.  However, it was 
essential to ascertain whether a vacuum drying time of 1 hr was satisfactory to 
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remove sufficient DCM for biocompatibility.  The scaffolds were therefore compared 
against similar PCL scaffolds, manufactured with acetic acid, which were known to 
be biocompatible. 
 
Although similar total cell numbers were present at the end of the test period in all of 
the test scaffold and control groups, there were differences in the very low amount of 
cell death seen in all groups.  The groups with scaffolds processed with acetic acid 
either unprocessed or vacuum dried for 24 hrs showed statistically significant 
increases in hMSC cell death (0.92±0.02% and 1.75±0.66% respectively) compared 
to the treated tissue culture (TC) plastic (0.28±0.08%) control for at least two out of 
three patients tested, although cell death remained below 4% in all treatment groups.  
While these differences were statistically significant, they were thought to not be of 
physiological significance. 
 
In contrast, no significant elevation in cell death was observed for the DCM 
processed scaffolds, at any of the vacuum drying times tested, compared to the TC 
plastic control. 
 
It was observed that the groups with scaffolds processed with acetic acid, as well as 
the non-dried PCL/DCM scaffolds showed abnormal hMSC morphology.  It was 
found that normal morphology was restored when the PCL/DCM scaffolds were 
vacuum dried for 1 hr or more, thus a vacuum drying time of 1 hr was deemed 
adequate to remove enough DCM for cell-compatibility.  Such scaffolds were 





As discussed in §1.2.2, the two most important design criteria for materials used in 
regenerative medicine are; biocompatibility, and the lack of potential to produce 
adverse effects, such as an immune response, or the induction of neoplasia.  The 
latter is very difficult to test without using animal models.  However, in vitro 
methods of studying biocompatibility are widely accepted for the purpose of primary 
screening, before preclinical trials are undertaken (Wang et al., 2009a; Carinci et al., 
2007; Paul and Sharma, 2007).  They also have the advantage of giving good control 
over the variables, and their sensitivity is thought, by some authors, to be at least 
equal to that of in vivo studies (Ho et al., 2008). 
 
Although there are several definitions of the term “biocompatible”, it has recently 
been eloquently defined as: 
“…the ability of a biomaterial to perform its desired function with respect to a 
medical therapy, without eliciting any undesirable local or systemic effects in the 
recipient or beneficiary of that therapy, but generating the most appropriate 
beneficial cellular or tissue response in that specific situation, and optimising the 
clinically relevant performance of that therapy.” (Williams, 2008). 
 
In the context of bone regenerative medicine, the biocompatibility of materials is 
commonly taken to mean the lack of cytotoxicity, as well as osteoconductivity. 
Cytotoxicity is commonly measured using; MTT or MTS assays (Sgouras and 
Duncan, 1990; Ignatius and Claes, 1996), lactate dehydrogenase assays (Unger et al., 
2007; Serrano et al., 2004) or calcein-acetoxymethyl (calcein-AM) in combination 
with a dye such as propidium iodide (PI) (Papadopoulos et al., 1994; Curran et al., 
2005; Wang et al., 1993; Adhirajan et al., 2009; Giacomello et al., 1999). 
 
Calcein-AM is a widely used dye in cell viability assays (Lichtenfels et al., 1994; 
Roden et al., 1999).  The dye is well retained in the viable cell targets, and it is 
relatively insensitive to pH.  There is also no stain transfer between cells 
(Papadopoulos et al., 1994).  Calcein-AM is lipid-soluble and can therefore diffuse 
passively across cell membranes.  Inside viable cells, it is converted by esterases to 
fluorescent calcein, which is lipid-insoluble (see Figure 3.1) (Neri et al., 2001). 
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PI is a dye commonly used for fluorescent deoxyribonucleic acid (DNA) and 
ribonucleic acid (RNA) staining.  It fluoresces red when excited at either 568 or 488 
nm (Suzuki et al., 1997).  It is incapable of diffusing across intact cellular plasma 
membranes, hence it can be used in a number of studies to stain cells that are either 
necrotic, or in the final stages of apoptosis (Palma et al., 2008; McKeague et al., 
2003; Goodell et al., 1996). 
 
As described in the previous chapter, a number of potential scaffold coatings were 
developed.  Since these would potentially form the primary cell-scaffold interface, it 
was very important to assess the biocompatibility of each coating.  Therefore, in the 
work of this chapter, the cell-compatibility of each of the potential coatings was 
assessed by the addition of both calcein-AM and PI to the cultures of test cells. 
 
The optimum scaffold base material was first assessed on the basis of drug 
encapsulation efficiency and desirability of the release profile, in Chapter 4.  
However, it was also important to assess whether the optimum scaffold for drug 
release had a cytotoxic effect.  Here, this was assessed by culturing staining test cells 






Figure 3.1: Mode of action of calcein-AM. 
A cartoon of the viable cellular response to calcein-AM.  The dye diffuses across the 
cell membrane, and is converted to fluorescent calcein by esterases present in viable 
cells (adapted from http://commons.wikimedia.org/wiki/File:Calcein-AM.png). 
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3.3. Materials and Methods 
Unless otherwise stated, all reagents were purchased from Sigma, UK.  All the 
techniques described below were conducted in a sterile cell culture environment, 
using sterilised equipment. 
3.3.1. Cell Culture 
The media referred to as ‘growth media’ consists of Dulbecco’s Modified Eagle’s 
Medium – high glucose (DMEM), supplemented with 10% (v/v) FCS (Autogen 
Bioclear, UK), L-glutamine (2 mM) (Gibco, UK), penicillin (100 IU/ml) and 
streptomycin (100 µg/ml) (Gibco, UK). 
3.3.1.1. Human MSC Isolation and Culture 
After written consent from the patients and approval from the local ethical committee 
(Lothian local research ethics committee), human femoral head tissue was obtained 
from patients who had undergone elective arthroplasty.  Tissue was collected from a 
total of three patients; a 68 year-old male (542), a 66 year-old male (544), and a 61 
year-old female (549).  The tissue samples were allocated an anonymous number 
based on the chronological order of the sample collection. 
 
The samples were stored at 4°C in sterile phosphate buffered saline (PBS) (Oxoid, 
UK) directly after surgery.  The hMSC isolation protocol used was as previously 
described by Tremoleda et al. (2008) and with minor modifications from Gronthos et 
al. (1998) and Gundle et al. (1995), was started less than 4 hr after surgery. 
 
Using bone cutters, the trabecular bone was removed from the femoral head and 
placed in a 30 ml conical-bottomed universal container.  Then 9 ml of growth media 
was added to the bone chips, and the mixture was stirred vigorously for 
approximately 1 min with a 5 ml pipette (Corning, USA).  Afterwards the bone 
material was allowed to settle to the bottom of the universal container and the 
supernatant, containing cells, was transferred to a new 30 ml universal.  This process 




The majority of the 21 ml of media was transferred to a 75 cm2 tissue culture flask 
(Corning, USA), leaving behind the layer of fat (approximately 1 ml) at the top of the 
media.  The cells were maintained in a humidified air incubator at 37°C with 5% 
(v/v) carbon dioxide (CO2), undisturbed for 4 days.  At this time, non-adherent cells 
were removed by washing with 10 ml of PBS, before 10 ml of fresh growth media 
was added to the flasks. 
 
Primary isolates were incubated at 37°C with 5% (v/v) CO2.  The growth media was 
refreshed at regular intervals three times every 7 days.  When the cells were 
approximately 80% confluent, they were washed three times with PBS, and passaged 
by adding 1 ml of trypsin solution (2.5 mg/ml) in PBS (Invitrogen, UK).  After 15 
min incubation at 37°C, 9 ml of growth media were added to the flasks.  Then 5 ml 
of cell suspension and 5 ml of fresh growth media were added to new tissue culture 
flasks (75 cm2).  The flasks were then incubated and refreshed with new growth 
media as before.  The hMSCs underwent routine characterisation as described in 
Appendix G. 
3.3.1.2. Human Osteoblasts 
After written consent from the patients and approval from the local ethical committee 
(Lothian local research ethics committee), human femoral head tissue was obtained 
from a patient who had undergone elective arthroplasty.  Tissue was collected from a 
52 year-old male (431). 
 
The samples were stored at 4°C in sterile PBS directly after surgery.  The human 
osteoblast (hOB) isolation protocol, which included minor modifications from the 
techniques previously described by Gallagher (2003) and Bland et al. (1999), was 
started less than 4 hr after surgery. 
 
After the majority of the trabecular bone had been removed from the femoral head as 
described in §3.3.1.1, the tissue sample was wrapped in plastic.  It was then broken 
open with a 1 kg steel mallet.  The resulting bone chips were cut into smaller pieces 
using bone cutters, and placed in a 30 ml universal container.  The chips were 
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washed four times with 15 ml of Hanks’ balanced salt solution (HBSS) to remove 
non-adherent marrow-associated cells, which were then discarded. 
 
The bone fragments were then incubated with 2 ml of trypsin, and agitated for 10 
min at 37°C, before being washed with 9 ml of growth media.  The bone chips were 
then incubated with Collagenase (2 ml, 1 mg/ml) in HBSS at 37°C for 3 hr.  After 
washing with HBSS, the bone fragments were transferred to a tissue culture flask (75 
cm2) with 20 ml of growth media. 
 
The tissue culture flask was maintained in a humidified air incubator at 37°C with 
5% (v/v) CO2, undisturbed for 4 days.  After which time, non-adherent cells were 
removed by washing with 10 ml of PBS, before 10 ml of fresh growth media was 
added to the flask. 
 
Primary isolate was incubated at 37°C with 5% (v/v) CO2.  The growth media was 
refreshed at regular intervals three times every seven days.  When the cells were 
approximately 80% confluent, they were washed three times with PBS, and passaged 
by adding 1 ml of 2.5 mg/ml trypsin solution in PBS.  After 15 min incubation at 
37°C, 9 ml of growth media were added to each flask.  Then 5 ml of cell suspension 
and 5 ml of fresh growth media were added to new tissue culture flasks (75 cm2).  
The flasks were then incubated and refreshed with new growth media as before. 
3.3.1.3. MG63 
The osteosarcoma-derived osteoblast-like cell line MG63 (European Tissue Culture 
Agency, UK) (Heremans et al., 1978) was cultured with minor modifications as from 
Lincks et al. (1998).  MG63 cells were cultured in growth media, in tissue culture 
flasks (75 cm2), incubated at 37°C with 5% (v/v) CO2.  The growth media was 
refreshed at regular intervals three times every seven days.  When the cells were 
confluent, they were washed three times in PBS, and passaged by adding 1 ml of 2.5 
mg/ml trypsin solution in PBS.  After 5 min incubation at 37°C, 9 ml of growth 
media were added to each of the flasks.  Then 1 ml of cell suspension was added to 
new tissue culture flasks (75 cm2).  An additional 9 ml of fresh growth media were 
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then added to each new flask.  The flasks were then incubated and refreshed with 
new growth media as before. 
3.3.2. Test Coatings 
For the experiments involving hMSCs, six wells were used per group for each patient 
tissue isolate.  For the experiments using hOBs and MG63 cells, three wells were 
used per group. 
3.3.2.1. Alginate 
A 3% (w/v) stock solution of alginate (Alginic Acid Sodium salt from Brown Algae) 
was dissolved in an aqueous solution of 0.5 M sodium chloride (NaCl). The alginate 
stock was incubated at room temperature for three days, to dissolve, before being 
autoclaved. A 1.5% (w/v) alginate solution in 0.5 M NaCl was then made up by 
diluting the stock alginate solution. 
 
200 µl of 1.5% (w/v) alginate solution were added per well of 48-well tissue culture 
(TC) plastic plates (Corning, USA).  Excess alginate was aspirated off, and 400 µl of 
0.1 M aqueous calcium chloride solution were added for 30 min, to crosslink the 
hydrogel.  Each well was then washed three times with PBS (Oxoid, UK).  The PBS 
was aspirated off and discarded.  The coated wells were then ready for cell seeding. 
3.3.2.2. Chitosan 
A stock solution of chitosan (Chitosan from Crab Shells, minimum 85 % 
deacetylated) was dissolved at 3% (w/v) in an aqueous solution of 0.5% (v/v) acetic 
acid (Fluka, Germany). The chitosan stock was incubated at room temperature for 
three days before being autoclaved.  A 1.5% (w/v) chitosan solution in 0.5% (v/v) 
acetic acid was then made up by diluting the stock chitosan solution. 
 
200 µl of 1.5% (w/v) chitosan solution were added per well of tissue culture (TC) 
plastic (Corning, USA).  Excess chitosan was aspirated off, and 400 µl of either 2% 
(w/v) aqueous sodium tripolyphosphate (TPP) or 1 M aqueous sodium hydroxide 
(NaOH) solution was added for 30 min, to crosslink the hydrogel.  Each well was 
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then washed three times with PBS.  The PBS was aspirated off and discarded.  The 
coated wells were then ready for cell seeding. 
3.3.2.3. Collagen and Gelatin 
Type-I collagen solution (1 mg/ml) in 0.1 M aqueous acetic acid, and Type-A 
aqueous gelatin solutions (1% and 2% (w/v)) were used to coat wells of 48-well non-
TC plastic plates (ultra-low binding, Corning, USA).  The two solutions were filter 
sterilised using 0.22 µm filters (Millipore, UK).   
 
50 µl of the solutions were added to the wells.  The plates were agitated to distribute 
the solutions evenly over the well surfaces.  After 10 min, the excess liquid was 
removed from each well.  The plates were then left to dry at room temperature for 4 
hr.  The coated wells were then ready for cell seeding. 
3.3.3. Test Scaffold Manufacture 
PCL (Mn 42,500) scaffolds were manufactured using two methods, utilising two 
different solvents: DCM and acetic acid. 
3.3.3.1. Scaffolds Made Using DCM 
Scaffolds were manufactured using the protocol with no plotting media, described in 
§2.3.2.1.1, with a plotting speed and pressure of 168 mm/min and 1.00 bar (gauge 
pressure).  The following modifications were made:   
 
The NC code used was written to produce two-layer scaffolds with a strand spacing 
of 1.6 mm in both the X and Y axes (with the dimensions 20 × 20 mm), and a Z 
spacing of 0.14 mm, see Appendix D.  These scaffolds were either not dried, or 
vacuum dried for 1 or 24 hr at 75 mbar (absolute pressure), using a freeze dryer 
(Alpha 1-4, Christ, Germany).  They were then frozen at -80°C. 
3.3.3.2. Scaffolds Made Using Acetic Acid 
Scaffolds were manufactured using the protocol with 100% IMS as the plotting 
media, described in §2.3.2.1.1, with a plotting speed and pressure of 168 mm/min 
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and 1.00 bar (gauge pressure).  The following modifications were made to produce 
scaffolds similar to those described by Vadillo, (2009): 
 
The plotting solution was 30% (w/v) PCL in glacial acetic acid, which had 
previously been dissolved in an orbital incubator (Stuart S150), set to 120 rpm 
(orbital diameter: 1.5 cm) and 37°C, for 72 hr.  The NC code used was that used in 
§3.3.3.1, see Appendix D.  These scaffolds were either not dried, or vacuum dried 
for 1 or 24 hr at 75 mbar (absolute pressure), using a freeze dryer (Alpha 1-4, Christ, 
Germany).  They were then frozen at -80°C. 
3.3.4. Live/Dead Assay 
3.3.4.1. Test Coatings 
Tissue culture flasks (75 cm2) containing confluent hMSCs (passage 2), hOBs 
(passage 4), and MG63 (passage 20) were washed three times in PBS, and the cells 
were detached from the flask using trypsin and growth media, as described in §3.3.1.  
The cell density of the suspensions was measured using a haemocytometer.  After 
appropriate dilution with growth media, the cells were added to the coated wells 
(described in §3.3.2) at a density of 10,000 cells/well (in 400 µl of media).  Cells at 
the same density were also added to uncoated TC plastic and non-TC plastic 48-well 
cell culture plates.  For the hMSCs, six wells were used per group.  For the hOBs and 
MG63s, three wells were used for each group.  Extra wells of cells on TC plastic 
were set aside to be fixed to act as positive (+ve) controls for PI.  The experiment 
was repeated using cells from three different patients. 
 
The cells were maintained in a humidified air incubator at 37°C with 5% (v/v) CO2.  
After 3 days, the cells set aside for the +ve PI control were fixed in 4% (w/v) 
paraformaldehype in PBS for 10 min.  The wells were washed with PBS (twice) and 
dH2O (once): 2 min per wash.  The wells were left to dry for 4 hr.  Since none of the 
cells would be viable, and all the cell membranes would be permeated after such 




The media was then completely changed to growth media containing 2 µM calcein 
AM and 2 µg/ml PI.  The cells were incubated in the dark at 37°C with 5% (v/v) CO2 
for 5 min.  Afterwards, the wells were washed three times with PBS for 2 min each.  
After the washes were discarded, 200 µl of PBS were added to each well.  The plates 
were then photographed using a mounted camera (Nikon, DXM1200) on an inverted 
microscope (Nikon, Eclipse TS 100) set for fluorescence, at × 10 magnification.  
Three randomly selected fields of view were photographed per well, representing 
6.0% of the growth area of the wells. 
 
The number of calcein and PI +ve cells were counted with the aid of ImageJ 
(National Institute of Health, USA) using a batch image processing macro (see 
Appendix E).  A manual count of randomly selected images was used to confirm the 
accuracy of the ImageJ counts (six images per patient).  The percentage differences 
between the manual and automated counts were calculated. 
3.3.4.2. Test Scaffolds 
The scaffolds, manufactured as described in §3.3.3, were de-frosted and cut into four 
approximately equal (10 × 10 mm) parts.  The scaffolds were immersed in IMS for 
10 min. They were washed with dH2O, then PBS and then immersed in PBS for 5 
min.  Afterwards, the scaffolds were placed flat at the bottom of 48-well TC plates. 
 
Tissue culture flasks (75 cm2)  containing confluent hMSCs (passage 2) were washed 
three times in PBS, and the cells were detached from the flask using trypsin and 
growth media, as described in §3.3.1.  The cell density of the cell suspensions was 
measured using a haemocytometer.  After appropriate dilution with growth media, 
the cells were added to the wells containing scaffolds at a density of 10,000 
cells/well (in 400µl of media).  Cells at the same density were also added to TC 
plastic wells which did not contain scaffolds.  Six wells were used for each patient’s 
tissue per group.  Extra wells of cells on TC plastic were set aside to be fixed to act 
as positive (+ve) controls for cell membrane disruption and PI staining. 
 
The cells were maintained in a humidified air incubator at 37°C with 5% (v/v) CO2.  
After 3 days, the cells cultured to act as the +ve PI control were fixed in 4% (w/v) 
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paraformaldehyde in PBS for 10 min.  The wells were washed with PBS (twice) and 
dH2O (once): 2 min per wash.  The wells were left to dry for 4 hr. 
 
After the test incubation period of 3 days, the media and scaffolds were removed 
from the wells and discarded.  Growth media containing 2 µM calcein AM and 2 
µg/ml PI was added.  The cells were incubated in the dark at 37°C with 5% (v/v) 
CO2 for 5 min.  After which time the wells were washed three times with PBS for 2 
min each.  After the washes were discarded, 200 µl of PBS were added to each well.  
The plates were then photographed using a fluorescent inverted microscope at × 10 
magnification.  Three randomly selected fields of view were photographed per well. 
 
The number of calcein (NC) and PI (NP) +ve cells in field i was counted with the aid 
of ImageJ (National Institute of Health, USA) using a batch image processing macro 
(see Appendix E).  A manual count of randomly selected images was used to 
confirm the accuracy of the ImageJ counts (six images per patient). 
 
The total cell count and percentage of PI +ve cells were determined for each well 
using Equation 3.1 and Equation 3.2 respectively.  The average for each group was 
found by taking the mean of the cell counts, and percentages of PI +ve cells, for all 
the wells in that group. 
 
Equation 3.1 
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3.3.5. Statistical Analysis 




The data on the test coatings were found not to satisfy Levene’s test for homogeneity 
of variance, even after the use of mathematical transformations.  Parametric tests, 
such as one-way analysis of variance (ANOVA), were therefore unsuitable.  Hence, 
the non-parametric test Kruskal-Wallis was used to test for statistical significance for 
each data set.  The statistical significance between the groups was found using the 
Mann-Whitney U test (Zar, 1984; Petrie and Sabin, 2005). 
 
The statistical difference in the cell numbers between the collagen and gelatin groups 
was calculated using the Wilcoxon Signed Ranks test. 
 
The data on the test scaffolds were found to be normally distributed using the 
Kolmogorov-Smirnov test.  Levene’s test was applied to confirm homogeneity of 
variance for the cell counts.  The percentage of PI +ve cells required transformation.  
The square root of each percentage was transformed into its arcsine.  Levene’s test 
was again applied to confirm homogeneity of variance.  The parametric test ANOVA 
was then employed.  This was followed by using the Tukey-Kramer post hoc test, to 
determine the statistical differences between the groups (Zar, 1984; Petrie and Sabin, 
2005).  p < 0.05 was considered to be statistically significant. 
 
The mean was used throughout, and all results are expressed as the sample means ± 
standard error of the mean (SEM). 
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3.4. Results 
3.4.1. Test Scaffold Manufacture 
Test scaffolds made from PCL (Mn 42,500) were successfully manufactured using 
either DCM or acetic acid as the processing solvent.  Using a strand spacing of 1.6 
mm in the XY plane, a more open porous structure was achieved (see Figure 3.2). 
3.4.2. Live/Dead Assay 
Under normal tissue culture conditions, virtually all the cells stained positive for 
calcein, and only very few stained positive with PI (see Figure 3.3).  In contrast, on 
cells which had previously been fixed with 4% (w/v) paraformaldehyde, all the cells 
stained positive with PI and negative for calcein (see Figure 3.3).  Randomly chosen 




Figure 3.2: Test Scaffold. 
A representative of the test scaffolds, with an XY strand spacing of 1.6 mm.  This 
particular scaffold was made from 30% (w/v) PCL/acetic acid solution, with a 








Figure 3.3: Controls for Live/Dead Assay 
Representative images of hMSCs on TC plastic, both fixed with 4% (w/v) 
paraformaldehyde, and un-fixed, stained with both calcein AM and PI.  Viable cells 
were stained green with calcein, whereas cells with non-intact plasma membranes 
were stained red with PI.  The bar represents 50 µm. 
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3.4.2.1. Test Coatings 
For the test coatings of alginate, chitosan (TPP crosslinked) and chitosan (NaOH 
crosslinked), significantly lower cell counts were observed compared to TC plastic 
for all hMSC test patients, as well as for the hOBs and MG63 cells (see Figure 3.4, 
Figure 3.6a and Figure 3.7a).  Similarly, there was a statistically significant increase 
in the percentage of dead (PI +ve) cells in the alginate groups for the hOBs and 
MG63 cells, and for one of the three hMSC patients (see Figure 3.5, Figure 3.6b 
and Figure 3.7b).  Chitosan, whether crosslinked with TPP or NaOH, statistically 
significantly increased the percentage of PI +ve cells compared to TC plastic, for all 
the cells tested. 
 
In contrast, the cell counts for the collagen and gelatin groups were statistically 
significantly higher than the non-TC plastic controls, for all the hMSC patient 
isolates tested as well as for the MG63 cells (see Figure 3.4 and Figure 3.7a).  
Indeed, the cell counts for the collagen and gelatin groups were comparable to the 
TC plastic control for all hMSC and hOB experiments.  It should be noted that higher 
cell counts were observed in the collagen groups than in the gelatin groups, in all the 
experiments conducted on test coatings (21±3%, p = 0.043). 
 
It was also found that a statistically significantly lower percentage of PI +ve cells 
was observed in the collagen and gelatin groups compared to the non-TC control in 
two out of three hMSC patient isolates (see Figure 3.5).  However, this difference 
may not be physiologically relevant since the cell death in the non-TC control was 







Figure 3.4: hMSCs total counts on coating materials. 
The average total cell counts per field of view for hMSCs seeded onto different 
coating materials.  Each figure represents data from a different patient a) 542, b) 544, 
and c) 549.  The error bars represent the SEM, n = 6 in each case.  * and † denote p < 





Figure 3.5: hMSCs percentage of PI +ve cells on coating materials. 
The average percentages of PI +ve hMSCs on different coating materials.  Each 
figure represents data from a different patient a) 542, b) 544, and c) 549.  The error 
bars represent the SEM, n = 6 in each case.  * and † denote p < 0.05, and ** and †† 







Figure 3.6: hOBs on coating materials. 
a) The average total cell counts per field of view for hOBs seeded onto different 
coating materials.  The error bars represent the SEM, n = 3 in each case.  b) The 
average percentage of PI +ve hOBs on different coating materials.  The error bars 
represent the SEM, n = 3 in each case.  * and † denote p < 0.05, and ** and †† 







Figure 3.7: MG63 cells on coating materials. 
a) The average total cell counts per field of view for MG63 cells seeded onto 
different coating materials.  The error bars represent the SEM, n = 3 in each case.  b) 
The average percentage of PI +ve MG63 cells on different coating materials.  The 
error bars represent the SEM, n = 3 in each case.  * and † denote p < 0.05, and ** 
and †† denote p < 0.01 compared to the TC and non-TC controls respectively. 
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Qualitatively, there were marked differences in morphology of the cells seeded onto 
the different surfaces (see Figure 3.8).  The cells on alginate were found to be 
rounded, and often clumped together.  The morphology of cells seeded onto chitosan, 
crosslinked with either TPP and NaOH, were found to be very similar to each other.  
The cells were rounded, though many had developed cellular processes or dendrites.  
The dendrites were particularly evident in the hMSCs seeded onto chitosan 
crosslinked with NaOH, where more than 10 cellular processes were observed on 
many of the cells (see Figure 3.8). 
 
For the gelatin coating, there was a visible difference between the two concentrations 
used.  At the higher concentration, the hMSCs had a more elongated, fibroblastic 
appearance than the more rounded cells on the lower concentration (see Figure 3.8). 
 
All the different cell types seeded onto the collagen coating, had a very similar 
morphology to that on TC plastic.  This was in marked contrast to the morphology of 
the cells on non-TC plastic, the material over which the collagen was coated.  The 
hMSCs seeded onto the collagen were observed to have an elongated, fibroblastic 
morphology (see Figure 3.8). 
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Figure 3.8: Cells on the test coating materials. 
Combined bright-field and fluorescence images of hMSCs, hOBs and MG63 cells on 
the test coating materials.  Viable cells were stained green with calcein, whereas cells 
with non-intact plasma membranes were stained red with PI.  The arrows indicate PI 
+ve cells.  The bar represents 100 µm. 
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3.4.2.2. Test Scaffolds 
The cell counts of the hMSCs exposed to the test scaffolds, showed no consistent 
statistical differences compared to the growth media controls (see Figure 3.9).  
Indeed, no consistently significant effect was observed for the different test scaffold 
vacuum drying times (see Figure 3.9). 
 
However, this was not the case for the percentages of PI +ve cells.  There was a 
consistent, though small, increase in the PI +ve percentages for all the acetic acid 
processed scaffolds (the positive control for scaffold cell-compatibility), compared to 
the growth media control (see Figure 3.10).  This difference was statistically 
significant in two (p = 0.013, 0.031), one (p = 0.002) and three (p = 0.001, 0.001, 
0.027) patient isolates for the non-dried, 1 hr dried and 24 hr dried scaffolds 
respectively.  In contrast, no statistically significant change in the percentage of PI 
+ve cells was observed for the DCM scaffolds, compared to the growth media 
control (see Figure 3.10).  However, it should be noted that the proportions of cell 
death were relatively low.  For the test scaffold groups, the highest percentage of PI 
+ve cells was found to be less than 3.5%. 
 
For the data on percentages of PI +ve cells, no consistent trend was observed 
between scaffolds processed with the same solvent and vacuum dried for different 
times.  However, differences could be observed in the morphology of the cells.  
hMSCs exposed to non-dried scaffolds, processed with either solvent, were found to 
be more rounded and dendritic compared to the growth media control (see Figure 
3.11).  For the DCM processed scaffolds, a drying time of 1 hr was found to be 
sufficient to maintain the normal morphology of the hMSCs.  However, this was not 
the case for the acetic acid processed scaffolds, as the abnormal morphology was 





Figure 3.9: hMSC total counts exposed to test scaffolds. 
The average total cell counts per field of view for hMSCs exposed to differently 
prepared scaffolds.  Each figure represents data from a different patient isolate a) 
542, b) 544, and c) 549.  The error bars represent the SEM, n = 6 in each case.  * and 
† denote p < 0.05, and ** and †† denote p < 0.01 compared to the growth media and 
corresponding non-dried controls respectively. 
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Figure 3.10: hMSC percentage of PI +ve cells exposed to test scaffolds. 
The average percentages of PI +ve hMSCs exposed to differently prepared scaffolds.  
Each figure represents data from a different patient isolate a) 542, b) 544, and c) 549.  
The error bars represent the SEM, n = 6 in each case.  * and † denote p < 0.05, and 
** and †† denote p < 0.01 compared to the growth media and corresponding non-








Figure 3.11: hMSCs exposed to test scaffolds. 
Combined calcein and PI fluorescence images of hMSCs exposed to differently 
processed scaffolds.  Viable cells were stained green with calcein.  The bar 




As outlined in §1.2.2 and §3.2, it was imperative that both the potential scaffolds and 
scaffold coatings, developed as discussed in Chapter 2, should be as compatible with 
cell survival and growth as possible.  To this end, the aims of the experiments 
described in the current chapter were; to select the most cell-compatible coating, and 
to determine the necessary scaffold vacuum drying time for sufficient removal of 
DCM.  It was also important to assess whether the final combination of scaffold and 
coating were capable of supporting cellular differentiation.  This was examined in the 
studies described in Chapter 6 and Chapter 7. 
 
In order to compare the different scaffolds and scaffold coatings, a quantitative 
system was thought to be necessary.  As discussed in §3.2, both calcein AM and PI 
are widely used to test for cell viability and death.  They were, therefore, considered 
to be a suitable quantitative system to determine the cell-compatibility of test 
materials. 
 
Since over 1900 images were taken for the experiments described in this chapter, an 
automated approach to cell counting was necessary.  The image analysis package 
ImageJ has previously been used for such applications (Sieuwerts et al., 2008; 
Collins, 2007), and automated counts were found to give good agreement with the 
randomly chosen manual counts. 
3.5.1. Coating Assessment 
Many studies have individually shown the biocompatibility of alginate (Choi et al., 
2007), chitosan (Risbud et al., 2002), gelatin (Unger et al., 2005) and collagen 
(Sandeman et al., 2000).  However, to the knowledge of the author, no direct 
comparison has been made of the biocompatibility of these materials. 
 
Since hMSCs are thought to be the most promising current cell source for bone 
regenerative medical applications (see §1.2.3), they were used as possibly the most 
important test cell types.  In addition it was recognised that in vivo, the scaffold 
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would also come into contact with osteoblasts, either formed from the hMSCs 
delivered with the scaffold, or by host cell in-growth.  Hence, hOBs were used as an 
additional, more differentiated, test group.  MG63 cells were used as the final test 
group to represent more proliferative cells.  This cell line has previously been used to 
test the cell-compatibility of a variety of materials (Amaral et al., 2008; Barron et al., 
2007; Takagishi et al., 2006; Carinci et al., 2004). 
 
It is interesting to note that the cell densities of the MG63 cells were higher than 
those of hMSCs and hOBs.  This is consistent with the findings of previous studies 
(Billiau et al., 1977).  It has been found that accumulation of hyaluronan matrix 
decreases contact inhibition of cell growth (Itano et al., 2002), and MG63 cells are 
thought to have an abundant hyaluronan-rich cell associated matrix (Hosono et al., 
2007). 
 
A higher proportion of cell death was observed for the more differentiated hOBs than 
for the relatively undifferentiated hMSCs in the collagen, gelatine and non-TC 
plastic groups, although the rates of cell death were comparable for the alginate and 
chitosan groups.  It is possible that this was due to the higher sensitivity of hOBs to 
the lack of cell-cell adhesion.  Expression of the cell-cell adhesion proteins E-
cadherin and N-cadherin is thought to be higher in hOBs than hMSCs (Marie, 2002; 
Hay et al., 2000).  These proteins are known to play a role in the protection of hOBs 
from apoptosis (Marie, 2002).  Hence, this may explain the elevated cell death for 
this cell type, and the inversely proportional relationship between the cell density and 
the death rate observed for all the cell types (see Figure 3.4, Figure 3.5, Figure 3.6 
and Figure 3.7).  However, testing this hypothesis would require further study. 
 
It was found that the total cell counts for the hydrogels alginate and chitosan were 
significantly reduced compared to the TC plastic controls for all cell types tested (see 
Figure 3.4, Figure 3.6 and Figure 3.7).  The percentage of PI +ve cells was also 
higher in these groups, indicating elevated levels of cell death (see Figure 3.5, 
Figure 3.6 and Figure 3.7), although for alginate this was statistically significant for 
one of the three hMSC patients. 
185 
 
The precise mechanism for this result is unclear.  The decreased cell counts could 
have been due to; reduced proliferation, increased cell death, low cell adhesion, or 
any of these factors in combination.  Nevertheless, whichever hypothesis is correct, it 
would appear that alginate and chitosan do not have sufficient cell-compatibility to 
be used as effective scaffold coatings.  However, it is possible that these data may be 
explained by the cell adhesion characteristics of the hydrogels.  Mammalian cells are 
thought to lack receptors for either alginate or chitosan.  Indeed this has led some 
authors to covalently attach RGD sequences to the polymers in an attempt to 
alleviate this problem (Augst et al., 2006; Ho et al., 2005).  The predominantly round 
morphology of the cells on the hydrogels may indicate that the level of cell-hydrogel 
interaction was relatively low (Watanabe et al., 2002).  This lack of cell adhesion 
may have resulted in the relatively high observed rates of cell death, by anoikis 
(Benoit et al., 2007). 
 
In contrast, for collagen and both concentrations of gelatin, hMSC and MG63 cell 
counts were comparable to the TC plastic control, and significantly higher than the 
non-TC plastic control (see Figure 3.4 and Figure 3.7).  Also, both coating materials 
statistically significantly reduced the apparent cell death for two of the three hMSC 
patients tested, compared to the non-TC plastic control (see Figure 3.5).  Indeed the 
coatings reduced the apparent cell death on non-TC plastic to the level of the TC 
plastic control for all cell types tested.  Although it should be noted that the 
percentage of cell death in the non-TC plastic group was still relatively low 
(2.2±1.8%).  The level of hMSC death on tissue culture plastic was found to be 
comparable to that found in previous studies (Santiago et al., 2009).  It was 
concluded that coatings of collagen and gelatin were more cell-compatible than the 
hydrogels alginate and chitosan. 
 
These data are consistent with the hypothesis that both collagen and gelatin improve 
cell adhesion to the non-TC plastic.  Integrin binding and focal adhesion assemblies 
are known to be critical to cell attachment.  Type-I collagen has been found to up-
regulate integrin expression in hMSCs (Chen et al., 2008).  In addition, Type-I 
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collagen has been found to enhance the adhesion, spreading and proliferation of rat 
osteoblasts (Cowles et al., 2000; Geissler et al., 2000).  This is thought to be due to 
the binding of its specific motif, GFOGER, to integrin (Knight et al., 2000).  
Although integrin binding to gelatin is thought to be compromised by the 
denaturation process used in its manufacture (Zaman, 2007), cellular integrin binding 
is still possible (Davis, 1992).  As stated above, this is likely to reduce the rate of cell 
death by anoikis in these groups. 
 
Of the two gelatin concentrations assessed, the 0.2% (w/v) coating consistently 
produced higher cell counts than the 0.1% (w/v) coating.  This effect was particularly 
pronounced for the MG63 cells (see Figure 3.7).  However, Type-I collagen 
consistently produced the highest cell counts of all the test coatings.  Furthermore, a 
very low incidence of cell death was observed in the collagen coated test wells.  Thus 
it was reasoned that Type-I collagen was the most cell-compatible potential scaffold 
coating of the materials tested. 
 
Hence, Type-I collagen coated scaffolds were subjected to further testing as 
described in Chapters 4, 5, 6 and 7. 
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3.5.2. Scaffold Assessment 
While DCM is considered to be, chemically, a relatively mild solvent from the 
viewpoint of retaining growth factor bioactivity, it can be cytotoxic.  Indeed, the 
USFDA has set an upper limit for the presence of DCM residue of 600 parts per 
million for clinical treatments (Howard et al., 2008).  DCM is, however, highly 
volatile, making it relatively easy to extract. 
 
Previous studies have employed either vacuum drying or freeze drying to remove 
residual DCM from regenerative medical constructs (Wei et al., 2007; DeFail et al., 
2006).  Consequently, this was thought to be a potentially useful strategy for 
processing the scaffolds made with DCM to a biocompatible state. 
 
Clearly it is difficult to assess whether sufficient DCM had been removed, without 
employing an animal model.  However, it was possible to compare the scaffolds 
processed with DCM, with very similar scaffolds which were known to be 
biocompatible.  Vadillo (2009) and Martin et al. (2008) found that PCL scaffolds, 
processed using acetic acid as the solvent and 100% IMS as the plotting medium, 
were biocompatible, using a calvarial defect model in NOD/SCID mice.  The DCM-
processed scaffolds were therefore tested against scaffolds similar to those used by 
Vadillo (2009) and Martin et al. (2008), using calcein AM and PI to stain the test 
cells.  The acetic acid-processed scaffolds would, therefore, act as a positive control 
for cell-compatibility. 
 
For this test, the XY strand distance of the scaffolds was increased, to allow more 
cells to fall through the pores to the TC plastic beneath.  It was decided to study the 
cells on TC plastic rather than on the scaffolds. This avoided complicating the 
experimental system, by potentially adding the additional variables of differences in 
scaffold geometry and surface topography. 
 
Surprisingly it was found that, despite the presence of the scaffolds in the wells, all 
the cell counts were comparable with the TC plastic control.  It would seem that the 
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cells were capable of filling the gaps left in the cell seeding by the scaffold.  No 
consistent difference was found between any of the test scaffold groups and the TC 
plastic control (see Figure 3.9).  Similarly, no consistent differences were observed 
between the scaffold groups manufactured using different solvent, and dried for 
different times. 
 
However, the percentages of PI +ve cells, indicating cell death, were consistently 
higher for all the scaffolds groups processed with acetic acid compared to the TC 
plastic control, although the actual differences in cell death were very small.  The 
level of hMSC death on tissue culture plastic was found to be comparable to that 
found in previous studies (Santiago et al., 2009).  In contrast, no statistically 
significant difference was found between any of the DCM processed scaffolds and 
the control (see Figure 3.10).  These data suggest that the PCL scaffolds processed 
using DCM were at least comparable to the acetic acid-processed scaffolds, which 
were used as the positive control for cell-compatible scaffolds.  Hence, since there 
was no physiologically significant difference between the DCM-processed scaffolds 
and the scaffolds known to be biocompatible (Martin et al., 2008; Vadillo, 2009), it 
was concluded that these findings do not preclude the DCM-processed scaffolds 
from use in bone regenerative medical applications on the grounds of cell-
compatibility. 
 
It should be noted that although cell death was elevated in the acetic acid groups, it 
remained relatively low (> 3.5%).  Hence the elevated death rate was not sufficient to 
prevent the hMSCs from becoming confluent by the end of the test period. 
 
Interestingly, no evidence was obtained from either the data on the cell counts, or the 
+ve PI percentages, to suggest that vacuum drying had any impact on the cell-
compatibility of the scaffolds.  Nevertheless, it was found that there were marked 
differences in cell morphology between the groups (see Figure 3.11).  The groups of 
PCL/DCM scaffolds which had not been dried, as well as all PCL/acetic acid 
scaffolds, contained a large number of rounded or dendritic hMSCs.  This 
morphology is thought to be one of the most ubiquitous characteristics of cell death, 
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regardless of the stimulus (Bortner and Cidlowski, 2003; Doonan and Cotter, 2008).  
Since it is known that cells of the osteoblastic lineage are very sensitive to even small 
changes in pH, even in the range of pH 7.37 – pH 7.29 (Brandao-Burch et al., 2005), 
it is possible that the residual acetic acid within the scaffolds was capable of 
deceasing the pH sufficiently to induce a slight increase in the rate of apoptosis.  This 
was in contrast to the control, and the groups containing PCL/DCM scaffolds which 
had been dried for 1 and 24 hr.  In these groups, the hMSC morphology was similar 
to that described by Gronthos et al. (1998) and Tremoleda et al. (2008), with very 
few rounded or dendritic hMSCs.  This evidence indicates that a vacuum drying time 
of a least 1 hr is required for the PCL/DCM scaffolds to obtain the required level of 
cell-compatibility. 
 
PCL (Mn 42,500) scaffolds processed with DCM and vacuum dried for 1hr, were 
therefore subjected to further testing as described in chapters 5, 6 and 7. 
3.6. Conclusion 
A quantitative system, based on the use of calcein AM and PI, was used to assess the 
relative cell-compatibility of coatings of alginate, chitosan, gelatin and Type-I 
collagen, based on cell viability and morphology in both progenitor (hMSCs) and 
differentiated human cells (hOBs and MG63 cells) of the osteoblastic lineage.  The 
hydrogels alginate and chitosan were found to perform poorly compared to gelatin 
and collagen. This was in terms of decreased total cell counts, increased proportions 
of apparent cell death, and a morphology more associated with apoptosis.  Type-I 
collagen was found to be the most cell-compatible coating, as it was found to be 
consistently superior to gelatin in terms of the total cell count.  Type-I collagen 
coated scaffolds were therefore subjected to further testing, as described in chapters 
4, 5, 6 and 7 of this thesis. 
 
PCL scaffolds, processed using DCM as the solvent, and vacuum dried for different 
times, were also quantitatively and qualitatively assessed for their cell-compatibility.  
This was done relative to PCL/acetic acid scaffolds, which have previously been 
shown, by others, to be biocompatible in an animal model.  This was achieved by 
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incubating hMSCs, which had been exposed to the scaffolds, with calcein AM and 
PI.  The morphology of the cells was also examined to test for abnormalities. 
 
From the data on the total cell counts, and the proportion of apparent cell death, it 
was found that the PCL/DCM scaffolds were at least comparable in terms of cell-
compatibility to the PCL/acetic acid scaffolds, which had been used as a positive 
control for cell-compatibility.  From the morphology studies, it was concluded that a 
vacuum drying time of 1 hr was sufficient for satisfactory DCM removal. 
 
Having shown their cell-compatibility, such scaffolds were subjected to further 
















Chapter 4 : Quantitative Release 
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4.1. Scaffold Nomenclature 
CoatPBS   Collagen coating with PBS (rhBMP-7 control) 
CoatBMP 1.25   Collagen coating with rhBMP-7 (1.25 µg/ml) 
ScaffPBS   Scaffold encapsulating PBS (rhBMP-7 control) 
ScaffBMP 1.25   Scaffold encapsulating rhBMP-7 (1.25 µg/ml) 
4.2. Abstract 
For all regenerative medical drug delivery devices, it is important to assess the 
potential drug loading capacity, the drug release profiles, and the consistency 
between batches.  In this chapter, the model drug methylene blue was used to select 
the optimum scaffold material, from those developed during the studies described in 
Chapter 2.  Once identified in this way, the favoured candidate scaffold material, and 
the collagen coating, were loaded with recombinant human bone morphogenetic 
protein-7 (rhBMP-7).  The release of this growth factor was confirmed using an 
enzyme-linked immunosorbent assay (ELISA). 
 
The encapsulation efficiency of scaffold made from poly(ε-caprolactone) (PCL) (Mn 
42,500 and 80,000), poly(lactide-co-glycolide) (PLGA), and blends of PCL (Mn 
42,500) with PLGA, were assessed.  The efficiency was found to be both relatively 
high and consistent for both Mn 42,500 and 80,000 PCL as well as PCL:PLGA 
66:33, at 71±6%, 71±5%, and 78±10% respectively, relative to the low efficiencies 
recorded for both PCL:PLGA 66:33 and PLGA: 57±5% and 38±10% respectively.  It 
was also found that PCL (Mn 42,500) scaffold, made using a plotting medium of 
IMS, did not contain detectible levels of the model drug. 
 
The release rate of methylene blue from PCL (Mn 42,500), was found to be relatively 
slow, controlled, and consistent between batches (between 21±2% and 20±3% 
released in the first 24 hr).  Despite the release rate being consistent for PCL (Mn 
80,000), the release rate was thought to be too high, since between 29±3% and 
39±5% of the test compound was released in the first 24 hr period.  The release rate 
of methylene blue from the PCL/PLGA blends (between 17±2% – 30±7% and 
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18±4% – 31±6% in the first 24 hr) and PLGA (between 7.1±3.4% – 9.3±2.9% in the 
first 24 hr) were found to be inconsistent, and low in the case of PLGA, even taking 
the different loading efficiencies into account.  Therefore, PCL (Mn 42,500) was 
selected as the favoured candidate scaffold material. 
 
The loading content and release profiles from methylene blue loaded collagen 
scaffold coatings were also evaluated.  The drug loading capacity was found to be 
suitable for use as a drug delivery system (65±5 µg/g of methylene blue per unit 
scaffold mass).  The release of methylene blue was observed to be rapid (between 
54±10% – 70±17% in the first 24 hr), which was thought to be desirable for the 
coating delivery system, if, for example, a dual temporal mode of release is favoured 
using one or more compounds. 
 
The growth factor rhBMP-7 was loaded in collagen scaffold coatings and 
encapsulated within PCL (Mn 42,500) scaffolds.  Both delivery systems were found 
to release detectable quantities of rhBMP-7 (releasing 2.8±0.2 µg/g and 87±7 ng/g 
respectively in the first 24 hr), even after 14 days.  The release rate of the growth 
factor from the scaffold coating was higher than that from the encapsulating 
scaffolds.  However, the cumulative release profiles were found to deviate from the 
desired ideal release profiles, and burst release was observed from both delivery 
systems.  Although differences were observed for the two delivery systems, this 
difference may not be of clinical significance.  Nevertheless, scaffolds with less than 
ideal delivery properties may still be of potential clinical use. 
 
Evidence was also obtained that while the primary mode of release from the 
encapsulating scaffolds was diffusion, degradation may play a significant role in the 
release from the scaffold coatings. 
 
The scaffolds were therefore found to be capable of releasing immuno-reactive 




As discussed in §1.2.6.3.4, the delivery of various bioactive factors, with different 
release profiles, may be necessary for the success of some regenerative medical 
constructs.  The drug delivery strategy chosen for the studies described in this thesis, 
was to release bioactive factors from two separate delivery systems: the scaffold and 
the scaffold coating.  It was intended that release from the scaffold coating would be 
rapid, whereas release from the encapsulating scaffolds would be more prolonged. 
 
To assess both the encapsulation efficiency and the in vitro release profiles from 
potential drug delivery devices, it is common practice to conduct preliminary 
experiments using model drugs.  There are two main reasons for this.  First, the 
model drugs may be easy to detect, and may not undergo significant degradation in 
the release media, in contrast to active factors.  Second, the cost of both the model 
drugs themselves, and the methods used for their detection, may be several orders of 
magnitude less than for the active factors. 
 
However, care must be taken when choosing a model drug.  Factors such as 
electrostatic charge and molecular weight are known to affect their diffusivity and 
therefore the profile of release (Weadock et al., 1987; Simon et al., 1999; Fredenberg 
et al., 2005; Lee et al., 2007). 
4.3.1. Model Drug Rational 
In general terms, two modes of drug release exist for drug delivery devices for 
regenerative medical applications: diffusion and degradation (Wada et al., 1995; 
Tabata et al., 1999).  In reality, both methods of release will operate simultaneously, 
however one mode is usually dominant in a given situation and timepoint. 
 
Where there is a strong charge interaction between the drug and the drug delivery 
device, release by degradation is usually the dominant mode of release.  For 
example, Lee et al. (2004a) achieved the release of a growth factor (TGF-β1) from a 
hydrogel (chitosan) with the same charge.  However, Lee et al. (2004a) failed to 
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achieve release from TGF-β1 from alginate by diffusion, where there is significant 
charge interaction.  Similarly, Tabata et al. (1999) varied the release of bFGF from 
oppositely charged gelatin by altering the degradation properties of the carrier. 
 
In contrast, where there is no charge interaction and the degradation time of the 
carrier is relatively long, diffusion is likely to be the dominant mode of release 
(Ritger and Peppas, 1987a; Ritger and Peppas, 1987b; Wada et al., 1995). 
 
While drug release by degradation is thought to be proportional to the degradation of 
the carrier, release by diffusion, where there is no strong charge interaction, is 
governed by the principles first investigated by Fick (1855).  Fick’s first law, see 
Equation 4.1, relates flux of a component (VJA) to its composition gradient (dcA/dz) 




Fick’s First Law of diffusion in one dimension: 
dz
dc
DJ AABAV −=  
 
In solving the equation for three dimensions, the “shape” of the release curves is 
affected by the geometry of the carrier.  Examples are shown in Equation 1.1, 
Equation 1.2 and Equation 4.2. 
 
Equation 4.2 













It is thought that diffusivity varies approximately inversely with the cube root of the 
molecular weight of the compound (Goodhill, 1997).  However, altering the 
molecular weight does not affect other aspects of the theoretical release profiles 
(Ritger and Peppas, 1987a; Ritger and Peppas, 1987b; Wada et al., 1995).  Although 
altering the molecular weight will alter the rate of release, this effect should be the 
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same across different carrier materials, assuming the geometry is similar.  That is to 
say: if the release rate from carrier X is faster than carrier Y, for drug A, the release of 
X should theoretically be faster than carrier Y for drug B (assuming A and B have 
similar charges but different molecular weights).  In contrast, as stated above, 
altering the charge interactions has been found to alter the mode of release (Lee et 
al., 2004a) 
 
The protein bovine serum albumin (BSA) has been employed as a model drug for a 
variety of potential drug delivery devices (Ginty et al., 2008; Ho et al., 2008; 
Habraken et al., 2008).  This is primarily because the molecular weight of BSA (66.4 
kDa) is similar to many growth factors commonly used for regenerative medical 
applications (see Figure 4.1).  However, in the physiological pH range of 7.35 – 7.45 
(Waugh et al., 2006), BSA is negatively charged (Lee et al., 2007; Blanco and 
Alonso, 1998).  This is in contrast to many growth factors of interest for bone 
regenerative medical applications, such as; fibroblast growth factor-2 (FGF-2), 
platelet derived growth factor (PDGF), bone morphogenetic protein-2 (BMP-2) and 
bone morphogenetic protein-7 (BMP-7), which carry a net positive charge (see 
Figure 4.1).  Potentially, this difference in charge could mean that the release 
kinetics would be very different to the growth factors listed above.  BSA may not, 
therefore, be an appropriate model drug for bone regenerative medical applications.  
 
Methylene blue is another commonly used model drug (De and Robinson, 2003; Wu 
et al., 1996; Tu et al., 2005).  It is a positively charged aromatic compound, hence it 
has the same charge as many growth factors under physiological conditions.  
Although the molecular weight is relatively low (320 Da), the mode of release, 
though not the rate, is likely to be similar to positively charged growth factors, as 
discussed above.  Therefore, the model drug methylene blue is thought to be a useful 
model drug to evaluate potential bone regenerative medical drug delivery devices 
(Wu et al., 1996). 
197 
4.3.2. Growth Factor Release 
While model drugs may be effective for the purposes of preliminary testing and 
screening, it is thought to be necessary to confirm the actual in vitro release profile 
using growth factors themselves (Wang et al., 2009b).  Such release profiles are 
normally investigated using either radioactively labelled forms of the growth factors 
(Wei et al., 2007; Hosseinkhani et al., 2007; Bodde et al., 2008), or by using an 
appropriate enzyme-linked immunosorbent assay (ELISA) (Kim and Valentini, 2002; 
Moioli et al., 2006; Jaklenec et al., 2008). 
 
As indicated in Chapter 2, a number of potential scaffolds were developed.  In the 
studies described in the current chapter, these were evaluated based on their 
encapsulation efficiencies and release profiles of methylene blue.  The scaffold 
coating Type-I collagen, which was found to be the most cell-compatible of the 
potential coatings developed, was evaluated in a similar fashion.  The release profile 
of rhBMP-7 was then evaluated from both the favoured candidate scaffold and 









Figure 4.1: Growth factor chemical properties. 
The molecular weights and isoelectric points of growth factors commonly employed 
in regenerative medical applications (taken from Quaglia (2008)). 
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4.4. Materials and Methods 
Unless otherwise stated, all reagents were purchased from Sigma, UK. 
4.4.1. Encapsulation Efficiency 
4.4.1.1. Methylene Blue Phase Partition 
A methylene blue stock aqueous solution of 5 mg/ml was diluted with distilled water 
(dH2O) to a concentration of 62.5 µg/ml.  This solution was serially diluted with 
dH2O to produce concentrations of 31.3, 15.6, 7.81, 3.91, 1.95 and 0.98 µg/ml.  Each 
of the diluted solutions as well as a dH2O blank (150 µl) were added to 
dichloromethane (DCM) (1.5 ml) in 15 ml centrifuge tubes (Corning, UK).  Three 
replicates were used for each methylene blue concentration. 
 
The tubes were placed in an orbital incubator (Stuart S150), set to 120 rpm (orbital 
diameter: 1.5 cm) and 37°C.  After 4 hr, 100 µl of the aqueous solution were 
aspirated from each tube, and added to the wells of a 96-well plate (Corning, UK).  
The optical densities of the test wells, along with a calibration curve of aqueous 
methylene blue (62.5, 31.3, 15.6, 7.81, 3.91, 1.95, 0.98 and 0 µg/ml) were then 
measured using an automated 96-well plate reader (Cytofluor multiwall reader, 
Series 4000) set at 630 nm.  The apparent methylene blue concentrations were then 
derived using the data from the calibration curve. 
4.4.1.2. Scaffold Encapsulation Efficiency 
Scaffolds were manufactured from PCL (both Mn 42,500 and Mn 80,000), and 
PLGA, as well as two blends of PCL and PLGA.  Scaffolds were also fabricated 
from PCL (Mn 42,500) using a plotting medium of 100% IMS.  The protocols for 
scaffold manufacture were as previously stated in §2.3.2.1.2, §2.3.2.2, §2.3.2.3 and 
§2.3.2.4 (see Table 4.1), except that the scaffolds were not vacuum dried.  This was 
necessary to ensure the methylene blue remained in solution.  The scaffolds 
encapsulated methylene blue as described in Chapter 2: methylene blue stock 




Table 4.1: Scaffold plotting parameters. 
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Two batches of each scaffold formulation were manufactured.  The masses were 
determined for four scaffolds from each batch.  These scaffolds were then completely 
immersed in DCM (3 ml) in 15 ml centrifuge tubes, then 300 µl dH2O were added to 
each tube.  The tubes were placed in an orbital incubator, set to 120 rpm and 37°C.  
After 4 hr, 200 µl of the aqueous solution were aspirated from each tube, and added 
to the wells of a 96-well plate (100 µl per well).  The optical densities of the test 
wells, along with a calibration curve of aqueous methylene blue (62.5, 31.3, 15.6, 
7.81, 3.91, 1.95, 0.98 and 0 µg/ml) were then measured using an automated 96-well 
plate reader set at 630 nm.   
 
The apparent methylene blue concentrations were then calculated using the data from 
the calibration curve, after which the results were corrected to take into account the 
phase partition of the methylene blue from the results reported in §4.5.1.1.  The mass 
of methylene blue per scaffold, normalised against the scaffold mass, was then 
calculated. 
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4.4.1.3. Scaffold Coating Encapsulation Efficiency 
PCL (Mn 42,500) scaffolds were manufactured and then coated with Type-I collagen 
(rat tail) containing methylene blue, as described in §2.3.3.3.  Two separate scaffold 
batches were fabricated, with four scaffolds randomly selected from each batch. 
 
After the mass of each scaffold had been measured, the scaffolds were cut into four 
approximately equal parts.  The scaffolds were then completely immersed in 1 ml of 
0.1 M aqueous acetic acid in 1.5 ml Eppendorf tubes.  The tubes were placed in an 
orbital incubator, set to 120 rpm (orbital diameter: 1.5 cm) and 37°C.  After 4 hr, 200 
µl of the aqueous was aspirated from each solution, and added to the wells of a 96-
well plate (100 µl per well).  The optical densities of the test wells, along with a 
calibration curve of methylene blue in 0.1 M aqueous acetic acid (62.5, 31.3, 15.6, 
7.81, 3.91, 1.95, 0.98 and 0 µg/ml) were then measured using an automated 96-well 
plate reader set at 630 nm.  The apparent methylene blue concentrations were then 
found using the data from the calibration curve.  The mass of methylene blue per 
scaffold, normalised against the scaffold mass, was then calculated. 
4.4.2. Methylene Blue Release 
Four scaffolds from each of the batches manufactured for the experiments described 
above in §4.4.1.2 and §4.4.1.3, were either vacuum dried for 1 hr at 75 mbar 
(absolute pressure) using a freeze dryer (Alpha 1-4, Christ, Germany) or air dried for 
4 hr, respectively.  The mass of each scaffold was then determined.  The scaffolds 
which were not coated in collagen, were immersed in IMS for 10 min before being 
washed with dH2O (5 min) and PBS (Oxoid, UK) (5 min) in order to approximate the 
scaffold sterilisation process. 
 
Every scaffold was then cut into 16 approximately equal parts before being placed in 
0.5 ml Eppendorf tubes, along with 250 µl of PBS.  Care was taken that all the 
scaffold parts were completely immersed in the PBS.  The tubes were then sealed 
and placed in an orbital incubator, set to 120 rpm and 37°C. 
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After 1, 2, and 3 days, all the PBS was aspirated from the tubes and retained, before 
250 µl of fresh PBS were added to each tube.  After 4 days, all the PBS was removed 
from each tube and retained.  All the PBS which had previously been in contact with 
the scaffolds was stored at 4°C in sealed 0.5 ml Eppendorf tubes. 
 
The following day, 200 µl of the supernatant containing released methylene blue, 
was aspirated from each solution, and added to the wells of a 96-well plate (100 µl 
per well).  The optical densities of the test wells, along with a calibration curve of 
aqueous methylene blue solutions in PBS (62.5, 31.3, 15.6, 7.81, 3.91, 1.95, 0.98 and 
0 µg/ml) were then measured using an automated 96-well plate reader set at 630 nm.  
The apparent methylene blue concentrations were then calculated using the data from 
the calibration curve.  The mass of methylene blue released in each 24 hr period was 
then calculated and normalised against the scaffold masses and encapsulation 
efficiencies. 
4.4.3. rhBMP-7 Release 
All of the dH2O and phosphate buffered saline (PBS) used in the experiments 
described in this section, was filter sterilised using 0.22 µm filters (Millipore, UK).  
The scaffold manufacture and coating steps described in §4.4.3.1 were conducted in 
a sterile environment, using sterilised equipment.  Sterile conditions were used so 
that the same procedure could be used to manufacture sterile scaffolds for studies 
involving cells (see Chapter 5, Chapter 6 and Chapter 7). 
4.4.3.1. rhBMP-7 Release from Scaffolds 
A stock solution of 1 mg/ml rhBMP-7 was diluted with PBS to a concentration of 25 
µg/ml.  This was added at 1% (v/v) to 25% (w/v) solutions of PCL (Mn 
42,500)/DCM.  This yielded a final mass ratio of rhBMP-7 to PCL of 1.00 µg/g or 
1.25 µg/ml for the PCL/DCM solution (allowing for evaporation). 
 
Once the plotting solutions were prepared, emulsions were created by vigorous 
manual mixing, using sterile 3 ml transfer pipettes (Fisher, UK), for approximately 
30 seconds. The resulting emulsions were loaded into the syringe of the Bioplotter™.  
Scaffolds were then manufactured, with no plotting medium, using the optimised 
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plotting parameters determined in §2.4.1.1.1, and then vacuum dried at 75 mbar 
(absolute pressure) for 60 min.  These scaffolds were designated ScaffBMP 1.25. 
 
Scaffolds were also manufactured in a similar fashion, replacing the 25 µg/ml 
rhBMP-7 solution with PBS.  These scaffolds were designated ScaffPBS. 
 
All the scaffolds were immersed in industrial methylated spirit (IMS) for 10 min 
before being washed with dH2O (5 min) and PBS (Oxoid, UK) (5 min).  The stock 
solution of rhBMP-7 (1 mg/ml) was then added to 1 mg/ml Type-I collagen (rat tail) 
in 0.1 M aqueous acetic acid, to yield a final concentration of 1.25 µg/ml.  The 
equivalent volume of PBS was added to a similar solution of Type-I collagen. 
 
All the scaffolds were then immersed for 5 min in one of the collagen solutions either 
containing or lacking rhBMP-7.  The scaffolds were designated with the prefixes 
CoatBMP 1.25 or CoatPBS respectively.  Afterwards, the scaffolds were removed, and 
allowed to air dry for 4 hr at room temperature.  Once dry, the scaffolds were stored 
at -80°C. 
 
The above protocol was conducted a total of three times using separate batches of 
materials.  For each batch, three scaffolds were in each of the groups 
(CoatPBSScaffPBS, CoatBMP 1.25ScaffPBS, CoatPBSScaffBMP 1.25, CoatBMP 1.25ScaffBMP 1.25).  
After the scaffolds had been defrosted, the mass of each scaffold was measured.  
Every scaffold was then cut into 16 approximately equal parts before being placed in 
0.5 ml Eppendorf tubes, along with 250 µl of 0.1% (w/v) BSA in PBS.  Care was 
taken that all the scaffold parts were completely immersed in the solution.  The tubes 
were then sealed and placed in an orbital incubator, set to 120 rpm (orbital diameter: 
1.5 cm) and 37°C. 
 
Over the next 14 days, the 250 µl of BSA/PBS solution was removed from the 
individual tubes and replaced with fresh BSA/PBS every 24 hr.  The conditioned 
solutions, which were aspirated from each of the tubes, were retained in new 0.5 ml 
Eppendorf tubes, and labelled to enable identification of the sample source.  The 
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tubes were immediately sealed and frozen at -80°C.  The concentration of the 
rhBMP-7 was then measured for the samples collected on days 1, 2, 3, 4, 7 and 14.  
This was achieved using the ELISA protocol, as described in §4.4.3.2.  It should be 
noted that samples for CoatBMP 1.25ScaffPBS and CoatBMP 1.25ScaffBMP 1.25 for days 1 and 
2 were diluted 100-fold with 0.1% (w/v) BSA in PBS.  This was necessary to reduce 
the concentration to within the range of the ELISA concentration curve.  The 
calculated concentrations of these samples were later adjusted to take the degree 
dilution into account. 
4.4.3.2. rhBMP-7 ELISA Procedure 
The rhBMP-7 concentrations were quantified using a DuoSet human BMP-7 ELISA 
kit (R&D Systems, USA).  The protocol was followed according to the 
manufacturer’s instructions.  Briefly, EIA 96-well plates (Costar, USA) were coated 
with the Capture Antibody (100 µl per well) (R&D Systems, USA) overnight.  The 
plate was washed with Wash Buffer (0.05% (v/v) Tween 20, in PBS), before being 
blocked with Reagent Diluent (300 µl per well) (R&D Systems, USA) for 1 hr. 
 
After washing with Wash Buffer, 100 µl of test samples and standards for the 
calibration curve were added to the wells for 2 hr.  The concentrations of the 
standards used were 4000, 2000, 1000, 500, 250, 125, 62.5 and 0 pg/ml.  Two wells 
were used per standard.  After washing the plate, the Detection Antibody (R&D 
Systems, USA) was added to each well (100 µl).  After 2 hr, the plate was washed 
again. 
 
Following 2 hr of incubation at room temperature, the plate was washed before 
Streptavidin-HRP (R&D Systems, USA) was added to each well (100 µl).  After 
incubating for 20 min in the dark, the plate was re-washed.  Then, Substrate Solution 
(R&D Systems, USA), containing hydrogen peroxide and tetramethylbenzidine, was 
added to each well (100 µl).  Following 20 min of incubation in the dark, Stop 
Solution (1 M sulphuric acid) was added to each well (50 µl). 
 
The optical densities of the wells was then read using an automated 96-well plate 
reader set at 540 nm, using a reference filter of 750 nm.  The apparent rhBMP-7 
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concentrations were then calculated using the data from the calibration curve.  The 
mass of rhBMP-7 released in each 24 hr period was then calculated and normalised 
against the scaffold masses. 
4.4.4. Statistical Analysis 
The mean was used throughout, and all results are expressed as the sample means ± 
standard error of the mean (SEM).  All correlations were derived from calibration 
curves using Excel 2003.  All correlations used, had R2 values greater than 0.99. 
 
The data were found not to satisfy Levene’s test for homogeneity of variance, even 
after the use of mathematical transformations as the p-values obtained were less than 
0.05.  Parametric tests, such as one-way analysis of variance (ANOVA), were 
therefore unsuitable.  Hence, the non-parametric test Kruskal-Wallis was used to test 
for statistical significance for each data set.  The statistical significance between the 
groups was found using the Mann-Whitney U test (Zar, 1984; Petrie and Sabin, 
2005).  p < 0.05 was considered to be statistically significant, as calculated using the 
statistical software package SPSS 14.0 for Windows. 
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4.5. Results 
4.5.1. Encapsulation Efficiency 
4.5.1.1. Methylene Blue Phase Partition 
In the range of methylene blue concentrations (CMB) examined, a linear relationship 
between the concentration and the optical density (OD) at 630 nm, was found.  
Linear correlations were therefore calculated by linear regression.  Unknown 
methylene blue concentrations were calculated using such correlations (see Figure 
4.2a). 
 
For the encapsulation efficiency experiments, it was necessary to determine what 
quantity of methylene blue was lost to the DCM phase.  As can be seen in Figure 
4.2b, the loss of methylene blue to the DCM phase was measureable, and was most 
pronounced at low methylene blue concentrations.  The apparent methylene blue 
concentrations (CMB,A) were compared to the standards of known methylene blue 
concentrations, and a correlation, taking into account the methylene blue lost to the 








Figure 4.2: Methylene blue phase separation. 
Figure a) shows a representative calibration curve, relating the optical density at 630 
nm to the concentration of methylene blue.  Figure b) shows the proportion of 
methylene blue lost to the DCM phase under the same conditions as the 
encapsulation efficiency protocol.  Figure c) shows the correction necessary to find 
the total methylene blue concentration in the aqueous/DCM system, from the 
apparent methylene blue concentration in the aqueous phase.  This takes into account 




4.5.1.2. Encapsulation Efficiency 
The methylene blue content for two separate batches of methylene blue 
encapsulating scaffolds made from PCL (Mn 42,500 and 80,000) and PLGA, as well 
as from blends of PCL (Mn 42,500) and PLGA, was determined (see Figure 4.3).  In 
each case the methylene blue lost to the DCM phase was taken into account, using 
the results from §4.5.1.1.  Similarly, the methylene blue content of methylene blue 
loaded collagen coatings, on PCL (Mn 42,500) scaffolds, was assessed.  Again, two 
separate batches were assessed (see Figure 4.3).  Although the methylene blue 
encapsulation efficiency percentage of PCL (Mn 42,500), plotted with IMS, was 
measured, all the results were below the limit of detection of the assay (data not 
shown). 
 
It was found that the scaffolds made from PCL, of both molecular weights (Mn 
42,500 and 80,000), as well as the PCL:PLGA 33:66 blend, had both a high and a 
relatively consistent methylene blue content (157±20 – 126±11 µg/g, 155±12 – 
131±16 µg/g, and 193±30 – 120±6 µg/g between batches respectively).  In contrast, 
the methylene blue of the PCL:PLGA 66:33 blend was found to be inconsistent 
between batches (130±5 – 96±15 µg/g).  Although the methylene blue content of 
PLGA scaffolds was consistent between batches, the total encapsulation was 
approximately half that of the PCL scaffolds (89±39 – 64±8 µg/g) (see Figure 4.3).  
The methylene blue content of the collagen coating on PCL scaffolds was found to 
be relatively consistent between batches.  The mass of methylene blue per unit mass 
of scaffold was found to be comparable to the results obtained for the encapsulating 
scaffolds (see Figure 4.3).   
 
The encapsulation efficiencies were calculated, based on the maximum theoretical 
encapsulation of 200 µg/g (see Table 4.2). 






















Figure 4.3: Methylene blue content of different scaffold preparations. 
These figures show the apparent methylene blue content of scaffolds prepared from 
different polymers, or polymer blends, as well as scaffolds coated with Type 1 
Collagen.  Data from two separate batches are shown.  Each data point represents the 
mean of four repeats.  * denotes p < 0.05 between the groups indicated. 
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4.5.2. Methylene Blue Release 
The release of methylene blue from scaffolds was quantified for each 24 hr period.  
This was normalised against the total theoretical methylene blue content of the 
scaffolds for each batch, as calculated from the results in Table 4.2 (see Figure 4.4 
and Figure 4.5).  The release of methylene blue from scaffolds of PCL (Mn 42,500) 
was found to be relatively consistent between batches as no significant difference 
was observed between them at any time point (see Figure 4.5a).  The cumulative 
release profiles were also found to be relatively consistent (see Figure 4.4a).  The 
release from the PCL (Mn 80,000) was higher than that from PCL (Mn 42,500) (by 
66.9±0.1% in the first 24 hr period), however release from the two different batches 
were calculated to differ significantly from each other at all time points tested (see 
Figure 4.5b).  Differences in the cumulative release profiles between the two 
different batches were also observed (see Figure 4.4b). 
 
Although relatively consistent within batches, the release of methylene blue from 
scaffolds of the two blends of PCL (Mn 42,500) with PLGA, statistically significant 
differences between the batches were observed (see Figure 4.5c and d).  This was 
also reflected in the cumulative release profiles (see Figure 4.4c and d).  In contrast, 
the variability of release from the PLGA scaffolds within the same batch was 
relatively large, while no statistically significant differences were observed between 
different batches.  For the two PCL/PLGA blends, the mean normalised release rates 
were found to be similar to those of PCL (Mn 42,500).  In contrast, even taking into 
account the reduced encapsulation efficiency, the release rates from the PLGA 
scaffolds were considerably lower than those of PCL (Mn 42,500) (see Figure 4.5e).  
Again, this was reflected in the cumulative release profiles (see Figure 4.4e). 
 
The methylene blue release rates from scaffolds coated with methylene blue loaded 
collagen, were found to be high.  The release was observed to be relatively 









Figure 4.4: Cumulative methylene blue release from scaffolds. 
These figures represent the cumulative release of methylene blue from encapsulating 
scaffolds manufactured from; a) PCL 42,500, b) PCL 80,000, c) PCL:PLGA 66:33, 
d) PCL:PLGA 33:66, and e) PLGA.  Figure f) represents the release of methylene 
blue from the collagen coating on PCL 42,500 scaffolds.  The results were 
normalised against the encapsulation efficiency for each scaffold batch.  Each data 








Figure 4.5: Methylene blue release from scaffolds. 
These figures represent the release of methylene blue from encapsulating scaffolds 
manufactured from; a) PCL 42,500, b) PCL 80,000, c) PCL:PLGA 66:33, d) 
PCL:PLGA 33:66, and e) PLGA.  Figure f) represents the release of methylene blue 
from the collagen coating on PCL 42,500 scaffolds.  The results were normalised 
against the encapsulation efficiency for each scaffold batch.  Each data point 
represents the mean of four repeats.  * denotes p < 0.05 between the group indicated, 





4.5.3. rhBMP-7 Release 
Following the manufacturer’s instructions, log-log plots were graphed for all the 
calibration curves for the rhBMP-7 ELISA.  As can be seen from the representative 
calibration curve in Figure 4.6, the log-log plots yielded a linear relationship 
between the optical density and the concentration of rhBMP-7 (CrhBMP-7).  
Correlations, derived from log-log plots of the calibration curves, were used to find 
the apparent rhBMP-7 concentrations throughout this section. 
 
For each batch tested, the control CoatPBSScaffPBS scaffolds, which were 
manufactured without rhBMP-7, were found not to give a false positive ELISA 
reading (see Figure 4.8a).  In contrast, rhBMP-7 was observed to have been released 
from all the scaffolds loaded with the growth factor. 
 
The rate of release of rhBMP-7 from the CoatPBSScaffBMP 1.25 scaffolds, normalised 
by scaffold mass, was found to decrease statistically significantly with time between 
each consecutive time point (see Figure 4.8b) (for example, decreasing from 
86.9±6.5 ng/g to 21.5±2.1 ng/g [p = 0.001] in the first and second 24 hr periods 
respectively).  The release profile was similar to that obtained using the model drug 
methylene blue.  The release of rhBMP-7 was found to be consistent, both within and 
between batches.  Detectable levels of rhBMP-7 were measured from each batch of 
scaffolds on each 24 hr period tested, even after 14 days in the BSA/PBS solution.  
The cumulative release from the CoatPBSScaffBMP 1.25 scaffolds showed that 
12.2±0.9% of the theoretical rhBMP-7 was released in the first 24 hour period, and 
by day 4 17.8±0.4% had been released (see Figure 4.7a). 
 
Similar to the results for the model drug, the release rate of rhBMP-7 from the 
scaffold coating (CoatBMP 1.25ScaffPBS) was considerably higher than that for 
CoatPBSScaffBMP 1.25 (see Figure 4.8c).  However, the release profile was observed to 
“tail off” more quickly towards a release rate of zero.  The release of rhBMP-7 was 
found to be consistent, both within and between scaffold batches.  Detectable levels 
of rhBMP-7 were measured from each batch of scaffolds on each 24 hr period tested, 
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even after 14 days.  The cumulative release from the Coat BMP 1.25ScaffPBS scaffolds 
showed that 23±2% of the theoretical rhBMP-7 was released in the first 24 hour 
period, and by day 4 28.8±0.4% had been released (see Figure 4.7b). 
 
The release profiles from the CoatBMP 1.25ScaffBMP 1.25 scaffolds were very similar to 
those from the CoatBMP 1.25ScaffPBS scaffolds (see Figure 4.8d).  Since the release rate 
from the coating was much greater than the release from the encapsulating scaffold, 
it is unsurprising that this effect would dominate the release profiles.  However, the 
release of rhBMP-7 was less consistent between batches, as significant differences 
between batches were observed.  Again, detectable rhBMP-7 concentrations were 
measured at each time point tested. 
 
Log-log plots of cumulative growth factor release against time were graphed for 
CoatPBSScaffBMP 1.25 and CoatBMP 1.25ScaffPBS scaffolds.  The purpose of this was to 
assess the mode of rhBMP-7 release.  The values of R2 for the linear model for the 
CoatBMP 1.25ScaffPBS scaffolds, were found to be relatively low (the mean being 
0.927±0.020), indicating a statistically significant deviation from the linear model 
(see Figure 4.9a).  In contrast, the CoatPBSScaffBMP 1.25 showed good agreement with 
the linear model, the mean R2 being 0.988±0.003 (see Figure 4.9b). 
4.5.3.1. Scaffold Loading Capacity 
From the methylene blue studies, the encapsulation efficiency of scaffold delivery 
system was 71±6%.  Therefore the loading of rhBMP-7 in ScaffBMP 1.25 scaffolds, was 
calculated to be 710 ng/g. 
 
The methylene blue loading capacity in the coating delivery system was 65±5 µg/ml, 
using a methylene blue stock solution of 5 mg/ml.  Since the rhBMP-7 stock solution 
was 1 mg/ml,  the rhBMP-7 loading capacity in CoatBMP 1.25 scaffolds was calculated 










Figure 4.6: rhBMP-7 calibration curve. 
A representative calibration curve relating the concentration of rhBMP-7 with the 
optical density.  From this calibration curve, the correlation log10[CrhBMP-7] = 
1.018×log[OD] + 3.177 (R2 = 0.9992) was derived.  Each data point represents the 




Figure 4.7: rhBMP-7 cumulative release from scaffolds. 
These figures represent the cumulative release of rhBMP-7 from three batches of 
scaffolds loaded as a) CoatPBSScaffBMP 1.25, b), CoatBMP 1.25ScaffPBS and c) CoatBMP 







Figure 4.8: rhBMP-7 released from scaffolds. 
These figures represent the release of rhBMP-7 from three batches of rhBMP-7 
encapsulating scaffolds manufactured with different formulations; a) CoatPBSScaffPBS, 
b) CoatPBSScaffBMP 1.25, c) CoatBMP 1.25ScaffPBS, d) CoatBMP 1.25ScaffBMP 1.25.  The 
results were normalised against the scaffold mass in each case.  Each data point 
represents the mean of three repeats.  * denotes p < 0.05 between the group 
indicated, and the previous 24 hr period.  † denotes p < 0.05 between the different 




Figure 4.9: Log-log plots of rhBMP-7 cumulative release from scaffolds. 
These figures represent log-log plots of the cumulative release of rhBMP-7 from 
three batches of scaffolds loaded as a) CoatBMP 1.25ScaffPBS, b) CoatPBSScaffBMP 1.25.  
Lines of linear regression are displayed for each batch, along with the equations of 
the lines and their R2 values.  Each data point represents the mean of three repeats. 
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4.6. Discussion 
4.6.1. Encapsulation Efficiency 
Methylene blue was chosen as the model drug to measure the encapsulation capacity 
of the different scaffold materials, as well as the collagen scaffold coating.  The 
reasons for employing a model drug to study these systems include; favourable 
model drug stability, ease of detection, and economic cost (see §4.3). 
 
In particular, methylene blue was an almost ideal choice for the encapsulation 
efficiency studies.  This is because methylene blue is hydrophilic, hence the majority 
of the methylene blue encapsulated in scaffolds was successfully recovered after 
dissolving them in DCM.  A similar method was employed by Cao and Shoichet 
(1999).  However, as such systems reach equilibrium, inevitably some of the 
methylene blue was lost to the DCM phase.  The phase partition of methylene blue 
between dH2O and DCM was difficult to predict theoretically (Perry et al., 1997, 
Sandler, 1999), therefore there was a need to find it experimentally. 
 
As can be seen from Figure 4.2b, the proportion of methylene blue lost to the DCM 
phase was more pronounced at lower concentrations.  After the DCM phase became 
saturated, a linear correlation was applied to take this loss of methylene blue mass 
into account (see Figure 4.2c).  This correlation was used to adjust for the loss of 
methylene blue in all the encapsulation experiments using DCM. 
 
The methylene blue content of the scaffolds was found.  For the encapsulating 
polymer scaffolds, these data were compared against the theoretical methylene blue 
loading of 200 µg/g (see Table 4.2).  The encapsulation efficiency of the PCL 
scaffolds, for both Mn 42,500 and 80,000, was calculated to be 71±6% and 71±5% 
respectively.  The encapsulation efficiency was found to be relatively consistent, 
both between and within batches.  This loading efficiency was found to be similar to 
other potential drug delivery devices (Rai et al., 2005; Silva et al., 2006). 
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In contrast, the methylene blue content of the PCL (Mn 42,500) plotted in IMS was 
found to be below the detection limit of the methylene blue assay.  The use of such 
scaffolds was therefore discontinued, as they were found to be an extremely 
inefficient potential drug delivery system.  This was an unfortunate result, as it 
limited the scope for the manipulation of the three dimensional (3D) geometry.  
However, as discussed in §2.5.1.1.3, the building up of 3D geometry may not be 
necessary for the creation of an effective bone regenerative medical treatment. 
 
The PCL:PLGA 33:66 encapsulation efficiency was the highest measured (78±10%) 
and although variation within the batches was relatively high, no significant 
difference was found between the batches.  Both the PCL:PLGA 66:33 blend and the 
PLGA encapsulation efficiencies were found to be relatively low at 57±5% and 
38±10%.  Furthermore, a statistically significant difference between the PCL:PLGA 
66:33 batches was found.  Therefore, of the polymers tested, PCL of either molecular 
weight and the PCL:PLGA 33:66 blend were the most promising materials regarding 
encapsulation efficiency. 
 
It is possible that the differences in encapsulation efficiency were due to the 
differences in both the viscosities and densities of the polymer solutions.  This would 
affect the rate at which the aqueous droplets would rise to the top of the solution in 
the syringe during the scaffold manufacturing process.  In principle, the 
encapsulation efficiencies could be increased by increasing the polymer 
concentration in the solution, thus increasing the viscosity of the solution.  However, 
as investigated in Chapter 2, this would be difficult to achieve. 
 
The encapsulation efficiency for the collagen coated scaffolds could not be 
calculated in the same way as for the encapsulating polymer scaffolds, as the 
quantity of coating on the scaffolds was difficult to determine directly.  However, in 
terms of the model drug content, this drug delivery system was found to be 
comparable to the encapsulating scaffolds (see Figure 4.3).  The coating was 
therefore thought to be acceptable regarding model drug encapsulation. 
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4.6.2. Methylene Blue Release 
Despite the similarities in the encapsulation efficiencies, there were differences in the 
methylene blue release profiles from the two molecular weights of PCL.  It is 
interesting to note that the release rate from PCL (Mn 80,000) was higher than that 
from PCL (Mn 42,500) (for example by 1.7±0.1 fold in the first 24 hr period) (see 
Figure 4.5a and b). 
 
Fick’s first law, see Equation 4.1, relates flux of a component to its composition 
gradient, employing a constant of proportionality called diffusivity (Fick, 1855; 
Perry et al., 1997).  It is also known that the diffusivity of PCL decreases as the 
molecular weight increases (Gilmore et al., 1980).  Therefore it was hypothesised 
that the release rate of the model drug from the higher molecular weight of PCL 
would be less than for the lower molecular weight PCL.  The fact that this is not the 
case, implies that the microstructure of the scaffolds may be different.  Since a slow 
release rate, consistent between batches, was desired for the scaffolds, PCL (Mn 
42,500) was thought to be the better option of the two. 
 
It was observed that the release profiles of methylene blue from scaffolds of both the 
PCL/PLGA blends as well as PLGA were relatively inconsistent (see Figure 4.5c, d 
and e, and Figure 4.4c, d and e).  Also, it was found that there was relatively little 
scope for adjusting the release profile by altering the proportions of PCL and PLGA.  
Furthermore, the addition of PLGA considerably increases the capital cost of the 
scaffolds.   
 
Therefore, since no significant benefit was observed over PCL (Mn 42,500), either in 
terms of the release profiles or the encapsulation efficiency, PCL (Mn 42,500) was 
considered to be the favoured candidate material tested.  Therefore, scaffolds 
manufactured from PCL (Mn 42,500) were subjected to further testing as described 
and discussed in §4.4.3, §4.5.3, and §4.6.3, as well as chapters 5, 6 and 7. 
 
The release rate of methylene blue from the collagen coating was found to be 
relatively high (see Figure 4.5f).  The burst release in the first 24 hr period, was 
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similar to that observed for most formulations of microparticles (Wei et al., 2007; 
Holland et al., 2003).  Release from the coating was found to have reached 
approximately 100% by the 96 hr mark (see Figure 4.4f). 
 
It was thought to be desirable that the release profiles of the scaffold and scaffold 
coating should be different.  This would allow the early release of one active factor, 
and the more controlled release of a second factor.  It was believed that this aim 
would be best achieved using the scaffold coating as a fast delivery system, while 
employing  the scaffold itself as a more controlled one.  The results from collagen as 
a scaffold coating, and PCL (Mn 42,500) scaffolds, were therefore thought to be 
compatible with the design philosophy of this study (see §1.4.2.1). 
4.6.3. rhBMP-7 Release 
As discussed in §1.2.4, there is a variety of active factors which are thought to have 
the potential for therapeutic use in bone regenerative medicine.  It is currently 
unclear which combination of active factors will ultimately provide the most 
effective treatment for fracture non-unions.  Indeed it is possible that this may vary 
from patient to patient.  In the absence of this information, and since measuring the 
release profiles of each potential active factor was not economically feasible, a 
growth factor was chosen as a representative of the group. 
 
rhBMP-7 was selected as the representative growth factor, for two main reasons.  
First, its charge and molecular weight are similar to many other active factors of 
potential therapeutic application (Quaglia, 2008), including; FGF-2, PDGF, TGF-β1, 
-β2, -β3, and BMP-2 (see Figure 4.1).  Second, rhBMP-7 is one of only two growth 
factors currently licensed by the USFDA for the treatment of fracture non-unions 
(USFDA, 2001). 
 
It was observed that the release profiles of rhBMP-7 obtained using the ELISA were 
similar in form to those found using the model drug methylene blue.  This provides 
some evidence to justify both the choice of methylene blue as the model drug, and 
the conclusions on material selection based upon it, as discussed in §4.6.1 and §4.6.2. 
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As predicted by the methylene blue model, it was found that the release rate of 
rhBMP-7 from the collagen coating was considerably higher than that from the 
encapsulating scaffolds (see Figure 4.8).  The release from the collagen coating was 
also found to “tail off” more quickly.  This was consistent with the design philosophy 
employed in this thesis.  Potentially, active factors encouraging angiogenesis or cell 
proliferation could be released early on from the coating.  Whereas, factors 
encouraging osteogenic differentiation could be released in a more controlled 
fashion, and for a longer amount of time, from within the scaffold. 
 
It was found that the release of rhBMP-7 from the CoatBMP 1.25ScaffPBS and 
CoatPBSScaffBMP 1.25 scaffolds was relatively consistent both within and between the 
batches (see Figure 4.8b and c).  Whereas, CoatBMP 1.25ScaffBMP 1.25 scaffolds showed 
small, but statistically significant, differences in release rate between batches (see 
Figure 4.8d).  Consistency between different scaffolds is an obvious precondition for 
therapeutic application.  In this respect, these data would seem not to preclude these 
scaffold designs from clinical use. 
 
Based on the laws of Fickian diffusion, Ritger and Peppas (1987a; 1987b) derived a 
general relation between the fraction of drug released (Mt/M∞) and time (t), using the 
constants k and n (see Equation 4.3).  In order to determine the primary mode of 
release, log-log plots of cumulative drug release against time were graphed (see 
Figure 4.9).  Since Mt/M∞ is likely to be proportional to the normalised mass of drug 











It was found that the release profile of rhBMP-7 from the CoatPBSScaffBMP 1.25 
scaffolds fitted the diffusion model with a mean R2 value of 0.988±0.003.  This 
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indicates that diffusion was the primary mode of release from these scaffolds.  In 
contrast, the release profile from CoatBMP 1.25ScaffPBS scaffolds deviated more from 
the diffusion model.  In this case, the mean R2 value was 0.927±0.020.  This might 
indicate that degradation played a role in the mode of growth factor release from the 
coating. 
 
In the studies described in this chapter, the release of the immuno-reactive form of 
rhBMP-7 from the scaffolds was confirmed.  Despite some studies which claim to 
use ELISAs to confirm bioactivity (Douglas et al., 2008), it is currently unknown 
whether the bioactive and immuno-reactive forms of growth factors are identical.  
Therefore, studies were conducted to confirm the bioactivity of the rhBMP-7 
released (see Chapter 5). 
4.6.3.1. Comparison to Ideal Release Profile 
The rhBMP-7 release profiles (see Figure 4.7) were found to differ from the ideal 
release profiles detailed in §1.4.1 and Figure 1.18. 
 
From Figure 4.7b, it would appear that approximately 30% of the rhBMP-7 
theoretically loaded into the scaffold coating was available for release.  23±2% of the 
theoretical loading capacity was released in the first 24 hr period.  This represents 
approximately 77% of the total available rhBMP-7 available for release.  Therefore 
the burst release from the coating, which appeared to be largely exhausted in the first 
72 hr did not match the ideal “rapid” release profile detailed in Figure 1.18. 
 
From Figure 4.7a, it would appear that the release of rhBMP-7 from the ScaffBMP 1.25 
delivery system tended towards a maximum release of approximately 20% of the 
growth factor theoretically encapsulated, after approximately 96 hr.  Five potential 
explanations why only 20% of rhBMP-7 was available for release are as follows.  
First, loosely bound rhBMP-7 may be lost during the scaffold sterilisation process, 
before the collagen coating.  Second, a proportion of rhBMP-7 may have been 
degraded during the scaffold manufacturing process.  Third, a proportion of rhBMP-
7 may have been unavailable for diffusive release, and may have only been available 
upon degradation, similar to the findings of Wei et al. (2007), in the release of 
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rhBMP-7 from PLGA 50:50 (64 kDa).  Fourth, a proportion of the rhBMP-7 may 
have degraded in the release media once released from the scaffolds.  Five, a 
proportion of the rhBMP-7 may have become bound to the collagen coating after 
diffusing from the PCL scaffold base. 
 
Although 12.2±0.9% of the theoretical rhBMP-7 loading was released in the first 24 
hr period, this represents approximately 60% of the rhBMP-7 seemingly available for 
release.  Hence this burst release was inconsistent with the ideal release profile 
detailed in Figure 1.18, where a delay to facilitate the action of the “rapidly” 
delivered growth factor was desired.  In addition, the majority of the release was 
found to occur in the first 4 days, rather than between days 7 and 28 which was 
detailed in the ideal release profile (see Figure 1.18). 
 
Hence ideal release was not achieved from either delivery system.  In addition, 
although the release profiles were found to be different, this difference may not be of 
clinical significance.  However, delivery systems with less than ideal release kinetics 
may still be of potential clinical use.  For example, scaffolds loaded with rhBMP-7 
were capable of inducing ectopic bone formation in rats in 6 weeks when implanted 
subcutaneously (Wei et al., 2007).  This was despite in vitro release kinetics with 
indicated that ~50% of all the rhBMP-7 released in the first 6 weeks occurred in the 
first 24 hr.  The scaffolds were therefore tested further in studies described in chapter 
5, 6 and 7. 
4.7. Conclusion 
Scaffolds manufactured from PCL (Mn 42,500 and 80,000), PLGA, as well as blends 
of PCL (Mn 42,500) and PLGA, were evaluated using the model drug methylene 
blue.  The encapsulation efficiencies, and the release profiles of methylene blue, 
were quantitatively assessed.   
 
It was found PCL (Mn 42,500) scaffolds had high encapsulation efficiencies, and 
released the methylene blue at a controlled rate.  The results were found to be 
consistent between different batches.  While the encapsulation efficiency was 
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similarly high for PCL (Mn 80,000), significant differences in the release from 
different scaffold batches were observed.  In addition, the rate of methylene blue 
release was thought to be too high for the encapsulating delivery system. 
 
The PLGA, and PCL/PLGA blends were found to perform poorly.  The methylene 
blue release rates from the PCL/PLGA blends were found to be relatively 
inconsistent between batches.  The encapsulation efficiencies of PLGA and 
PCL:PLGA 66:33 were also relatively low.  PCL (Mn 42,500) scaffolds, made 
without plotting media, were therefore considered to be the favoured candidate 
scaffold material. 
 
The drug loading potentials, as well as model drug release profiles from collagen 
coatings on PCL (Mn 42,500) scaffolds, were similarly assessed.  The fast methylene 
blue release rate, and methylene blue content of the scaffolds, were found to be 
compatible with the design philosophy employed in this thesis. 
 
The release profiles of the growth factor rhBMP-7, from both encapsulating scaffolds 
and loaded collagen scaffold coatings, were measured using an ELISA.  As with the 
methylene blue results, the collagen coating was found to release rhBMP-7 at a faster 
rate than the encapsulating PCL (Mn 42,500) scaffolds.  The release profiles were 
found to deviate from the desired ideal release profiles, and burst release was 
observed from both delivery systems.  Although differences were observed for the 
two delivery systems, this difference may not be of clinical significance. 
 
Nevertheless, having shown that the encapsulating PCL (Mn 42,500) scaffolds, and 
the loaded collagen scaffold coatings, were capable of releasing detectable amounts 
of rhBMP-7 for up to 14 days, the bioactivity of this release was then assessed as 




















Chapter 5 : Bioactive Release 
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5.1. Scaffold Nomenclature 
CoatPBS  Collagen coating with PBS (rhBMP-7 control) 
CoatBMP 0.63  Collagen coating with low rhBMP-7 dose (0.63 µg/ml) 
CoatBMP 1.25  Collagen coating with high rhBMP-7 dose (1.25 µg/ml) 
Coatethanol  Collagen coating with ethanol (1,25(OH)2D3 control) 
Coat1,25(OH)2D3  Collagen coating with 1,25(OH)2D3 
ScaffPBS  Scaffold encapsulating PBS (rhBMP-7 control) 
ScaffBMP 0.63  Scaffold encapsulating low rhBMP-7 dose (0.63 µg/ml) 
ScaffBMP 1.25  Scaffold encapsulating high rhBMP-7 dose (1.25 µg/ml) 
Scaffethanol  Scaffolds encapsulating ethanol (1,25(OH)2D3 control) 
Scaff1,25(OH)2D3  Scaffolds encapsulating 1,25(OH)2D3 
5.2. Abstract 
It is essential that all regenerative medical drug delivery devices have the ability to 
release active factors which are still bioactive.  It is also important to identify the 
range of concentrations of the released bioactive factors which have the desired 
effect on the target cells. 
 
The range of recombinant human bone morphogenetic protein-7 (rhBMP-7) 
concentrations capable of stimulating the osteogenic differentiation of human 
marrow stromal cells (hMSCs) was investigated.  This was achieved by 
quantitatively assessing the area of alkaline phosphatase (ALP) staining, normalised 
against the cell count.  Although the increase was relatively slight, normalised ALP 
expression was statistically significantly elevated for each of the test concentrations 
(5, 20, and 50 ng/ml), in hMSCs from at least three of the four test patients.  No 
universal optimum concentration was found, and each test concentration appeared to 
have very similar osteoinductive potential. 
 
As before, rhBMP-7 was used as a clinically relevant model drug to assess the 
feasibility of releasing water-soluble growth factors from the scaffolds.  The 
bioactivity of the rhBMP-7 released from the test scaffolds was assessed by 
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quantifying the area of normalised ALP staining of hMSCs.  It was found that the 
release of rhBMP-7 from the collagen coating of the poly(ε-caprolactone) (PCL) (Mn 
42,500) scaffolds was capable of statistically significantly increasing hMSC 
normalised ALP expression, although the actual differences were often relatively 
small.  Therefore, at least a proportion of the growth factor released is likely to have 
been bioactive.  The release from scaffolds encapsulating rhBMP-7 did not have this 
effect on the hMSCs, indicating that either the concentration released was too low, or 
the growth factor released was no longer bioactive. 
 
However, the cells were likely to experience a different environment and growth 
factor concentration when seeded directly onto the scaffolds.  Therefore, this was 
assessed in the studies described in Chapter 6 and Chapter 7. 
 
1,25-dihydroxyvitamin D3 (1,25(OH)2D3) was used as a model drug to assess the 
feasibility of releasing lipid-soluble active factors from the scaffolds.  Concentrations 
of 10 nM were found to significantly stimulate normalised ALP expression of hMSC 
compared to the base media.  Similarly, the release of 1,25(OH)2D3 from the loaded 
collagen scaffold coatings and the encapsulating scaffolds significantly increased 
ALP expression compared to the control scaffold groups (by 115±28% and 69±25% 
respectively).  Furthermore, ALP expression was significantly increased when the 
two delivery systems were used together, when compared to either delivery system 
on its own. 
 
These data suggest that the delivery of lipid-soluble active factors is feasible from 
collagen coated PCL scaffolds, and that the coating and encapsulating delivery 





In Chapter 4 it was found that PCL (Mn 42,500) scaffolds, and scaffold coatings of 
Type-I collagen, were capable of releasing immuno-reactive rhBMP-7.  However, 
immuno-reactivity does not necessarily show that active factor released remained 
bioactive.  Since the antibodies used in enzyme-linked immunosorbent assays 
(ELISAs) only bind to a small region of the complete protein structure, the proteins 
detected may only have been deactivated fragments of the original active factors 
(Bae et al., 2006). 
 
For all potential regenerative medical drug delivery devices, it is important to assess 
whether the active factors released are capable of affecting cells.  Traditionally this 
has been achieved using an appropriate bioassay (DeFail et al., 2006; Premaraj et al., 
2006; Partridge et al., 2002).  This is commonly achieved employing cell lines, using 
changes in such properties as cell proliferation or ALP expression as outcome 
measures (Meager, 1991; Garrigue-Antar et al., 1995; Parker et al., 2002).  However, 
such assays, which often employ transformed non-human cells, yield little 
information on how primary human cells would behave or what dose of active factor 
is most appropriate. 
 
Expression of ALP is not restricted to bone, as it is also found in both liver and 
kidney tissue (Tylzanowski et al., 2001; Fernandez and Kidney, 2007; Martins et al., 
2001).  However, it is commonly used in assays for osteogenesis (Hoemann et al., 
2008; Tsiridis et al., 2006).  This is because, in cells of the osteoblastic lineage, it is 
considered to be an early marker for osteogenic differentiation (Yoon et al., 1987; 
Zaidi, 2007), see Figure 1.3. 
 
Although there is debate in the literature about whether rhBMP-7 primarily causes 
chondrogenic or osteogenic differentiation of MSCs in vitro, there is broad 
agreement that ALP expression is increased (Knippenberg et al., 2006; Edgar et al., 
2007; Tsiridis et al., 2007).  Similarly, as discussed in §1.2.4.2, 1,25(OH)2D3 is 
known to induce osteogenic differentiation of MSCs cultured in vitro, in the presence 
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of growth media supplemented with ascorbic acid and β-glycerophosphate (Zhou et 
al., 2006).  This effect is further enhanced by the addition of TGF-β (Bosetti et al., 
2007; Liu et al., 1999). 
 
rhBMP-7 and 1,25(OH)2D3 were used as hydrophilic and hydrophobic model drugs 
(respectively) to investigate the feasibility of releasing water-soluble and lipid-
soluble active factors from both loaded scaffolds and scaffold coatings.  During the 
studies described in this chapter, the dose of rhBMP-7 necessary to induce 
osteogenic differentiation of hMSCs was investigated.  The bioactivity of rhBMP-7 
released from both rhBMP-7 encapsulating PCL (Mn 42,500) scaffolds and loaded 
Type-I collagen scaffold coatings, were evaluated.  Similar studies were also 
conducted using 1,25(OH)2D3 containing scaffolds.   
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5.4. Materials and Methods 
Unless otherwise stated, all reagents were purchased from Sigma, UK.  All the 
techniques described below were conducted in a sterile environment, using sterilised 
equipment. 
5.4.1. hMSC Isolation and Culture 
After written consent from the patients and approval from the local ethical committee 
(Lothian local research ethics committee), human femoral head tissue was obtained 
from patients who had undergone elective arthroplasty.  Tissue was collected from a 
total of seven patients (see Table 5.1).  The tissue samples were allocated an 
anonymous number based on the chronological order of the sample collection.  The 
hMSCs were isolated and cultured as described in §3.3.1.1.  The hMSCs underwent 
routine characterisation as described in Appendix G. 
 
Table 5.1: hMSC patient details. 
In-House 
Patient Number 
496 506 513 518 542 544 549 
Patient Age 51 76 79 74 68 66 61 
Patient Sex Male Male Male Male Male Male Female 
 
5.4.2. rhBMP-7 Release 
5.4.2.1. Scaffold Manufacture 
A stock solution of 1 mg/ml rhBMP-7 (Stryker, USA) was diluted with phosphate 
buffered saline (PBS) (Oxoid, UK) to concentrations of 25 µg/ml and 12.5 µg/ml.  
These solutions were added at 1 % (v/v) to 25% (w/v) solutions of PCL (Mn 
42,500)/dichloromethane (DCM).  This yielded final mass ratios of rhBMP-7 to PCL 
of 1.00 µg/g or 0.50 µg/g respectively.  
 
Once added, emulsions were created by vigorous manual mixing, using sterile 3 ml 
transfer pipettes (Fisher, UK), for approximately 30 seconds.  The resulting 
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emulsions were loaded into the syringe of the Bioplotter™. Scaffolds were then 
manufactured, with no plotting medium, using the optimised plotting parameters 
determined in §2.4.1.1.1, and then vacuum dried at 75 mbar (absolute pressure) for 
60 min.  Each scaffold was then cut by scalpel into four approximately equal parts.  
The scaffolds with an rhBMP-7 to PCL mass ratio of 1.00 µg/g or 0.50 µg/g were 
designated ScaffBMP 1.25 and ScaffBMP 0.63 respectively. 
 
Control scaffolds were also manufactured in a similar fashion, replacing the rhBMP-
7 solutions with PBS.  These scaffolds were designated ScaffPBS. 
 
All the scaffolds were immersed in IMS for 10 min before being washed with 
distilled water (dH2O) (5 min) and PBS (5 min).  The stock solution of rhBMP-7 (1 
mg/ml) was added to 1 mg/ml Type-I collagen in 0.1 M aqueous acetic acid, to yield 
final concentrations of 1.25 µg/ml and 0.63 µg/ml respectively.  The equivalent 
volume of PBS was added to a similar solution of Type-I collagen. 
 
The scaffolds were immersed in one of the collagen solutions either lacking rhBMP-
7, or containing it at 1.25 µg/ml or 0.63 µg/ml.  The scaffolds were designated with 
the prefixes CoatPBS, CoatBMP 1.25 or CoatBMP 0.63 respectively.  The resulting scaffold 
types were; CoatPBSScaffPBS,  CoatBMP 0.63ScaffPBS, CoatBMP 1.25ScaffPBS, 
CoatPBSScaffBMP 0.63, and CoatPBSScaffBMP 1.25.  Afterwards, the scaffolds were 
removed, and allowed to air dry for 4 hr at room temperature.  Once dry, the 
scaffolds were stored at -80°C. 
 
The above protocol was conducted twice to produce two separate scaffold batches.  
Batch 1 was used for the experiments involving hMSC patients 496 and 506.  Batch 
2 was used with hMSC patients 513 and 518. 
5.4.2.2. hMSC Reaction to rhBMP-7 
Tissue culture flasks (75 cm2) containing confluent hMSCs (passage 2) from patients 
496, 506, 513, and 518 (in separate flasks), were washed three times in PBS, and the 
cells were detached from the flasks using trypsin solution (2.5 mg/ml) in PBS 
(Invitrogen, UK) and growth media, as described in §3.3.1.  The cell density of the 
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suspensions was measured using a haemocytometer.  After appropriate dilution with 
growth media, the cells were added to wells of 48-well treated tissue culture (TC) 
plastic plates (Corning, USA) at a density of 8,000 cells/well (in 400 µl of media).  
For each patient’s tissue used, 60 wells were seeded.  The plates were then 
maintained in a humidified air incubator at 37°C with 5% (v/v) CO2, for 3 days, to 
become confluent. 
 
Once the cells had become confluent, fresh cell media was prepared.  Growth media 
(see §3.3.1) was supplemented with β-glycerophosphate disodium hydrate (10 mM), 
L-ascorbic acid-2-phosphate (50 µM, from a 10 mM stock solution in PBS).  This 
media was designated OS-D media.  A portion of OS-D media was supplemented 
with dexamethasone (100 nM, from a 1 mM stock solution in ethanol).  This media 
was designated OS media.  rhBMP-7 was also added to OS-D media at three 
concentrations (5, 20 and 50 ng/ml). 
 
All the old media was aspirated from the cells.  The wells were divided into groups 
of six.  Growth media, OS media, and rhBMP-7 at each concentration in OS-D 
media, were added to one group of wells for each patient (400 µl/well).  OS-D media 
was added to six groups (of six wells) for each patient (400 µl/well) (see Figure 5.1). 
 
The scaffolds were thawed by incubation at room temperature for 30 min.  The 
quarter scaffolds were then added directly to wells containing hMSCs in OS-D 
media.  Each scaffold type was added to one group of wells per patient.  One scaffold 
was added per well, and care was taken such that the scaffolds were fully immersed 
in the media, without being in direct contact with the cells at the bottom of the wells 
(see Figure 5.1).  The empty wells were then filled with growth media (see Figure 
5.1). 
 
The plates were then maintained in a humidified air incubator at 37°C with 5% (v/v) 
carbon dioxide (CO2).  The media was replaced with fresh media, of the same 
composition as the original experimental media, at regular intervals three times every 
7 days.  After 14 days, the scaffolds and media were removed from the wells before 
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the cells were fixed in 4% (w/v) paraformaldehyde in PBS for 10 min.  The wells 
were washed with PBS (twice) and dH2O (once): 2 min per wash.  The wells were 
left to dry for 4 hr before being stored at 4°C.  The plates were then stained for ALP 






Figure 5.1: Plate plan for experiments involving rhBMP-7. 
A cartoon showing the plate plan of the 48-well plates used for the experiments 
involving rhBMP-7.  The media composition, and either scaffold or media 
supplements are indicated.  The shaded wells indicate the test well, containing 
hMSCs used during the experiments.  The white wells indicate wells containing 
growth media only.  This plate plan was used for each of the four hMSC test patients. 
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5.4.3. 1,25(OH)2D3 Release 
5.4.3.1. Scaffold Manufacture 
A stock solution of 24 µM (10 mg/ml) 1,25-dihydroxyvitamin D3 (1,25(OH)2D3) was 
made up in ethanol.  This solution was added at 5% (v/v) to 25% (w/v) solutions of 
PCL (Mn 42,500)/DCM.  This yielded a final moles/mass ratio of 1,25(OH)2D3 to 
PCL of 4.8 nmoles/g. 
 
Once added, the two miscible solutions were mixed together, using sterile 3 ml 
transfer pipettes, for approximately 30 seconds.  The resulting emulsions were loaded 
into the syringe of the Bioplotter™.  Scaffolds were then manufactured, with no 
plotting medium, using the optimised plotting parameters determined in §2.4.1.1.1, 
and then vacuum dried at 75 mbar (absolute pressure) for 60 min.  Each scaffold was 
then cut into four approximately equal parts, using a scalpel.  These scaffolds were 
designated Scaff1,25(OH)2D3. 
 
Control scaffolds were also manufactured in a similar fashion, replacing the 
1,25(OH)2D3 solution with ethanol.  The ethanol was added at 5% (v/v) to the 
plotting solution of 25% (w/v) PCL (Mn 42,500)/DCM.  The resulting scaffolds were 
designated Scaffethanol. 
 
All the scaffolds were immersed in IMS for 10 min before being washed with dH2O 
(5 min) and PBS (5 min).  The stock solution of 1,25(OH)2D3 (24 µM) was added to 
1 mg/ml Type-I collagen in 0.1 M aqueous acetic acid, to yield a final concentration 
of 3.6 µM.  The equivalent volume of ethanol was added to a similar solution of 
Type-I collagen. 
 
The scaffolds were immersed in one of the collagen solutions either containing or 
lacking 1,25(OH)2D3.  The scaffolds were designated with the prefixes Coat1,25(OH)2D3 
and Coatethanol respectively.  Afterwards, the scaffolds were removed, and allowed to 
air dry for 4 hr at room temperature.  Once dry, the scaffolds were stored at -80°C. 
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5.4.3.2. hMSC Reaction to 1,25(OH)2D3 
Tissue culture flasks (75 cm2) containing confluent hMSCs (passage 2) from patients 
542, 544 and 549, were washed three times in PBS, and the cells were detached from 
the flask using trypsin and growth media, as described in §3.3.1.  The cell density of 
the suspensions was measured using a haemocytometer. After appropriate dilution 
with growth media, the cells were added to wells of 48-well TC plastic plates 
(Corning, USA) at a density of 8,000 cells/well (in 400 µl of media).  For each 
patient’s tissue used, 48 wells were seeded.  The plates were then maintained in a 
humidified air incubator at 37°C with 5% (v/v) CO2, for 3 days, to become confluent. 
 
Once the cells had become confluent, new cell media was prepared.  OS media was 
supplemented with recombinant human transforming growth factor-β3 (rhTGF-β3) 
(R&D Systems, USA) at 10 ng/ml.  This media was designated OST media.  
1,25(OH)2D3 was also added to OST media at three concentrations (0.1, 1 and 10 
nM). 
 
All the media was aspirated from the cells and discarded.  The wells were divided 
into groups of six.  Growth media and 1,25(OH)2D3, at each concentration in OST 
media, were added to one group of wells for each patient (400 µl/well).  OST media 
was added to four groups for each patient (400 µl/well) (see Figure 5.2). 
 
The scaffolds were thawed by incubation at room temperature for 30 min.  The 
quarter scaffolds were then added directly to wells containing hMSCs in OST media.  
Each scaffold type was added to one group of wells per patient. One scaffold was 
added per well, and care was taken such that the scaffolds were fully immersed in the 
media, without being in direct contact with the cells at the bottom of the wells (see 







Figure 5.2: Plate plan for experiments involving 1,25(OH)2D3. 
A cartoon showing the plate plan of the 48-well plates used for the experiments 
involving 1,25(OH)2D3.  The media composition, and either scaffold or media 
supplements are indicated.  The shaded wells indicate the test well, containing 
hMSCs used during the experiments.  The white wells indicate wells containing 
growth media only.  This plate plan was used for each of the three hMSC test 
patients.   
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The plates were then maintained in a humidified air incubator at 37°C with 5% (v/v) 
CO2.  The media was replaced with fresh media, of the same composition as the 
original experimental media, at regular intervals three times every 7 days.  After 14 
days, the scaffolds and media were removed from the wells before the cells were 
fixed in 4% (w/v) paraformaldehyde in PBS for 10 min.  The wells were washed 
with PBS (twice) and dH2O (once): 2 min per wash.  The wells were left to air dry 
for 4 hr before being stored at 4°C.  The plates were then stained for ALP as 
described in §5.4.4. 
5.4.4. Cell Staining 
The cells, prepared as described in §5.4.2.2 and §5.4.3.2, were stained for ALP using 
an Alkaline Phosphatase kit.  The protocol was followed according to the 
manufacturer’s instructions.  Briefly, 250 µl of sodium nitrate solution (0.1 M) were 
added to 250 µl of Fast Blue Base-Alkaline Solution (5 mg/ml).  The mixture was 
inverted and allowed to stand at room temperature.  After 2 min, 11.25 ml of dH2O 
and 250 µl of Naphthol AS-BI Alkaline Solution (4mg/ml) were added.  After 
mixing, 180 µl of this solution were added to each of the wells in the 48-well plates. 
 
The plates were then incubated in the dark at room temperature for 15 min, before 
each well was washed with PBS.  The cells prepared in §5.4.2.2 were then stained 
with 2 µg/ml propidium iodide (PI) (180 µl/well).  Similarly, the cells prepared in 
§5.4.3.2 were stained with 2 µg/ml 4’,6-diamino-2-phenylindole (DAPI) (180 
µl/well).  The cells were incubated in the staining solutions in the dark for 15 min, 
before being washed twice with PBS.  After the washes were discarded, 200 µl of 
dH2O were added to each well.  The plates were then photographed using a mounted 
camera (Nikon, DXM1200) on an inverted microscope (Nikon, Eclipse TS 100) set 
for both bright-field and fluorescence, at × 10 magnification.  Three randomly 
selected fields were photographed per well, with both bright-field and fluorescence. 
 
The area of +ve ALP staining was quantified with the aid of ImageJ (National 
Institute of Health, USA) using a batch image processing macro (see Appendix F).  
A similar method was used by Zhu et al. (2006).  The number of either PI or DAPI 
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+ve cells was also counted using a batch image processing macro (see Appendix E) 
for ImageJ.  A manual count of randomly selected images was used to confirm the 
accuracy of the ImageJ counts. 
 
For each well, the mean area of ALP staining per cell was calculated from the areas 
of +ve  ALP staining (Ai), and the cell count (Ni), in field i (see Equation 5.1).  The 
normalised area of staining was then found for each group by dividing the mean 
areas of staining per cell, with that found for the appropriate base media, for the same 
patient (see Equation 5.2). 
 
Equation 5.1 




























5.4.5. Statistical Analysis 
All data were analysed using the statistical software package SPSS 14.0 for 
Windows. 
 
The data collected for the rhBMP-7 release experiments were found not to satisfy 
Levene’s test, even after mathematical transformations.  Parametric tests, such as 
one-way analysis of variance (ANOVA), were therefore unsuitable.  Hence, the non-
parametric Kruskal-Wallis test was used to test for statistical significance for each 
data set.  The statistical significance between the groups was found using the Mann-




All the data collected for the 1,25(OH)2D3 studies required the transformation of 
log10 to satisfy Levene’s test and that of Kolmogorov-Smirnov.  ANOVA was then 
applied, followed by the Tukey-Kramer post hoc test to determine the statistical 
differences between the groups. 
 
The mean was used throughout, and all results were expressed as the sample means ± 
standard error of the mean (SEM). 
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5.5. Results 
5.5.1. rhBMP-7 Release 
Positive ALP staining of the hMSCs, prepared as described in §5.4.2.2 and §5.4.4, 
was observed in all the groups tested.  Although differences in the staining were 
observed visually (see Figure 5.3), it was necessary to quantify the staining through 
image analysis using ImageJ. 
 
This was achieved by “thresholding” the images to discard areas of staining below a 
certain intensity (see Figure 5.4).  For each patient, a range of images from the 
growth media (–ve ALP control) and the OS media (+ve ALP control).  The 
threshold was selected such that areas judged to be ALP +ve were included, whereas 
areas of ALP –ve shadow were excluded. 
 
Similarly, a range of PI images were examined for each patient.  Both the threshold 
and the size range were adjusted such that all visually identified cells were counted, 
and all objects identified as artefacts were excluded.  The numbers of cells per field 
were then counted using the images of PI stained cells (see Figure 5.5).  Randomly 
chosen manual cell counts, from the PI stained images, showed a mean deviation 
from the automated ImageJ counts of 0.98±0.24%.  It should be noted that, due to a 
fungal contamination, some of the groups of rhBMP-7 coated and encapsulating 
scaffolds were lost.  These groups were; CoatPBSScaffBMP 0.63 and CoatPBSScaffBMP 1.25 
from patient 496, and CoatBMP 0.63ScaffPBS and CoatBMP 1.25ScaffPBS from patient 513. 
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Figure 5.3: ALP staining for the rhBMP-7 release experiments. 
Bright-field images of hMSCs stained for ALP in response to various test media and 
scaffolds.  These representative images were taken at × 10 magnification, of tissue 




Figure 5.4: Area of ALP staining quantification. 
Figure a) shows a representative bright-field image of the ALP stained hMSCs, at × 
10 magnification.  The threshold of these images was taken, to produce images such 
as that shown in figure b).  The areas of shading were then quantified using ImageJ.  




Figure 5.5: hMSC cells stained for ALP and PI. 
A representative field of hMSCs treated with OS-D media, photographed at × 10 
magnification.  In this case, the cells were exposed to a CoatBMP 1.25ScaffPBS scaffold.  
The hMSC patient was 496.  Figure a) shows a bright-field view of ALP staining.  
Figure b) shows the PI image of the same field.  Figure c) shows a combined image 
of the two fields.  The bar represents 50 µm. 
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It was found that there was considerable patient variability in both the area of ALP 
staining, and the cell counts (see Figure 5.6 and Figure 5.7).  However, more 
consistent results were observed between patients when the ALP staining was 
normalised against both the cell count and the results for the base media (see Figure 
5.8). 
 
For cells maintained in OS media, both ALP and normalised ALP staining were 
significantly higher than the base media for all patients tested.  OS media was also 
associated with a significant decrease in the observed cell density in two of the four 
patients (decreases of 32±3%, p < 0.01, and 18±1%, p < 0.01). 
 
Normalised ALP staining was statistically significantly increased, from the base 
media, for at least one concentration of rhBMP-7 for each patient (see Figure 5.6 
and Figure 5.8).  However, the rhBMP-7 concentration associated with the highest 
normalised ALP staining varied from patient to patient.  In addition, no threshold 
rhBMP-7 concentration was observed above which ALP staining was consistently 
enhanced.  No consistent difference in the cell density was measured for any 
concentration of rhBMP-7 compared to the base media. 
 
For the scaffolds containing rhBMP-7 in the collagen coating, normalised ALP 
staining was significantly increased, compared to the control scaffolds, for two out of 
three of the patients tested (p < 0.01).  The average increases in normalised ALP 
staining compared to the control scaffolds were 290±250% for the low rhBMP-7 
dose, and 210±170% for the high dose.  However this trend was not observed for the 
rhBMP-7 encapsulating scaffolds (see Figure 5.8). 
 
For the test scaffolds groups, no obvious trend in the cell densities was observed, 
except for the CoatPBSScaffBMP 1.25 group.  For these scaffolds, the mean cell densities 
were significantly reduced, compared to the control scaffold group, for two of the 
three patients tested (see Figure 5.7b). 
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Figure 5.6: Areas of ALP staining of hMSCs. 
The mean areas of +ve ALP staining of hMSCs.  Figure a) shows the data for the 
cells exposed to rhBMP-7 and other test media, with no scaffold present.  * and ** 
denote p < 0.05 and 0.01 respectively, compared to the base OS-D media.  Figure b) 
shows the data for the cells exposed to the test scaffolds in OS-D media.  * and ** 
denote p < 0.05 and 0.01 respectively, compared to the control CoatPBSScaffPBS 




Figure 5.7: Cell counts of hMSCs. 
The mean cell densities of hMSCs.  Figure a) shows the data for the cells exposed to 
rhBMP-7 and other test media, with no scaffold present.  * and ** denote p < 0.05 
and 0.01 respectively, compared to the base OS-D media.  Figure b) shows the data 
for the cells exposed to the test scaffolds in OS-D media.  * and ** denote p < 0.05 
and 0.01 respectively, compared to the control CoatPBSScaffPBS group.  The error bars 




Figure 5.8: Normalised areas of ALP staining of hMSCs. 
The average areas of +ve ALP staining of hMSCs per cell, normalised against the 
OS-D group.  Figure a) shows the data for the cells exposed to rhBMP-7 and other 
test media, with no scaffold present.  * and ** denote p < 0.05 and 0.01 respectively, 
compared to the base OS-D media.  Figure b) shows the data for the cells exposed to 
the test scaffolds in OS-D media.  * and ** denote p < 0.05 and 0.01 respectively, 
compared to the control CoatPBSScaffPBS group.  The error bars represent the SEM, n 
= 6 in each case. 
256 
5.5.2. 1,25(OH)2D3 Release 
5.5.2.1. Scaffold Manufacture 
It was noted that the addition of the ethanol solutions to the plotting solution had no 
effect on the optimum plotting parameters found in §2.4.1.1.1.  The resulting scaffold 
geometry appeared to be very similar to that of the optimised PCL scaffold, as 
described in §2.4.1.1.1 (see Figure 2.2e). 
5.5.2.2. hMSC Reaction to 1,25(OH)2D3 
During preliminary experiments, it was determined that PI was not a suitable stain 
for accurate cell counts for the experiments described in §5.4.3.  This was because 
the nuclei were not distinctively stained.  In contrast, DAPI was thought to be 
sufficient for accurate cell counts to be performed (see Figure 5.9). 
 
Positive ALP staining of the hMSCs, prepared as described in §5.4.3.2 and §5.4.4, 
was observed in each group tested.  Differences in staining between the groups were 
observed (see Figure 5.10).  However, it was again necessary to quantify the area of 
staining through image analysis using ImageJ.  For each patient, a range of images 
from the OST media (–ve ALP control) and the 10 nM 1,25(OH)2D3 group (+ve ALP 
control).  The threshold was selected such that areas judged to be ALP +ve were 
included, whereas areas of ALP –ve shadow were excluded. 
 
Similarly, a range of DAPI images were examined for each patient.  Both the 
threshold and the size range were adjusted such that all visually identified cells were 
counted, and all objects identified as artefacts were excluded.  Randomly chosen 
manual cell counts, from the DAPI stained images, showed a mean deviation from 





Figure 5.9: hMSC cells stained for ALP and with PI and DAPI. 
A representative field of view of hMSCs treated with OST media, photographed at × 
10 magnification.  In this case the media was supplemented with 1,25(OH)2D3 at 10 
nM.  The hMSC patient number was 544.  Figure a) shows a bright-field view of the 
ALP staining.  Figures b) and c) show PI and DAPI staining respectively.  The bar 
represents 50 µm. 
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Figure 5.10: ALP staining for the 1,25(OH)2D3 release experiments. 
Bright-field images of hMSCs stained for ALP in response to various test media and 
scaffolds.  These representative images were taken at × 10 magnification, of patient 
544.  The bar represents 100 µm. 
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It was observed that ALP staining, whether normalised or not, was significantly 
increased for the 10 nM 1,25(OH)2D3 group compared to the OST media control, for 
all the hMSC patients tested (see Figure 5.11a and Figure 5.13a).  Although there 
was little obvious pattern to the data on the cell densities, the highest 1,25(OH)2D3 
concentration was associated with a significant increase in the cell counts compared 
to the OST media control for two of the three patients (see Figure 5.12a).  
 
For the Coat1,25(OH)2D3Scaffethanol and Coat1,25(OH)2D3Scaff1,25(OH)2D3 groups, significant 
increases in both the area of ALP staining (133±20% and 361±43% average 
increases respectively) and normalised ALP expression (115±28% and 303±76% 
average increases respectively) were calculated for all hMSC patients compared to 
the CoatethanolScaffethanol control (p < 0.01) (see Figure 5.11b and Figure 5.13b).  
Similarly the CoatethanolScaff1,25(OH)2D3 scaffolds were associated with elevated ALP 
staining and normalised ALP staining (96±37% and 69±25% average increases 
respectively)) for two of the three patients (p < 0.01).  It was also observed that 
normalised ALP expression was significantly increased for the 
Coat1,25(OH)2D3Scaff1,25(OH)2D3 scaffolds compared to either delivery system alone, for 
two of the three patients (p < 0.01) (see Figure 5.13b). 
 
The Coat1,25(OH)2D3Scaff1,25(OH)2D3 scaffolds were also associated with a statistically 
significant increase in the cell density, compared to the CoatethanolScaffethanol control, 
for two hMSC patients (p < 0.01) (see Figure 5.12b).  The average increase was 






Figure 5.11: Areas of ALP staining of hMSCs. 
The mean areas of +ve ALP staining of hMSCs.  Figure a) shows the data for the 
cells exposed to 1,25(OH)2D3 and other test media, with no scaffold present.  * and 
** denote p < 0.05 and 0.01 respectively, compared to the base OST media.  Figure 
b) shows the data for the cells exposed to the test scaffolds in OST media.  * and ** 
denote p < 0.05 and 0.01 respectively, compared to the control CoatethanolScaffethanol 
group.  The error bars represent the SEM, n = 6 in each case. 
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Figure 5.12: Cell counts of hMSCs. 
The mean cell densities of hMSCs.  Figure a) shows the data for the cells exposed to 
1,25(OH)2D3 and other test media, with no scaffold present.  * and ** denote p < 
0.05 and 0.01 respectively, compared to the base OST media.  Figure b) shows the 
data for the cells exposed to the test scaffolds in OST media.  * and ** denote p < 
0.05 and 0.01 respectively, compared to the control CoatethanolScaffethanol group.  The 




Figure 5.13: Normalised areas of ALP staining of hMSCs. 
The mean areas of +ve ALP staining of hMSCs per cell, normalised against the 
OST group.  Figure a) shows the data for the cells exposed to 1,25(OH)2D3 and other 
test media, with no scaffold present.  * and ** denote p < 0.05 and 0.01 respectively, 
compared to the base OST media.  Figure b) shows the data for the cells exposed to 
the test scaffolds in OST media.  * and ** denote p < 0.05 and 0.01 respectively, 
compared to the control CoatethanolScaffethanol group.  †† denotes p < 0.01 compared to 
both the Coat1,25(OH)2D3Scaffethanol and CoatethanolScaff1,25(OH)2D3 groups.  The error bars 
represent the SEM, n = 6 in each case. 
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5.6. Discussion 
5.6.1. Rational for Normalisation of ALP staining 
Common practice in previous studies has been to couple ALP assays with methods of 
determining cell numbers (Holtorf et al., 2005; Dadsetan et al., 2008; Bjerre et al., 
2008).  This was because ALP expression per cell was thought to yield more 
information, as it was capable of distinguishing between low or moderate expression 
of ALP by a large number of cells, and high ALP expression by a smaller cell 
population.  Therefore, the area of ALP staining was normalised by the number of 
cells present in that field. 
 
The data on ALP staining divided by the cell counts per field, were then normalised 
to the control group for each hMSC patient.  There were three main reasons for this.  
First, in an effort to reduce the effects of patient variability on the data.  As can be 
seen in Figure 5.6a, patient variability in the control media group was evident.  This 
reduction in patient variability also made trends in the data more apparent.  Second, 
this reduced potential variability in the ALP staining solution, which was made up in 
different batches for the different test patients.  Third, this reduced the potential for 
variability in the light conditions between batches, as the brightness of the 
microscope bulb was not precisely calibrated.  Potentially, this could have introduced 
variability between test patients since the image analysis was based on colour 
brightness.  The resulting normalised data are displayed in Figure 5.8. 
5.6.2. rhBMP-7 Release 
The purposes of the experiments involving rhBMP-7 described in this chapter were 
two-fold.  First: to find the optimum growth factor dose for hMSC osteogenic 
differentiation.  Second: to ascertain whether the rhBMP-7 released from the 
scaffolds was bioactive, and thereby assess the feasibility of delivering growth 
factors and other water-soluble active factors from such scaffolds. 
 
The optimum dose of rhBMP-7 for the induction of osteogenic differentiation of 
hMSCs is unclear from the literature.  Currently, the majority of in vitro studies have 
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been conducted using mouse or rat MSCs, however the response of these cells to 
rhBMP-7 may differ from that of human MSCs.  For example, Diefenderfer et al. 
(2003) found that ALP activity was increased by factors of 3 and 8 times for rat and 
mouse MSCs respectively when cultured in media containing rhBMP-2 (100 ng/ml) 
for 6 days.  In contrast, no significant change in ALP activity was observed for 
hMSCs.  Therefore, the optimum concentration for humans cannot be deduced from 
these studies.  Nevertheless, there is broad agreement that MSC expression of ALP, 
an early marker for osteogenic differentiation, is increased in response to rhBMP-7 in 
the range 10 – 100 ng/ml (Knippenberg et al., 2006; Edgar et al., 2007; Tsiridis et 
al., 2007).  Normalised ALP expression was therefore used as the main outcome 
measure for these studies. 
 
For these experiments, OS media, as previously described by Tremoleda et al. (2008) 
and Sottile et al. (2003), was used as a positive control for ALP staining.  This media 
contained dexamethasone, which is known to stimulate osteogenic differentiation of 
hMSCs (Beresford et al., 1994; Jorgensen et al., 2004b; Kotobuki et al., 2005).  
Ascorbic acid, another component of OS media, is thought to support both the 
proliferation and osteogenic differentiation of hMSCs at concentrations of 50 µM 
and above (Choi et al., 2008).  β-glycerophosphate is also commonly added to 
osteogenic media, as a substrate for matrix mineralisation, usually at a concentration 
of 10 mM (Maniatopoulos et al., 1988; Noble et al., 1995; Tremoleda et al., 2008). 
 
OS media without dexamethasone was used as the base media for the rhBMP-7 
studies.  The OS-D media was thought capable of supporting osteogenic 
differentiation, without stimulating ALP activity directly.  A similar media was used 
by Knippenberg et al. (2006) to study the osteogenic effects of both rhBMP-2 and -7.  
It was decided to analyse the ALP expression of the hMSCs after 14 days, as 
previous studies have found that in vitro ALP reaches a maximum at approximately 
this time point, before decreasing again as the hMSCs differentiate further (Edgar et 
al., 2007; Santoni et al., 2007; Fisher and Reddi, 2003; Liao et al., 2008). 
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It was found that the area of ALP staining, as well as the normalised ALP expression, 
was statistically significantly higher for the OS media compared to the OS-D control 
for all of the patients tested (see Figure 5.6a and Figure 5.8a).  This indicated that 
the hMSCs from each patient were capable of osteogenic differentiation. 
 
Both the ALP and normalised ALP expression were found to be statistically 
significantly increased for at least two patients at each concentration of rhBMP-7 
(see Figure 5.6a and Figure 5.8a) although the actual sizes of the increases were 
often small.  Although normalising the area of ALP staining yielded more consistent 
results between patients, no consistent optimum rhBMP-7 concentration was found.  
Instead, each rhBMP-7 concentration tested appeared to have similar potential to 
stimulate ALP staining.  This might indicate that the optimum concentration range of 
rhBMP-7 is relatively broad compared to other growth factors.  For example and by 
way of contrast, the optimum concentration range of TGF-β1 for inducing motility in 
epithelial cells is only between 1 and 2 ng/ml (Kutz et al., 2001). 
 
From the data collected as shown in Chapter 4, the mean PCL (Mn 42,500) scaffold 
mass was found to be 19.6±1.0 mg.  Therefore the mean quarter scaffold mass was 
thought to be 4.90±0.25 mg.  The theoretical sum of the release of rhBMP-7 per unit 
scaffold mass was found to be 3540±45 ng/g and 119±4 ng/g for the CoatBMP 
1.25ScaffPBS and CoatPBSScaffBMP 1.25 scaffolds respectively.  Although potentially this 
may be an underestimate due to degradation of rhBMP-7 in the release media.  The 
maximum theoretical loading in the scaffolds was 12.5±1.0 µg/g and 710±6 ng/g. 
 
Therefore the hMSCs may have been exposed to concentrations in the media as high 
as 153±15 ng/ml and 8.7±0.5 ng/ml for the CoatBMP 1.25ScaffPBS and CoatPBSScaffBMP 
1.25 scaffolds respectively, although the release in the bulk media may be as low as 
43±3 ng/ml and 1.46±0.09 ng/ml at the end of the first 3 days.  The latter values 
assume that there was no difference in the release profiles of rhBMP-7 between the 
OS-D media and the bovine serum albumin/PBS solutions.  This assumption may not 
hold due to the degradation of the active form of rhBMP-7 once released.  The 
bioactive form of BMP-7 consists of a dimer of two of two identical monomer units, 
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held together by a single disulphide bond (Griffith et al., 1996).  Although little is 
known about the breakdown of rhBMP-7 in growth media, disulphide bonds are 
known to be susceptible to cleavage either chemically (in reducing environments) or 
by enzymes (Stryer, 1995).  The in vivo clearance rate is also thought to be rapid 
(Bishop and Einhorn, 2007). 
 
The release of rhBMP-7 from the CoatBMP 1.25ScaffPBS and CoatBMP 0.63ScaffPBS 
scaffolds may have been in the range of concentrations found to stimulate ALP 
staining.  Since ALP and normalised ALP expression was elevated for two out of 
three test patients, it is likely that a proportion of the rhBMP-7 released from the 
CoatBMP 1.25ScaffPBS and CoatBMP 0.63ScaffPBS scaffolds was bioactive (see Figure 5.6b 
and Figure 5.8b).  Interestingly, there was little difference in the ALP expression 
between the CoatBMP 1.25ScaffPBS and CoatBMP 0.63ScaffPBS scaffold groups.  It is likely 
that this was due to the broad range of rhBMP-7 concentrations able to induce a 
similar osteogenic response (see Figure 5.6a and Figure 5.8a).  Hence the assay was 
not able to distinguish between the different concentrations of growth factor released.  
This may, in part, be as a result of the assay measuring the area of ALP staining 
rather than ALP activity.   
 
The release from the scaffold coatings (CoatBMP 1.25 and CoatBMP 0.63) may have been 
comparable to some of the test concentrations used, theoretically as high as 153±15 
ng/ml and 76.5 ±8 ng/ml, for the high and low doses respectively.  However, this 
release is unlikely to have been sustained for as long as the test concentrations.  
Nevertheless, previous studies have found that treatments as short as 15 min with 
concentrations of rhBMP-7  and rhBMP-2 as low as 10 ng/ml, have been found to 
influence the differentiation of MSCs (Knippenberg et al., 2006).  It should also be 
noted that the cells may have experienced concentrations of rhBMP-7 higher than the 
bulk media concentrations reported above.  This is because, although the scaffolds 
were not in physical contact with the cells, the scaffolds may have been relatively 
close to the cells as they were at the bottom of the wells.  Since the distance was 
relatively short, the cells are likely to have experienced higher concentrations than 
the bulk media concentrations.  Also, since a non-linear relationship between 
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increases in normalised ALP staining and rhBMP-7 concentration, it is feasible that 
lower concentrations than the 5 ng/ml or high rhBMP-7 doses sustained for a short 
period of time, could be capable of causing ALP staining comparable to that 
achieved between 5 and 50 ng/ml sustained for 14 days. 
 
Unfortunately, the data from Chapter 4 would imply that the release of rhBMP-7 
from the CoatPBSScaffBMP 1.25 and CoatPBSScaffBMP 0.63 scaffolds may have been below 
the range of growth factors concentrations tested.  This assumes that no degradation 
of rhBMP-7 occurred in the ELISA release media, although the maximum theoretical 
release from the scaffolds of 8.7±0.5 ng/ml and 4.4±0.3 ng/ml respectively.  This 
was calculated from the methylene blue encapsulation efficiency of PCL (Mn 42,500) 
scaffolds which was found to be 71±6% in Chapter 4.  Therefore it is uncertain 
whether the lack of significant increases in the normalised ALP staining was caused 
by the release being too low to affect the hMSCs, or whether the rhBMP-7 released 
was no longer bioactive (see Figure 5.6b and Figure 5.8b). 
 
It is interesting that the CoatPBSScaffBMP 1.25 scaffolds were associated with a 
significant decrease in cell density (see Figure 5.7b).  This was in contrast to the 
rhBMP-7 test concentrations, where only a slight decrease in cell numbers was 
observed at 20 ng/ml (see Figure 5.7a).  While it is possible that a decrease in cell 
density occurs as a result of a low rhBMP-7 dose, it is perhaps more likely that this is 
a Type-I statistical error.  Alternatively, the decrease in cell numbers, possibly as a 
result of reduced proliferation, and reduced ALP staining, may indicate that the cells 
in this group were more differentiated than the cells in the other scaffold groups.  For 
many adult cell types, proliferation is thought to be poorly compatible with 
differentiation (Xia et al., 2006), this is also thought to be the case for the 
osteoblastic lineage (Stein et al., 2004).  In addition, while high ALP activity is a 
marker of early osteoblastic differentiation, it is known to decrease as differentiation 
progresses (Stein et al., 2004; Zaidi, 2007). 
 
From these data, it would seem that release of rhBMP-7 from the CoatBMP 1.25ScaffPBS 
and CoatBMP 0.63ScaffPBS scaffolds was sufficient to affect cells not in direct contact 
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with the scaffolds, whereas the release from the CoatPBSScaffBMP 1.25 and 
CoatPBSScaffBMP 0.63 scaffolds was not.   
 
However, as discussed in §1.2.6.1, how the growth factors are presented to the target 
cells is extremely important.  Cells on tissue culture plastic will obviously experience 
a different environment to those seeded directly onto the scaffolds.  This is both in 
terms of cell-scaffold surface interaction, as well as the growth factor concentration 
the cells experience.  Therefore the scaffolds with the highest rhBMP-7 loadings, 
CoatBMP 1.25ScaffPBS and CoatPBSScaffBMP 1.25, were subjected to further testing as 
described in Chapter 6 and Chapter 7. 
5.6.3. 1,25(OH)2D3 Release 
As discussed previously in §1.2.4.2, 1,25(OH)2D3 has been considered as a potential 
compound of interest for bone regenerative medicine, particularly in combination 
with an isoform of transforming growth factor-β (TGF-β) (Bosetti et al., 2007).  
However, 1,25(OH)2D3 can easily be delivered systemically to patients.  Indeed the 
normal serum concentration range of 1,25(OH)2D3 is 80 – 150 nM (Heaney, 2004): 
an order of magnitude higher than the highest concentration tested in the studies 
described in this chapter.  In adults, it is thought this concentration can be maintained 
by the daily consumption of 5 – 15 µg (IOM, 1997), though it is recommended that 
healthy adults should avoid regular daily consumption of more than 250 µg 
(Hathcock et al., 2007).   
 
Therefore the clinical advantages of the local delivery of 1,25(OH)2D3 from scaffolds 
may be limited, although the short term exposure of cells on the scaffolds to 
1,25(OH)2D3 may prove to be advantageous, particularly pre-implantation.  
However, it was thought that 1,25(OH)2D3 could act as a model drug for the lipid-
soluble active factors of interest in bone regenerative medicine.  For example, many 
cathepsin K inhibitors are hydrophobic (Wang et al., 2004). 
 
The purposes of the experiments involving 1,25(OH)2D3 in this chapter, were to 
assess the feasibility of releasing lipid-soluble active factors, and to determine 
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whether the coating and encapsulating delivery systems were mutually compatible in 
this case.  For these studies, rhTGF-β3 was added to OS media as the base media 
because isoforms of TGF-β, at 10 ng/ml, have been found to inhibit ALP expression.  
However, on the addition of 1,25(OH)2D3, hMSC ALP expression was 
synergistically enhanced (Liu et al., 1999). 
 
Interestingly, for the cells grown in OST media, PI did not stain the cell nuclei 
distinctively (see Figure 5.9b).  This was in contrast to the distinct staining observed 
in the experiments using OS-D (see Figure 5.5b).  However, DAPI was able to stain 
the nuclei distinctly (see Figure 5.9c).  Since PI stains both deoxyribonucleic acid 
(DNA) and ribonucleic acid (RNA), while DAPI stains only DNA (Suzuki et al., 
1997), it is possible that the cytoplasm of the cells in OST media contained more 
RNA than those in OS-D.  Images of the cells stained with DAPI were therefore used 
to perform the cell counts for these experiments. 
 
It was found that both ALP and normalised ALP expression were significantly 
increased for the 10 nM 1,25(OH)2D3 groups, for each hMSC patient, compared to 
the OST control (see Figure 5.11a and Figure 5.13a).  The increase in normalised 
ALP expression, for these groups, was found to be both greater and more consistent 
between patients than that for the experiments involving rhBMP-7 (see Figure 5.8a 
and Figure 5.13a).  Hence, it was thought that the test for 1,25(OH)2D3 was more 
sensitive than that for rhBMP-7. 
 
Unlike the studies involving rhBMP-7, the release profile of 1,25(OH)2D3  from the 
scaffolds was unknown.  The maximum possible release from the 
Coat1,25(OH)2D3Scaffethanol scaffolds was therefore derived from the data in Chapter 4.  
It was previously found that the mean methylene blue content per unit mass of the 
coated scaffolds was 64.9±5.0 µg/g.  Since the concentration of methylene blue in 
the coating was 50 µg/ml, the volume of collagen solution coated per gram of 
scaffold was calculated to be 1.3±0.1 ml/g.  The mean quarter scaffold mass was 
4.90±0.25 mg.  Therefore the mean volume of coating per quarter sheet was 6.4±0.6 
µl.  Since the concentration of 1,25(OH)2D3 in the coating solution was 3.6 µM, the 
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1,25(OH)2D3 content of the quarter scaffolds was 23±2 pmoles.  Hence the 
maximum possible concentration achievable for the Coat1,25(OH)2D3Scaffethanol 
scaffolds in 0.4 ml of media was 57.5±5.0 nM. 
 
For the CoatethanolScaff1,25(OH)2D3 scaffolds, the 1,25(OH)2D3 was added to the plotting 
solution at a final moles/mass ratio of 1,25(OH)2D3 to PCL of 4.8 nmoles/g.  Since 
the mean scaffold mass was 4.90±0.25 mg, the 1,25(OH)2D3 content was calculated 
to be 23.5±1.2 pmoles per scaffold.  Hence the maximum possible concentration 
achievable for the CoatethanolScaff1,25(OH)2D3 scaffolds in 0.4 ml of media was 58.8±3.0 
nM. 
 
Therefore the maximum potential 1,25(OH)2D3 release from the 
Coat1,25(OH)2D3Scaffethanol, CoatethanolScaff1,25(OH)2D3 and Coat1,25(OH)2D3Scaff1,25(OH)2D3 
scaffolds were theoretically capable of releasing, were well above the 10 nM 
threshold for increasing hMSC ALP expression.  
 
The ALP and normalised ALP expression was significantly increased for two and 
three of the hMSC patients for the CoatethanolScaff1,25(OH)2D3 and 
Coat1,25(OH)2D3Scaffethanol scaffolds respectively, compared to the OST control (see 
Figure 5.11b and Figure 5.13b).  Although these data do not yield information of 
the release profile, it is likely that bioactive 1,25(OH)2D3 was released from both the 
encapsulating and loaded-coating delivery systems.  Hence, it was concluded that it 
was feasible to deliver lipid-soluble active factors from both of the encapsulating and 
collagen coating delivery systems. 
 
Levels of ALP and normalised ALP expression were also significantly elevated in all 
three hMSC patients for the Coat1,25(OH)2D3Scaff1,25(OH)2D3 scaffolds, compared to the 
OST control.  Furthermore, the normalised ALP expression was significantly 
increased compared to either delivery system on its own for two of three test patients 




A quantitative system, based on the image analysis of ALP staining and PI cell 
counts, was used to assess the osteogenic potential of rhBMP-7, and the release from 
growth factor incorporating scaffolds.  Each of the rhBMP-7 concentrations tested (5, 
20, and 50 ng/ml) was found to increase the normalised area of ALP staining 
statistically significantly compared to the base media.  This might indicate that 
rhBMP-7 is able to stimulate the osteogenic differentiation of hMSCs over a 
relatively wide range of concentrations. 
 
The release from the CoatBMP 1.25ScaffPBS and CoatBMP 0.63ScaffPBS scaffolds was 
found to stimulate hMSC ALP staining compared to the control scaffolds.  This 
indicated that at least a proportion of the rhBMP-7 released was bioactive.  In 
contrast, the release from CoatPBSScaffBMP 1.25 and CoatPBSScaffBMP 0.63 was found not 
to enhance hMSC ALP staining.  Either the growth factor released was not bioactive, 
or the dose was insufficient to influence the cells measurably. 
 
It was thought that the cells would experience a different environment and different 
growth factor concentrations if the cells were seeded directly on to the scaffolds.  
The scaffolds incorporating rhBMP-7 were therefore tested further, as described in 













Image analysis of ALP staining, normalised against DAPI cell counts, was used to 
assess quantitatively the ability of the Coat1,25(OH)2D3Scaffethanol, 
CoatethanolScaff1,25(OH)2D3 and Coat1,25(OH)2D3Scaff1,25(OH)2D3 scaffolds to release 
1,25(OH)2D3.  Normalised ALP expression of the hMSCs was significantly increased 
for each of the 1,25(OH)2D3 loaded scaffold types compared to the control scaffolds.  
Furthermore, ALP expression was significantly enhanced for the dual delivery 
scaffolds over and above that for either delivery system on its own.  It was therefore 
concluded that the PCL scaffolds coated with collagen could be capable of releasing 

















Chapter 6 : Cell/Scaffold Interactions 
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6.1. Scaffold Nomenclature 
CoatPBS   Collagen coating with PBS (rhBMP-7 control) 
CoatBMP 1.25   Collagen coating with rhBMP-7 (1.25 µg/ml) 
ScaffPBS   Scaffold encapsulating PBS (rhBMP-7 control) 
ScaffBMP 1.25   Scaffold encapsulating rhBMP-7 (1.25 µg/ml) 
6.2. Abstract 
Previous studies, described in the preceding chapters, have assessed the cell-
compatibility of the scaffold materials, and examined the quantity and bioactivity of 
recombinant human bone morphogenetic protein-7 (rhBMP-7) released from the 
scaffolds.  However, it was unknown how the clinically relevant human marrow 
stromal cells (hMSCs) would react to the combined stimuli, when seeded directly 
onto the scaffolds.  This was therefore assessed in this chapter by quantifying the 
activity of alkaline phosphatase (ALP), the mass of calcium phosphate deposited, and 
the number of cells on the scaffolds. 
 
The apparent number of cells on the scaffolds was quantified via a deoxyribonucleic 
acid (DNA) assay, using PicoGreen.  The apparent quantity of hMSC per quarter 
scaffold was found to range from 1.36 × 105 and 3.60 × 105.  The cells were also 
found to have completely spanned the majority of the scaffold pores. 
 
The activity of ALP was assessed by quantifying the degradation of para-
nitrophenylphosphate to para-nitrophenol, and normalising this against the apparent 
mass of DNA in the scaffold cell lysate.  In the range of rhBMP-7 concentrations 
tested (5, 20, and 50 ng/ml), higher concentrations of the growth factor were 
associated with elevated activity of ALP (increased by 98±18% for 50 ng/ml on the 
control).  Statistically significantly elevated levels of ALP activity were also found 
for the CoatBMP 1.25ScaffBMP 1.25 and CoatPBSScaffBMP 1.25 scaffold groups for hMSCs 
derived from two and three patients respectively (increased by 35±10% and 39±10 
on the control respectively), whereas this was the case for only one patient’s cells for 
the CoatBMP 1.25ScaffPBS scaffolds (increased be 35±14% on the control). 
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The apparent mass of calcium phosphate deposited on the scaffolds was quantified 
using the o-cresolphthalein complexone method.  This was also normalised by the 
mass of DNA in the scaffold cell lysate.  However, significant increases in calcium 
deposition were only observed in one of the three hMSC patients, compared to the 
control.  
 
These data indicate that the osteogenic differentiation of hMSCs, although not 
mineralisation, was supported by the CoatBMP 1.25ScaffBMP 1.25 and CoatPBSScaffBMP 1.25 
scaffolds, when the cells were seeded directly onto them.  It was also found that the 
osteogenic effect of the scaffolds was not significantly enhanced by the rhBMP-7 
loaded Type-I collagen scaffold coating.  This leaves a potential for the loading of 
different active factors in the coating delivery system for the final “product” intended 
for clinical use.  However, this is beyond the scope of the studies described in this 
thesis.  The potential of the scaffolds loaded with rhBMP-7 to induce osteogenic 
differentiation in cells seeded upon them was investigated further in Chapter 7. 
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6.3. Introduction 
The aim of the studies described in Chapter 2 was to develop scaffolds and scaffold 
coatings which had geometries suitable for bone regenerative medical applications.  
Chapter 3 describes how the cell-compatibility of Type-I collagen coatings and 
poly(ε-caprolactone) (PCL) (Mn 42,500) scaffolds was assessed.  In chapters 4 and 5, 
the release of rhBMP-7 was examined, both in terms of the quantity released, and the 
effect this release had on hMSCs.  However, it was unknown how these cells would 
behave in response to being seeded directly onto the scaffolds and being exposed to 
the combination of stimuli described above. 
 
As discussed in §1.1.1.5, ALP expression and matrix mineralisation are well 
established indicators of osteogenic differentiation.  Therefore, quantifications of 
ALP activity and calcium deposition, normalised per unit mass of DNA, protein or 
scaffold, are frequently used as outcome measures for assessing the osteoinductive 
potential of bone regenerative medical scaffolds.  ALP expression is commonly 
quantified using para-nitrophenylphosphate (pNPP) (Bjerre et al., 2008; Liu et al., 
2008b; Moreau and Xu, 2009).  ALP catalyses the conversion of pNPP to para-
nitrophenol (pNP), the concentration of which can be determined using a 
colourimetric assay (see Figure 6.1) (Bretaudiere and Spillman, 1984). 
 
A well established method for quantifying calcium concentrations in solution, 
employs o-cresolphthalein complexone (Moorehead and Biggs, 1974; Toffaletti and 
Kirvan, 1980).  Under basic conditions, colourless o-cresolphthalein complexone 
reacts with calcium ions to yield Ca-cresolphthalein complexone, which is purple.  
Hence, the concentration of calcium can be quantified using a colourimetric assay.  
This technique has been used by a number of authors to quantify the deposition of 
calcium by cells on bone regenerative medical scaffolds (Holtorf et al., 2005; 












Figure 6.1: Mode of action of pNPP. 
A cartoon of chemical reaction by which ALP catalysis the conversion of pNPP to 
pNP.  The activity of ALP can therefore be assessed by calculating the rate of the 
reaction by quantifying the concentration of pNP.  Since pNP is yellow and pNPP is 
colourless, a colourimetric assay can be applied. 
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Data obtained on ALP activity or calcium deposition, to give an accurate indication 
of the osteogenic differentiation of cells on scaffolds, should be normalised against 
the number of cells present.  This may be achieved using a protein assay.  However 
these tests are not suitable for all types of scaffolds, such as those which have a 
significant protein content.  Alternatively, the number of cells can be found using a 
DNA assay. 
 
Currently one of the most accurate DNA assays available employs PicoGreen.  
Assays using this fluorescent dye are capable of detecting DNA concentrations as 
low as 25 pg/ml: 400-fold more sensitive than using Hoechst 33258 (Singer et al., 
1997).  PicoGreen has been successfully employed by many authors in studies 
involving scaffolds (Dadsetan et al., 2008; Moreau and Xu, 2009; Holtorf et al., 
2005). 
 
During the studies described in this chapter, the osteogenic differentiation of hMSCs 
on Type-I collagen coated PCL (Mn 42,500) scaffolds, loaded with rhBMP-7, was 
investigated.  This was assessed by quantifying the ALP activity, calcium deposition, 
and DNA content of the scaffolds. 
6.4. Materials and Methods 
Unless otherwise stated, all reagents were purchased from Sigma, UK. All the 
techniques involving cell culture, described below, were conducted in a sterile 
environment, using sterilised equipment. 
6.4.1. hMSC Isolation and Culture 
After written consent from the patients and approval from the local ethical committee 
(Lothian local research ethics committee), human femoral head tissue was obtained 
from patients who had undergone elective arthroplasty.  Tissue was collected from a 
total of three patients (see Table 6.1).  The tissue samples were allocated an 
anonymous number based on the chronological order of the sample collection.  The 
hMSCs were isolated and cultured as described in §3.3.1.1.  The hMSCs underwent 
routine characterisation as described in Appendix G. 
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Table 6.1: hMSC patient details 
In-House 
Patient Number 
549 553 569 
Patient Age 61 65 69 
Patient Sex Female Female Male 
 
6.4.2. hMSC DNA Content 
A tissue culture flask (75 cm2) containing confluent hMSCs (passage 2) from patient 
553 was washed three times in PBS, and the cells were detached from the flask using 
2.5 mg/ml trypsin in phosphate buffered saline (PBS) (Invitrogen, UK) and growth 
media, as described in §3.3.1.  The cell density of the cell suspensions was measured 
using a haemocytometer.  After appropriate dilution with growth media, the cells 
were added to wells of a 48-well TC plastic plate (Corning, USA), at cell densities of 
20000, 10000, 5000, 2500, 1250, and 625 cells/well (in 400 µl of media).  Three 
wells were seeded for each cell density.  The plate was then maintained in a 
humidified air incubator at 37°C with 5% (v/v) CO2.  After 4 hr, the media was 
removed by inverting the plate, and quickly blotted with a sterile dry medical wipe 
(Kimberly Clark, UK).  The plate was then frozen at -80°C. 
 
The following day, the plate was thawed for 30 min at 37°C and 200 µl of distilled 
water (dH2O) were added to each well.  The plate was then subjected to two 
freeze/thaw cycles of freezing at -80°C for 1 hr, and thawing at 37°C for 30 min, as 
previously described with minor modifications from Rago et al. (1990).  Then 50 µl 
of the cell lysate from each well was transferred to the wells of a 96-well plate 
(Costar, USA). 
 
DNA sodium salt from herring testes stock solution (10 mg/ml in PBS) was diluted 
to a concentration of 16 µg/ml in dH2O.  A calibration curve was then pipetted into 
the 96-well plate, by performing two-fold dilutions in dH2O from the 16 µg/ml until 
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a final concentration of 250 ng/ml was reached.  A blank of dH2O was also added.  
The final volume in each well was 50 µl, two wells were used for each concentration. 
 
A DNA assay using PicoGreen (Invitrogen, UK) was performed according to the 
manufacturer’s instructions.  A working solution of PicoGreen was prepared by 
diluting the stock solution 200-fold in TE buffer: Trizma® hydrochloride (10 mM) 
and ethylenediaminetetraacetic acid (1 mM) at pH7.5.  After mixing, 50 µl of the 
PicoGreen working solution were added to each of the test wells in the 96-well plate.  
The plate was “tapped” to aid the mixing of the solutions and was then incubated in 
the dark, at room temperature, for 5 min.  The fluorescence of the wells was then 
measured using a CytoFluor® Series 400 spectrometer, exciting at a wavelength of 
485 nm and reading at 520 nm. 
6.4.3. Scaffold Manufacture 
A stock solution of 1 mg/ml rhBMP-7 (Stryker, USA) was diluted with PBS to a 
concentration of 25 µg/ml.  This was added at 1% (v/v) to 25% (w/v) solutions of 
PCL (Mn 42,500)/dichloromethane (DCM).  This yielded a final mass ratio of 
rhBMP-7 to PCL of 1.00 µg/g or 1.25 µg/ml for the PCL/DCM solution. 
 
Once added, emulsions were created by vigorous manual mixing, using sterile 3 ml 
transfer pipettes (Fisher, UK), for approximately 30 seconds. The resulting emulsions 
were loaded into the syringe of the Bioplotter™.  Scaffolds were then manufactured, 
with no plotting medium, using the optimised plotting parameters determined in 
§2.4.1.1.1, and then vacuum dried at 75 mbar (absolute pressure) for 60 min.  These 
scaffolds were designated ScaffBMP 1.25. 
 
Control scaffolds were also manufactured in a similar fashion, replacing the 25 
µg/ml rhBMP-7 solution with PBS.  These scaffolds were designated ScaffPBS. 
 
All the scaffolds were immersed in IMS for 10 min before being washed with dH2O 
(5 min) and PBS (Oxoid, UK) (5 min).  The stock solution of rhBMP-7 (1 mg/ml) 
was then added to 1 mg/ml Type-I collagen in 0.1 M aqueous acetic acid, to yield a 
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final concentration of 1.25 µg/ml.  The equivalent volume of PBS was added to a 
similar solution of Type-I collagen. 
 
All the scaffolds were then immersed for 5 min in one of the collagen solutions either 
containing or lacking rhBMP-7.  The scaffolds were designated with the prefixes 
CoatBMP 1.25 or CoatPBS respectively.  Afterwards, the scaffolds were removed, and 
allowed to air dry for 4 hr at room temperature.  Once dry, the scaffolds were cut into 
approximately equal quarters using a scalpel.  The scaffolds were then stored at -
80°C. 
6.4.4. hMSC Culture on Scaffolds 
After the quarter scaffolds, prepared as described in §6.4.3, were thawed, they were 
individually placed at the bottom of the well of 48-well non-TC plastic plates 
(Corning, USA).  Care was taken to ensure the scaffolds were flat against the bottom 
of the wells, and that they were held in place by the scaffolds corners’ contact with 
the wells’ sides.  The number of CoatPBSScaffPBS, CoatBMP 1.25ScaffPBS, 
CoatPBSScaffBMP 1.25 and CoatBMP 1.25ScaffBMP 1.25 quarter scaffolds used for each 
hMSC patient was 62, 16, 16 and 16 respectively. 
 
Tissue culture flasks (75 cm2) containing confluent hMSCs (passage 2) from patients 
549, 553, and 569 (in separate flasks), were washed three times in PBS, and the cells 
were detached from the flasks using 2.5 mg/ml trypsin in PBS (Invitrogen, UK) and 
growth media, as described in §3.3.1.  The cell density of the suspensions was 
measured using a haemocytometer.  After appropriate dilution with growth media, 
the cells were added to wells of the 48-well non-TC plastic plates, containing 
scaffolds (except for six CoatPBSScaffPBS scaffolds), at a density of 16,000 cells/well 
(in 400 µl of media).  Similarly, 400 µl of growth media with no hMSCs were added 
to the wells containing the non-seeded scaffolds.  Growth media was also added to 
the empty wells (400 µl/well) to reduce edge evaporation effects.  The plate plan was 
as shown in Figure 6.2.  The plates were then maintained in a humidified air 




Figure 6.2: Plate plan for experiments involving hMSCs seeded onto 
scaffolds. 
A cartoon showing the plate plan of the 48-well plates for the experiments involving 
hMSCs seeded onto scaffolds.  The media composition, media supplements, and 
scaffold Type-Are indicated.  The shaded wells indicate the test wells containing 
hMSCs, whereas the crosshatched wells indicate the test wells containing media and 
scaffolds without cells.  The white wells indicate wells containing growth media 
only.  This plate plan was used for each of the hMSC test patients. 
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The following day, all the media was changed.  The media of the wells containing 
CoatBMP 1.25ScaffPBS, CoatPBSScaffBMP 1.25 and CoatBMP 1.25ScaffBMP 1.25 scaffolds was 
replaced with OS-D media.  For each patient, 16 of the wells containing 
CoatPBSScaffPBS hMSC seeded scaffolds were refreshed with OS-D media, whereas in 
six wells the media was replaced with either OS-D containing rhBMP-7 (5, 20 or 50 
ng/ml) or OS media (see Figure 6.2).  OS-D media was added to the wells 
containing the non-seeded scaffolds.  The plates were then maintained in a 
humidified air incubator at 37°C with 5% (v/v) CO2.  The media was replaced with 
fresh media, of the same composition, at regular intervals three times every 7 days.  
After 21 days, the scaffolds were treated as follows. 
 
Three CoatPBSScaffPBS, CoatBMP 1.25ScaffPBS, CoatPBSScaffBMP 1.25 and CoatBMP 
1.25ScaffBMP 1.25 scaffolds, which had been cultured in OS-D, were fixed in 4% (w/v) 
paraformaldehyde in PBS for 10 min.  The scaffolds were washed with PBS (twice) 
and dH2O (once): 2 min per wash.  The scaffolds were left to dry for 4 hr before 
being stored at 4°C.  The scaffolds were then stained for ALP and with DAPI, using 
the protocol described in §5.4.4.  They were then photographed using an upright 
microscope (Nikon Eclipse E800) with a mounted camera (Nikon DXM1200), and 
using an inverted microscope (Axio Observer, Carl Zeiss Ltd., Germany). 
 
One CoatPBSScaffPBS, CoatBMP 1.25ScaffPBS, CoatPBSScaffBMP 1.25 and CoatBMP 
1.25ScaffBMP 1.25 scaffold each from patient 569, which had been cultured in OS-D, 
were fixed overnight in 3% (w/v) gluteraldehyde in 0.1 M sodium cacodylate buffer 
(pH = 7.3).  The CoatBMP 1.25ScaffBMP 1.25 scaffold was then prepared for examination 
using a scanning electron microscope as described in §6.4.5.  The remaining samples 
were not prepared for examination. 
 
For the remainder, the scaffolds were removed from the well and placed in individual 
1.5 ml eppendorf tubes.  The scaffolds were then assayed for their DNA content and 
either the ALP activity or calcium content, as described in §6.4.6 and §6.4.7. 
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6.4.5. Electron Microscope Sample Preparation 
The CoatBMP 1.25ScaffBMP 1.25 scaffold was prepared for scanning electron microscopy 
as previously described by Leus et al. (2004) and Macdonald et al. (2008).  After 
treatment with glutaraldehyde, the scaffold was immersed overnight in 2% (w/v) 
guanidine hydrochloride and 2% (w/v) tannic acid.  It was subsequently post-fixed in 
2% (w/v) osmium tetroxide in dH2O for 8 hr. 
 
The scaffold was then dehydrated in graded concentrations of acetone (50%, 70%, 
90%, and 100%).  This was followed by critical point drying using CO2.  After 
mounting on an aluminium stub, the scaffold was sputter coated with 20 nmoles of 
gold/palladium.  Photographs of the sample were then taken using a Phillips 505 
scanning electron microscope. 
6.4.6. ALP/DNA Assay 
For each patient, six scaffolds from the CoatBMP 1.25ScaffPBS, CoatPBSScaffBMP 1.25 and 
CoatBMP 1.25ScaffBMP 1.25 groups, as well as the CoatPBSScaffPBS exposed to different 
rhBMP-7 concentrations (six scaffolds per concentration), were thawed.  The 
scaffolds were then examined using a combined ALP/DNA assay based on that 
described previously by Dadsetan et al. (2008).  After 30 min at 37°C, 200 µl of 
dH2O were added to each eppendorf tube.  Care was taken to immerse each scaffold 
completely.  The tubes were frozen at -80°C for 60 min before being thawed at 37°C 
for 30 min.  The tubes were then sonicated in a bath sonicator (KS200, Kerry 
Ultrasonics, UK) filled with ice water for 30 min.  The freeze/thaw/sonicate cycle 
was then repeated. 
6.4.6.1. DNA Assay  
After mixing, half of the cell lysate (100 µl) was removed from the tubes.  The 
remaining lysate, for the ALP assay, was stored at 4°C.  Then 50 µl of the cell lysate 
extracted were added to the wells of 96-well plates.  Calibration curves of known 
DNA concentrations was added to the plates, as described in §6.4.2.  PicoGreen 
working solution (50 µl) was added to each of the test wells.  The plates were then 
“tapped” to aid the mixing of the solutions. 
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After incubating the plates at room temperature, in the dark, for 5 min, the 
fluorescence of the wells was measured (excitation 485 nm, emission 520 nm).  The 
apparent concentrations of DNA in the samples were calculated using the calibration 
curves.  The apparent number of cells was found using the correlation between the 
DNA concentration and the number of cells calculated in §6.5.1. 
6.4.6.2. ALP Assay 
An ALP assay, with minor modifications from Modrovich (1979) and Bjerre et al. 
(2008), was applied to the cell lysate set aside as described in §6.4.6.1.  Tablets of 4-
nitrophenyl phosphate disodium salt hexahydrate (5 mg) were added to an aqueous 
solution of 16.7 mM 2-amino-2-methylpropanol and 2.2 mM magnesium chloride 
(MgCl2) (pH 10.3).  The final pNPP concentration was 50 mM. 
 
Then 300 µl of the pNPP solution were added to each eppendorf tube.  After mixing, 
the tubes were incubated in the dark, at room temperature.  After 60 min, 100 µl of 3 
M NaOH were added to each tube.  The samples were diluted at a ratio of 1:1 with 
aqueous 10.0 mM 2-amino-2-methylpropanol, 1.32 mM MgCl2 and 0.6 M NaOH.  
100 µl of the samples were then added to 96-well plates. 
 
A calibration curve of 16 concentrations of pNP, in aqueous 10.0 mM 2-amino-2-
methylpropanol, 1.32 mM MgCl2 and 0.6 M NaOH, was added to the 96-well plates.  
The starting concentration of pNP was 50 mM.  A further 14 two-fold dilutions were 
made from the starting concentration, and a blank was included.  The final volume in 
each well was 100 µl. 
 
The optical densities of the wells were read using an automated 96-well plate reader 
set at 405 nm.  The apparent concentrations of pNP were calculated for each of the 
samples using the calibration curves, taking the 1:1 sample dilution into account.  
The ALP activity was then calculated for each scaffold, by dividing the number of 
moles of pNP produced per hour, by the mass of DNA in the lysate for that scaffold. 
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6.4.7. Calcium/DNA Assay 
For each patient, six scaffolds from the CoatPBSScaffPBS, CoatBMP 1.25ScaffPBS, 
CoatPBSScaffBMP 1.25 and CoatBMP 1.25ScaffBMP 1.25 groups were defrosted.  They were 
then examined using a combined assay to assess their calcium and DNA content. 
 
After 30 min at 37°C, 200 µl of dH2O were added to each eppendorf.  Care was 
taken to immerse each scaffold completely.  The tubes were frozen at -80°C for 60 
min before being thawed at 37°C for 30 min.  The tubes were then sonicated in a 
bath sonicator (KS200, Kerry Ultrasonics, UK) filled with ice water for 30 min.  The 
freeze/thaw/sonicate cycle was then repeated. 
6.4.7.1. DNA Assay 
The scaffolds were assayed for their DNA content, as described in §6.4.6.1. 
6.4.7.2. Calcium Assay 
The cell lysate which was not used for the DNA assay was transferred from the 
eppendorf tubes containing the scaffolds, to new tubes.  A calcium assay was then 
performed on the scaffolds, based on the underlying chemistry described by 
Moorehead and Biggs (1974) and Toffaletti and Kirvan (1980).  The o-
cresolphthalein complexone method has been used previously to assess calcium 
deposition on scaffolds by Vadillo (2009), Kim et al. (2006), and Holtorf et al. 
(2005).  Afterwards, 200 µl of 1 M hydrochloric acid (HCl) were added to each tube 
containing scaffolds.  Similarly, 100 µl of 2 M HCl were added to each tube of cell 
lysate.  The tubes were then incubated overnight in an orbital incubator (Stuart 
S150), set to 120 rpm (orbital diameter: 1.5 cm) and 37°C. 
 
Two solutions were prepared: AMP buffer and Colour reagent.  AMP buffer 
consisted of 15.12 % (v/v) 2-amino-2-methyl-1-propanol in dH2O (pH 10.7).  The 
Colour reagent was made from 0.1 mg/ml o-cresolphthalein complexone (Fluka, UK) 
and 1 mg/ml 8-hydroxychinolin in 6 % (v/v) aqueous HCl.   
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Known concentrations of dibasic calcium phosphate (CaHPO4) in 1 M HCl were 
prepared.  The highest concentration was 1.28 mg/ml, and a further eight two-fold 
dilutions were made.  A blank of 1 M HCl was also included. 
 
Equal quantities of AMP buffer and Colour reagent were added together.  For each 
sample and known calcium phosphate concentration, 10 µl were added to 400 µl of 
the AMP buffer and Colour reagent mixture.  After mixing, 100 µl of each solution 
were added to the wells of 96-well plates. 
 
The optical densities of the wells were read using an automated 96-well plate reader 
set at 540 nm.  The apparent calcium phosphate concentrations of the samples were 
calculated using the calibration curves.  The apparent mass of calcium phosphate 
deposited on each scaffold was normalised by dividing by the mass of DNA in the 
lysate for that scaffold. 
6.4.8. Statistical Analysis 
All correlations derived from calibration curves using Excel 2003.  All correlations, 
had R2 values greater than 0.99.  All other data were analysed using the statistical 
software package SPSS 14.0 for Windows. 
 
The data collected for the combined ALP/DNA assay were found not to satisfy 
Levene’s test, even after mathematical transformations.  Parametric tests, such as 
one-way analysis of variance (ANOVA), were therefore unsuitable.  Hence, the 
nonparametric test Kruskal-Wallis was used to test for statistical significance for 
each data set.  The statistical significance between the groups was found using the 
Mann-Whitney U test (Zar, 1984; Petrie and Sabin, 2005).  p < 0.05 was considered 
to be statistically significant. 
 
All the data collected for the Calcium/DNA assay required the transformation of 
log10 to satisfy Levene’s test and that of Kolmogorov-Smirnov.  ANOVA was then 
applied, followed by the Tukey-Kramer post hoc test to determine the statistical 
differences between the groups. 
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The mean was used throughout, and all results are expressed as the sample means ± 
standard error of the mean (SEM). 
6.5. Results 
6.5.1. hMSC DNA Content 
In the range of DNA concentrations examined, a linear relationship between the 
concentration and the fluorescence was found.  A correlation was therefore 
calculated by linear regression.  Unknown DNA concentrations were calculated 
using the resulting correlation (see Figure 6.3a). 
 
Similarly, a linear relationship between the number of cells seeded per well, and the 
apparent DNA concentration in the cell lysate, was found (see Figure 6.3b).  A 
correlation was calculated by linear regression.  This correlation was used to estimate 




Figure 6.3: DNA and Cell Calibration Curves. 
Figure a) shows a calibration curve, relating DNA concentration to fluorescence.  
Each data point represents two repeats.  The resulting correlation was used to find 
unknown concentrations of DNA.  Figure b) shows a calibration curve, relating the 
number of cells to the apparent DNA concentration.  Each data point represents three 
repeats.  The resulting correlation was used to find unknown cell counts from 
apparent DNA concentrations. 
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6.5.2. ALP Activity on Scaffolds 
In the range of pNP concentrations examined, a linear relationship between the 
concentration and the optical density at 405 nm, was found.  Linear correlations were 
therefore calculated by linear regression.  Unknown pNP concentrations were 
calculated using these correlations.  A representative calibration curve is shown in 
Figure 6.4.  As observed in the results described in §6.5.1, the DNA concentration 
was found to yield a linear relationship with the fluorescence.  The resulting 
calibration curves were similar to that shown in Figure 6.3a. 
 
For all hMSC patients, both pNP production and ALP activity were significantly 
increased for the scaffolds in OS media compared to the control scaffolds (by 
165±32% and 224±42% respectively) (see Figure 6.5a and c).  pNP production was 
elevated for the hMSCs exposed to rhBMP-7 (by 52±25% for 50 ng/ml on the 
control).  ALP activity was also increased significantly for the hMSCs exposed to 
rhBMP-7 (by 98±18% for 50 ng/ml on the control).  Unlike the raw pNP data, ALP 
activity was found to significantly increase with increasing rhBMP-7 concentrations.  
The ALP activity data were also found to be more consistent between different 
hMSC patients.  Apparent pNP concentration and ALP activity were statistically 
significantly increased for the CoatPBSScaffBMP 1.25 and CoatBMP 1.25ScaffBMP 1.25 
scaffold groups for at least two patients, compared to the CoatPBSScaffPBS scaffolds 
(by 39±12% and 35±10% respectively) (see Figure 6.5a and c). 
 
The apparent number of cells on the scaffolds was observed to decrease as the 
concentration of rhBMP-7 in the media was increased (by 25±5% for 50 ng/ml on 
the control) (see Figure 6.5b).  The cell count was also significantly decreased for 
the CoatPBSScaffPBS scaffolds in OS media, compared to the control in OS-D, for two 
out of three patients (by an average of 18±4%).  Although the cell counts were found 
to decrease in two of three patients for the CoatBMP 1.25ScaffPBS scaffolds (by an 
average of 17±5% on the control), this trend was less pronounced for the 
CoatPBSScaffBMP 1.25 and CoatBMP 1.25ScaffBMP 1.25 groups (by 9.5±4.2% and 4.8±3.3% 












Figure 6.4: Optical density against pNP concentration. 
A representative calibration curve, relating the optical density at 405 nm to the 
concentration of pNP.  The resulting linear correlation was used to calculate 














Figure 6.5: Results for the ALP/DNA assay. 
The response of hMSCs seeded onto Type-I collagen coated PCL (Mn 42,500) 
scaffolds.  Figure a) shows the apparent production of pNP, from pNPP, in the cell 
lysate.  Figure b) shows the apparent number of cells on the scaffolds.  Figure c) 
shows the apparent ALP activity of the cells, by normalising the pNP produced, by 
the mass of DNA in the cell lysate.  * and ** denote p < 0.05 and 0.01 respectively, 
compared to the control CoatPBSScaffPBS group.  The error bars represent the SEM, n 
= 6 in each case. 
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It should be noted that the concentrations of pNP and DNA for the “lysate” from the 
scaffolds devoid of cells, were below the detection limit of the assays.  These data 
are therefore not shown. 
6.5.3. Calcium Deposition on Scaffolds 
In the range of calcium phosphate concentrations examined, a linear relationship 
between the concentration and the optical density at 540 nm, was found.  A linear 
correlation was therefore calculated by linear regression.  Unknown apparent calcium 
phosphate concentrations were calculated using this correlation (see Figure 6.6). 
 
The data collected for the apparent mass of calcium phosphate were very similar, 
whether normalised against the mass of DNA in the cell lysate or not (see Figure 
6.7a and b).  Significant changes in apparent calcium phosphate levels were only 
observed for hMSC patient 549.  For this patient, normalised apparent calcium 
phosphate deposition was significantly enhanced for the CoatBMP 1.25ScaffBMP 1.25 and 
especially the CoatPBSScaffBMP 1.25 scaffold groups, compared to the CoatPBSScaffPBS 
control (by 290±140% and 1700±400% respectively).  The CoatBMP 1.25ScaffPBS 
groups were not associated with elevated calcium phosphate deposition for any of the 












Figure 6.6: Optical density against calcium phosphate concentration. 
The calibration curve, relating the optical density at 540 nm to the concentration of 
calcium phosphate.  The resulting linear correlation was used to calculate unknown 





Figure 6.7: Results for the Calcium/DNA assay. 
The response of hMSCs seeded onto Type-I collagen coated PCL (Mn 42,500) 
scaffolds.  Figure a) shows the apparent deposition of calcium phosphate on the 
scaffolds.  Figure b) shows the apparent calcium phosphate deposition, normalised 
against the mass of DNA in the cell lysate.  * and ** denote p < 0.05 and 0.01 
respectively, compared to the control CoatPBSScaffPBS group.  The error bars 
represent the SEM, n = 6 in each case. 
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6.5.4. Scaffold Imaging 
6.5.4.1. Electron Microscopy 
Cell-like structures were observed on the surface of the CoatBMP 1.25ScaffBMP 1.25 (see 
Figure 6.8a and b).  The morphology of the cells was observed to be rounded, and 
relatively few extended cell processes to the surface were observed.  However, much 
of the scaffold’s surface appeared to have been damaged by the sample preparation 
process (see Figure 6.8c and d).  The majority of the surface was free from cell-like 
structures. 
6.5.4.2. Light Microscopy 
Using bright-field microscopy, positive ALP staining was observed on the scaffolds.  
This was particularly the case for the CoatPBSScaffBMP 1.25 and CoatBMP 1.25ScaffBMP 1.25 
groups (see Figure 6.9).  It was noted that the positive ALP staining was observed 
spanning the “pores” of the scaffolds. 
 
Using fluorescence microscopy, cell nuclei were observed to cover the surface of the 
scaffolds (see Figure 6.10).  The cell density was found to be relatively high.  Again 
cells were found to cover the span between the scaffold “pores”. 
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Figure 6.8: Electron microscope images of a scaffold. 
Scanning electron microscope images of a CoatBMP 1.25ScaffBMP 1.25 Type-I collagen 
coated PCL (Mn 42,500) scaffold seeded with hMSCs from patient 569.  Figures a) 
and b) depict high magnification images (the bars represent 10 µm).  Figures c) and 









Figure 6.9: Bright-field images of ALP stained scaffolds. 
Bright-field images of different Type-I collagen coated PCL (Mn 42,500) scaffolds 
seeded with hMSCs from patient 549, stained for ALP.  The images were taken at × 
10 magnification.  The bar represents 500 µm. 
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Figure 6.10: Fluorescence and bright-field images of scaffolds. 
Fluorescence and corresponding bright-field images of different Type-I collagen 
coated PCL (Mn 42,500) scaffolds seeded with hMSCs from patient 549, and stained 




The purpose of the studies described in this chapter was to assess the cell-scaffold 
interactions with scaffolds containing rhBMP-7.  Although the studies described in 
previous chapters had investigated cell interactions with the Type-I collagen coating 
(Chapter 3), and with the rhBMP-7 released from the scaffolds (Chapter 5), the 
cellular response to these combined stimuli was unknown. 
 
As discussed in §1.1.1.5, both ALP and calcium deposition are well established 
markers for osteogenic differentiation.  These markers, along with a DNA assay to 
assess the number of cells per scaffold, were therefore quantitatively assessed to 
examine the extent of hMSC differentiation. 
6.6.1. Number of hMSCs on the Scaffolds 
In general, the apparent number of cells per scaffold was relatively high.  For the 
hMSCs used in these experiments, the highest number of cells found in a confluent 
tissue culture flask (75 cm2) was found to be approximately 1 × 106 (data not shown).  
This corresponds to an approximate cell density of 1.3 × 104 cells/cm2.  However, 
making the crude assumption that the surface area of the scaffolds was 
approximately 2 cm2, the cell density varied from 6.8 × 104 and 1.8 × 105 cells/cm2 
on the scaffolds. 
 
Even taking into account the likely error in the estimation of the scaffold surface 
area, the cell density was considerably higher than expected.  However, the 
fluorescence images of DAPI stained cells on the scaffolds (see Figure 6.10) 
confirmed that the cell density was, indeed, high compared to TC plastic (see Figure 
3.3 and Figure 3.11).  The results for the apparent number of cells per scaffold, 
displayed in Figure 6.5b, are therefore likely to be accurate.  Coupled with the 
observation that the cells bridged the scaffold pores (see Figure 6.10), these data 
provide evidence that the scaffolds are relatively cell-compatible. 
 
Meaningful comparison of the cell densities achieved with those previously reported 
for bone regenerative medical scaffolds is non-trivial.  Many studies that quantify 
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cell densities fail to specify scaffold dimensions sufficiently for a fair comparison 
(Bjerre et al., 2008; Holtorf et al., 2005), use scaffolds with very different geometries 
(Dadsetan et al., 2008), or do not report cell densities directly (Tsiridis et al., 2007). 
 
Li et al. (2005) seeded hMSCs at 250,000 cells/scaffold onto 1 cm2 “mats” of 
electrospun PCL.  The cells were cultured in media designed to induce chondrogenic 
differentiation.  Approximately 1 µg of DNA was extracted per scaffold after 21 
days, equating to approximately 140,000 cells/scaffold (using the correlation shown 
in Figure 6.3b).  While the cell densities reported above (136,000 – 360,000 
cells/scaffold) compare favourably with those measured by Li et al. (2005), the 
comparison is still not a fair one, as the culture conditions were different. 
 
It was found that higher rhBMP-7 concentrations, OS media, and CoatBMP 1.25ScaffPBS 
scaffold groups were associated with significant decreases in the apparent number of 
cells on the scaffolds, compared to the control (see Figure 6.5b).  This could indicate 
increased differentiation of the hMSCs in these groups, as this is associated with 
decreased proliferation (Stein et al., 2004). 
6.6.2. Morphology of hMSCs on the Scaffolds 
The morphology of the hMSCs on the scaffolds was to be assessed using scanning 
electron microscopy.  However, due to the damage to the surface of the sample, 
accurate assessment of the cell morphology was not possible. 
6.6.3. ALP Activity on Scaffolds 
The purpose of examining the scaffolds using an ALP/DNA assay was to assess 
whether the scaffolds loaded with rhBMP-7 were capable of supporting the 
osteogenic differentiation of hMSCs seeded onto the scaffolds. 
 
It should be noted that the photographic method for the assessment of the area of 
ALP staining, used in Chapter 5, could not be used in conjunction with scaffolds.  
This was because of the strong shadows cast by the scaffold struts. 
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It was found that the activity of ALP was significantly higher for the OS media 
groups compared to the CoatPBSScaffPBS in OS-D control, for all the hMSC patients 
tested (see Figure 6.5c).  This indicated that the hMSCs from each patient were 
capable of osteogenic differentiation.  
 
As was observed in Chapter 5, rhBMP-7 was associated with statistically significant 
increases in ALP activity for each patient (see Figure 5.8 and Figure 6.5a and c).  
However, the data obtained in the current chapter were more consistent between 
patients, and revealed more pronounced differences between the groups than the data 
obtained in Chapter 5.  It is possible that the ALP assay based on pNPP may be more 
sensitive than the photographic method, or the cells may respond differently when on 
the scaffolds for 21 days, rather than TC plastic for 14 days.  However, there was 
more evidence for the latter hypothesis, as more pronounced differences in ALP 
staining were observed on the scaffolds than in the TC plastic wells (see Figure 6.9 
and Figure 5.3). 
 
For the cells on the scaffolds, it was found that the rhBMP-7 concentration yielding 
the highest ALP activity was 50 ng/ml for each patient (Figure 6.5a).  Indeed the 
higher the rhBMP-7 concentration, the higher was the observed ALP activity.  Again 
this is in contrast to the data obtained in Chapter 5, where the cells were on a 
different substrate. 
 
The CoatBMP 1.25ScaffBMP 1.25 and CoatPBSScaffBMP 1.25 groups were associated with 
statistically significant increases in ALP activity, compared to the CoatPBSScaffPBS 
control scaffolds, for two and three hMSC patients respectively.  These data imply 
not only that bioactive rhBMP-7 was released from these groups, but also that the 
doses were appropriate to induce a degree of osteogenic differentiation in the 
hMSCs.  It should be noted that this is the first evidence presented in this thesis to 
support the hypothesis that the rhBMP-7 released from the CoatPBSScaffBMP 1.25 
scaffolds was bioactive. 
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In contrast, statistically significant increases in ALP activity were observed for only 
one hMSC patient for the CoatBMP 1.25ScaffPBS scaffolds.  Since it was known from 
the studies described in Chapter 5 that these scaffolds were capable of releasing 
bioactive rhBMP-7, this may be a result of a Type-II statistical error.  It was, 
however, possible that the release profile of the growth factor from the scaffold 
coating may be unsuitable to encourage the osteogenic differentiation of the hMSCs 
on the scaffolds. 
 
The ALP activity values were found to be between a factor of 10 (Bjerre et al., 2008; 
Tsiridis et al., 2007) and 10,000 (Dadsetan et al., 2008; Moreau and Xu, 2009) lower 
compared to studies using animal MSCs or transformed hMSCs on scaffolds, 
cultured in osteogenic media.  However, this was not a fair comparison, as the cell 
sources were different to the clinically relevant hMSCs used in the studies described 
in this chapter. 
 
Due to the significant increases in ALP activity compared to the control scaffolds 
(see Figure 6.5c), it was concluded that the CoatPBSScaffBMP 1.25 and CoatBMP 
1.25ScaffBMP 1.25 scaffolds were able to support the osteogenic differentiation of 
primary hMSCs.  Indeed the osteogenic effects of the encapsulating delivery system 
do not appear to be enhanced by the release of rhBMP-7 from the collagen coating.  
Potentially this leaves the coating delivery system available for the release of other 
active factors, such as VEGF, which could enhance in vivo bone formation, by 
stimulating angiogenesis.  However, this is beyond the scope of the studies described 
in this thesis. 
6.6.4. Calcium Deposition on Scaffolds 
The purpose of examining the scaffolds using a calcium/DNA assay was to assess 
further whether the scaffolds loaded with rhBMP-7 were capable of supporting the 
osteogenic differentiation of hMSCs seeded onto them.  This was assessed by 
quantifying matrix mineralisation. 
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The o-cresolphthalein complexone method, employed in the studies described in this 
chapter, was capable of quantifying calcium ions.  However, it was unable to 
determine whether the ions detected originally formed part of calcium phosphate, let 
alone whether it was in the form of hydroxyapatite.  Indeed, the most rigorous 
method of determining the presence of hydroxyapatite remains X-ray crystallography 
(Leventouri, 2006).  Nevertheless, as discussed in §6.3, the o-cresolphthalein 
complexone method is commonly used to assess the mineral content of bone 
regenerative medical scaffolds.  This may be due to its speed, simplicity, and 
repeatability. 
 
Significant increases in the apparent mineral content of the scaffolds were only 
observed for cells from patient 549.  It was noted that this patient was also associated 
with the lowest observed ALP activity of all the test patients.  This was consistent 
with the cells from this patient having progressed further along the osteoblastic 
lineage to the point where ALP expression decreases as matrix mineralisation 
increases, as discussed in §1.1.1.5 (see Figure 1.3).  However, these data do not 
support the hypothesis that the scaffolds loaded with rhBMP-7 were able to induce 
mineralisation in the hMSCs seeded on them. 
 
It is interesting to note that CoatBMP 1.25ScaffBMP 1.25 scaffolds were associated with 
statistically significantly elevated levels of either ALP activity or calcium deposition 
in hMSCs from all the patients tested (see Figure 6.5 and Figure 6.7).  Taken 
together with the ALP studies, the data presented in the current chapter appear to 
support the hypothesis that CoatBMP 1.25ScaffBMP 1.25 scaffolds were able to support the 
osteogenic differentiation of clinically relevant hMSCs.  However, it must be 
stressed that since calcium deposition was only significantly increased in one patient, 
these data do not support the hypothesis that the scaffolds loaded with rhBMP-7 were 
capable of increasing mineralisation in hMSCs. 
 
Osteogenic differentiation of cells on the scaffolds was assessed with more rigour in 
Chapter 7.  The expression of the osteogenic markers Type-I collagen, ALP, 
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osteopontin, osteocalcin and Runx2 was examined using quantitative reverse 
transcription polymerase chain reaction. 
6.7. Conclusion 
Combined ALP/DNA and calcium/DNA assays were used to assess whether the 
Type-I collagen coated PCL (Mn 42,500) scaffolds loaded with rhBMP-7, were 
capable of supporting the osteogenic differentiation of hMSCs, seeded onto them. 
 
ALP activity was found to increase with increasing concentrations of rhBMP-7 in the 
range of concentrations tested (5, 20, and 50 ng/ml).  ALP was also statistically 
significantly stimulated for the CoatPBSScaffBMP 1.25 and CoatBMP 1.25ScaffBMP 1.25 
scaffold groups.  These data indicated that these scaffolds were capable of 
stimulating the osteogenic differentiation of hMSCs seeded onto them. 
 
Levels of calcium deposition were only stimulated in the cells of one of the three 
hMSC patients tested.  These data do not support the hypothesis that the rhBMP-7 
loaded scaffolds tested were able to induce mineralisation in the hMSCs seeded on 
them. 
 
The data collected in the studies described in this chapter suggest that the osteogenic 
effect of the encapsulation delivery system was not enhanced by the release from the 
coating.  Therefore in the final “product” for clinical use, the coating delivery system 
















Chapter 7 : Functional Assay 
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7.1. Scaffold Nomenclature 
CoatPBS   Collagen coating with PBS (rhBMP-7 control) 
CoatBMP 1.25   Collagen coating with rhBMP-7 (1.25 µg/ml) 
ScaffPBS   Scaffold encapsulating PBS (rhBMP-7 control) 
ScaffBMP 1.25   Scaffold encapsulating rhBMP-7 (1.25 µg/ml) 
7.2. Abstract 
The studies described in Chapter 6 investigated the reaction of human marrow 
stromal cells seeded onto scaffolds, loaded with recombinant human bone 
morphogenetic protein-7 (rhBMP-7).  However this was only achieved by examining 
the activity of the enzyme alkaline phosphatase (ALP), and mineralisation.  The 
current chapter describes cellular reaction to the scaffold in terms of the expression 
of genes associated with osteogenesis.  This was done by exploring the expression of 
Type-I collagen (Col1), osteopontin (OP), ALP, osteocalcin (OC) and runt related 
transcription factor 2 (Runx2), by quantitative reverse transcription polymerase chain 
reaction (qRT-PCR).  The cells selected for these studies were of the murine 
myoblast cell line C2C12. 
 
C2C12 cells cultured on CoatPBSScaffPBS scaffolds, exposed to 200 ng/ml rhBMP-7 in 
the media, were found to upregulate OP, ALP, OC and Runx2 after 24 hr compared 
to the control (by 64±15%,  385±68%, 127±66%, and 76±43% respectively). 
 
Similarly, the CoatBMP 1.25ScaffPBS scaffolds, without rhBMP-7 in the media, were 
found to have an early osteoinductive effect on the C2C12 cells cultured on them.  
OP, ALP, OC and Runx2 were found to be statistically significantly up-regulated 
during the first 2 days only, compared to the control (e.g. by 44±12%, 128±42%, 
60±25% and 46±25% respectively at the 24 hr mark). 
 
The CoatPBSScaffBMP 1.25 scaffolds also had an osteoinductive effect on the cells, 
which was more sustained than that observed for the CoatBMP 1.25ScaffPBS group.  
While OP, ALP and Runx2 were up-regulated in the first 24 hr compared to the 
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control (by 38±10%, 208±82% and 72±31% respectively), statistically significant 
up-regulation of the late marker OC was delayed until the 48 hr mark (by 73±49%).  
The effect was found to be sustained until day 7, when OC and Runx2 were both 
statistically significantly up-regulated compared to the control (by 151±91% and 
93±27% respectively). 
 
The CoatBMP 1.25ScaffBMP 1.25 scaffolds were found to combine the early effect of the 
CoatBMP 1.25ScaffPBS scaffolds, with the more sustained effect of the CoatPBSScaffBMP 
1.25 scaffolds.  ALP, OC and Runx2 were all up-regulated at the 24 hr mark (by 
312±56%, 329±39% and 96±25% respectively).  This osteoinductive effect was 
sustained until day 7 when Col1, ALP and Runx2 were still up-regulated compared 
to the control (by 174±78%, 72±24% and 178±78% respectively). 
 
These data suggest that the scaffolds containing rhBMP-7 have a weak 
osteoinductive effect on the cells seeded onto them.  The different delivery systems 
were found to affect the cells differently.  The clinical significance of this was not 
assessed in these studies. 
7.3. Introduction 
The purpose of the work described in Chapter 6 was to assess the reaction of human 
marrow stromal cells (hMSCs) to the scaffolds in terms of their ability to induce 
increased alkaline phosphatase expression and mineralisation.  The purpose of the 
studies described in the current chapter was to assess the ability of the scaffolds to 
up-regulate the expression of genes associated with osteogenesis.  This was achieved 
using quantitative reverse transcription polymerase chain reaction (qRT-PCR).   
 
The cell type selected for these studies was the murine myoblast cell line C2C12.  
Though originally derived from murine muscle tissue (Yaffe and Saxel, 1977), 
previous studies have shown that the differentiation pathway can be shifted from 
myoblastic to osteoblastic in the presence of either recombinant human bone 
morphogenetic protein-2 (rhBMP-2) (Lee et al., 1999; Katagiri et al., 1994; Kim et 
al., 2009) and -7 (rhBMP-7) (Gu et al., 2004b; Yeh et al., 2002; Tou et al., 2003). 
310 
 
The genes of interest selected for the current study were; runt related transcription 
factor 2 (Runx2), Type 1 collagen (Col1), osteocalcin (OC), osteopontin (OP) and 
alkaline phosphatase (ALP).  The transcription factor Runx2, also called core binding 
factor alpha1 (Cbfa1), has been found to be necessary for bone development in 
murine developmental models and is thought to be essential for osteoblastic 
differentiation (Komori et al., 1997; Otto et al., 1997).  Indeed the expression of 
Runx2 has been described as being necessary and sufficient for osteoblast 
differentiation (Karsenty, 2003). 
 
Runx2 is thought to act as a “master switch” during the commitment of mesenchymal 
stem cells to the osteoblastic lineage, and is expressed before the development of the 
osteoblastic phenotype (Ducy et al., 1997).  Expression of Runx2 also increases 
during osteoblast maturation (Banerjee et al., 2001), and is present during the 
transdifferentiation of premuscle (C2C12) cells to the osteoblastic lineage (Lee et al., 
1999).  It has also been found that calvarial-derived cells from mice with a mutated 
Runx2 locus, express ALP only weakly and lack expression of either osteopontin or 
osteocalcin.  Examination of the skeletal system of such mice also shows a complete 
lack of mineralisation (Komori et al., 1997).  Runx2 has also been described as being 
the earliest transcription factor necessary for bone formation (Stein et al., 2004). 
 
Col1 expression is an early maker of osteoblastic differentiation and is first 
expressed by osteoprogenitor cells but not by MSCs (Liu et al., 1994).  Col1 is the 
most abundant protein in bone extracellular matrix.  In both humans and mice, the 
gene Col1 α1(I) contains Runx2 binding sites (OSE2) in its promoter, suggesting it is 
up-regulated by the transcription factor Runx2 (Kern et al., 2001). 
 
The osteocalcin gene also contains a Runx2 binding site (OSE2) in its promoter 
(Ducy and Karsenty, 1995; Ducy et al., 1997).  It is one of the few genes thought to 
be specific to osteoblasts and odontoblasts (Desbois et al., 1994).  Osteocalcin is 
thought to play a role in mineralisation and calcium homeostasis, as well as being a 
marker of mature osteoblasts (Liu et al., 1994). 
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Similarly, the osteopontin gene contains a Runx2 binding site in its promoter (Ducy 
et al., 1997).  It is thought to play a role in the anchoring of osteoclasts (Reinholt et 
al., 1990), and serves as a marker of preosteoblasts (Liu et al., 1994).  OP is, 
however, not specific to osteoblasts, and it is also expressed in hypertrophied 
chondrocytes (Mark et al., 1988; Nomura et al., 1988). 
 
Runx2 has also been found to up-regulate expression of ALP (Harada et al., 1999), 
although it is possible that BMP-7 induction of ALP expression may be through the 
Wnt autocrine loop, as is thought to be the case with BMP-2 (Rawadi et al., 2003).  
As previously discussed in §5.3, although ALP expression is not confined to bone 
tissue, it is commonly used in assays for osteogenesis.  ALP mRNA expression is 
also a marker of immature osteoblasts, but is thought to occur later than osteopontin 
(Liu et al., 1994). 
 
In turn previous studies have demonstrated that rhBMP-7 increases the expression of 
Runx2 in C2C12 (Tou et al., 2003; Gu et al., 2004b).  BMP-7 is thought to activate 
Smad1 and Smad5.  This is in contrast to BMP-2 which activates Smad1, -5, and -8 
(Aoki et al., 2001).  After BMP-7 binds to BMP receptor I or II, the receptor is 
thought to phosphorylate the receptor-regulated Smads (Smad-1 and -5), which in 
turn bind to the coSmad (Smad4) (Shen et al., 2002) (see Figure 7.1).  The resulting 
complex translocates to the nucleus, where it influences the expression of target 
genes including Dlx5, which in turn induces the expression of Runx2 (Miyama et al., 
1999; Lee et al., 2003b). 
 
During the studies described in this chapter, the osteogenic differentiation of C2C12  
on Type-I collagen coated PCL (Mn 42,500) scaffolds, loaded with rhBMP-7, was 
investigated.  This was achieved using qRT-PCR to quantify the up-regulation of 









Figure 7.1: BMP Signal Transduction. 
A cartoon representing BMP signal transduction.  The binding of BMP-7 to BMP 
receptors I and II causes the phosphorylation of Smad 1 and Smad 5.  These bind to 
Smad 4, and the resulting complex translocates to the nucleus where target genes are 
influenced (adapted from Roelen and Dijke (2003)). 
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7.4. Methods and Materials 
Unless otherwise stated, all reagents were purchased from Sigma, UK.  All 
techniques involving cell culture, described below, were conducted in a sterile 
environment, using sterile equipment.  All consumables used during PCR procedures 
were certified as being RNAse free by the manufacturers. 
7.4.1. C2C12 Culture 
The murine myoblast cell line C2C12 (Yaffe and Saxel, 1977) was cultured as 
previously described by Gu et al.,(2004b).  C2C12 cells were cultured in growth 
media (as described in §3.3.1), in tissue culture flasks (75 cm2) (Corning, UK), 
incubated at 37°C with 5% (v/v) CO2.  The growth media was refreshed every 2 – 3 
days.  When the cells were 70% confluent, they were washed three times in 
phosphate buffered saline (PBS) (Oxoid, UK), and passaged by adding 1 ml of 2.5 
mg/ml trypsin solution in PBS.  After 10 min incubation at 37°C, 9 ml of growth 
media were added to each of the flasks.  Then 1 ml of cell suspension was added to 
new tissue culture flasks (75 cm2).  An additional 9 ml of fresh growth media were 
then added to each new flask.  The flasks were then incubated and refreshed with 
new growth media as before. 
7.4.2. Primer Testing 
Primers were purchased from Integrated DNA Technologies, UK.  The sequences, 





Table 7.1: Primer sequences for qPCR. 






(Gu et al., 2004b) 
























(Kim et al., 2009) 
 
7.4.2.1. RNA Extraction 
It was desirable to determine a single annealing temperature suitable for all the 
primer pairs.  A 70% confluent tissue culture flask (75 cm2) of C2C12 cells (passage 
18) was washed three times with PBS, and the cells were detached from the flask 
using trypsin and growth media as described in §7.4.1.  The cell suspension was 
centrifuged (1,000 rpm for 5 min), the supernatant was discarded and the cell pellet 
was resuspended in 1 ml of TRIzol® Reagent (Invitrogen, UK).  After 5 minutes of 
incubation at room temperature and mixing with a pipette, the sample was transferred 
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to a 1.5 ml eppendorf tube (Axygen, USA) with 200 µl of chloroform.  The sample 
was vortexed for 15 seconds and incubated at room temperature for 3 min before 
centrifugation at 4°C for 15 min at 13,000 rpm (eppendorf centrifuge 5417R).  The 
aqueous (upper) phase was carefully transferred into a new tube after which an equal 
volume of phenol/chloroform (1:1) was added.  After vortexing for 15 seconds, the 
sample was centrifuged at 13,000 rpm for 3 min at room temperature. 
 
The aqueous phase was transferred to a fresh tube with an equal volume of 
chloroform.  After vortexing (15 seconds) the tube was again centrifuged at 13,000 
rpm for 3 min at room temperature.  Following the transfer of the aqueous phase to a 
fresh tube, an equal volume of isopropyl alcohol was added, before re-vortexing (15 
seconds) and centrifugation (13,000 rpm for 50 min at 4°C). 
 
The supernatant was removed and 800 µl of 70% ethanol were added.  Following 
centrifugation (13,000 rpm at 4°C for 2 min) the supernatant was carefully removed, 
and the RNA pellet was air dried at room temperature for 5 min.  The pellet was then 
dissolved in 50 µl of DEPC-treated water (Invitrogen, UK).   
 
The concentrations of the RNA sample was measured using the NanoDrop™ 1000 
(Thermo Scientific, UK).  The 260/280 and 260/230 ratios, used to assess the purity 
of the nucleic acid, were recorded as 1.94 and 2.15.  The RNA sample was then 
treated as described in §7.4.2.2. 
7.4.2.2. Complementary DNA (cDNA) Synthesis 
SuperScript™ III First-Strand Synthesis SuperMix for qRT-PCR (Invitrogen, UK) 
was used to synthesis the first strand of cDNA from the RNA templates.  The 
reaction was set up as follows: 2X RT Reaction Mix (20 µl), RT Enzyme Mix (4 µl), 
RNA sample (1 µl), DEPC-treated water (15 µl). 
  
After mixing, the reaction mixtures were incubated for 10 min at room temperature 
before being incubated at 50°C for 60 min then 85°C for 5 min.  After cooling on ice 
for 5 min, 2 µl (4 U) of E. coli RNAse H were added before incubation at 37°C for 
20 min.  RT-PCR was then conducted on the sample. 
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7.4.2.3. RT-PCR 
For each primer pair (see Table 7.1), 5 µl of both forward and reverse primers (10 
nM) were added to 36 µl of DEPC-treated water (Invitrogen, UK).  For each 
solution, 11.5 µl were added to fresh eppendorf tubes with 12.5 µl of Thermo-Start 
PCR Master Mix (Thermo Fisher Scientific) and either 1 µl of cDNA or 1 µl of 
DEPC-treated water (hereafter referred to as the non-template (NT) control).  The 
reaction was then performed using an automatic DNA Thermal Cycler (Peltier 
Thermal Cycler, MJ Research PTC-200) at temperatures corresponding to the three 
steps of the reaction: denaturation, annealing and elongation.  The reactions were run 
twice (for separate samples) using two different programs (see Table 7.2). 
 
Table 7.2: Thermal cycler programs for RT-PCR. 
Run 1 Run 2 
Temperature Time Cycles Temperature Time Cycles 
95°C 15 min ×1 95°C 15 min ×1 
95°C 30 sec  95°C 30 sec  
57°C 30 sec ×40 59°C 30 sec ×40 
72°C 15 sec 
} 
 72°C 15 sec 
} 
 
4°C Forever* ×1 4°C Forever* ×1 
* The term “forever” denotes holding the samples at the specified temperature, until 
manual retrieval of the samples. 
 
Afterwards, the PCR products were visualised and sized by agarose gel 
electrophoresis. 
7.4.2.4. Agarose Gel Electrophoresis 
The protocol used was previously described by Voultsiadou (2009).  SeaKem GTG 
Agarose (FMC Bioproducts, USA) was dissolved in 100 ml of TBE Buffer (89 mM 
Tris Base, 89 mM Boric Acid, 2 mM EDTA) at 1.5 % (w/v).  The mixture was 
heated in a microwave oven for approximately 2 min, until the agarose had 
dissolved.  After cooling under running tap water, 5 µl ethidium bromide (10 mg/ml) 
were added prior to the gel being cast in a mould.  When the gel had set, the 
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electrophoresis tank was filled with TBE buffer.  2.5 µl of Orange G loading dye 
(1% (w/v)) were added to each of the 25 µl samples prepared as described in 
§7.4.2.3.  After vortexing, 10 µl were added per well in the gel.  100 volts were 
applied across the gel until the dye front had migrated two thirds from the end of the 
gel.  Gels were visualised using a UV transilluminator (Uvidoc, UVItec, BTS-20-M).  
The product size was measured relative to size markers: 10 µl of Tracklt™ 100bp 
DNA ladders (Invitrogen) which were run alongside samples. 
7.4.3. Scaffold Manufacture 
Poly(ε-caprolactone) scaffolds containing or lacking rhBMP-7 (designated ScaffBMP 
1.25 and ScaffPBS respectively) were manufactured and coated with collagen either 
containing or lacking rhBMP-7 (designated with the prefixes CoatBMP 1.25 and 
CoatPBS respectively) as described in §6.4.3. 
7.4.4. C2C12 Culture on Scaffolds 
After the quarter scaffolds, prepared as described in §7.4.3, were defrosted, they 
were individually placed at the bottom of the well of 48-well non-TC plastic plates 
(Corning, USA).  Care was taken to ensure the scaffolds were flat against the bottom 
of the wells, and that they were held in place by the scaffolds corners’ contact with 
the wells’ sides.  The number of CoatPBSScaffPBS, CoatBMP 1.25ScaffPBS, 
CoatPBSScaffBMP 1.25 and CoatBMP 1.25ScaffBMP 1.25 quarter scaffolds used was 27, 12, 12 
and 12 respectively. 
 
Tissue culture flasks (75 cm2) containing 70% confluent C2C12 cells (passage 18), 
were washed three times in PBS, and the cells were detached from the flasks using 
2.5 mg/ml trypsin in PBS (Invitrogen, UK) and growth media, as described in §3.3.1.  
The cell density of the suspensions was measured using a haemocytometer.  The 
cells were centrifuged (1,000 rpm, 5 min) and resuspended in half-serum media 
[Dulbecco’s Modified Eagle’s Medium – high glucose (DMEM), supplemented with 
5% (v/v) FCS (Autogen Bioclear, UK), L-glutamine (2 mM) (Gibco, UK), penicillin 
(100 IU/ml) and streptomycin (100 µg/ml) (Gibco, UK)], such that the final cell 
density was 4 × 105 cells/ml. 
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The cells were added to wells of the 48-well non-TC plastic plates, containing 
scaffolds.  The cells seeded onto 12 of the CoatPBSScaffPBS scaffolds were 
supplemented with rhBMP-7 to a final concentration of 200 ng/ml.  The remaining 
wells in the 48-well plates were filled with growth media to limit the rate of 
evaporation of media from the test wells.  The plates were then maintained in a 
humidified air incubator at 37°C with 5% (v/v) CO2. 
 
After 4 hr, three of the CoatPBSScaffPBS scaffolds were removed from the wells and 
analysed for DNA content, as described in §7.4.6.  On day 1, the media was removed 
from the wells, and wells were washed with PBS to remove non-adhered cells from 
the wells, before fresh media was added.  After 24, 48 and 72 hr, three scaffolds from 
each group were processed as described in §7.4.5.1.  On days 3 and 6, the media on 
the remaining scaffolds was refreshed before they were also processed as described 
in §7.4.5.1 after 168 hr (7 days). 
7.4.5. qRT-PCR Analysis 
7.4.5.1. RNA extraction from Scaffolds 
The scaffolds to be processed were extracted from the wells of the 48-well plates and 
placed in 0.5 ml eppendorf tubes (Axygen, USA) with 200 µl TRIzol® Reagent.  The 
samples were incubated for 5 min at room temperature.  After mixing with a pipette, 
the liquid was extracted from the tubes and stored in fresh eppendorf tubes at -80°C. 
 
RNA was then extracted from the samples as described in §7.4.2.1 with the 
modification that 40 µl of chloroform were added to each tube rather than 200 µl, 
since the sample volume was smaller.  The RNA pellets were also resuspended in 20 
µl of DEPC-treated water.  260/280 and 260/230 ratios were found using the 
NanoDrop™ 1000 Spectrophotometer.  All the samples prepared for qRT-PCR 
analysis had 260/280 ratios greater than 1.80, and 260/230 ratios greater than their 
respective 260/280 ratios. 
 
The cDNA was synthesised from the RNA samples as described in §7.4.2.2 with the 
modification that the reactions were set up as follows: 2X RT Reaction Mix (10 µl), 
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RT Enzyme Mix (2 µl), RNA sample (x µl), DEPC-treated water ([8 – x] µl).  In this 
case, x was 8 µl when the RNA sample was 125 ng/µl or less, and adjusted such that 
1 µg of RNA was added when the concentration was greater than 125 ng/µl.  The 
samples were then diluted five-fold with water before storage at -80°C. 
7.4.5.2. qRT-PCR 
The cDNA samples described in §7.4.5.1 were analysed using qRT-PCR.  Reaction 
mixtures were prepared for each primer pair as follows using materials from 
GoTaq® qPCR Master Mix kit (Promega, USA) : 39.8% Nuclease-Free Water, 
55.6% GoTaq® Reaction mix, 2.2% forward primer, 2.2% reverse primer, 0.2% 
Reference Dye.  18 µl of the mixture was added to the wells of MicroAmp® Optical 
96-well reaction plates (Applied Biosystems) along with 2 µl of cDNA samples. 
 
The plates were subsequently analysed using a 7500 Fast Real-Time PCR System 
(Applied Biosystems) set to “Standard Runs” using the parameters described in 
Table 7.3.  This was followed by dissociation steps.  GAPDH was used as the 
endogenous control throughout. 
 
Table 7.3: Thermal cycler programs for qRT-PCR. 
Temperature Time Cycles 
50°C 2 min ×1 
95°C 10 min ×1 
95°C 15 sec 
57°C 1 min } 
 
      ×40 
 
The resulting data were analysed using the 7500 Fast Real-Time PCR Software 1.4.0. 
7.4.6. DNA Assay 
The scaffolds extracted from the wells 4 hr after cell seeding, as described in §7.4.4, 
were assayed for their DNA content as previously described in §6.4.6 and §6.4.6.1. 
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7.4.7. Statistical Analysis 
All correlations were derived from calibration curves using Excel 2003.  All 
correlations had R2 values greater than 0.99.  All other data were analysed using the 
statistical software package SPSS 14.0 for Windows. 
 
Since three biological repeats were used for the qRT-PCR studies, parametric tests, 
such as one-way analysis of variance (ANOVA), were unsuitable.  Hence, the 
nonparametric Kruskal-Wallis test was used to assess statistical significance for each 
data set.  The statistical significance between the groups was found using the Mann-
Whitney U test (Zar, 1984; Petrie and Sabin, 2005).  p < 0.05 was considered to be 
statistically significant. 
 
The mean was used throughout, and all results are expressed as the sample means ± 
standard error of the mean (SEM). 
7.5. Results 
7.5.1. Primer Testing 
Photographs of the electrophoresis gels visualising the RT-PCR reactions run as 
described in §7.4.2.3 and §7.4.2.4, are shown in Figure 7.2.  At both 57°C and 59°C, 
a single band of amplicons were found to have been produced for each primer pair.  
However, amplicons were found to be present in the NT control for the osteocalcin 
primer pair at 57°C (see Figure 7.2a).  On increasing the temperature to 59°C, no 
bands were observed for the NT controls for any of the primer pairs (see Figure 












Figure 7.2: Electrophoresis Gels for Primer Testing 
These figures represent electrophoresis gels, visualising the RT-PCR products 
derived from reaction temperatures of a) 57°C (note the presence of a band for the 
NT control for OC), and b) 59°C.  The photographs are shown as negatives. 
 
7.5.2. qRT-PCR Analysis 
The dissociation curves for each primer pair are shown in Figure 7.3.  For each 
primer pair, a single peak was observed.  The melting temperature was found to be 








Figure 7.3: Dissociation Curves 
These figures represent typical dissociation curves of the amplicons produced during 
qRT-PCR reactions for the following target genes; a) Runx2, b) Col1, c) OC, d) OP, 




For Runx2, mRNA expression was statistically significantly increased compared to 
the CoatPBSScaffPBS controls in; the CoatPBSScaffPBS + rhBMP-7 group on day 1 
(76±43%), the CoatBMP 1.25ScaffPBS group on days 1 and 2 (46±25% and 19±10% 
respectively), the CoatPBSScaffBMP 1.25 group on days 1, 2 and 7 (72±43, 28±8 and 
93±27% respectively), and the CoatBMP 1.25ScaffBMP 1.25 group on days 1, 2 and 7 
(96±25%, 35±13% and 178±78% respectively) (see Figure 7.4a).  Runx2 expression 
in the CoatPBSScaffPBS group was also found to increase statistically significantly on 
day 3 (69±45%) and decrease on day 7 (49±7%) compared to day 1 (see Figure 
7.5a). 
 
Levels of mRNA expression of OC were found to be elevated statistically 
significantly compared to the CoatPBSScaffPBS controls in; the CoatPBSScaffPBS + 
rhBMP-7 group on day 1 (127±66%), the CoatBMP 1.25ScaffPBS group on days 1 and 2 
(60±25% and 236±98% respectively), the CoatPBSScaffBMP 1.25 group on days 2 and 7 
(73±49% and 151±91%) and the CoatBMP 1.25ScaffBMP 1.25 group on days 1 and 2 
(329±39% and 244±67% respectively) (see Figure 7.4b).  OC expression was also 
found to increase statistically significantly in the CoatPBSScaffPBS group on days 2, 3 
and 7 compared to day 1 (287±55%, 1390±240% and 785±261% respectively) (see 
Figure 7.5b). 
 
For ALP, mRNA expression was statistically significantly increased compared to the 
CoatPBSScaffPBS controls for; the CoatPBSScaffPBS + rhBMP-7 group on days 1 and 2 
(385±68% and 100±36% respectively), the CoatBMP 1.25ScaffPBS group on day 1 
(128±42%), the CoatPBSScaffBMP 1.25 group on day 1 (208±82%), and the CoatBMP 
1.25ScaffBMP 1.25 group on days 1, 2 and 7 (312±56%, 82±29% and 72±24% 
respectively) (see Figure 7.4c).  However it was decreased for the CoatPBSScaffBMP 
1.25 group on day 3 (37±13%).  ALP mRNA expression was also found to increase 
statistically significantly for CoatPBSScaffPBS on days 3 and 7 compared to day 1 
(490±134% and 128±32% respectively) (see Figure 7.5c). 
 
OP expression was increased statistically significantly in the CoatPBSScaffPBS + 
rhBMP-7, CoatBMP 1.25ScaffPBS and CoatPBSScaffBMP 1.25 groups compared to the 
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CoatPBSScaffPBS control on day 1, and in the CoatPBSScaffBMP 1.25 group on day 2, by 
64±15%, 44±12%, 38±10% and 163±71% respectively (see Figure 7.4d).  OP 
mRNA expression was also statistically significantly decreased in the CoatBMP 
1.25ScaffBMP 1.25 on day 1 compared to the CoatPBSScaffPBS control by 40±6%. 
 
It was found that mRNA expression of Col1 was increased statistically significantly 
for the CoatPBSScaffBMP 1.25 and CoatBMP 1.25ScaffBMP 1.25 groups compared to the 
CoatPBSScaffPBS control on days 2 and 7 respectively by 72±29% and 174±78% (see 
Figure 7.4e).  Col1 was also found to decrease statistically significantly for 








Figure 7.4: Gene expression in C2C12 cells cultured on scaffolds. 
These figures represent the fold change, compared to the CoatPBSScaffPBS controls, in 
mRNA expression of genes associated with osteogenesis for C2C12 cells cultured on 
Type-I collagen coated PCL (Mn 42,500) scaffolds.  The relative expression was 
assessed by qRT-PCR, using GAPDH as the endogenous control.  The target genes 
were; a) Runx2, b) OC, c) ALP, d) OP, and e) Col1.  * denotes p < 0.05 compared to 
the CoatPBSScaffPBS control for the same time point.  The error bars represent the 





Figure 7.5: Gene expression in C2C12 cells cultured on control 
scaffolds. 
These figures represent the fold change, compared to the CoatPBSScaffPBS day 1 
control, in mRNA expression of genes associated with osteogenesis for C2C12 cells 
cultured on Type-I collagen coated PCL (Mn 42,500) scaffolds.  The relative 
expression was assessed by qRT-PCR, using GAPDH as the endogenous control.  
The target genes were; a) Runx2, b) OC, c) ALP, d) OP, and e) Col1.  * denotes p < 
0.05 comparing the CoatPBSScaffPBS controls to the CoatPBSScaffPBS day 1 control.  
The error bars represent the SEM, n = 3 in each case. 
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7.5.3. DNA Assay 
Using calibration curves similar to those shown in Figure 6.3a and Figure 6.3b, the 
number of C2C12 cells successfully seeded into the CoatPBSScaffPBS scaffolds was 
67,700±12,000 cells.  This corresponds to a seeding efficiency of 42±8%. 
7.6. Discussion 
7.6.1. Primer Testing 
By electrophoresis, it was determined that an annealing temperature of 59°C was 
sufficiently high for primer dimers not to form for each of the primer pairs (see 
Figure 7.2b).  At 59°C, single bands were formed at approximately the same sizes as 
the predicted fragment lengths.  Taking this evidence together with the single peaks 
observed for each primer pair during qRT-PCR (see Figure 7.3), it was concluded 
that the primer pairs were specific for the target genes of interest. 
7.6.2. DNA Assay 
A previous study investigating the differentiation of C2C12 cells using rhBMP-7, 
conducted by Gu et al.,(2004b), seeded the cells as 2 × 104 cells/cm2 24 hr before 
exposure to the growth factor.  The doubling time of C2C12 cells has previously 
been reported as being approximately 19 hr (Pisani et al., 2004), hence the cell 
density at T0 is likely to have been approximately 4.8 × 104 cells/cm2. 
 
Making the crude assumption that the upper surface area of the scaffolds was 1 cm2, 
the cell density at T0 used in the studies described this chapter was (6.77±0.12) × 104 
cells/cm2 on the scaffolds.  This is, therefore, comparable to the T0 cell density used 
in the C2C12 differentiation studies reported by Gu et al.,(2004b). 
7.6.3. qRT-PCR Analysis 
Previous studies have examined the ability of rhBMP-7 to shift the differentiation 
pathway from myoblastic to osteoblastic.  In these studies, rhBMP-7 at 200 ng/ml in 
the culture media was sufficient for this shift in differentiation pathway (Gu et al., 
332 
2004b; Tou et al., 2003; Yeh et al., 2002).  Hence, this concentration of rhBMP-7 
was chosen as a positive control. 
 
Runx2 is thought to be another specific marker for osteogenesis, as this transcription 
factor has been described as the “master switch” for osteogenesis (see §7.3).  Runx2 
was found to be up-regulated statistically significantly for the rhBMP-7 positive 
control, in the first 24 hr period only, compared to the negative CoatPBSScaffPBS 
control (see Figure 7.4a).  Gu et al. (2004b) found that Runx2 was up-regulated in 
C2C12 cells after 24 hr of exposure to rhBMP-7.  However, the effect appeared to be 
damped on the CoatPBSScaffPBS scaffolds: 1.76±0.42 fold difference as opposed to the 
5.5 fold difference observed by Gu et al. (2004b).  Nevertheless, the observation by 
Gu et al. (2004b) that Runx2 expression in response to rhBMP-7 was transient, and 
peaked compared to the control at approximately the 24 hr mark, was repeated for 
the cells on the CoatPBSScaffPBS scaffolds (see Figure 7.4a). 
 
A weak but nevertheless statistically significant up-regulation in Runx2 was 
observed for all the scaffold groups containing rhBMP-7, compared to the 
CoatPBSScaffPBS controls, on days 1 and 2 (see Figure 7.4a).  A more sustained effect 
was found for the CoatPBSScaffBMP 1.25 and CoatBMP 1.25ScaffBMP 1.25 groups, as 
statistically significant up-regulation of Runx2 was observed on day 7.  This provides 
evidence that all the scaffold groups loaded with rhBMP-7 had an osteoinductive 
effect on the C2C12 cells. 
 
It is interesting to note that Runx2 expression was increased statistically significantly 
in the CoatPBSScaffPBS control group on day 3 compared to day 1 (see Figure 7.5a), 
possibly indicating that the base CoatPBSScaffPBS scaffolds had a weak osteogenic 
effect on the C2C12 cells with no rhBMP-7 present.  However, this effect appears to 
be relatively short-lived, as a slight but statistically significant decrease was observed 
on day 7.  Alternatively, since these effects are relatively slight, they could have 
occurred as a result of Type-I statistical errors. 
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Osteocalcin is thought to be a specific marker of mature osteoblasts, see §7.3.  OC 
was found to be up-regulated statistically significantly for the rhBMP-7 positive 
control, in the first 24 hr period only, compared to the negative CoatPBSScaffPBS 
control (see Figure 7.4b).  Gu et al. (2004b) similarly found OC was up-regulated in 
C2C12 cells after 24 hr of exposure to rhBMP-7.  However, again the effect 
observed in the current study (2.3±1.1 fold difference) was weaker than that 
observed by Gu et al. (2004b) (approximately 55 fold) in similar culture conditions, 
on tissue culture plastic.  Again, it is possible that the CoatPBSScaffPBS scaffolds 
damped the effects of the rhBMP-7. 
 
OC was up-regulated early for the CoatBMP 1.25ScaffPBS and CoatBMP 1.25ScaffBMP 1.25 
groups compared to the CoatPBSScaffPBS controls.  Statistically significant increases 
were observed on days 1 and 2, whereas the up-regulation of OC for the 
CoatPBSScaffBMP 1.25 group, relative to the CoatPBSScaffPBS controls, appeared to occur 
later: on days 2 and 7.  Again, this provides evidence that all the scaffold groups 
loaded with rhBMP-7 had an osteoinductive effect on the C2C12 cells. 
 
Again, the base CoatPBSScaffPBS scaffolds appeared to have a weak osteogenic effect 
on the C2C12 cells, as OC expression was statistically significantly increased in the 
CoatPBSScaffPBS control group on days 2, 3 and 7 compared to day 1 (see Figure 
7.4b).  No increase in OC was observed under similar culture conditions on tissue 
culture plastic (Katagiri et al., 1994; Lee et al., 1999). 
 
As discussed above in §7.3, ALP is a marker of immature osteoblasts that is thought 
to be expressed later than OP.  ALP was found to be up-regulated statistically 
significantly for the rhBMP-7 positive control, in the first and second 24 hr periods 
compared to the negative CoatPBSScaffPBS control (see Figure 7.4c).  The trend was 
similar to that observed in previous studies.  However, the 4.9±0.4 fold increase in 
ALP expression was relatively weak when compared to the 350 fold increase 
observed in C2C12 cells exposed to rhBMP-7 observed by Gu et al. (2004b). 
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All scaffold groups containing rhBMP-7 showed weak but statistically significant 
increases in ALP expression at the 24 hr mark, compared to the CoatPBSScaffPBS 
control.  This effect was most sustained in the CoatBMP 1.25ScaffBMP 1.25 group, with 
statistically significant increases in ALP expression also occurring on days 2 and 7.  
Again, this provides evidence that all the scaffold groups loaded with rhBMP-7 had 
an osteoinductive effect on the C2C12 cells. 
 
As with Runx2 and OC, there was a slight but statistically significant up-regulation 
in ALP expression on days 3 and 7 compared to the CoatPBSScaffPBS group, compared 
to day 1 (see Figure 7.5c).  It should also be noted that previous studies have 
reported no significant increases in ALP expression under similar culture conditions 
in tissue culture plastic (Katagiri et al., 1994; Lee et al., 1999).  Again, this provides 
some evidence that the base CoatPBSScaffPBS scaffolds may have a weak osteogenic 
effect on the C2C12 cells. 
 
Osteopontin, as discussed in §7.3, is an early marker of osteogenesis.  OP was found 
to be up-regulated statistically significantly for the rhBMP-7 positive control, in the 
first 24 hr period only, compared to the negative CoatPBSScaffPBS control (see Figure 
7.4d).  Again, few studies have examined the expression of this gene in C2C12 cells 
in response to rhBMP-7.  However this result was consistent with the findings of 
previous studies where osteoblastic differentiation of C2C12 cells exposed to 
rhBMP-7 was observed to begin in the first 24 hrs (Gu et al., 2004b). 
 
Similarly, OP was up-regulated in the CoatBMP 1.25ScaffPBS and CoatPBSScaffBMP 1.25 
groups.  This observation is consistent with the hypothesis that these scaffolds had an 
osteoinductive effect on the cells.  Again, it should be noted that the up-regulation of 
OP was relatively weak when compared to other studies such as those of Huang et al. 
(2004), where OP was up-regulated in rabbit MSCs by a factor of approximately 50-
fold.  Interestingly, OP was statistically significantly down-regulated in the CoatBMP 
1.25ScaffBMP 1.25 compared to the CoatPBSScaffPBS control.  It was possible that 
differentiation could be more advanced in this group, as OP is thought to be down-
regulated as osteoblastic differentiation progresses (Stein et al., 2004).   
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As discussed in §7.3, Col1 is an early marker of osteoblastic differentiation and is 
first expressed by osteoprogenitor cells.  For both the positive and negative controls, 
no consistent trend in the data on Col1 expression was observed for days 1, 2 and 3 
(see Figure 7.4e).  However, Col1 appeared to be down-regulated in all the groups 
tested on day 7 (see Figure 7.4e and Figure 7.5e).  Potentially, this down-regulation 
could be caused by the progress of osteogenic differentiation.  Alternatively, the fall 
in Col1 expression in all the groups could be explained by the onset of myogenic 
differentiation.  Indeed previous studies by Alexakis et al. (2007) found that 
expression of Col1 decreased as C2C12 cells underwent myogenic differentiation.  
Potentially this hypothesis is more likely, as C2C12 cells are known to undergo 
spontaneous myogenic differentiation (Yaffe and Saxel, 1977; Gu et al., 2004b). 
 
Col1 expression has been largely neglected in studies involving C2C12 cells and 
rhBMP-7, nevertheless Yeh et al. (2002) reported a weak increase in Col1 gene 
expression in response to rhBMP-7.  However, in their case, a different substrate was 
used, potentially affecting the outcome. 
 
Small, but statistically significant increases in Col1 expression were observed in the 
CoatPBSScaffBMP 1.25 and CoatBMP 1.25ScaffBMP 1.25 groups on days 2 and 7 respectively.  
This provides some evidence that these scaffolds had a weak osteoinductive effect on 
the C2C12 cells.  It should be noted, however, that this effect was relatively weak 
when compared to studies such as those reported by Huang et al. (2004) in which 
rabbit MSCs seeded onto PLGA scaffolds, exposed to rhBMP-2, were found to up-
regulate the expression of Col1 by approximately 140 fold after 7 days. 
 
In general, the data indicate that the CoatBMP 1.25ScaffPBS group had a weak 
osteoinductive effect on the C2C12 cells early on, indicating that a portion of the 
rhBMP-7 released from the Type-I collagen coating was bioactive, and capable of 
having a functional effect on the C2C12 cells.  ALP was found to be up-regulated on 
day 1, and OC and Runx2 expression was elevated on days 1 and 2.  However, none 
of the markers were up-regulated from day 3 onwards.  These observations are 
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consistent with the data described in §4.5.3, where the release of rhBMP-7 from the 
CoatBMP 1.25ScaffPBS scaffolds was relatively rapid. 
 
The weak osteoinductive effect on the C2C12 cells for the CoatPBSScaffBMP 1.25 
scaffolds occurred later, and was more sustained than for the CoatBMP 1.25ScaffPBS 
scaffolds.  Indeed, statistically significant up-regulation of the late osteogenic marker 
OC did not occur until day 2 for the CoatPBSScaffBMP 1.25 group.  This occurred on day 
1 for the CoatBMP 1.25ScaffPBS scaffolds.  Additionally, Runx2 and OC were both 
statistically significantly upregulated on day 7, indicating a more sustained effect 
than the CoatBMP 1.25ScaffPBS scaffolds, where no up-regulation was observed.  Again, 
these data are consistent with that found in §4.5.3, where the release of rhBMP-7 
from the CoatPBSScaffBMP 1.25 scaffolds was less rapid, and relatively more sustained 
than for the CoatBMP 1.25ScaffPBS scaffolds.  These data also provide further evidence 
that a portion of the released rhBMP-7 was bioactive, and was capable of having a 
functional effect on the C2C12 cells. 
 
The CoatBMP 1.25ScaffBMP 1.25 group combined the early effect of the CoatBMP 
1.25ScaffPBS scaffolds, with the more sustained effect observed for the CoatPBSScaffBMP 
1.25 scaffolds.  Expression of Runx2, ALP and OC were all elevated at the 24 hr 
timepoint.  However a sustained effect was also evident, as Col1, ALP and Runx2 
were all statistically significantly elevated on day 7 compared to the CoatPBSScaffPBS 
control.  Again, these data provide further evidence that a portion of the rhBMP-7 
released from the CoatBMP 1.25ScaffBMP 1.25 was bioactive, and was capable of having a 
functional effect on the C2C12 cells. 
 
Although there were differences in the osteogenic effects the rhBMP-7 loaded 
scaffold groups had on the C2C12 cells, the differences may not be of clinical 
significance and would need to be evaluated further.  
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7.7. Conclusion 
The functional osteoinductive capacity of Type-I collagen coated PCL (Mn 42,500) 
scaffolds loaded with rhBMP-7 was assessed using C2C12 cells seeded onto the 
scaffolds, and quantified using qRT-PCR.  The genes of interest were; Type-I 
collagen, osteopontin, alkaline phosphatase, osteocalcin and Runx2.  Similar to the 
findings of previous studies (Gu et al., 2004b; Tou et al., 2003; Yeh et al., 2002), 
rhBMP-7 was found to up-regulate the expression of genes associated with 
osteogenesis in C2C12 cells when cultured on base CoatPBSScaffPBS scaffolds. 
 
The CoatBMP 1.25ScaffPBS scaffolds had an early osteoinductive effect on the C2C12 
cells, as ALP, OC and Runx2 were elevated during the first 2 days only.  These data 
indicate that the collagen coating delivery system was suitable for the early release of 
bioactive growth factors, capable of having a functional effect on the cells seeded 
onto the scaffolds. 
 
The data collected for the CoatPBSScaffBMP 1.25 scaffolds, showed that this group was 
capable of a more delayed and sustained osteoinductive effect on the cells.  The late 
osteogenic marker, OC, was only elevated after 2 days, however Runx2 and OC were 
both statistically significantly upregulated on day 7.  These data indicate that the 
encapsulating delivery system was also capable of releasing bioactive growth factors 
which had a more sustained functional effect than the coating delivery system. 
 
Finally, the CoatBMP 1.25ScaffBMP 1.25 group appeared to combine the early effect of the 
CoatBMP 1.25ScaffPBS scaffolds, with the more sustained effect observed for the 
CoatPBSScaffBMP 1.25 scaffolds.  Runx2, ALP and OC were all elevated at the 24 hr 
mark, however after 7 days, up-regulation of Col1, ALP and Runx2 was still evident.  
These data provide further evidence to the findings described in Chapter 6, that the 
two delivery systems are mutually compatible in their ability to release bioactive 
growth factors.  However, the difference in the effects of the two delivery systems 



















Chapter 8 : General Conclusions and 
Further Work 
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8.1. Scaffold Nomenclature 
CoatPBS  Collagen coating with PBS (rhBMP-7 control) 
CoatBMP 0.63  Collagen coating with low rhBMP-7 dose (0.63 µg/ml) 
CoatBMP 1.25  Collagen coating with high rhBMP-7 dose (1.25 µg/ml) 
Coatethanol  Collagen coating with ethanol (1,25(OH)2D3 control) 
Coat1,25(OH)2D3  Collagen coating with 1,25(OH)2D3 
ScaffPBS  Scaffold encapsulating PBS (rhBMP-7 control) 
ScaffBMP 0.63  Scaffold encapsulating low rhBMP-7 dose (0.63 µg/ml) 
ScaffBMP 1.25  Scaffold encapsulating high rhBMP-7 dose (1.25 µg/ml) 
Scaffethanol  Scaffolds encapsulating ethanol (1,25(OH)2D3 control) 
Scaff1,25(OH)2D3  Scaffolds encapsulating 1,25(OH)2D3 
8.2. General Conclusions 
Fracture non-unions and bone defects represent a recalcitrant problem in the field of 
orthopaedic surgery.  Although the current gold-standard treatment, autologous bone 
grafting, has a relatively high success rate, the technique is not without problems.  
These include; limited donor bone supply and quality, and the possibility of 
substantial morbidity at the donor site.  The emerging field of regenerative medicine 
may have the potential to provide an alternative treatment. 
 
A number of growth factors, operating at different times, are believed to regulate 
many of the events crucial to normal bone fracture healing.  Therefore the delivery, 
to the defect site, of both cells and multiple growth factors with different release 
profiles, may be required for a successful artificial bone graft substitute.  However, a 
satisfactory delivery system for achieving this has yet to be developed.  The studies 
described in this thesis report the development of novel scaffolds and their 
subsequent testing for their potential to fulfil these functions with regard to potential 
application in bone regenerative medicine, by testing the following thesis hypothesis:  
It is possible to manufacture cell-compatible scaffolds, with sufficient porosity for the 
diffusion of cellular nutrients and waste products, incorporating two delivery 
systems, each capable of releasing a bioactive growth factor with clinically 
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significantly different release profiles.  It was concluded that the data reported in this 
thesis did not confirm the hypothesis. 
 
A range of scaffolds was developed from poly(ε-caprolactone) (PCL) (Mn 42,500 
and 80,000), poly(lactide-co-glycolide) (PLGA) and two blends of PCL (Mn 42,500) 
and PLGA.  The scaffolds were manufactured utilising a novel modified fused 
deposition modelling (FDM) system, based on polymer/dichloromethane (DCM) 
solutions processed using a Bioplotter™.  The PCL (Mn 42,500) scaffolds were 
found to have a pore diameter of 373±9.5 µm in the Y-direction, and 460±13 µm in 
the X-direction.  Previous studies have found that scaffolds with pore diameters 
ranging from 96 – 350 µm were capable of being pervaded with fluids in bioreactor 
systems (Jungreuthmayer et al., 2008), and Robinson et al. (1995) found that in the 
size range 100 – 350 µm, the largest pore size allowed the most bone ingrowth.  
Indeed, Karageorgiou and Kaplan (2005) found that pore sizes greater than 300 µm 
in diameter favoured vascular ingrowth and intramembranous ossification.  The 
scaffold pore sizes were therefore thought to be suitable for bone regenerative 
medical applications.  The remaining scaffolds were observed to possess a similar 
architecture.  Five scaffold coatings were also developed from alginate, chitosan, 
Type-I collagen and Type-A gelatin.  Each scaffold coating was found not to 
interfere with the scaffold porosity. 
 
The scaffolds were found to be only 52±3 µm in height, whereas the strand 
thicknesses were found to be 444±3.5 µm and 353±9.7 µm in the X and Y-directions 
respectively.  This means that the two-layer scaffolds were relatively flat.  It was 
found that 3D geometry was difficult to fabricate using the process developed in 
§2.4.1.1.1 and §2.4.1.1.2.  This was undesirable, as direct control of the complete 3D 
geometry was the favoured strategy (van Griensven et al., 2008; Zhang and Ma, 
2004), though it may not be a necessary requirement (Karp et al., 2003). 
 
The cell-compatibility of the scaffold coatings was assessed using human marrow 
stromal cells (hMSCs), human osteoblasts (hOBs), and MG63 cells, via a 
quantitative live/dead assay, based on calcein AM and PI staining.  The hydrogels 
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alginate and chitosan were found to perform poorly compared to gelatin and 
collagen, both in terms of total cells counts and the proportion of dead cells present.   
For hMSCs, their dead rates were found to be 19.1±6.3% for alginate, 5.3±3.6% and 
2.9±1.4% for chitosan crosslinked with tripolyphosphate and sodium hydroxide 
respectively, compared to 0.11±0.07% for Type-I collagen, and 0.15±0.13% and 
0.16±0.12% for 0.1% and 0.2% gelatin respectively. 
 
Type-I collagen was found to be the most cell-compatible coating, as it was 
consistently associated with higher cell counts than Type-A gelatin.  In addition, 
Type-I collagen was thought to be a suitable coating material for bone regenerative 
medical scaffolds, as collagen may mediate the osteogenic response of hMSCs (Yang 
et al., 2004; Mizuno et al., 2000), and this material has also been used to release 
rhBMP-2 and -7 in USFDA approved devices for the treatment of fracture non-
unions (Govender et al., 2002; Friedlaender et al., 2001). 
 
A similar system, employing hMSCs, was used to assess the PCL (Mn 42,500) 
scaffolds.  Vacuum drying times of 60 min or more, before the application of cells, 
were found to have no detectable effect on the total cell count, the proportion of cell 
death, or the morphology.  These data support the hypothesis that the PCL (Mn 
42,500) scaffolds, dried for 60 min, were cell-compatible.   
 
Scaffolds manufactured from PCL (Mn 42,500 and 80,000), PLGA, as well as blends 
of PCL (Mn 42,500) and PLGA, were evaluated using the model drug methylene 
blue.  The encapsulation efficiencies and the release profiles of methylene blue were 
quantitatively assessed.  It was found that PCL (Mn 42,500 and 80,000) scaffolds had 
relatively high encapsulation efficiencies.  The encapsulation efficiency of the PCL 
scaffolds, for both Mn 42,500 and 80,000, was calculated to be 71±6% and 71±5% 
respectively.  The encapsulation efficiency was found to be relatively consistent, 
both between and within batches.  This loading efficiency was found to be similar to 
other potential drug delivery devices (Rai et al., 2005; Silva et al., 2006), and 
superior to the PCL and PLGA microspheres studied by Cao et al. (1999) and the 
PLA scaffolds of Murphy et al. (2000). 
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The release rate of the model drug methylene blue from scaffolds manufactured from 
PCL (Mn 42,500) was found to be consistent between batches.  This was in contrast 
from the release from PCL (Mn 80,000).  The release rate of methylene blue from 
PCL (Mn 80,000) was also thought to be higher than desired. 
 
The PLGA, and PCL/PLGA blends were found to perform poorly.  The methylene 
blue release rates from the PCL/PLGA blends were found to be relatively 
inconsistent between batches and the encapsulation efficiencies of PLGA and 
PCL:PLGA 66:33 were also relatively low (38±10% and 57±5% respectively).  The 
encapsulation efficiency of PCL:PLGA 33:66, although high, was found to be 
relatively inconsistent between batches (78±10%).  PCL (Mn 42,500) scaffolds, made 
without plotting media, were therefore considered to be the optimum scaffold 
material. 
 
The drug loading potentials, as well as model drug release profiles from collagen 
coatings on PCL (Mn 42,500) scaffolds, were similarly assessed.  The fast methylene 
blue release rate, and the methylene blue content of the scaffolds, were found to be 
compatible with the design philosophy of this thesis: slow release from the 
encapsulating delivery system and fast release from the scaffold coating. 
 
The release profiles of the growth factor human bone morphogenetic protein-7 
(rhBMP-7), from both encapsulating scaffolds and loaded collagen scaffold coatings, 
were measured using an enzyme-linked immunosorbent assay (ELISA).  As with the 
methylene blue results, the collagen coating was found to release rhBMP-7 at a faster 
rate than the encapsulating PCL (Mn 42,500) scaffolds.  While this was consistent 
with the design philosophy of the thesis, the manner of release was not.  Although, 
from the ELISA data, it was found that the encapsulating PCL (Mn 42,500) scaffolds, 
and the loaded collagen scaffold coatings, were capable of releasing detectable 
amounts of rhBMP-7 with different release profiles for up to 14 days, burst release 
from both delivery systems was observed. 
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Release from the collagen coating (CoatBMP 1.25) in the first 24 hr represented 23±3% 
of the theoretical rhBMP-7 loading, although this may represent approximately 77% 
of the total available for release.  Similarly, 12±2% of the theoretical rhBMP-7 
loading capacity was released from the ScaffBMP 1.25 delivery system in the first 24 hr 
period, although this may represent approximately 60% of the total available for 
release.  The release of rhBMP-7 from the two delivery systems was found not to 
match the ideal release profile (see Figure 1.18).  However, it was noted that 
scaffolds with less than ideal release profiles, may still have potential for clinical use 
(Wei et al., 2007). 
 
The studies quantifying rhBMP-7 release using an ELISA did not determine whether 
the growth factor released was bioactive.  Therefore studies were undertaken to 
examine the bioactivity of the release from the scaffolds. 
 
A quantitative system, based on the image analysis of alkaline phosphatase (ALP) 
staining and propidium iodide (PI) cell counts of hMSCs, was used to assess the 
osteogenic potential of rhBMP-7, and the release from growth factor incorporating 
scaffolds.  Each of the rhBMP-7 concentrations tested (5, 20, and 50 ng/ml) was 
found to increase the normalised area of ALP staining statistically significantly 
compared to the base media for at least three of the test patients, although often the 
actual difference was small.  This could indicate that rhBMP-7 is able to stimulate 
the osteogenic differentiation of hMSCs over a relatively wide range of 
concentrations. 
 
The release from the CoatBMP 1.25ScaffPBS and CoatBMP 0.63ScaffPBS scaffolds was 
found to statistically significantly stimulate hMSC ALP staining compared to the 
control scaffolds, although the actual differences were small.  This indicated that at 
least a proportion of the rhBMP-7 released was bioactive.  In contrast, the release 
from CoatPBSScaffBMP 1.25 and CoatPBSScaffBMP 0.63 was found not to enhance hMSC 
ALP staining.  Either the growth factor released was not bioactive, or the dose was 
insufficient to influence the cells measurably. 
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Image analysis of ALP staining, normalised against 4’,6-diamino-2-phenylindole 
(DAPI) cell counts, was used to assess quantitatively the ability of the 
Coat1,25(OH)2D3Scaffethanol, CoatethanolScaff1,25(OH)2D3 and Coat1,25(OH)2D3Scaff1,25(OH)2D3 
scaffolds to release 1,25-dihydroxyvitamin D3 (1,25(OH)2D3).  Normalised ALP 
expression of the hMSCs was significantly increased for each of the 1,25(OH)2D3 
loaded scaffold types compared to the control scaffolds.  Furthermore, ALP 
expression was significantly enhanced for the dual delivery scaffolds over and above 
that for either delivery system on its own.  It was therefore concluded that the PCL 
scaffolds coated with collagen could be capable of releasing bioactive lipid-soluble 
active factors, and that both delivery systems were mutually compatible. 
 
The cell-compatibility of the scaffold materials had previously been assessed in 
Chapter 3, and the quantity and bioactivity of rhBMP-7 released from the scaffolds 
was examined in Chapter 4 and Chapter 5.  However, it was unknown how the 
clinically relevant hMSCs would react to the combined stimuli, when seeded directly 
onto the scaffolds.  Combined ALP/deoxyribonucleic acid (DNA) and calcium/DNA 
assays were therefore used to assess whether the Type-I collagen coated PCL (Mn 
42,500) scaffolds, loaded with rhBMP-7, were capable of supporting the osteogenic 
differentiation of hMSCs, seeded onto them. 
 
ALP activity on the scaffolds was found to increase with increasing concentrations of 
rhBMP-7 in the range of concentrations tested (5, 20, and 50 ng/ml).  For example, 
ALP activity was increased by 98±18% for 50 ng/ml of rhBMP-7 compared to the 
control group.  ALP activity was also statistically significantly stimulated in hMSCs 
for the CoatPBSScaffBMP 1.25 and CoatBMP 1.25ScaffBMP 1.25 scaffold groups for three and 
two patients out of three respectively (increased by 35±10% and 39±10 on the 
control respectively), whereas this was the case for only one patient’s cells for the 
CoatBMP 1.25ScaffPBS scaffolds (increased be 35±14% on the control).  These data 
indicated that the CoatPBSScaffBMP 1.25 and CoatBMP 1.25ScaffBMP 1.25 scaffolds were 
capable of stimulating the osteogenic differentiation of hMSCs seeded onto them. 
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Calcium deposition was only stimulated in the cells of one of the three hMSC 
patients tested.  Since the osteogenic effect of the encapsulation delivery system was 
not enhanced by the release from the coating, in the final “product” for clinical use 
the coating delivery system could be better employed in the delivery of a different 
active factor. 
 
The functional osteoinductive capacity of Type-I collagen coated PCL (Mn 42,500) 
scaffolds loaded with rhBMP-7 was assessed using C2C12 cells seeded onto the 
scaffolds, and quantified using qRT-PCR.  The genes of interest were; Type-I 
collagen (Col1), osteopontin (OP), ALP, osteocalcin (OC) and Runx2.  Similar to the 
findings of previous studies (Gu et al., 2004b; Tou et al., 2003; Yeh et al., 2002), 
rhBMP-7 was found to up-regulate the expression of genes associated with 
osteogenesis in C2C12 cells when cultured on the control CoatPBSScaffPBS scaffolds.  
C2C12 cells cultured on CoatPBSScaffPBS scaffolds, exposed to 200 ng/ml rhBMP-7 in 
the media, were found to upregulate OP, ALP, OC and Runx2 after 24 hr compared 
to the control (by 64±15%, 385±68%, 127±66%, and 76±43% respectively). 
 
The CoatBMP 1.25ScaffPBS scaffolds had an early osteoinductive effect on the C2C12 
cells, as ALP, OC and Runx2 were elevated during the first 2 days only, compared to 
the control (for example, by 44±12%, 128±42%, 60±25% and 46±25% respectively 
at the 24 hr mark).  These data indicate that the collagen coating delivery system 
(CoatBMP 1.25) was suitable for the early release of bioactive growth factors, capable 
of having a functional effect on the cells seeded onto the scaffolds. 
 
The CoatPBSScaffBMP 1.25 scaffolds also had an osteoinductive effect on the cells, 
which was more sustained than that observed for the CoatBMP 1.25ScaffPBS group.  
While OP, ALP and Runx2 were up-regulated in the first 24 hr compared to the 
control (by 38±10%, 208±82% and 72±31% respectively), statistically significant 
up-regulation of the late marker OC was delayed until the 48 hr mark (by 73±49%).  
The effect was found to be sustained until day 7, when OC and Runx2 were both 




The CoatBMP 1.25ScaffBMP 1.25 scaffolds were found to combine the early effect of the 
CoatBMP 1.25ScaffPBS scaffolds, with the more sustained effect of the CoatPBSScaffBMP 
1.25 scaffolds.  ALP, OC and Runx2 were all up-regulated at the 24 hr mark (by 
312±56%, 329±39% and 96±25% respectively).  This osteoinductive effect was 
sustained until day 7 when Col1, ALP and Runx2 were still up-regulated compared 
to the control (by 174±78%, 72±24% and 178±78% respectively).  These data 
provide further evidence to the findings described in Chapter 6, that the two delivery 
systems are mutually compatible in their ability to release bioactive growth factors. 
 
These data suggest that the scaffolds containing rhBMP-7 have a weak 
osteoinductive effect on the cells seeded onto them.  The different delivery systems 
were found to affect the cells differently.  The clinical significance of this was not 
assessed in these studies. 
8.3. Comparison with other Dual Delivery Systems 
As discussed in §1.2.6.3.4, the dual delivery of growth factors with different 
temporal release profiles may be advantageous, yet few examples exist.  At least 
three studies have described scaffolds with two independent delivery systems. 
 
Ginty et al. (2008) used supercritical CO2 foaming to create poly(lactic acid) 
scaffolds, coupled with PCL microparticles or entrapped alginate to release RNase 
and horseradish peroxidase as model drugs.  However, unlike the scaffolds studied in 
this thesis, release of bioactive growth factors was not examined, neither was the 
cell-compatibility assessed. 
 
Sohier et al. (2006) manufactured scaffolds of poly(ethylene glycol)- terephthalate 
(PEGT) and poly(butylene terephthalate) (PBT) with successive coatings of the same 
material.  They achieved different release kinetics from the layers of myoglobin and 
lysozyme, used as model drugs.  Like the studies conducted by Ginty et al. (2008), 




Perhaps the most promising of the dual drug delivery systems was presented by 
Richardson et al. (2001).  PLGA scaffolds, produced by scCO2 gas foaming, and 
microparticles delivery systems were combined, and used to deliver bioactive VEGF 
and PDGF in a controlled manner.  However, release from the microparticle delivery 
system presented, was either very similar to the release from the scaffold, or was too 
slow to be of clinical significance.  This scaffold system has been found to stimulate 
angiogenesis, although it was not applied to bone regenerative medical applications.  
As discussed in §1.2.5.9, PLGA used in bulk, has properties which may prove to be 
disadvantageous for bone regenerative medical applications because of its acidic 
breakdown products and their self-accelerated degradation (Sokolsky-Papkov et al., 
2007). 
 
Without parallel in vivo experiments, it is uncertain whether the scaffolds developed 
by Richardson et al. (2001), or the scaffolds developed in this thesis would be more 
suitable for bone regenerative medical applications.  The release properties from the 
PLGA scaffolds developed by Richardson et al. (2001) are likely to be more 
favourable, however the Type-I collagen coated PCL scaffolds developed in this 
thesis may prove to be more cell-compatible and osteoinductive, as collagen may 
mediate the osteogenic response of hMSCs (Yang et al., 2004; Mizuno et al., 2000). 
 
The lack of intrinsic 3D structure of the scaffolds developed in this thesis may prove 
to be disadvantageous compared to the other dual delivery scaffolds described above.  
Potentially, this problem could be alleviated by packing the wound site with multiple 
scaffolds (see §2.5.1.1.3).  If future in vivo studies found packing to be an unsuitable 
solution, future work should focus on the development of intrinsic 3D geometry. 
8.4. Testing of Thesis Hypothesis 
The evidence reported in this thesis indicates that the Type-I collagen coated PCL 
(Mn 42,500) scaffolds; were cell-compatible, and had sufficient porosity to allow the 
adequate diffusion of cellular nutrients and waste products.  Two delivery systems 
were developed which were capable of releasing bioactive growth.  However, release 
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profiles may not have been clinically different from the two delivery systems.  In 
addition, the release profile were found to deviate significantly from the ideal release 
profiles described in §1.4.1.  It was therefore concluded that the data reported in this 
thesis did not confirm the thesis hypothesis. 
8.5. Future Work 
The studies described in this thesis employed rhBMP-7 and 1,25(OH)2D3 to assess 
the effectiveness of the scaffolds as delivery systems.  However, as discussed in 
§1.2.4, a number of active factors are available which have the potential to enhance 
the efficacy of bone regenerative medicine constructs.  Future studies could examine 
the possibility of releasing factors to promote angiogenesis or hMSC proliferation 
from the scaffold coating early on, followed by the slower release of factors to 
encourage the osteogenic differentiation of hMSCs from the scaffold itself.  The 
efficacy of these scaffolds could be examined using in vivo animal fracture non-
union models, to determine the optimum growth factor combination and dose.  
Candidate growth factors could include; recombinant human vascular endothelial 
growth factor (rhVEGF) and recombinant human fibroblast growth factor-2 (rhFGF-
2) in the coating, with recombinant human bone morphogenetic protein-2 (rhBMP-2) 
and rhBMP-7 within the scaffolds. 
 
The manufacturing technique could be used to constrict scaffolds from synthetic 
polymers other than PCL and PLGA.  For example PLA, or blends of PLA could be 
used.  Potentially the use of this polymer could enhance the scaffold mechanical 
properties, and slow the rate of active factor release because of its semicrystaline 
structure at physiological temperatures (see §1.2.5.9).  Blending with other synthetic 
polymers, or altering the monomer composition of PLA to alter the crystal structure 
may also present opportunities to alter the active factor release characteristics (Ginty 
et al., 2008). 
 
Microparticles of PLGA or another synthetic polymer could be employed as a third 
potential delivery system.  As discussed in §1.2.6.3.3, there is scope for altering the 
release profiles by changing their composition and average size. 
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As discussed in §2.5.1.1.3, two-layer scaffolds may be sufficient to create the 3D 
geometry required for successful clinical application.  However, direct manipulation 
of the 3D scaffold geometry may prove to be advantageous.  Scaffold manufacture 
with a height greater than two layers should therefore be investigated, if future in 
vivo studies found the packing of multiple scaffold sheets to be an unsuitable 
solution. 
 
The same materials used in different scaffold manufacturing techniques.  For 
example, a freezing and freeze drying technique similar to that described by Khan et 
al. (2010) could be used.  Although direct control of scaffold geometry would be 























NC code program to produce two-layer scaffolds with a strand spacing of 0.80 mm in 
































NC code program to produce two-layer scaffolds with a strand spacing of 1.00 mm in 



























NC code program to produce 16-layer scaffolds with a strand spacing of 0.80 mm in 





















































































































































































































NC code program to produce two-layer scaffolds with a strand spacing of 1.60 mm in 






















ImageJ macro program for the automated batch counting of PI +ve cells. 
 
macro "Batch Measure" { 
    requires("1.33n");  
    dir = getDirectory("Choose a Directory "); 
    list = getFileList(dir); 
    start = getTime(); 
    setBatchMode(true); 
    for (i=0; i<list.length; i++) { 
        path = dir+list[i]; 
        showProgress(i, list.length); 
        if (!endsWith(path,"/")) open(path); 




setThreshold(set lower bound, set upper bound); 
run("Convert to Mask"); 
run("Analyze Particles...", "size=set lower bound cell size-infinity circularity=0.00-
1.00 show=Nothing display summarize"); 
            close(); 
        } 
    } 





ImageJ macro program for the automated batch calculation of the area of +ve ALP 
staining. 
 
macro "Batch Measure" { 
    requires("1.33n");  
    dir = getDirectory("Choose a Directory "); 
    list = getFileList(dir); 
    start = getTime(); 
    setBatchMode(true); 
    for (i=0; i<list.length; i++) { 
        path = dir+list[i]; 
        showProgress(i, list.length); 
        if (!endsWith(path,"/")) open(path); 





setThreshold(set lower bound, set upper bound); 
run("Threshold", "thresholded remaining black"); 
run("Analyze Particles...", "size=0.00004-44.44 circularity=0.00-1.00 bins=200 
show=Nothing display summarize"); 
            close(); 
        } 
    } 
  //print((getTime()-start)/1000); 
} 
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Appendix G: hMSC Characterisation 
G.1. Abstract 
This appendix describes the characterisation procedure for the cells isolated from 
human femoral heads.  Routine characterisation involved osteogenic, chondrogenic 
and adipogenic differentiation of the cells.  This was assessed by von Kossa, Safranin 
O and Oil Red-O staining respectively.  Weak positive staining was observed after 
14 days while strongly positive staining was observed after 21 days. 
 
In cells from one patient (652), this differentiation was further investigated using 
reverse transcription polymerase chain reaction (RT-PCR) by examining the 
expression of Runx2, PPARγ2 and Col2A1.  Expression of these markers for 
osteogenesis, chondrogenesis and adipogenesis was observed on days 14 and 21, 
after exposure to differentiation media. 
 
From the routine staining evidence, and the data from patient 652, it was concluded 
that the cultured cells were capable of undergoing osteogenic, chondrogenic and 
adipogenic differentiation, in vitro. 
 
Cells from three patients (514, 523 and 531), were examined for two markers 
associated with MSCs: CD105 and Stro-1.  The cells were found to be 92±1%  and 
30±5% positive for CD105 and Stro-1 respectively.  This compared favourably with 
previous studies characterising MSCs. 
 
Only very limited evidence was presented that multipotent cells were present in the 
cell cultures, therefore the term “Mesenchymal Stem Cells” was thought to be 
inappropriate.  However, it was concluded that the term “Marrow Stromal Cells” was 
appropriate for these cell populations. 
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G.2. Introduction 
In recent years, there has been much interest in the study of human marrow stromal 
cells (hMSCs), also termed mesenchymal stem cells and marrow stromal cells.  This 
is primarily because of their potential for use in regenerative medical applications, as 
discussed in §1.2.3.3.  In the past, a variety of different protocols have been used to 
characterise hMSCs.  The majority of these stress the importance of both plastic-
adhesion and the ability to undergo osteogenic, chondrogenic and adipogenic 
differentiation (Pittenger et al., 1999; Baddoo et al., 2003; Dominici et al., 2006).  
The identification of surface markers is also thought to be important, however since 
there is a lack of a specific marker for MSCs (Horwitz et al., 2005), there is debate 
regarding the markers for which it is most important to test. 
 
A common source of contamination in MSC cultures are cells of haematopoietic 
origin.  CD105 is thought to be expressed by MSCs, but not cells of the 
haematopoietic lineage (Haynesworth et al., 1992b), furthermore CD105 expression 
is thought to disappear upon differentiation (Barry et al., 1999; Goussetis et al., 
2005).  CD105, also called endoglin, is thought to form part of the TGF-β signalling 
system (Cheifetz et al., 1992).  It is, however, not specific to MSCs, as it has also 
been detected in endothelial cells (Gougos and Letarte, 1990).  Nevertheless, in 
conjunction with other markers, CD105 has been widely used in characterisation 
processes for MSCs (Keating, 2006; Liu et al., 2008a; Kotobuki et al., 2005; Harting 
et al., 2008; Meinel et al., 2004).  
 
Simmons and Torok-Strob (1991) first identified an association between Stro-1 and 
fibroblast colony-forming cells (CFU-F) in human bone marrow.  The osteogenic 
potential of bone marrow aspirates, selected for Stro-1, was assessed by Gronthos et 
al. (1994).  After culture in osteogenic media, 90% of the cells in the colonies were 
found to be positive for alkaline phosphatase (ALP).  Similarly, Howard et al. (2002) 
found enriching for Stro-1 from bone marrow aspirates, led to a 300% increase in the 
ratio of CFU-F isolated.  The Stro-1 positive fraction also showed increased ALP 
activity over unselected marrow cell cultures.  In addition, Stewart et al. (1999) 
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found Stro-1 to be characteristic of relatively undifferentiated cells capable of 
osteoblastic differentiation.  Stro-1 has, therefore, been used to characterise MSCs in 
previous studies (Wang et al., 2003; Tuli et al., 2003; Coipeau et al., 2009; Zhang et 
al., 2009). 
 
The aim of the studies described in this appendix was to characterise hMSCs, 
prepared as described in preceding chapters of this thesis.  To achieve this, the ability 
of the cells to undergo osteogenic, chondrogenic and adipogenic differentiation, was 
assessed.  The presence of the markers CD105 and Stro-1 was also examined using 
flow cytometry. 
G.3. Materials and Methods 
Unless otherwise stated, all reagents were purchased from Sigma, UK. 
G.3.1. Cell Culture 
G.3.1.1. Human MSC Isolation and Culture 
After written consent from the patients and approval from the local ethical committee 
(Lothian local research ethics committee), human femoral head tissue was obtained 
from patients who had undergone elective arthroplasty.  In addition to routine 
characterisation, tissue was collected from four patients (see Table G.1).  The tissue 
samples were allocated an anonymous number based on the chronological order of 
the sample collection.  It should be noted that the patient numbers for routine 
characterisation are not listed below. 
 
Table G.1: hMSC patient details for non-routine characterisation. 
In-House Patient Number 514 523 531 652 
Patient Age 60 57 58 57 
Patient Sex Male Female Female Female 
 
The samples were stored at 4°C in sterile phosphate buffered saline (PBS) (Oxoid, 
UK) directly after surgery.  The hMSCs were isolated from the samples and cultured 
as described above in §3.3.1.1. 
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G.3.2. Human MSC Differentiation 
The experiments described in sections §G.3.2.1, §G.3.2.4 and §G.3.2.5 were 
conducted by Miss Kate Cameron. 
G.3.2.1. Differentiation Protocol for Patient 652 
The media referred to as “osteogenic media” was identical to the OS media described 
in §5.4.2.2.  “Chondrogenic media” consisted of Dulbecco’s Modified Eagle’s 
Medium – high glucose (DMEM), supplemented with L-glutamine (2 mM) (Gibco, 
UK), penicillin (100 IU/ml), streptomycin (100 µg/ml) (Gibco, UK), dexamethasone 
(100 nM), L-ascorbic acid-2-phosphate (50 µg/ml), sodium pyruvate (1 mM), proline 
(40 µM), TGF-β3 (10 ng/ml), insulin (6 µg/ml) transferrin (6 µg/ml) and bovine 
serum albumin (1.25 mg/ml).  “Adipogenic media” consisted of growth media (as 
described in §3.3.1) supplemented with dexamethasone (1 µM), 3-isobutyl-1-
methylxanthine (0.5 mM), insulin (1 µg/ml), and indomethacin (0.1 mM). 
 
Tissue culture flasks (75 cm2) containing confluent hMSCs (passage 3) from patient 
652, were washed three times in PBS, and the cells were detached from the flasks 
using trypsin solution (2.5 mg/ml) in PBS (Invitrogen, UK) and growth media, as 
described in §3.3.1.  The cell density of the suspensions was measured using a 
haemocytometer.  After appropriate dilution with growth media, the cells were added 
to wells of 12-well treated tissue culture (TC) plastic plates (Corning, USA) at a 
density of 2 × 104 cells/well (in 2 ml of media).  The plates were then maintained in a 
humidified air incubator at 37°C with 5% (v/v) CO2, for 3 days, to become confluent. 
 
Afterwards, the culture media was replaced with osteogenic media, chondrogenic 
media or adipogenic media.  The cells were maintained in a humidified air incubator 
at 37°C with 5% (v/v) CO2, and the media was refreshed at regular intervals three 
times every 7 days.  After 7, 14 and 21 days, three wells of cells were fixed with 
paraformaldehype as described in §3.3.4.1.  TRIzol® Reagent (Invitrogen, UK) was 
added to a further three wells per time point (200 µl/well).  After 5 min of incubation 
at room temperature and mixing by repeated aspiration, RNA was extracted from the 
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samples as described in §7.4.2.1 and complimentary DNA was synthesised as 
described in §7.4.2.2, and stored at -80°C. 
 
The fixed cells were stained as described below in §G.3.2.3.  RT-PCR was used to 
analyse the cDNA samples, as described below in §G.3.2.5. 
G.3.2.2. Routine Differentiation Protocol  
Routine characterisation of hMSCs cultured in the laboratory was conducted by Dr 
Nusrat Khan.  The cells were cultured and exposed to osteogenic, chondrogenic and 
adipogenic media as described in §G.3.2.1.  These cells were subsequently fixed and 
stained using the von Kossa technique, and stained using Safranin O and Oil Red-O 
as described below in §G.3.2.3. 
G.3.2.3. Staining 
The fixed cells were stained as previously described by Tremoleda et al. (2008).  
Mineralisation was identified using the von Kossa technique (Bills et al., 1971).  
Three wells of cells per time point were incubated in 0.5% (w/v) silver nitrate under 
strong light for 1 hr at room temperature.  Following a 5 min wash with dH2O, the 
cells were incubated in 5% (w/v) sodium thiosulphate for 5 min at room temperature.  
The cells were then washed twice with dH2O, before 200 µl of dH2O were added to 
the wells. 
 
Proteoglycan production was indicated using Safranin O staining (Rosenberg, 1971) 
of three wells per time point.  The cells were washed with dH2O and incubated in 
Safranin O solution (0.5% (w/v) in 0.1 M sodium acetate buffer pH 4.6) for 10 min at 
room temperature.  Following washing with dH2O, the cells were dehydrated with 
95% ethyl alcohol, absolute ethyl alcohol and xylene (using 2 changes each, 2 min in 
each solution).  The cells were mounted using Pertex non-aqueous mountant.  
 
Adipogenesis was identified using Oil Red-O staining (Pittenger et al., 1999) of three 
wells per time point.  The cells were first covered with 60% (v/v) isopropanol for 3 
min and then with 3 mg/ml Oil Red-O (3 parts of 5 mg/ml Oil Red-O to 2 parts 
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dH2O) for 10 min.  The cells were then washed twice with dH2O, before 200 µl of 
dH2O were added to the wells. 
 
The plates were then photographed using a mounted camera (Nikon, DXM1200) on 
an inverted microscope (Nikon, Eclipse TS 100) set for bright-field at × 10 
magnification. 
G.3.2.4. Positive control for RT-PCR 
Bone chips were prepared from the femoral head from patient 652 as described in 
§3.3.1.2.  RNA was then extracted as previously described by Voultsiadou (2009).  
Bone chips attached to both adipose and cartilage tissue were selected, and the 
sample was pulverised in liquid nitrogen using a mortar and pestle.  The 
homogenised sample was suspended in TRIzol® Reagent and allowed to incubate at 
room temperature for 5 min before being centrifuged (2 min at 13,000 rpm 
(eppendorf centrifuge 5417R)) to remove any debris.  The supernatant was 
transferred to a new eppendorf tube.  The RNA was extracted from the sample as 
described in §7.4.2.1 and complimentary DNA was synthesised as described in 
§7.4.2.2.  The sample was stored at -80°C. 
G.3.2.5. RT-PCR 
RT-PCR was used to analyse the cDNA samples described in §G.3.2.1 and G.3.2.4.  
The samples were processed and visualised on agarose gels using the general 
procedure described in §7.4.2.3 and §7.4.2.4, substituting the primers for the human 
genes PPARγ2, Runx2, Type-II Collagen, and GAPDH.  The latter acting as a 
housekeeping gene to confirm equal loading.  The primer sequences, annealing 
temperatures and cycle numbers used are shown in Table G.2. 
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Table G.2: Primer sequences for PCR 
Gene Temperature Number 
of cycles 
Sequence and Fragment Size 
PPARγ2 50.0°C 40 5’-AAACTCTGGGAGATTCTCCT-3’ 
5’-TCTTGTGAATGGAATGTCTT-3’ 
 (Sottile et al., 2002) 
Runx2 57.5°C 35 5’-CCGCACGACAACCGCACCAT-3’ 
5’-CGCTCCGGCCTACAAATCTC-3’ 
 (Kozhevnikova et al., 2008) 
Type-II 
Collagen 
55.0°C 40 5’-GAAACCATCAATGGTGGCTT C-3’ 
5’-CGATAACAGTCTTGCCCCA C-3’ 
(designed in-house) 




G.3.3. Flow Cytometry 
The experiments described in this section were conducted by Dr Aimee Reynolds  
and Mrs Kay Samuel. 
 
Tissue culture flasks (75 cm2) containing confluent hMSCs from patients 514 
(passage 5), 523 (passage 3) and 531 (passage 4) (in separate flasks), were washed 
three times in PBS, and the cells were detached from the flasks using trypsin solution 
(2.5 mg/ml) in PBS (Invitrogen, UK) and growth media, as described in §3.3.1.  The 
cell density was measured using a haemocytometer.  The cell suspensions were 
centrifuged (1,000 rpm for 5 min), the supernatant was discarded and the cell pellets 
were resuspended in FACS-PBS (PBS supplemented with 0.1% BSA and 0.1% 
sodium azide) to a final cell density of 1 × 107 cells/ml.  Aliquots of 1 x 106 cells 
were incubated for 40 min at 4°C with optimum concentration (determined by 
titration), of primary antibody to STRO-1 (mouse IgM) (BioLegend) or CD105-APC 
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(mouse IgG) (BioLegend).  The cells were washed twice to remove unbound 
antibody and resuspended in 100 µl FACS-PBS.  Binding of primary antibody was 
detected using optimum concentration (determined by titration) of appropriate 
isotype specific fluorochrome labelled secondary antibody: anti-mouse IgM-PE and 
anti-mouse IgG-PE (Jackson Labs). 
 
After incubation for 40 min at 4°C, the cells were washed twice and finally 
resuspended in 250 µl.  Unstained cells and cells labelled with secondary antibody 
alone were included as controls.  Dead and apoptotic cells, and debris were excluded 
from analysis using an electronic ‘live’ gate on forward scatter and side scatter 
parameters.  Data for 5,000 - 100,000 ‘live’ events were acquired for each sample 
using a FACSCaliber cytometer equipped with 488nm and 633nm lasers and 
analysed using CellQuest software (Becton Dickinson). 
G.4. Results 
G.4.1. Human MSC Differentiation 
G.4.1.1. Staining 
Negative staining was observed for all samples at day 7 for each staining technique 
(see Figure G.1).  Weak positive von Kossa, Safranin O, and Oil Red-O staining was 
observed after 14 days for the cells cultured in osteogenic, chondrogenic and 
adipogenic media respectively.  Stronger positive staining was routinely observed 












Figure G.1: hMSC Staining for Differentiation. 
Bright-field images of hMSCs.  The figures represent a) hMSCs cultured in 
adipogenic media stained with Oil Red-O, b) hMSCs cultured in osteogenic media 
stained using the von Kossa technique and, c) hMSCs cultured in chondrogenic 
media and stained using Safranin O.  These representative images were taken at × 20 
magnification, of tissue from a representative patient (patient 652).  The bar 
represents 50 µm. 
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G.4.1.2. RT-PCR 
For each primer pair, single bands were observed in the electrophoresis gels for the 
positive control.  These bands had approximately the number of base pairs predicted 
(see Table G.2).  PPARγ2 expression for the cells treated with adipogenic media, 
was not evident at day 7 but was observed on days 14 and 21 (see Figure G.2).  
PPARγ2 expression appeared to be higher on day 21 than day 14. 
 
Runx2 expression was not found on day 7 in the cells cultured in osteogenic media 
(see Figure G.2).  Runx2 was up-regulated on days 14 and 21, with expression on 
day 14 being the higher of the two time points. 
 
Again, Type-II collagen alpha 1 (Col2A1) expression was not found on day 7 in the 
cells cultured in chondrogenic media (see Figure G.2).  Col2A1 expression was 










Figure G.2: Electrophoresis Gels for RT-PCR of differentiated hMSCs. 
These figures represent electrophoresis gels, visualising the RT-PCR products for 
hMSCs exposed to a) adipogenic media, b) osteogenic media, and c) chondrogenic 
media.  The genes of interest, and the time points are as indicated. 
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G.4.2. Flow Cytometry 
Data plots were derived from flow cytometry, see Figure G.3.  It was found that 
92±1% of the live cells were CD105 positive, and 30±5% were Stro-1 positive. 
 
 
Figure G.3: Graphs of flow cytometry. 
These figures represent data plots collected using flow cytometry for hMSCs from 




As discussed in §5.6.2, the OS media used in the current study is known to induce 
hMSCs to undergo osteogenic differentiation.  Mineralisation, as determined by 
staining using the von Kossa technique, is a widely used indicator of osteogenesis 
(Howard et al., 2002; Kim et al., 2005; Tremoleda et al., 2008). 
 
Mineralisation was routinely observed after 21 days of exposure to osteogenic media 
(see Figure G.1).  This implies that at least a subpopulation of the hMSCs cultured 
was capable of osteogenic differentiation. 
 
The chondrogenic media used during these studies, has been shown previously to 
induce chondrogenic differentiation in hMSCs (Pittenger et al., 2002).  Positive 
Safranin O staining is a widely accepted method of detecting chondrogenic 
differentiation (Rosenberg, 1971; Kim et al., 2005; Tremoleda et al., 2008). 
 
Consistently positive Safranin O staining was observed after 21 days of exposure to 
chondrogenic media (see Figure G.1).  This provides evidence that at least a 
subpopulation of the hMSCs cultured was capable of chondrogenic differentiation. 
 
Again, the adipogenic media used in the studies described above has previously been 
shown to stimulate the adipogenic differentiation of hMSCs (Pittenger et al., 2002).  
Positive Oil Red-O staining is often used to identify adipogenic differentiation 
(Asahina et al., 1996; Pittenger et al., 1999; Tremoleda et al., 2008). 
 
Positive Oil Red-O staining was routinely observed after 21 days of exposure to 
adipogenic differentiation (see Figure G.1).  Again, this would provide evidence that 
at least a subpopulation of the hMSCs cultures was capable of adipogenic 
differentiation.  Hence it was concluded that, consistently, cells were present in the 




The cells isolated were also found to have fibroblastic morphology similar to that 
described for CFU-F (Gronthos et al., 1994).  The cells were also found to be within 
the 20 – 150 µm diameter size range reported for MSCs cultured in vitro (Curran et 
al., 2006; Noth et al., 2002; Salasznyk et al., 2004; Liu et al., 2003; Hong et al., 
2005; Santiago et al., 2009; Sengers et al., 2010). 
G.5.3. RT-PCR 
For one patient (652), the differentiation process was examined further.  As 
previously discussed in §7.3, Runx2 is thought to act as the “master switch” for 
osteogenic differentiation.  Similarly, the adipocyte specific transcription factor 
PPARγ2 is thought to stimulate adipogenesis in MSCs and to inhibit osteogenesis 
(Lecka-Czernik et al., 2002), hence PPARγ2 expression is used widely as an 
indicator of adipogenic differentiation (Duque and Rivas, 2007; Kim et al., 2007b; 
Shang et al., 2007). 
 
Unlike Runx2 and PPARγ2, Col2A1 is not a transcription factor, instead this gene 
codes for a structural protein.  Type-II collagen forms a high proportion of the 
extracellular matrix of articular cartilage (Herbage et al., 1977).  Therefore, Col2A1 
has become a widely used marker for chondrogenesis (Kawakami et al., 2005; 
Dickhut et al., 2008; Zimmermann et al., 2008). 
 
The up-regulation of these markers of MSC differentiation (see Figure G.2), gives 
further evidence, at least in the case of patient 652, that at least a subpopulation of 
the cells cultured was able to undergo osteogenic, chondrogenic and adipogenic 
differentiation.  In addition, this presents some evidence that the cultures were in a 
relatively undifferentiated state before day 7, implying the presence of multipotent 
cells.  However, it should be emphasised that these data relate to one patient only, 
and do not indicate if this was consistent for cells derived using the isolation 
procedure described in §3.3.1.1.  
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G.5.4. Flow Cytometry 
Relatively high numbers of hMSCs isolated using the technique described in 
§3.3.1.1, were found to be CD105 positive (see Figure G.3).  Levels recorded in the 
studies described above (92±1%) were comparable to those found by Liu et al. 
(2008a) (approximately 97%), and superior to those found by Sakaguchi et al. (2004) 
(74±41%) and Meinel et al. 2004 (approximately 87%).  CD105 is thought to be 
expressed by MSCs, but not by cells of the haematopoietic lineage (Haynesworth et 
al., 1992b), furthermore CD105 expression is thought to disappear upon 
differentiation (Barry et al., 1999; Goussetis et al., 2005).  Therefore, if present, cells 
of the haematopoietic lineage represented a maximum of 8% of the cultured cells. 
 
Similarly, relatively high numbers of hMSCs were positive for Stro-1 (see Figure 
G.3).  The 30±5% recorded in the studies described above was found to be higher 
than that reported by Zhand et al. (2009) (10.4%) and Howard et al. (2002) 
(7.12±3.78% before Stro-1 positive cells were actively selected for), and was found 
to be comparable to levels reported by Stenderup et al. (2001) (27%).  As discussed 
in §G.2, Stro-1 positive cells are associated with relatively undifferentiated cells, 
capable of osteoblastic differentiation. 
 
These data, particularly for Stro-1, represent evidence that at least a subpopulation of 
the cultured cells was CFU-F, capable of osteogenic differentiation. 
G.5.5. Cell Classification 
The cell isolation procedure used for the studies described above, has been widely 
used by previous authors to extract hMSCs (Tremoleda et al., 2008; Gronthos et al., 
1998; Gundle et al., 1995). 
 
The routine characterisation procedure for the hMSCs indicates that, consistently, a 
proportion of the cells was able to undergo osteogenic, chondrogenic and adipogenic 
differentiation.  It should be noted, however, that evidence was not presented that the 
populations of progenitor cells for the three lineages represented the same 
population.  Whether multipotent MSCs were present, or whether the cultures 
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contained a mixture of committed progenitor cells, was unclear.  However, this is 
true of previous studies (Owen, 1988; Pittenger et al., 1999; Digirolamo et al., 1999; 
Kemp et al., 2005).  Indeed, in a given MSC population cultured in vitro, the 
frequency of multipotent cells may be low, with most cells being bi- or indeed uni-
potent (Digirolamo, 1999 #1051). 
 
For studies designed to examine the cell biology of MSCs in detail, a collection of 
markers must be examined (Kemp et al., 2005; Dominici et al., 2006).  The cells 
should not express haematopoietic markers such as CD34, CD45 and CD14 nor 
endothelial cell markers such as CD24, CD31 and VWF (Kemp et al., 2005; 
Pittenger et al., 1999; Prockop, 1997; Majumdar et al., 1998).  The cells should also 
express the adhesion molecule CD90 (Rege and Hagood, 2006; Campioni et al., 
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very limited evidence was presented that a subpopulation of the cells was 
multipotent, the term “Mesenchymal Stem Cells” was thought to be inappropriate for 
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The studies described in this appendix aimed to characterise the cells isolated from 
primary human tissue.  The ability of the cells to undergo osteogenic, chondrogenic 
and adipogenic differentiation was assessed using von Kossa, Safranin-O and Oil 
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The cells were also examined for markers associated with MSCs: CD105 and Stro-1.  
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Although only very limited evidence was presented that multipotent cells were 
present in the cell cultures, it was concluded that the term “Marrow Stromal Cells” 
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